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University of Stellenbosch 
Abstract 
QUANTITATIVE YEAST PHYSIOLOGY AND NITROGEN METABOLISM 
DURING HETEROLOGOUS PROTEIN PRODUCTION 
By Johann F. Görgens 
 
The physiology and nitrogen metabolism of the yeast, Saccharomyces cerevisiae, 
during heterologous xylanase production in a defined medium was quantified by the 
comparison of isogenic yeast strains, whereby several potential limitations in the 
production of the heterologous xylanase could be identified.  The presence of global 
sensing and regulatory mechanisms, by which the yeast is able to actively regulate 
both heterologous gene expression and the physiological response to the process, was 
also investigated. 
 
The deleterious effects of heterologous xylanase production on the physiology of the 
recombinant host were disproportionately large with respect to the amount of foreign 
protein produced.  The cellular processes involved in this response were identified by 
the transcriptional profiling of isogenic recombinant strains, in a novel analytical 
approach to investigating foreign protein production by S. cerevisiae.  Heterologous 
gene expression affected a combination of cellular processes and induced the yeast 
stringent stress response.  The corresponding loss of metabolic functionality resulted 
in the disproportionate physiological effects of foreign protein production, similar to 
previous observations in recombinant Escherichia coli, and a possible reduction in 
attainable production levels.  Reducing the propensity of recombinant gene expression 
to introduce metabolic stress may therefore increase production levels of foreign 
proteins by yeast.  The metabolic vitality of transformed strains was also reduced by 
the presence of multiple copies of active, plasmid-based PGK1-promoters in the cell 
without expression of the heterologous gene.  The negative effect was caused by an 
increase in the biosynthetic and glycolytic capacity of the strain at the expense of 
other processes.   
 
Production levels of heterologous xylanase were influenced by expression vector 
selection and the presence of auxotrophic mutations in transformed strains of S. 
cerevisiae.  The increased transcription levels obtained with the multicopy plasmid-
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based YEp-type expression system, compared to the integrative YIp-type expression 
system, resulted in higher levels of xylanase production.  Heterologous xylanase 
production thus did not saturate the secretory capacity of the host strain.  The genetic 
stability of the autoselective YEp-type expression system in long-term chemostat 
culture was also demonstrated.  High levels of heterologous xylanase production by 
transformed S. cerevisiae strains containing auxotrophic markers required the 
stabilisation of nitrogen metabolism via saturation of yeast cells with an excess of 
imported amino acids.  By the removal of excessive auxotrophic markers, high levels 
of xylanase production by a prototrophic transformant in defined medium without 
amino acid addition could be obtained.  Heterologous xylanase production by the 
prototrophic transformant was further enhanced by increasing the availability of 
preferred amino acids or succinate in the defined medium, indicating an additional 
requirement for metabolic precursors and building blocks for foreign protein 
synthesis.  Comparable levels of heterologous xylanase production were obtained in 
high cell density cultures of the alternative yeast, Pichia stipitis, by the proper 
induction of the native ADH2-promoter, the control of oxygenation, and addition of 
an amino acid mixture to the defined medium, indicating the presence of generic 
limitations in transcription, nutrient availability and the yeast biosynthetic capacity for 
foreign protein production by various yeasts. 
 
The presence of global sensing and regulatory mechanisms was confirmed by the 
physiological response of S. cerevisiae to heterologous protein production, which 
included the downregulation of biosynthesis and growth, and the induction of various 
processes involved in the stringent stress response.  Additionally, heterologous 
xylanase production was actively regulated on a posttranscriptional level by the 
auxotrophic transformants in response to the level of amino acid availability.  The 
biosynthetic capacity for foreign protein production by both recombinant S. cerevisiae 
and P. stiptis was also regulated in response to the physiological state of the yeast and 
the availability of nutrients.  The presence of these regulatory mechanisms 
complicated the manipulation of cellular biosynthesis at will. 
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Universiteit van Stellenbosch 
Opsomming 
KWANTITATIEWE GIS-FISIOLOGIE EN -STIKSTOF METABOLISME 
GEDURENDE HETEROLOË PROTEÏEN PRODUKSIE 
Deur Johann Ferdinand Görgens 
 
Die fisiologie en stikstof-metabolisme van die gis, Saccharomyces cerevisiae, 
gedurende heteroloë xilanase produksie in ‘n gedefiniëerde medium is gekarakteriseer 
deur isogeniese gis-rasse te vergelyk, waardeur verskeie moontlike beperkings in die 
produksie van die heteroloë xilanase uitgewys kon word.  Die teenwoordigheid van 
globale sensoriese- en beheer-meganismes, wat die gis in staat stel om beide heteroloë 
geen uitdrukking en die fisiologiese respons op die proses aktief te reguleer, is ook 
ondersoek. 
 
Die nadelige effekte van heteroloë xilanase produksie op die fisiologie van die 
rekombinante gasheer-organisme was uitermatig groot in vergelyking met die 
hoeveelheid vreemde proteïen wat geproduseer is.  Die sellulêre prosesse 
verantwoordelik vir hierdie respons is identifiseer deur die transkripsionele profiele van 
isogeniese rekombinante rasse te vergelyk, in ‘n nuwe analitiese benadering tot die 
bestudering van vreemde proteïen produksie deur S. cerevisiae.  Heteroloë geen 
uitdrukking het ‘n kombinasie van sellulêre prosesse geaffekteer en die gis se algemene 
voedingstres-respons geaktiveer.  Die gepaardgaande verlies aan metaboliese funksie 
het die uitermatige fisiologiese effek van vreemde proteïen produksie veroorsaak, 
soortgelyk aan vorige waarnemings met rekombinante Escherichia coli. Die haalbare 
produksie-vlakke is moontlik ook verlaag deur hierdie respons.  ‘n Verlaging van die 
geneigdheid van rekombinante geen uitdrukking om metaboliese stres te veroorsaak, 
mag dus die produksievlakke van vreemde  proteïene in gis verbeter.  Die metaboliese 
groei-potensiaal van die getransformeerde rasse is ook verlaag deur die teenwoordigheid 
van etlike aktiewe kopieë van plasmied-gebaseerde PGK1-promotors in die sel, sonder 
uitdrukking van die heteroloë geen, deur ‘n toename in die biosintetiese en glikolitiese 
kapasiteit ten koste van die ander sellulêre prosesse. 
 
Die produksievlakke van heteroloë xilanase is deur die keuse van uitdrukkings-sisteem 
en die teenwoordigheid van autotrofiese mutasies in die getransformeerde rasse van S. 
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cerevisiae beïnvloed.  Die verhoogde transkripsie vlakke wat met die multi-kopie, 
plasmied-gebaseerde YEp-tipe uitdrukkingsisteem, eerder as die geïntegreerde YIp-tipe 
sisteem, verkry is, het tot verhoogde xilanase produksie gelei.  Heteroloë xilanase 
produksie het dus nie die uitskeidingskapasiteit van die gasheer versadig nie.  Die 
genetiese stabiliteit van die autoselektiewe, YEp-tipe uitdrukkingsisteem in langtermyn 
chemostaat-kulture is ook gedemonstreer.  Hoë vlakke van xilanase produksie deur 
getransformeerde S. cerevisiae rasse met autotrofiese merkers het die stabilisering van 
die stikstof metabolisme, deur die versadiging van die sel met ingevoerde aminosure, 
vereis.  Die verwydering van oormatige autotrofiese merkers het tot hoë vlakke van 
xilanase produksie deur die prototrofiese transformant in gedefinieerde medium sonder 
aminosuur byvoeging gelei.  Heteroloë xilanase produksie deur die prototrofiese 
transformant kon verder verbeter word deur die byvoeging van voorkeur-aminosure of 
suksinaat tot die gedefinieerde medium, en ‘n addisionele behoefte aan metaboliese 
voorloper-molekules en bou-blokke vir vreemde proteïensintese het dus bestaan.  
Vergelykbare vlakke van heteroloë xilanase produksie is in kulture met hoë sel-digthede 
van die alternatiewe gis, Pichia stipitis, verkry deur die doeltreffende induksie van die 
eiesoortige ADH2-promotor en die byvoeging van ‘n aminosuur-mengsel tot die 
gedefinieerde medium, wat die teenwoordigheid van generiese beperkinge in 
transkripsie, voedingstof-beskikbaarheid en biosintetiese kapasiteit van die gis vir 
vreemde proteïen produksie deur verskeie giste uitgewys het. 
 
Die teenwoordigheid van globale sensoriese- en beheer-meganismes is bevestig deur die 
fisiologiese respons van S. cerevisiae tot heteroloë proteïen produksie, wat die afwaartse 
regulering van biosintese en groei, en die induksie van verskeie prosesse betrokke by 
die algemene voedingstres-respons, ingesluit het.  Heteroloë xilanase produksie is ook 
op ‘n na-transkripsionele vlak aktief gereguleer deur die autotrofiese transformante in 
reaksie tot die vlak van aminosuur beskikbaarheid.  Die biosintetiese kapasiteit vir 
vreemde proteïen-produksie van beide rekombinante S. cerevisiae en P. stipitis is ook in 
reaksie tot die fisiologiese toestand van die gis en die beskikbaarheid van 
voedingstowwe gereguleer.  Die teenwoordigheid van hierdie regulatoriese meganismes 
het die willekeurige manipulasie van sellulêre proteïen-biosintese bemoeilik. 
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1Chapter 1 
 
INTRODUCTION 
 
Heterologous protein production by yeast expression systems 
 
 
1.1. WHAT IS HETEROLOGOUS PROTEIN PRODUCTION? 
 
“Heterologous protein production” refers to the cloning, transfer and expression of 
genes from a specified microorganism into a host organism of choice, enabling the 
alternative host to produce the proteins encoded by the cloned genes.  Also referred to 
as “Recombinant gene expression,” this method enables the production of a variety of 
foreign proteins in a chosen host, provided that the necessary genetic tools and 
expression system are available.  The two major applications of heterologous protein 
production in industrial biotechnology is, (a) the development of microbial expression 
systems able to overproduce valuable proteins in a convenient manner, and (b) the 
engineering of new or improved pathways in microorganisms for the production of 
metabolites or proteins, also known as “metabolic engineering” (Bailey, 1991).  The 
alternative host organism may be better suited to the industrial production of a 
heterologous protein than the native host, due to factors such as improved growth and 
higher cell densities, a lower background of native protein levels resulting in the 
production of a more pure product, higher expression levels of the specific protein due 
to genetic manipulation and increased environmental acceptance of the organism due to 
reduced toxicity.  Some pharmaceutical proteins of human origin, such as interferons 
and interleukins cannot be produced otherwise than with a heterologous host (Swinkels 
et al., 1993; Walsh, 2000).  The profitability of heterologous proteins produced in such 
a manner for medical use is significant, with the industry producing these 
pharmaceuticals recently valued at US$12 billion (Walsh, 2000).  Other examples of 
human proteins produced in large volumes for medical use are: Interferon-α, Hepatitis 
B vaccine, granulocyte colony-stimulating factor (GC-SF) and tissue plasminogen 
activator (Koths, 1995; Walsh, 2000).   
2In the current work, the application of heterologous protein production for metabolic 
engineering applications – i.e. the development of a new or improved functionality in a 
host organism – was not considered, but rather the relationship between the physiology 
of the S. cerevisiae yeast host and production levels of a model recombinant protein, 
Trichoderma reesei xylanase II.   
 
1.2. WHY XYLANASE PRODUCTION? 
 
The cloning of T. reesei endo-1,4-xylanase II (XYN2 gene) and expression in yeast via 
transformation enabled heterologous xylanase production by S. cerevisiae (also known 
as baker’s or brewer’s yeast), which possesses no native xylanase genes (La Grange et 
al., 1996).  Xylanase is a hydrolytic enzyme that cleaves the polymeric backbone of the 
xylan hemicellulose, which is second only to cellulose in natural abundance as 
carbohydrate. 
 
The catalytic activity of endo-1,4-xylanases have found application in several 
industries, of which the most effective current use is in the prebleaching of kraft pulp, 
where environmental regulations restrict the use of chlorine (Buchert et al., 1992; 
Viikari et al., 1994).  Xylanase pretreatment has been shown to minimize the use of 
harsh chemicals in subsequent treatment steps and resulted in greater brightness of the 
final paper product.  The use of xylanases produced by yeast in these processes is 
especially advantageous, since these preparations contain no cellulase activity that will 
reduce the strength of the final paper product.  Extensive purification of xylanase from 
fungal sources is required for the removal of cellulase activity prior to application in 
bleaching processes (Bajpai, 1999; Kulkarni et al., 1999; Beg et al., 2001).   
 
Xylanases are also used in the baking industry due to the presence of hemicellulose in 
the raw material. Xylanase addition to wheat flour has improved dough handling and 
quality of baked products (bread volume) (Maat et al., 1992; Randez-Gill et al., 1999; 
Kulkarni et al., 1999).  The use of baking yeasts expressing heterologous xylanase can 
also eliminate the need for baking additives and thereby improve profit margins 
(Randez-Gill et al., 1999).  The nutritional properties of agricultural silage and grain 
feed, especially for poultry, can also be improved by the addition of xylanase (Bedford 
and Classen, 1992; Kudah and Singh, 1993).  Xylanases are also used in combination 
3with pectinase and cellulase for clarification of fruit juices (Biely, 1985; Kulkarni et al., 
1999), and in wine making where it has been shown that the fruity aroma of wine, made 
with recombinant yeasts producing Aspergillus nidulans xylanase A, was improved 
(Ganga et al., 1998; Ganga et al., 1999).  Xylanases are also useful in coffee making, oil 
recovery and the extraction of other organic compounds such as plant oils and starch 
(Wong and Saddler, 1992; Kulkarni et al., 1999).  Other possible applications of 
xylanase are in the production of liquid or gaseous fuels via renewable resource 
utilisation (Olsson and Hahn-Hägerdal, 1996), where the expression of xylanase genes 
in fermentative organisms could enable these organisms to directly convert xylan 
residue into liquid fuels (Kulkarni et al., 1999). 
 
In particular, the heterologous xylanases from T. reesei and Cryptococcus albidus were 
selected as model proteins in the present study due to the efficient secretion of the 
proteins by their yeast hosts, S. cerevisiae and P. stipitis, respectively.  Because of an 
absence of catalytic activity in metabolism, the actual production of these heterologous 
proteins could thus be studied in isolation from effects introduced by the enzymatic 
activity of the produced recombinant protein. 
 
1.3. REASONS FOR USING YEAST PRODUCTION SYSTEMS 
 
Heterologous gene expression may be obtained in a variety of host strains, ranging from 
simpler prokaryotes, such as recombinant E. coli, to lower eukaroyes, yeasts in 
particular, and higher eukaryotes, such as mammalian or insect cells.  A brief 
comparison of yeast expression systems with either bacterial or higher eukaryotic cells 
reveal a number of specific reasons why the former may be preferred. 
 
Heterologous gene expression by S. cerevisiae was first described in 1981 (Hitzeman et 
al., 1981).  Along with the “alternative” yeast species (most notably Pichia pastoris and 
Hansenula polymorpha), S. cerevisiae has become a strong favourite for the production 
of foreign proteins (Hinnen et al., 1995).  As with the frequently-used bacterial systems, 
this has partly been due to the prior experience with the microorganisms at industrial 
scale and the possibility to use cheap substrates, which allows the efficient scale-up of 
yeast expression systems into commercial processes (Swinkels et al., 1993; Schultz et 
al., 1994; Cereghino and Cregg, 1999).  Yeasts also offer the ease of gene manipulation 
4found in bacteria, as yeast genetics are relatively well known (Schultz et al., 1994; 
Cereghino and Cregg, 1999; Calado et al., 2002).  In contrast to bacterial systems, 
however, the ability of several yeast species to perform the posttranslational processing 
and secretion of foreign proteins is particularly advantageous, since exploiting the 
capabilities of the eukaryotic secretory apparatus of yeast is a direct means of producing 
a purer protein product with a high fidelity to the naturally occurring species (Wittrup et 
al., 1994; Schultz et al., 1994; Hinnen et al., 1995; Calado et al., 2002).  The latter is 
possible since yeasts, being a lower eukaryote, possess an intracellular environment 
with the ability to perform many eukaryotic-specific posttranslational modifications, 
such as proteolytic processing, folding, disulfide bridge formation and glycosylation, 
which is required to obtain a protein with the correct biological activity in higher 
eukaryotes (e.g. mammalian cells)  (Moreau et al., 1992; Romanos et al., 1992; 
Swinkels et al., 1993; Schultz et al., 1994; Cereghino and Cregg, 1999; Rosenfeld, 
1999).  Yeasts therefore have a significant advantage over bacteria, where the in vitro 
unfolding and refolding of the recombinant product is usually required to obtain 
biological activity (Lee et al., 1999).  Export of the protein product from the host cell 
also reduces the risk of protein degradation by intracellular proteases (Calado et al., 
2002), and since only a very small fraction (0.5%) of the native yeast proteins are 
secreted, a reasonably pure secreted product can be obtained, which simplifies 
downstream processing (Mendoza-Vega et al., 1994; Schultz et al., 1994; Vasavada, 
1995; De Baetselier and Van Broekhoven, 1998; Calado et al., 2002).  The yeast S. 
cerevisiae in particular does not produce endotoxins, contrary to several of the bacterial 
expression systems, and is considered safe for the production of health care and food 
products, and FDA approval of production processes can thus be obtained more readily 
(Romanos et al., 1992; Schultz et al., 1994; Vasavada, 1995; Kulkarni et al., 1999).  The 
GRAS (Generally Regarded As Safe) status of this organism is based on a long history 
of safe use as food organisms and this yeast is therefore more acceptable for the 
production of pharmaceutical or food proteins than e.g. prokaryotes (bacteria) or 
mammalian cells, which may pose the potential problems of pyrogenic endotoxins and 
oncogenic DNA, respectively (Swinkels et al., 1993).  S. cerevisiae has been used by at 
least 4 pharmaceutical companies in production processes, including human insulin 
production by Novo Nordisk (Denmark) (Alberghina et al., 1993).  Yeasts also offer 
faster growth rates than more complex (mammalian) expression systems, which result 
in less contamination and shorter production times, along with the ability for 
5propagation in large quantities with ease and at low cost (Vasavada, 1995; Law et al., 
1998; Cereghino and Cregg, 1999). 
 
However, the foremost reason for using yeast expression systems, i.e. the ability to 
perform the posttranslational modification and secretion of foreign proteins, may also 
represent their greatest limitation: due to the complexity of the protein secretion 
process, production levels of secreted proteins are likely to be lower than that of 
proteins produced intracellularly (Vasavada, 1995).  Thus, although the need for in vitro 
posttranslational maturation can be a limiting factor in the production of recombinant 
proteins with bacteria such as E. coli (Ljubijankic et al., 1999), yeast has not been used 
as frequently as E. coli for the production of therapeutic proteins due to the lower 
production levels usually obtained (Lee et al., 1999).  The selection of a bacterial, yeast 
or mammalian expression system for production of a recombinant protein depends on 
the nature of the protein, the required posttranslational modifications, the quantity 
needed and the cost of production (Vasavada, 1995), and is empirical in several cases 
(Bathurst, 1994).  The yeasts S. cerevisiae and P. pastoris are most frequently used for 
heterologous protein expression (Cereghino and Cregg, 1999) (see Chapter 2 for 
comparison of yeast species). 
 
1.4. LIMITATIONS IN THE PRODUCTION OF HETEROLOGOUS 
XYLANASES BY YEASTS 
 
To be suited for industrial cultivation, a microbial production system should possess 
strict genetic stability, leading to stable production levels and high yields in repeated 
fermentations, especially if an expensive substrate or very valuable protein is produced.  
In the present heterologous protein production system, however, low yields of xylanase 
production were initially observed, prompting a fundamental investigation into the 
factors that may limit the production of heterologous proteins by yeasts.  In an effort to 
identify possible limitations in the production and secretion of heterologous xylanase by 
S. cerevisiae, the physiology and nitrogen metabolism of isogenic, transformed strains 
were compared during cultivation under well-controlled conditions.   
 
The experimental approaches represented in the following chapters were based on the 
careful quantification of the yeast physiology (Fig. 1.1).  The heterologous xylanase 
6produced by S. cerevisiae was first purified to allow estimation of the mass amount of 
foreign protein produced (Chapter 3).  The yeast physiology was subsequently 
quantified in terms of the additional “load” of heterologous gene expression introduced 
in the metabolism, which reduced the metabolic vitality of the production strain and 
affected the cultivation performance thereof negatively (Chapter 4).  The deleterious 
effects of heterologous protein production on the physiology of the transformed strains 
can reduce the levels of biomass formation, while increasing the time required for 
completion of an industrial production process, thus affecting the overall productivity 
negatively.  The observed “metabolic load” was further investigated on a transcriptional 
level, whereby the nature of the physiological stress responsible for the reduced 
metabolic vitality could be identified (Chapter 5).  The potential limitation of 
heterologous xylanase production levels due to the choice of host genetic background or 
foreign gene expression system was investigated by the comparison of three potential 
production systems, whereby the influence of auxotrophic requirements and foreign 
gene copy number was demonstrated (Chapter 6).  The limited availability of nutrients 
that specifically enhance heterologous xylanase production may also reduce the 
production levels obtained with recombinant S. cerevisiae (Chapter 7).  The effect of 
nutrient availability and cultivation conditions on the level of promoter induction and 
foreign gene expression was also demonstrated in novel yeast host for heterologous 
protein production, P. stipitis (Chapter 8).   
 
The aforementioned experimental approaches provided data to support the central 
theme of the present dissertation:  Does the yeast possess global mechanisms for the 
sensing and active regulation of heterologous protein production and/or the 
physiological response to the production process?  Regulatory mechanisms in cellular 
metabolism may determine the physiological response of the yeast host to heterologous 
protein production, and determine the eventual production levels of heterologous 
proteins, and may therefore have a significant effect on the productivity of recombinant 
strains in industrial fermentations.  The identification of such regulatory mechanisms is 
therefore critical for understanding and improving the production of heterologous 
proteins by yeast. 
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Figure 1.1. Layout of experimental work 
Purification of
recombinant xylanase
Transcriptional profiling
Physiological characterisation
Physiological response to
heterologous xylanase production
Control of cultivation conditions (P. stipitis)
Nutrient availability in defined medium
Genetic background and expression vector
Factors affecting production
levels of heterologous xylanase
Limitations during heterologous
xylanase production
8Besides providing experimental data on the possible limitations in yeast metabolism 
during heterologous xylanase production, these investigations also demonstrated the 
importance of reproducible experimental procedures and accurate analytical techniques 
for investigating microbial physiology.  The experimental results obtained in Chapter 4 
to 8 were largely dependent on the reproducibility of the yeast cultures, and, more 
importantly, on the availability of analytical techniques such as transcriptional profiling, 
amino acid analysis, fermentation off-gas analysis and high performance liquid 
chromatography (HPLC).  Without adequate analytical techniques, the mechanistic 
investigation of microbial physiology and assimilation of a holistic view of metabolism 
would not be possible. 
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2.1. INTRODUCTION - Quantitative aspects of recombinant protein production 
in yeast 
 
The production of a secreted heterologous protein by yeast proceeds via three major 
steps:   
• During transcription mRNA (messenger RNA) molecules, which are 
complementary to the template DNA (the foreign gene being encoded), are 
synthesized in a process catalysed by the yeast RNA polymerase II. 
• Translation proceeds after transport of mRNA to the ribosomes, where proteins 
are synthesised via the addition of individual amino acids in sequential manner.  
Amino acids are transported to the ribosomes by the tRNA (transport RNA) 
molecules. 
• Posttranslational modification and secretion involves the processing of the 
synthesised protein through the yeast secretory apparatus, to obtain an 
extracellular, properly folded, mature protein with biological activity. 
 
The mechanisms that determine the efficiency of the native apparatus towards the 
production of a foreign protein are not well understood, and the presence of several 
limitations and large variations in production levels are evident from previous reports.   
Reported expression levels of foreign proteins in P. pastoris range from m g.l-1 to g.l-1 
(d’Anjou and Daugulis, 2001), whereas similar large variations in the levels of foreign 
protein secretion by S. cerevisiae may be attributed to variations in the characteristics of 
individual production systems (Ichikawa et al., 1989).  It should also be noted that 
production levels reported in the literature are typically from laboratory-scale 
experiments, not large-scale production (Hensing et al., 1995a). 
 
General factors known to influence the production level of a heterologous protein by a 
yeast expression system include (Calado et al., 2002; Bae et al., 1998; Shiba et al., 
1994; Weber et al., 1992; Ichikawa et al., 1989; Sleep et al., 1991; Romanos et al., 
1992; Vasavada, 1995): 
  
• Transcriptional efficiency and the availability of transcription factors 
• Nature and strength of promoter and terminator 
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• Type, stability and copy number (gene dosage) of expression vector (plasmid) 
• Efficiency of translation, based on the untranslated mRNA leader sequence, and 
codon bias 
• Efficiency of secretion 
• Signal/leader sequence and chaperone availability 
• Posttranslational modification and proteolytic protein processing 
• Nature and stability of the proteins produced 
• Host strain characteristics (some strain are known to overexpress or 
overproduce recombinant proteins) 
• Interaction between the host cell physiology, metabolism and the expression 
vector (plasmid) 
• Environmental factors such as bioreactor operational strategy and medium 
composition 
 
When attempting gene expression and secretion of a heterologous protein, barriers can 
therefore be encountered at numerous stages, from transcription through to the stability 
of secreted proteins (Romanos et al., 1992).  Versatile expression systems such as S. 
cerevisiae thus need to be optimised to ensure high production levels of heterologous 
proteins (Alberghina et al., 1993).  Due to the complex interaction of the factors that 
determine the efficiency of the expression and secretion process, the prediction of the 
yield of a recombinant protein is not possible, and most approaches for addressing the 
critical parameter(s) in production systems remain empirical in nature (Sleep et al., 
1991; d’Anjou and Daugulis, 2001).  As success with the production of a heterologous 
protein can seldom be ensured beforehand, the most suitable host-vector and gene 
expression systems for production of a given protein are usually determined by 
comparing the various candidate expression systems (Uchiyama et al., 1995).  Despite 
the highly empirical nature of heterologous protein production, the application of the 
various known “rules of thumb” can result in the improvement of heterologous protein 
production by yeast.  The inclusion of multiple genetic improvements in this manner 
frequently has cumulative effects on the production level of heterologous protein 
(Schultz et al., 1994).  In this review, the application of new and existing rational 
approaches for improving the levels of heterologous protein production by yeast are 
presented on the basis of several case studies. 
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2.2. TRANSCRIPTION 
 
As the first step in the synthesis of a foreign protein by yeast, transcription may either 
present the cell with an “excess” of heterologous mRNA molecules, or limit production 
of the protein due to inefficient mRNA production.  Various factors determine the 
eventual level of heterologous transcripts in the cell. 
 
2.2.1. Type of expression system 
For heterologous protein production in S. cerevisiae, three major types of expression 
systems can be employed.  Yeast Integrative plasmids (YIp) are based on the 
homologous recombination of sections in the expression vector at single sites in the 
yeast chromosome.  The use of YIp typically results in the integration of a single or few 
copies of the desired heterologous gene maintained with great stability during cell 
division (Mendoza-Vega et al., 1994a; Gellissen and Hollenberg, 1997).  Integrative 
plasmids in general have the advantage of not necessitating the inclusion of bacterial 
DNA sequences, which are potentially toxic to other organisms and may decrease 
vector stability (Lopes et al., 1996). 
 
Alternatively, yeast episomal plasmids (YEp) are stable genetic sequences maintained 
independent of chromosomal DNA within the nucleus of the cell, by the inclusion of 
the native yeast 2 μm sequence in the plasmid construct.  Typical components in a YEp 
vector are a selection marker for which the yeast is auxotrophic, the expression cassette 
and the bacterial sequences for amplification in E. coli.  YEp expression vectors are 
normally present at higher copy numbers than YIp vectors (Mendoza-Vega et al., 
1994a), in the order of 50-60 (Shuster et al., 1989) or 60-100 (Bae et al., 1998) copies 
per cell.  The copy number of the YEp expression vectors may also be increased by 
inclusion of the LEU2(d) selection marker in a leucine-auxotrophic background.  This 
partially defective gene is expressed at low levels, forcing the cell to maintain high copy 
numbers of the plasmid to ensure sufficient leucine availability (Erhart and Hollenberg, 
1983).  The increased copy number of the YEp vectors, resulting in an increased “gene 
dosage” of the foreign gene, may lead to an increase (sometimes proportional) in the 
production levels of the recombinant protein (Weber et al., 1992; Ljubijankic et al., 
1999; Park et al., 2000).  However, the genetic and physiological background of the 
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host strain may also overshadow the effects of increased copy number, as is discussed 
in the remainder of this review (Porro et al., 1992).  In Kluyveromyces lactis, production 
of a heterologous protein has also been increased through the use of a multicopy 
plasmid-based expression system (pKD1), rather then chromosomal integration (Fleer 
et al., 1991).  A large variation in the heterologous protein production levels between 
individual transformants may frequently be observed when the yeast 2 μm vectors are 
employed (Mendoza-Vega et al., 1994a).  Despite the presence of selection markers on 
the recombinant plasmid, YEp vectors may also suffer from severe segregational 
instability, resulting in the loss of the recombinant plasmid during cell division 
(Harashima, 1998).  The copy number and stability of these plasmids may therefore 
vary, depending on the selection marker, plasmid/promoter properties, gene expression 
level, expressed protein and growth conditions (Kjeldsen, 2000; Nacken et al., 1996; 
Buckholtz, 1993; Janes et al., 1990).  Nitrogen-limitation may improve the stability of 
the plasmid-containing population (Gupta and Mukherjee, 2002; Gupta et al., 2001).   
 
Due to the frequent instability of YEp vectors and the low copy number of YIp vectors 
(1-5), integrative expression systems based on repetitive chromosomal DNA sequences 
have been developed (Lopes et al., 1996; Gellissen and Hollenberg, 1997; Buckholtz, 
1993).  These expression systems offer a high copy number and high mitotic stability, 
which can be essential for a high expression level of heterologous proteins (Shiba et al., 
1998; Castelli et al., 1994; Fleer, 1992).  A novel vector system based on the integration 
of the expression cassette in the repetitive ribosomal DNA of the yeast, resulted in a 
high copy number, though the mitotic stability of these vectors decreased sharply for 
heterologous genes larger than 9-10 kb (Lopes et al., 1996).  Similar integrative 
expression systems based either on the repetitive Ty1 DNA sequences (Lee and Da 
Silva, 1996a; Lee and Da Silva, 1996b) or the repetitive δ sequences (Parekh et al., 
1996; Lee and Da Silva, 1997; Kim et al., 2001) have also been developed for S. 
cerevisiae.  Transcription from integrated expression cassettes may be more efficient 
than from YEp type vectors.  A recombinant S. cerevisiae strain harbouring 8 integrated 
copies of a heterologous expression cassette secreted a larger amount of recombinant 
protein than a strain containing the same cassette on the 2μm plasmid, the copy number 
of which can be several hundreds (Nomura et al., 1995a). 
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The transformation of P. pastoris is possible by integration only, because of the absence 
of endogenous plasmid sequences.  Multiple insertions of the expression cassette can 
occur at a single locus, with transformants containing gene copy numbers up to 30 
recovered by selection for increased G418 resistance (Rosenfeld, 1999; Pennell and 
Eldin, 1998; Sreekrishna et al., 1997).  In some cases a single integrated copy of a 
heterologous gene is sufficient for optimal production, whereas for other cases a high 
copy number is essential for the production of high levels of heterologous protein 
(Cereghino and Cregg, 2000; Romanos, 1995; Sreekrishna et al., 1997).  The type of 
expression system may therefore influence both the efficiency of transcription and the 
level of foreign mRNA in the cell.  However, the maximal level of recombinant protein 
production may be elicited by an optimal rather than maximal copy number of the 
expression vector (Rosenfeld, 1999). 
 
2.2.2. Autoselection systems 
Because of the ease of genetic manipulation, the 2 μm plasmids may, in some cases, 
still be the preferred expression vector for heterologous protein production in S. 
cerevisiae (Alberghina et al., 1993).  Several autoselection systems have therefore been 
developed, to ensure adequate plasmid stability and genetically stable recombinant 
strains.  Although YEp expression vectors normally contain a selection marker for 
which the host is auxotrophic, frequent instabilities have been observed, presumably 
due to uptake of the metabolite for which an auxotrophic requirement exists from the 
medium (Meinander, 1997).  To obtain “autoselection,” these single selection systems 
are complimented by an additional selection system, where either the uptake of a 
required metabolite from the cultivation medium is incapacitated, or an essential 
structural gene is disrupted on the chromosome and complimented on the recombinant 
plasmid, to fabricate double or triple selection. 
 
The first such autoselection system for S. cerevisiae was described by Loison et al. 
(1986), which utilized a disruption of the native FUR1-gene in combination with 
insertion of the URA3 gene on the recombinant plasmid, in a host strain that contains a 
mutation in URA3.  The reduced uracil uptake from the medium obtained by FUR1-
disruption, resulted in a transformant that showed excellent genetic stability, also in 
continuous culture (Marquet et al., 1987).  This autoselection system was further 
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improved by the additional disruption of the URID-K gene, which may also function in 
nucleotide uptake (Wang and Da Silva, 1993), and transformants were grown in 
complex medium without significant plasmid loss.  A double selection system based on 
the complementation of URA3-selection with FBA1-selection (FBA1 encodes the FDP 
aldose enzyme) has also been developed and tested (Compagno et al., 1993; Compagno 
et al., 1996).  A similar autoselection system that ensures plasmid stability in 
recombinant K. lactis has also been described (Hsieh and Da Silva, 1998).  These 
autoselection systems have greatly improved the genetic stability and stability of 
transformants containing YEp type vectors, whereby stable production levels under 
controlled cultivation conditions could be ensured. 
 
2.2.3. Comparison of promoters 
The characteristics of the promoter used to drive the expression of a recombinant gene 
can also influence production levels, as the strength of the promoter is an additional 
determinant of the transcription level of a heterologous gene (Kjeldsen, 2000; Park et 
al., 1993; Ruohonen et al. 1995; Park et al., 2000).  Although both constitutive and 
regulated promoters may be used for heterologous gene expression, tight regulation 
becomes essential if the produced protein has a strong deleterious effect on cellular 
metabolism (Buckholtz, 1993).  In S. cerevisiae, such regulated promoters are 
frequently used, since they are typically stronger, support a faster rate of transcription 
and restrict the time during which the recombinant protein is produced (Buckholtz and 
Gleeson, 1991; Fleer, 1992; Alberghina et al., 1993).  In comparison to the constitutive 
SUC2 promoter, for example, use of the regulatable GPD promoter resulted in a higher 
maximum protein production rate, although use of the SUC2 promoter supported a 
higher final product concentration (Park and Ramirez, 1990).  A further example of a 
regulated promoter is the yeast alcohol dehydrogenase (ADH2) promoter, which is 
normally inactive and requires positive activation for derepression (Beier et al., 1985).  
For this promoter, however, the availability of positive transcription factors for 
activation of the ADH2 promoter may limit gene expression from multicopy plasmids 
(Irani et al., 1987), and increased expression has been observed by overexpression of 
the Adr1p transcriptional activator (Price et al., 1990).  Similarly, the low availability of 
the GAL4 transcriptional activator is normally rate-limiting for the maximal induction 
of GAL promoters, and significant increases in the level of transcription, and 
heterologous protein production, from GAL promoters have been obtained by 
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overexpression of GAL4, both for integrated and plasmid-based expression systems 
(Neeper et al., 1990; Porro et al., 1992; Alberghina et al., 1993; Schultz et al., 1994; 
Pedersen et al., 1996; Lee et al., 1999).  Overexpression of GAL4 increased foreign 
protein production to similar levels in several yeast strains tested, despite differences in 
physiological and genetic background, indicating that a major generic limitation had 
been addressed (Porro et al., 1992).  In general, limitations in the availability of 
transactivators for expression from multicopy plasmids may thus be overcome by 
overexpression (Fleer, 1992; Buckholtz, 1993).  Several investigations have thus 
confirmed the potential effect of promoter characteristics on the final production level 
of heterologous protein. 
 
2.2.4. Additional factors 
In a groundbreaking example it was shown that homologous Pgk1p produced from a 
plasmid-expression system accumulated to 80% of the total soluble cellular protein, 
whereas heterologous protein production levels seldom exceed 1-5% of the total cellular 
protein, far below the theoretically attainable values.  The significant difference in 
production levels was explained by the lower steady-state levels of heterologous 
mRNAs in the cell (Chen et al., 1984; Mellor et al. 1985; Chen and Hitzeman, 1987), 
indicating that transcription may limit heterologous protein production.  Other examples 
of the influence of mRNA transcript levels on the level of foreign protein production 
have been reported (Aho et al., 1996; Skory et al., 1996). 
 
Besides the aspects of gene copy number and promoter strength, levels of heterologous 
transcripts are also influenced by the exact positioning of the heterologous gene on the 
recombinant plasmid, and the presence of foreign non-coding sequences at the 3’-end of 
the heterologous cDNA (Joseph-Liauzun et al., 1995).  3’ untranslated mRNA 
sequences may influence mRNA stability and the efficiency of transcription termination 
(Fleer, 1992) and removal of these regions has significantly increased foreign mRNA 
levels (Joseph-Liauzun et al., 1995; Lang and Looman, 1995; Broker et al., 1991).   
Similarly, murine interleukin-2 expression in yeast increased 10-fold by deleting the 
major part of the mammalian 3’ untranslated region, which was apparently responsible 
for rapid degradation of the murine IL-2 mRNA (Demolder et al., 1992). 
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In P. pastoris, insertion of the first ATG-site of the heterologous coding sequence as 
close as possible to the ATG position of the AOX1 generally also improves expression 
levels (Cereghino and Cregg, 2000).  In another yeast, H. polymorpha, a change in the 
site of integration increased production levels two-fold, demonstrating the possible 
effect of chromosomal topography on gene expression (Kang et al., 2001). 
 
Efficient termination of foreign gene transcription also influences gene expression in 
yeast, as was demonstrated by a 7-10 fold and 3-5 fold increase in production levels due 
to increased transcriptional termination efficiency (Bijvoet et al., 1991; Kanai et al., 
1996; Cho et al., 1997).  Stability of the multicopy pMIRY1 integrative vectors was 
also dramatically improved by including the transcription-terminating sequence of the 
rDNA units where it was integrated (Lopes et al., 1996). 
 
2.3. TRANSLATION 
 
Although the efficiency of translation may also limit heterologous protein production, 
relatively few investigations on the kinetics of the various processes involved in foreign 
protein synthesis have been undertaken.  An exception is the potential effect of codon 
bias on the efficient translation and production of a heterologous protein, which was 
recognised during the development of the early recombinant protein production 
systems.  The highly efficiency expression of a foreign gene may result in a mismatch 
between the demand and supply in the protein synthetic machinery, especially if the 
codon bias and/or amino acid content of the heterologous gene is significantly different 
to that of the production host.  In such a case the demands placed on host protein 
synthetic apparatus are not matched to its normal tRNA population, which can limit the 
synthesis of the protein, or result in significant translational errors (Kurland and Gallant, 
1996).  Native sequences for heterologous genes and signal peptides are therefore 
sometimes replaced by synthetically generated genes, based on the yeasts preferred 
codon usage (Bennetzen and Hall, 1982) to ensure the most efficient translation 
possible (e.g. Pohlig et al., 1996; Lee et al., 1999).  However, some reports have also 
questioned the likelihood of codon usage preventing high level of gene expression, 
unless extreme requirements are placed on the tRNA population (Fleer, 1992).  Adverse 
effects may also result from the proposed “optimisation of codon usage,” since 
changing the primary sequence of a gene may alter the primary and secondary structure 
21
of the mRNA, which may influence translation negatively (Fleer, 1992).  Neither does 
the drive for higher expression levels by recombinant protein production systems 
always lead to lower quality or authenticity of the protein product’s sequence or 
structure (Olins, 1996). 
 
A worthy consideration, however, is the sensitivity of translation initiation in yeast to 
the secondary structure of the 5’-untranslated region (UTR) of mRNA (Fleer, 1992), 
and the potential effect on translation efficiency.  The native SDH1 and SUC2 5’ UTRs 
were capable of conferring glucose-sensitive mRNA instability to other genes expressed 
in S. cerevisiae, and could also control the turnover of the transcripts (De la Cruz et al., 
2002; Cereghino et al., 1995).  These changes in the mRNA stability due to the 
manipulation of the 5’ UTR were correlated with changes in the translational efficiency 
for the corresponding transcripts, indicating a direct relationship (De la Cruz et al., 
2002).  An increase in levels of heterologous protein production by S. cerevisiae was 
also obtained by either the modification or removal of the 5’-end of the heterologous 
gene sequence (Joseph-Liauzun et al., 1995; Lang and Looman, 1995; Broker et al., 
1991).  An apparent correlation between the predicted stability of the local secondary 
structure within the region of translation initiation at the 5’-end of the heterologous 
cDNA, and the level of recombinant protein production was also observed (Joseph-
Liauzun et al., 1995).  Furthermore, the removal of the 5’-UTR from the recombinant 
human serum albumin (HSA) cDNA has led to a 5-fold increase in the production of 
the recombinant protein by H. polymorpha.  Differences in production levels due to 
changes in gene dosage, shown to increase the production levels prior to deletion of the 
5’-UTR, were thereby abolished, resulting in maximal production levels from a single 
integration copy, indicating that the effect of gene dosage was strongly related to 
inefficient translation (Kang et al., 2001).  For expression in P. pastoris the 5’-UTR of 
the heterologous cDNA should be as close as possible to AOX1 mRNA to ensure high 
production levels, as 50-fold changes in the expression levels by these adjustments have 
been observed (Sreekrishna et al., 1997). 
 
2.4. POSTTRANSLATIONAL MODIFICATIONS AND SECRETION 
 
The advantages of the secretory production of foreign proteins, compared to 
intracellular production, rely heavily on the efficient functioning of the posttranslation 
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and secretion machinery.  The exploitation of the ability of the yeast intracellular 
environment to perform many eukaryotic-specific posttranslational modifications, such 
as proteolytic processing, disulfide bridge formation and glycosylation, is a direct 
means of producing a protein product with high fidelity and biological activity in higher 
eukaryotes (Wittrup et al., 1994; Schultz et al., 1994; Calado et al., 2002; Moreau et al., 
1992; Romanos et al., 1992; Swinkels et al., 1993; Schultz et al., 1994; Cereghino and 
Cregg, 1999; Rosenfeld, 1999).  Biological activity is of such importance that the 
authenticity of the mature protein product in general, represents a more important 
consideration than the highest level of expression (Eckart and Bussineau, 1996). 
 
2.4.1. Maximum expression ≠ maximum secretion 
Although, for the production of an intracellular protein, maximum synthesis generally 
results in maximum accumulation, secretion of a heterologous protein often does not 
increase proportionally with increased expression (i.e. higher levels of foreign mRNA).  
The rate-limiting step in protein secretion is generally not synthesis (transcription and 
translation), but posttranslational processing, which represents a kinetic bottleneck 
(Wittrup et al., 1994; Romanos et al., 1992; Robinson et al., 1994).  Large amounts of 
heterologous protein synthesis may saturate the secretory pathway, thus resulting in a 
reduced overall production level (Harmsen et al., 1993; Wittrup et al., 1994; Parekh et 
al., 1995; Robinson and Wittrup, 1995). 
 
2.4.2. Summary of the secretory pathway 
To improve the secretion of a foreign protein, understanding and manipulating the 
secretory pathway is essential (Shuster, 1991; Tuite and Freedman, 1994).  Secretion 
and posttranslational modification of newly synthesised protein proceeds via several 
distinct steps (Kjeldsen, 2000; Ellgaard et al., 1999; Tuite and Freedman, 1994), as is 
presented in Fig. 2.1. 
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Figure 2.1. Eukaryotic secretory pathway
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Translocation from the cytoplasm (where proteins are synthesised) across the 
membrane of the endoplasmic reticulum (ER) proceeds during or after translation 
(depending on the type of protein being produced), where the attachment of N-linked 
carbohydrate chains, folding and maturation of proteins are performed.  The formation 
of secretory vesicles subsequently allows for transport from the ER to the Golgi 
apparatus, where further posttranslational modifications are completed.  Export from 
the Golgi to the cell (plasma) membrane and into the periplasmic space, from where the 
proteins are finally exported to the extracellular medium, is also facilitated by secretory 
vesicles.  Proteins destined for secretion typically feature a signal peptide (secretion 
signal) at the N-terminus, which facilitates the targeting of the protein from the 
cytoplasm to the ER.  Translocation into the ER requires the specific action of the ER’s 
resident chaperone BiP/Kar2p (“heavy chain binding protein”).  The posttranslational 
modifications performed in the ER include removal of the N-terminus signal peptide by 
the signal peptidases (such as Kex2p), the formation of disulfide bonds by protein 
disulfide isomerase (PDI), the attachment of core glycosylation, and folding.  Protein 
folding and tertiary structure formation are also completed to an advanced stage in the 
ER, as the presence of several quality control mechanisms ensures that only folded 
proteins are transported to the Golgi.  The primary quality control mechanism involves 
the association of newly folded proteins with chaperones and folding enzymes in the 
ER (e.g. BiP and PDI) which not only assist the folding and assembly process, but also 
retain immature proteins.  Degradation of misfolded proteins is an essential function of 
the quality control system of the ER, and the sorting of misfolded soluble proteins to the 
vacuole for this purpose, contributes to a stringent quality control system in S. 
cerevisiae.  The machineries in the ER and Golgi appear to recognize distinct structural 
features on misfolded heterologous proteins, and thereby guide them to different 
degradation pathways (Holkeri and Makarow, 1998).  The various foldases and 
chaperones thus have protein-specific activities and exert their effect on selected 
proteins or protein families.  Vesicular transport from the ER to the Golgi is also highly 
regulated.  In the Golgi the core carbohydrate chains of glycoproteins are further 
modified by outer-chain glycosylation.  Transport to the plasma membrane is generally 
considered to be the default route while retention in the secretory pathway or sorting to 
cellular compartments requires additional sorting signals. 
 
25
The secretory pathway of S. cerevisiae exhibits much of the structure and function of 
the mammalian secretory system.  However, the yeast has a smaller amount of ER 
structures, Golgi apparatus and secretory vesicles than plant and mammalian cells, and 
secretion is thus characterised by rapid transit times and low levels of precursors 
(Demolder et al., 1994; Parekh and Wittrup, 1997).  The observed difficulties in the 
folding and processing of (heterologous) proteins from other eukaryotic sources are 
therefore indicative of the measure of differentiation between different cell types 
(Ellgaard et al., 1999; Rokkones et al., 1994).  The lower intrinsic secretory capacity of 
yeasts compared to mammalian cells is generally compensated for by the ease of high 
cell density cultivation (Parekh and Wittrup, 1997). 
 
Despite these apparent limitations, some examples of complex posttranslational 
modifications performed S. cerevisiae have been reported.  In one case the three 
polypeptides of human fibrogen was successfully combined into a complete molecule, 
which was secreted at higher levels than by mammalian cells (Roy et al., 1995).  S. 
cerevisiae was also able to assemble multimeric human procollagen from the individual 
polypeptides, synthesised by a four-gene expression system, into a proper secondary 
structure (Toman et al., 2000).  A similar molecule was also produced by recombinant 
P. pastoris using single copy integrants (Vuorela et al., 1999; Myllyharju et al., 2000) 
with production levels by both yeast expression systems significantly higher than levels 
obtained with mammalian cell culturing.  Co-expressed α-globin and β-globin chains 
were also processed correctly and assembled into fully functional, tetrameric 
hemoglobin A by S. cerevisiae (Coghlan et al., 1992).  
  
2.4.3. Optimal expression 
Maximal use of the limited secretory capacity of S. cerevisiae for heterologous proteins 
may also require the application of optimal, rather than maximal, expression of the 
heterologous gene.  In some cases, large overexpression has resulted in the saturation of 
the secretory pathway and the accumulation of unfolded heterologous protein in the ER 
(Wittrup et al., 1994; Tuite and Freedman, 1994; Parekh et al., 1995; Parekh and 
Wittrup, 1997).  Overexpression has also resulted in a sharp decrease in the level of 
heterologous protein secretion, despite constant mRNA levels.  In one case, the optimal 
tuning of the expression level has resulted in an order of magnitude increase in 
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secretion, compared to levels obtained with maximal expression (Parekh and Wittrup, 
1997).  The sub-optimal use of the S. cerevisiae secretory capacity may also be 
responsible for the lower levels of heterologous protein production compared to other 
yeasts, such as P. pastoris (Kjeldsen et al., 1999; Cereghino and Cregg, 1999).  There 
have also been reports that high-level expression in P. pastoris may overwhelm the 
posttranslational machinery of the cell, causing a significant proportion of the foreign 
protein to be misfolded, unprocessed or mislocalised (Cereghino and Cregg, 2000).  
 
2.4.4. Limiting components in the secretory pathway 
The limited capacity of S. cerevisiae for the secretion of some heterologous proteins is 
evident from the above-mentioned reports.  However, the production of foreign proteins 
may be increased by a rational approach to increasing the folding-capacity of 
components of the secretory pathway via overexpression (Tuite and Freedman, 1994). 
 
The exit of proteins from the ER into the Golgi is generally believed to be the major 
rate-limiting step in protein secretion, as this is the point where the stringent quality 
control is exerted.  Quality control determines whether misfolded proteins or aggregates 
are retained in the ER and destroyed by the proteasome (Buckholtz, 1993; Harmsen et 
al., 1993; Robinson et al., 1994; Tuite and Freedman, 1994; Robinson and Wittrup, 
1995; Cha and Yoo, 1996).  The capacity of S. cerevisiae to process unnaturally large 
fluxes of heterologous proteins may therefore be limited by its ability to produce 
adequate quantities of lumenal (ER) chaperones and foldases to ensure proper folding 
and processing of the foreign protein (Robinson et al., 1994).  Two ER–resident, 
candidate proteins for overexpression are the heavy chain binding protein (BiP/Kar2p) 
and protein disulfide isomerase (PDI).  These proteins either associates transiently with 
normal proteins and form a more stable interaction with mutant or misfolded proteins 
(Buckholtz, 1993; Robinson and Wittrup, 1995), and catalyses disulfide bond formation 
within the oxidizing environment of the ER, along with chaperone functionality, 
respectively.  Levels of BiP and PDI were shown to decrease, probably due to titration, 
during constitutive high-level expression of heterologous proteins (Robinson and 
Wittrup, 1995).  Simultaneous overexpression of these proteins, which acted 
synergistically, together with optimisation of the level of foreign gene expression, has 
been undertaken.  This resulted in the first example of recombinant single-chain 
antibody fragments (scFv) secretion by S. cerevisiae, in a process that was previously 
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thought impossible.  Cumulative modifications to the expression temperature, vector 
system, and BiP and PDI levels, resulted in a 50-fold increase in scFv specific 
productivity (Shusta et al., 1998).  Increasing the BiP concentration in the ER increased 
heterologous protein secretion up to a certain point, beyond which increasing BiP levels 
provided no significant benefit (Robinson et al., 1996; Harmsen et al., 1996).  Negative 
effects associated with BiP overexpression have also been observed (Van der Heide et 
al., 2002).  Several examples of increased secretion of heterologous proteins due to PDI 
overexpression have been reported (Robinson et al., 1994; Schultz et al., 1994), which 
may be particularly relevant for the production of disulfide-bonded heterologous 
proteins (Robinson et al., 1994; Wittrup, 1995).  Overexpression of the ER-resident 
Ssa1p has also resulted in a 5-fold increase in extracellular production of human 
interferon β by S. cerevisiae (Demolder et al., 1994).  Polyubiquitin, though normally 
active in the targeting of abnormal or short-lived proteins for degradation, also 
functioned as a chaperone during overproduction, which increased the secretion level of 
a human leucocyte protease inhibitor by S. cerevisiae, despite constant mRNA levels 
(Chen et al., 1994).  Disruption of the Ca2+-ATPase PMR1 in S. cerevisiae has caused 
an increase in the secretion of several heterologous proteins, possibly due to the 
involvement of Ca2+ in the transport of secretory proteins from the ER, though secretion 
was unaffected in other cases, despite alterations in the glycosylation pattern of the 
protein (Smith et al., 1985; Harmsen et al., 1993).  Variable responses in the production 
of heterologous proteins due to disruption of PMR1 in the yeast Yarrowia lipolytica, 
depending on the nature of the protein, was also reported (Sohn et al., 1998).   
 
The secretory capacity of S. cerevisiae for overproduced proteins may also be increased 
by overexpression of secretory components active in the later stages of protein 
secretion.  Overexpression of the yeast syntaxins, Sso1p and Sso2p, which function at 
the targeting/fusion of Golgi-derived secretory vesicles to the plasma membrane, 
resulted in a proportional increase in secreted heterologous α-amylase levels and both 
the native- and over-expression production levels of extracellular invertase.  
Transcriptional levels of the heterologous proteins were unaffected (Ruohonen et al., 
1997).   
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Alternative means of increasing the secretory capacity of yeast have also been sought, 
such as the induction of membrane proliferation in S. cerevisiae by overexpression of 
the canine p180 ribosome binding protein, which resulted in a marked increase in 
secretory capacity through up-regulation of the entire secretory pathway (Becker et al., 
1999).  Posttranslational modification of a heterologous protein can also be 
temperature-dependent as is evident from higher secretion rates found at lower 
cultivation temperature (Ljubijankic et al., 1999; Cassland and Jönsson, 1999).  
Induction of heat shock protein and chaperone synthesis by heat shock treatment may 
also improve heterologous protein secretion (Rocha et al., 1996).  Finally, the secretion 
efficiency of heterologous proteins may also be increased by the addition of 
components such as glycerol (10%), which acts as a chemical chaperone to facilitate 
secretion (Figler et al., 2000) and Tween 80, which apparently interacts with the plasma 
membrane of S. cerevisiae, to the cultivation medium (Bae et al., 1998).  Cumulatively 
the range of case studies has indicated several possibilities for the rational manipulation 
of the secretory pathway of yeast to obtain higher levels of foreign protein production. 
 
2.4.5. Changing signal peptide and Kex2p activity 
Secretion of a protein leads to the in vivo complete removal of the N-terminal amino 
acid residue (signal peptide or secretion signal) of the synthesized foreign protein by 
signal peptidase activity in the ER.  This prevents the expressed proteins from being 
degraded by host cellular proteases (Lee et al., 1999).  Both the alternative yeasts and S. 
cerevisiae can clip off the signal peptide correctly, resulting in a fully processed protein 
(Buckholtz and Gleeson, 1991).  The presence of a signal sequence is therefore essential 
for the extracellular production of a heterologous protein by yeast (Takahashi et al., 
1998) and selection of the correct secretion signal can affect product yields (Sleep et al., 
1990; Buckholtz, 1993).  Several signal sequences of the yeast secretory proteins have 
been employed to ensure the secretion of foreign proteins, with the S. cerevisiae MFα 
secretion signal used most frequently.  This signal sequence has been shown to direct 
secretion of heterologous proteins in all yeast systems tested so far (Shuster et al., 1989; 
Harmsen et al., 1993; Gellissen and Hollenberg, 1997).  Other examples are the S. 
cerevisiae invertase signal sequence (Pohlig et al., 1996), the secretion signal of the K. 
lactis killer toxin (Fusetti et al., 1996), and the secretion signal derived from the 
Kluyveromyces marxianus inulinase (Kang et al., 1996; Chung et al., 1996).  In many 
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cases the native secretion signal of secretory proteins will also function correctly in 
most yeast expression systems (Gellissen and Hollenberg, 1997).  Several methods for 
improving the secretion of a recombinant protein via molecular engineering of the 
secretion signals have been demonstrated (Kjeldsen, 2000). 
 
The processing of the secretion signal by the ER-resident signal peptidases (such as 
Kex2p) may also limit the secretion of a heterologous protein (Buckholtz, 1993; Zhang 
et al., 2001).  Insertion of a spacer peptide between the start of the heterologous ORF 
and the peptidase signal cleavage site has resulted in a significant increase in the 
production levels of the secreted heterologous proteins by S. cerevisiae, due to the 
improved efficiency of the signal peptidase (Degryse et al., 1992; Parekh et al., 1995; 
Kjeldsen et al., 1996).  Insertion of the N-terminal fragment of human interleukin-1β, 
which is secreted efficiently by S. cerevisiae, between the existing leader peptide and 
the KEX2 cleavage site of heterologous protein, enhanced secretion 3- to 4-fold (Bae et 
al., 1998; Lee et al., 1999).  Changing the level of Kex2p in the strain may also alter the 
KEX2-processing pattern of secreted proteins (Takahashi et al., 1999).  
 
2.4.6. Properties of the secreted protein 
Despite the successful secretion of some heterologous proteins, poor secretion of a 
variety of other heterologous secretory proteins from S. cerevisiae may be attributed to 
the recognition and retention of these proteins in the endoplasmic reticulum (ER) via 
strong binding of ER molecular chaperones (Kowalski et al., 1998a; Ellgaard et al., 
1999).  The biophysical properties of the heterologous protein may thus partly 
determine its sorting in the degradation/secretory pathway (Zhang et al., 2001).  
However, the intrinsic biophysical property of the protein that determines the sorting 
thereof is not obvious (Kowalski et al., 1998b).  In one case, the fermentation yield of 
insulin analogue precursors expressed in yeast correlated with the folding stability of 
the corresponding insulin analogues (Kjeldsen, 2000).  In another example, the 
secretion of bovine pancreatic trypsin inhibitor was directly correlated with the in vitro 
unfolding temperature and the thermodynamic stability of the folded protein, though no 
relationship was observed between secretion efficiency and in vitro folding or unfolding 
rates of heterologous protein (Kowalski et al., 1998a).  Increasing the hydrophobicity of 
a heterologous cutinase, through fusion with various peptide tails, also significantly 
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reduced the secretion of the recombinant products (Calado et al., 2002).  Fusion of 
human apolipoprotein E (hApoE) to either Rhizomucor rennin or human serum 
albumin, both of which are secreted efficiently by S. cerevisiae, also contributed to the 
efficient secretion and protection from proteolysis of the fusion protein heterologous 
hApoE (Nomura et al., 1995a; Nomura et al., 1995b).  In P. pastoris secretion of the 
heterologous protein is usually reserved for proteins that are normally secreted by their 
native hosts (Cereghino and Cregg, 2000).  The intrinsic properties of the heterologous 
protein may thus be a major cause for low levels of secretory expression. 
 
2.4.7. Hyperglycosylation 
In some cases, the hyperglycosylation of heterologous proteins during secretion by 
yeasts, S. cerevisiae in particular, may significantly alter the biological activity of the 
produced protein.  Hyperglycosylation can reduce the antigenic activity of 
pharmaceutical proteins or the catalytic activity of recombinant enzymes and thereby 
negate any advantage that S. cerevisiae may have over E. coli and mammalian 
expression systems for the production of such proteins (De Baetselier and Van 
Broekhoven, 1998; Crabbe et al., 1996; Hodgson, 1993).  The ability of particular 
antibodies to bind to the heterologous protein may thus be lost due to 
hyperglycosylation, which requires the use of site-directed mutagenesis to remove the 
sites of hyperglycosylation, without affecting the activity of structure of the 
heterologous protein (Malissard et al., 1996).  Several mutations for the manipulation 
of glycosylation patterns have been identified, including disruption of the MNN1 and/or 
MNN9 genes, which represents an alternative approach to avoiding the problems 
associated with hyperglycosylation.  These mutations may, however, affect the growth 
characteristics of the recombinant strains in large-scale cultures (Buckholtz, 1993; 
Schultz et al., 1994).  Finally, although the correct glycosylation pattern may be 
essential for the biological activity of some proteins, several of the enzymes produced 
by S. cerevisiae have retained their native kinetic properties, despite hyperglycosylation 
(e.g. Valmaseda et al., 1992). 
 
2.4.8. S. cerevisiae lacks capacity for posttranslational folding of all proteins 
Posttranslational processing of malaria surface molecules during production in S. 
cerevisiae resulted in a series of stable conformers, each containing a different pattern 
of disulfide bond formation.  These observations indicate that S. cerevisiae might not 
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have the necessary machinery to correctly fold some proteins that require complex 
posttranslational processing (Stowers et al., 2001).  The availability of a sufficient 
secretory capacity, and optimal use thereof through molecular adaptation, is therefore a 
major factor that determines the extracellular production levels heterologous proteins. 
 
2.5. PRODUCT INSTABILITY AND PROTEOLYTIC DEGRADATION 
 
The proteolytic activity of the yeast expression host may significantly degrade a 
heterologous protein product, thereby reducing the quality and quantity of product 
obtained (Mendoza-Vega et al., 1994a).  Since S. cerevisiae has more than 20 
proteinases (mostly intracellular; Ogrydziak, 1993; Harashima, 1998), methods to 
develop protease-deficient strains and to inhibit or inactivate the proteolytic activity of 
the production organism have been investigated. 
 
2.5.1. Intracellular proteases 
The effect of intracellular proteases on production levels may be either due to the 
intracellular degradation of heterologous proteins during posttranslational processing – 
i.e. the proteolytic fragmentation of complete degradation of products; some products 
are rapidly degraded during or shortly after synthesis – or due to the release of 
intracellular proteases by cell lysis during high-cell density or long-term fermentation 
(Harashima, 1998; Cereghino and Cregg, 2000).  It is generally accepted that 
intracellular proteases are not directly involved in the hydrolysis of (extracellular) 
protein products, already secreted from the host, except through release by cell lysis 
(Rose, 1987).  Multiple factors affect the susceptibility of foreign proteins to proteolytic 
degradation, including the linear amino acid sequence and conformational structure 
(Gimenez et al., 2000).  Peptides shorter than 100 amino acids are typically subjected to 
significant intracellular proteolysis when expressed in S. cerevisiae, unless the peptide 
is constrained by a large number of disulfide bonds (Egel-Mitani et al., 2000). 
 
Wingfield and Dickinson (1992) first reported a 90% reduction in the activity of the 
major vacuolar proteinases, protease A and B, carboxypeptidase Y, amino peptidases 
and some RNAse species, in S. cerevisiae by disruption of the PEP4 gene.  The 
corresponding decrease in the expression of intracellular proteases resulted in higher 
production levels of a recombinant protein, without deleterious effects on cell growth.  
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However, the highest production levels were not obtained with the lowest vacuolar 
peptidase activity, but by tailoring the host strain peptidase activity to the heterologous 
protein (Wingfield and Dickinson, 1993).  More recently, the production of 
heterologous α-amylase increased 20-30 fold due to PEP4-disruption, though some 
deleterious growth effects were observed (Chen et al., 2000).  Figler et al. (2000) also 
observed an increase in the yield of a heterologous membrane protein due to PEP4-
disruption, whereas the production of two heterologous tonoplast intrinsic proteins in S. 
cerevisiae could only be detected in PEP4-disrupted strains (Inoue et al., 1997).  
Degradation of the heterologous fusion proteins were also reduced by using a host strain 
deficient in vacuolar protease activity (Nomura et al., 1995a).  However, these 
examples of increased production by PEP4-deficient strains of S. cerevisiae should be 
considered as exceptions, since PEP4-disruption do not normally appear to offer an 
advantage in their product yield of recombinant protein (Romanos et al., 1992; Copley 
et al., 1998).  Protease-deficient strains also exhibit a lower proliferative ability than 
wild-type strains, both for S. cerevisiae (sometimes dramatically lower) and P. pastoris 
(Chen et al., 1999; Romanos et al., 1992; Copley et al., 1998; Cereghino and Cregg, 
2000).  Production of heterologous proteins in P. pastoris more frequently benefits from 
protease deficiency than is the case for S. cerevisiae.  However, due to the 
corresponding negative growth effects, these strains should be used only when other 
measures to reduce proteolysis have yielded unsatisfactory results (Sreekrishna et al., 
1997; Rosenfeld, 1999).  The proliferative ability of PEP4-disruption S. cerevisiae cells 
may apparently be restored by using asparagine as a nitrogen source, rather than 
ammonium sulphate (Chen et al., 2000). 
 
Zhang et al. (1997a) reported that the yapsin 1 (YPS1 or YAP3) and yapsin 2 (MKC7 or 
YPS2) proteases act in the late Golgi secretory pathway of S. cerevisiae.  These 
proteases cleave proteins at basic (Arg and Lys) residues, which can result in the 
incorrect proteolytic cleavage of heterologous proteins, especially peptides.  
Intracellular proteolytic fragmentation of the heterologous peptides such as recombinant 
human albumin (rHA) fused to human albumin growth hormone (especially at high cell 
density), human parathyroid, insect diuretic hormone, leptin and neuropeptide was 
significantly reduced by disruption of YPS1 (YAP3) and/or MKC7 (YPS2) (Kerry-
Williams et al., 1998; Kang, 1998; Song and Chung, 1999; Copley et al., 1998; Egel-
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Mitani et al., 2000).  It is thus advisable to use YPS1-deficient mutants, or multiple 
mutants, to produce high amounts of recombinant proteins containing basic residues.  
Some peptides may also be cleaved by the Kex2p protease at Lys and Arg, necessitating 
the disruption thereof, or by the presence of uncharacterised endopeptidases (Kerry-
Williams et al., 1998; Rourke et al., 1997). 
 
2.5.2. Extracellular proteases 
The extracellular proteolytic degradation of several heterologous proteins produced by 
S. cerevisiae has frequently been observed, despite earlier claims that this yeast 
produces no or very few extracellular proteases (Ogrykziak, 1993).  The release of 
intracellular proteases through cell lysis may therefore represent an alternative source of 
extracellular proteases.  Extracellular protease activity is affected by nutritional 
conditions, and may increase due to glucose exhaustion or carbon starvation (Gimenez 
et al., 2000; Mendoza-Vega et al., 1994a).  The use of protease-deficient host strains 
and medium supplements may thus be required to significantly reduce extracellular 
proteolytic degradation (Vad et al., 1998). The addition of complex medium 
components, such as casein hydrolysate (casamino acids), peptides, amino acids, skim 
milk or bovine serum albumin (BSA), to the culture medium of recombinant S. 
cerevisiae and P. pastoris strains has shown to decrease the degradation of the 
heterologous proteins (Coppella and Djurjati, 1989; Nomura et al., 1995a; Kozlov et al., 
1995; Aho et al., 1996; Sreekrishna et al., 1997; Werten et al., 1999; Shiba et al., 1998; 
Choi et al., 2000; Boze et al., 2001; Juge et al., 2001; Goodrick et al., 2001).  These 
medium components apparently reduce the protease activity towards a heterologous 
protein of interest by providing large amounts of protein substrate.  The production of 
extracellular proteases may also be reduced in a medium that is rich in nitrogen sources.  
Addition of the amino acids arginine and lysine to cultures of S. cerevisiae in defined 
medium has also decreased proteolysis of the extracellular recombinant protein, 
probably due to inhibition of the proteolytic enzymes targeted to basic amino acid sites 
in the protein (Choi et al., 2000; Kang et al., 2000; Chung and Park, 1998).  Specific 
protease inhibitors, such as PMSF (phenyl methyl sulfonyl fluoride) may also be added 
to cultures, though only during the production phase since cell growth can be inhibited 
by their presence (Kim and Kang, 1996).  Kobayashi et al. (2000a) also observed that 
levels of ammonium lower than 0.3 mg.l-1 in the fermentation broth during P. pastoris 
cultivation significantly increased the activity of proteolytic enzymes, indicating an 
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association with nitrogen starvation.  Buffering the cultivation medium to a pH where 
protein degradation is minimised can also reduce the breakdown of heterologous 
proteins (Rosenfeld, 1999; Shiba et al., 1998; Nomura et al., 1995a; Kobayashi et al., 
2000a; Cox et al., 2000; Juge et al., 2001).  The higher levels recombinant protein 
production by P. pastoris were also observed at lower cultivation temperature, which 
was associated with better product stability, smaller release of proteases from dead cells 
and improved folding of the product (Hong et al., 2002).  Siegel and Brierly (1990) 
devised a cell recycle reactor whereby the recombinant product could be removed 
quickly from the fermentation broth, thus avoiding proteolytic degradation.  An 
extracellular heterologous protein may also lose activity due to polymerisation with 
other proteins, which can be avoided by adding 0.2% (w/v) Tween 80 to the medium 
and changing the pH thereof (Bae et al., 1999). 
 
2.6. NATURE OF HETEROLOGOUS PROTEIN 
 
Despite numerous references to the influence of the nature/structure of the heterologous 
protein on production levels attainable with the various yeast expression systems, no 
systematic study on the intrinsic characteristics of the protein that determine these levels 
has been undertaken.  Levels of accumulation of heterologous proteins in S. cerevisiae 
vary widely depending on the foreign gene expressed, and in some cases protein 
engineering techniques may also be required to achieve efficient expression in a host 
organism (Mendoza-Vega et al., 1994a; Fusetti et al., 1996).  Use of the P. pastoris 
expression system will not always result in high-level production of all proteins either, 
due to the influence of unspecific properties such as the amino acid sequence, codon 
bias, tertiary structure and the required posttranslational modifications and the site of 
expression (Sreekrishna et al., 1997; Loewen et al., 1999). 
 
2.7. HOST STRAINS 
 
The production levels of heterologous proteins are highly dependent on the genetic 
background of the host strain, as specific characteristics of the host may influence the 
level of heterologous transcript, translational and secretory efficiency, protein quantity 
and quality, plasmid stability, and plasmid copy number (Park et al., 2000; Eckart and 
Bussineau, 1996).  The magnitude of these differences between strains can render cross-
35
species comparisons very difficult (Fleer, 1992).  During screening for a suitable strain 
of S. cerevisiae for production of a heterologous glucose oxidase, a 100-fold difference 
in production levels was observed, with the maximum production eventually 
representing one of the highest levels of heterologous protein secretion by this yeast (De 
Baetselier et al., 1991).  Schultz et al. (1994) observed a 10-fold difference in 
production levels of a foreign protein during a similar screening of host strains with 
different genetic backgrounds.  Despite these large differences, the effect of host cell 
metabolism on the synthesis of heterologous proteins has not been systematically 
investigated, and the improvement of the genetic characteristics of the host strain has 
seldom been reported (Mendoza-Vega et al., 1994a; Chen et al., 1999).  To facilitate 
systematic investigations, the microbial physiology of the host strain, especially in 
terms of nutritional requirements, auxotrophic markers and protease activities, should 
be characterized prior to transformation (Mendoza-Vega et al., 1994a).   
 
2.7.1. Auxotrophic requirements in transformed strains 
An aspect of host strain physiology that has gone largely unnoticed is the potential 
influence of auxotrophic markers in transformant strains on the production levels of 
heterologous proteins.  Most laboratory strains of S. cerevisiae that have been used for 
recombinant protein production, originated from a series of genetic crosses of the 
S288C strain with other strains, as part of the early studies on the molecular biology and 
genetics of this yeast (Guthrie and Fink, 1991).  These laboratory strains were adopted 
for use in recombinant protein production, often without further modification, and are 
currently still used as host strains in numerous studies.  During the early genetic studies, 
however, the presence of auxotrophic mutations in these strains were not considered as 
a major limitation during cultivation, an idea that has been transferred to numerous 
molecular biologists of today.  Host strains with excessive auxotrophic mutations are 
therefore still used for recombinant protein production, resulting in transformant strains 
containing uncomplimented auxotrophic markers.  The effect of these auxotrophic 
markers in transformant strains has frequently been disregarded in modern molecular 
biology, as is evident from the plethora of physiological investigations conducted with 
such strains (Table 2.1). 
 
36
Table 2.1 Examples of the effect of auxotrophic markers in S. cerevisiae transformants 
disregarded during cultivation and recombinant protein production 
Shiba et al., 1998 
Choi et al., 2000 
Rao et al., 2000 
Song and Chung, 1999 
Takahashi et al., 1999 
Roy et al., 1995 
Janes et al., 1990 
Giuseppin et al., 1993 
Beretta et al., 1991 
De Baetselier et al., 1991 
Mendoza-Vega et al., 1996 
Mendoza-Vega et al., 1994b 
Monfort et al., 1999 
Nieto et al., 1999 – industrial strain 
O’Kennedy et al., 1995 
Rossini et al., 1993 
Pignatelli et al., 1998 
Zurbriggen et al., 1989 
Lang and Looman, 1995 
Lang et al., 1997 – pilot scale 
VanDusen et al., 1997 
Parekh and Wittrup, 1997 
Parekh et al., 1995 
Parekh et al., 1996 
Takahashi et al., 1999 
Fieschko et al., 1987 
Wittrup et al., 1994 
Morosoli et al., 1992 
Moreau et al., 1992 
Ganga et al., 1998 
Lee et al., 1999 
Pohlig et al., 1996 
Porro et al., 1992 
Okada et al., 1998 
Kanai et al., 1997 
Stone et al., 1995 
Shuster et al., 1989 
Castelli et al., 1994 
Wingfield and Dickinson, 1993 
Nomura et al., 1995a 
Inoue et al., 1997 
Neeper et al., 1990 
Law et al., 1998 
Papakonstantinou et al., 2000 
Zigova et al., 1999 
Zigova, 2000 
Joseph-Liauzun et al., 1995 
Ljubijankic et al., 1999 
Pyun et al., 1999 
Cook et al., 1998 
Robinson and Wittrup, 1995 
Robinson et al., 1994 
Robinson et al., 1996 
Wittrup and Benig, 1994 
 
However, the use of recombinant strains with auxotrophic markers can result in 
problems with growth, protein production and genetic stability at high cell densities and 
during scale-up (Mendoza-Vega et al., 1994a). The auxotrophic markers in the host 
strains that remain uncomplimented in transformant strains firstly require a sufficient 
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availability of the corresponding metabolite in the complex or defined cultivation 
medium.  Since yeasts have long been known to accumulate amino acids tenaciously 
(Eddy, 1982), the metabolite for which an auxotrophic requirement exists may be 
consumed beyond the amount that is stoichiometrically required for biomass formation, 
and result in a nutrient-deficiency towards the end of a fermentation.  An 
overconsumption of adenine, for which an auxotrophic requirement in the transformed 
strain existed, was demonstrated by VanDusen et al. (1997) whom observed a maximal 
consumption level of more than three times the amount required for maximal biomass 
formation.  Without considering the effect of metabolite overconsumption, however, 
most defined media used for shake-flask, or even large-scale, cultures still do not 
contain enough of the required metabolite to support minimum levels of biomass 
formation (Pronk et al., 1996).  Auxotrophy can thus result in a significant limitation of 
cell growth if a sufficient amount of the corresponding growth factor (amino acid) is not 
present in the medium (Chopra et al., 1999).  In such a case, the biomass yield of an 
auxotrophic recombinant strain will be strongly reduced, as has been demonstrated for 
histidine auxotrophy (Beretta et al., 1991).  The stress imposed by limiting 
concentrations of auxotrophic requirements during the cultivation of auxotrophic 
strains, will also result in an increase in the mutation and reversion rates of the 
corresponding markers (Korogodin et al., 1991; Çakar et al., 1999; Heidenreich and 
Wintersberger, 1997).  Auxotrophic strains may also have physiological alterations and 
sensitivities that are not generally recognized, and it is not clear exactly how much of 
the required substrate should be added to avoid these (Çakar et al., 1999). 
 
Besides growth defects, heterologous protein production may also be negatively 
influenced by auxotrophic mutations in the yeast host.  In one such example, Zigova et 
al. (1999) and Zigova (2000) observed a very low cell yield (0.25 gdry cell mass.gglucose 
consumed
-1) during the aerobic cultivation of an auxotrophic S. cerevisiae transformant on 
pilot plant scale, indicating that the availability of auxotrophic amino acids could very 
well have been limiting.  Further supplementation of the fermentation broth with amino 
acids also resulted in an increase in the specific production level of heterologous 
protein, indicating possible nitrogen limitation for protein synthesis.  The metabolic 
changes that occur when cloned genes are expressed in auxotrophic strains, may well 
arise from peculiarities of the auxotrophic host rather than from activity of the cloned 
proteins (Kozlov et al., 1995; Çakar et al., 1999).  VanDusen et al. (1997) observed that 
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maximum consumption of adenine also resulted in low levels of heterologous protein 
production, indicating that the concentrations of adenine required for biomass formation 
and maximum heterologous protein production were different.  Auxotrophic strains 
grown in nutrient supplemented medium are thus NOT necessarily physiologically 
equivalent to the complemented transformants (Pronk et al., 1996; Chopra et al., 1999).  
Excessive auxotrophic markers should preferentially be removed prior to transformation 
of the parental strain, as demonstrated by Motwani et al. (1996), since the advantages of 
using prototrophic transformants for physiological studies on laboratory, pilot plant and 
production scale should be evident from these results.   
 
Despite the disadvantages to the use of auxotrophic strains, two of the highest 
production levels of heterologous protein reported in S. cerevisiae were obtained by 
cultivating an auxotrophic transformant in complex medium (De Baetselier et al., 1991; 
Lee et al., 1999).  Chung et al. (1997) also did not observe any difference in production 
levels due to removal of excessive auxotrophic markers.  The effect of auxotrophic 
mutations in transformants on the production of heterologous proteins is thus not well 
understood. 
  
2.7.2. Comparison of auxotrophic S. cerevisiae transformants 
Several comparisons of production levels obtained with auxotrophic S. cerevisiae and 
“fully functional,” prototrophic versions of other yeasts have been reported, although 
the effect of auxotrophic mutations in the former on heterologous protein production 
was not clear.  Higher production levels of recombinant anticoagulant peptide (AcAP-5) 
were observed for P. pastoris, compared to those reported for a S. cerevisiae 
transformant retaining an adenine-requirement (Neeper et al., 1990; Inan et al., 1999).  
A similar observation was made during the comparative production of human glutamic 
acid decarboxylase (GAD) by these two yeasts: superior production levels for P. 
pastoris compared to an auxotrophic S. cerevisiae (Papakonstantinou et al., 2000).  
Giuseppin et al. (1993) compared guar-α-galactosidase production in defined medium 
by an auxotrophic S. cerevisiae transformant to production by a prototrophic H. 
polymorpha transformant, which produced more of the heterologous protein.  Both 
strains carried multiple integrations of the heterologous gene. 
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2.7.3. Selection of improved hosts 
Screening and selection of transformants or mutants that show increased production and 
secretion levels of heterologous proteins, is an alternative to the use of rational 
approaches, aimed at specific steps in synthesis and secretion, for improving 
heterologous protein production.  Smith et al. (1985) and Sakai et al. (1988) first 
described such mutant strains, demonstrating the potential of random selection 
procedures for increasing heterologous protein production.  Such random selection is 
especially useful in recombinant protein production since the discovery and rational 
improvement of important host cell properties for heterologous protein production 
remains difficult (Kozlov et al., 1995).  Despite more than 20 years of experience with 
heterologous protein production in yeast, the extensive knowledge of S. cerevisiae 
molecular genetics is yet to be fully exploited towards to development of more efficient 
production systems (Fleer, 1992; Harashima, 1998).  Secretion of a heterologous 
protein can be improved by a combination of both a rational approach and isolation of 
mutant strains that show elevated levels of production (Tuite and Freedman, 1994).  
  
Classical methods of strain improvement, such as random mutagenesis, are thus 
frequently used in industry due to the significant benefits (Fleer, 1992).  Park et al. 
(2000) recently used UV mutagenesis to increase the yield of recombinant protein 
production by S. cerevisiae, without negatively affecting the growth of the recombinant 
strain.  Conversely, previous investigations have reported a decrease in the growth rate 
of over-producing transformants obtained from a screening of random mutants (Aho et 
al., 1996).  Sleep et al. (1991) also used several rounds of chemical mutagenesis to 
obtain stable mutants able to produce elevated levels of intracellular heterologous 
proteins.  Adaptation of host strains under constant selection pressure is also an 
effective tool for host strain improvement, with one set of mutants showing a two-fold 
increase in glucoamylase production after 7 days of cultivation on solid maltose 
medium (Zhang et al., 1997b).  Similarly, stable mutants of PEP4-disrupted 
transformants, resistant to the negative effects of heterologous HBsAG protein 
production and having growth characteristics similar to the parental strains, were 
selected after long-term cultivation (25 days).  These strains also produced higher levels 
of recombinant α-amylase than the non-mutated transformants, though the mechanism 
for improved growth and recombinant protein production was not clear (Chen et al., 
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1999).  Long-term continuous cultivation of parental E. coli strains also resulted in 
improved physiological characteristics and stress resistance (Weikert et al., 1997).  
These strains showed 2- to 3-fold higher production levels when used for the production 
of heterologous proteins, indicating the importance of physiological robustness for 
recombinant protein production (Weikert et al., 1998).  Similarly, Gill et al. (2001) 
demonstrated that the “conditioning” of recombinant E. coli cells, by stimulating the 
cellular stress response prior to induction of heterologous protein synthesis, resulted in 
higher production levels of recombinant protein.  Though increased production levels of 
a specific heterologous protein may be obtained, isolated mutants do not always show 
enhanced production of other proteins, and limited analysis of overproducing mutants 
has not implicated mutations in genes encoding components of the secretory pathway 
(Harashima, 1998; Tuite and Freedman, 1994).  Much therefore remains to be learned 
about the major rate-limiting steps of the secretory pathways of eukaryotic hosts. 
 
2.8. METABOLIC BURDEN 
 
The situation where cells are challenged to produce abnormal quantities of a foreign 
protein is physiologically not well understood (Vasavada, 1995).  Transformants 
expressing heterologous proteins often exhibit growth retardation, reduction of survival 
rate and instability of the product yield (Romanos et al., 1992).  The observed 
“metabolic burden” or “load” has adverse effects on the productivity of large-scale 
bioprocesses, since the accumulation of biomass for heterologous protein production is 
retarded, and overcoming these factors to obtain high cell densities is not trivial 
(Vasavada, 1995).  The burden associated with the overproduction of a heterologous 
protein also causes the spontaneous creation of mutant populations with increased 
growth rates and reduced production rates, which are frequently detected after many 
generation times (Zelder and Hauer, 2000).  Strong selection pressure in favour of cells 
producing less recombinant protein may also result in structural instability in 
transformants (Fleer, 1992; Lopes et al., 1996). 
 
The origin of the “metabolic burden” associated with heterologous protein production is 
not clear.  In comparing two isogenic strains producing either a homologous (Pgk1p) 
and heterologous (prochymosin) protein from identical expression plasmids, Gopal et 
al. (1989) observed a reduced biomass yield for both transformants compared to the 
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host strain, though the production levels of heterologous protein was 10-fold lower than 
homologous proteins.  Heterologous protein production apparently imposed a greater 
drain on cellular energetic resources than homologous protein production.  In a similar 
case, overproduction of Pgk1p from a multicopy integrative expression system to 47% 
of the total soluble cellular protein, resulted in a 40% decrease in the growth rate of the 
host strain (Van der Aar et al., 1990).  Further examples of the deleterious effects of 
heterologous protein production on the host cell metabolism are: 
• Decreased growth rates for recombinant yeast strains producing various 
heterologous proteins, compared to the parental strain (Shuster et al., 1989; Da 
Silva and Bailey, 1991; Dequin and Barre, 1994; Giuseppin et al., 1993; Janes et 
al., 1990; Okada et al., 1998; Meinander, 1997; Snoep et al., 1995).   
• Decreased growth rates and biomass yields for mutants selected on the basis of a 
10-fold increase in heterologous protein production (Aho et al., 1996). 
• Decreased growth rates for clones selected on the basis of improved 
heterologous protein production (Skory et al., 1996). 
• Decreased the critical dilution rate of recombinant S. cerevisiae strains 
overproducing invertase from a multicopy plasmid-based expression system 
(Pyun et al., 1999) 
• Increased size and more complex internal structure of recombinant cells (Chau 
et al., 2001; Peterson and Patkar, 1992).   
 
However, for both plasmid-based and integrative expression systems, mutant strains 
partially able to overcome the deleterious effects of heterologous protein production and 
producing high levels of various heterologous proteins could be selected (Shuster et al., 
1989), indicating the ability of yeast strains to adapt to heterologous protein production. 
 
No clear conclusions on a possible correlation between the observation of deleterious 
metabolic effects of heterologous protein production on S. cerevisiae strains, and the 
presence of auxotrophic requirements in these strains can be made from available 
literature.  Although in some cases a “metabolic burden” was observed for strains 
containing auxotrophic requirements (Van der Aar et al., 1990; Skory et al., 1996; 
Shuster et al., 1989; Pyun et al., 1999; Janes et al., 1990; Giuseppin et al., 1993; Da 
Silva and Bailey, 1991; Aho et al., 1996; Vad et al., 1998), in other cases no deleterious 
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effects were associated with heterologous protein production, despite the presence of 
these markers (Okada et al., 1998; Papakonstantinou et al., 2000).   Examples of the 
presence of a “metabolic burden” in prototrophic production strains have also been 
reported, even during growth in complex medium where parental and transformed 
strains are usually more similar (Van Hoek et al., 1998; Dequin and Barre, 1994; Gopal 
et al., 1989; Lyness and Meaden, 1997).  The frequent presence of auxotrophic 
requirements in S. cerevisiae transformant strains exhibiting the deleterious effects of 
heterologous protein production is probably an artefact of the frequent use of 
auxotrophic strains for the production of heterologous proteins (see Section 2.7). 
 
2.9. CULTIVATION CONDITIONS AND NUTRIENT AVAILABILITY 
 
Microbial physiology and fermentation optimisation are important steps in developing a 
yeast-based system for heterologous protein production, since optimal cultivation 
conditions for the production of a foreign protein can be highly specific to the 
expression system used (Stouthamer and Van Verseveld, 1987; Bae et al., 1998).  It is 
also essential to consider that conditions for maximal biomass formation do not 
necessarily facilitate maximal production of the heterologous protein production, which 
is the aim of any optimisation procedure.  A first major consideration is the composition 
of the cultivation medium, which can affect both cell growth and product yield, 
depending on the strain and heterologous protein.  Medium composition should thus be 
balanced according to growth and production requirements, and should be matched to 
large-scale requirements (Vasavada, 1995; Rosenfeld, 1999; Mendoza-Vega et al., 
1994a).  Preference is usually given to the use of defined medium, which often allows 
for rapid scale-up and the production of a purer product (Choi et al., 1996; Greasham 
and Herber, 1997; Rosenfeld, 1999).  Besides medium composition, other cultivation 
parameters, such as temperature, pH, aeration and feeding profile may also affect 
production of heterologous proteins (Rosenfeld, 1999).  The examples presented here of 
improved heterologous protein production in response to altered cultivation conditions, 
were limited to cases where the changes in cultivation conditions had no direct effect on 
protease activity (discussed in Section 2.5), thus indicating a stimulation of microbial 
metabolism towards heterologous protein production.  However, despite the 
demonstrated advantages such optimisations, a review of literature would indicate that 
molecular genetics and the molecular adaptation of expression systems are more 
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powerful for increasing the production levels of heterologous proteins.  Whereas several 
examples of orders of magnitude increases in production levels through the latter 
approaches have been demonstrated, improvements smaller than 10-fold are typically 
obtained via the optimisation of cultivation conditions. 
 
2.9.1. Medium components 
To allow for high cell density fermentations and maximal heterologous protein 
production, the required medium components should be available for the duration of the 
bioprocess, and the use of a balanced medium is thus essential (Mendoza-Vega et al., 
1994a; Mendoza-Vega et al., 1994b; Vasavada, 1995).  The defined medium used most 
often for the cultivation of S. cerevisiae strains, comprises Yeast Nitrogen Base (YNB) 
(without amino acids; Difco) and glucose, and is frequently supplemented with casein 
hydrolysate (casamino acids) to improve the production of heterologous proteins.  
However, YNB medium without casamino acids (and possibly inisitol) are not able to 
support oxidative growth on ethanol, thus allowing only fermentative growth in batch 
culture (Chen et al., 1993; Gu et al., 1991; Vasavada, 1995).  YNB medium also 
contains several vitamins (biotin, thiamine, inisitol and pantothenic acid) and mineral 
trace elements that are required for the cultivation of certain strains of S. cerevisiae, and 
are considered as essential “growth factors” in the medium.  Amino acids required for 
the cultivation of microorganisms containing auxotrophic requirements are also 
considered as growth factors and should be added to the medium (Greasham and 
Herber, 1997).   
 
The addition of complex medium components (yeast extract, peptone, casamino acids, 
etc.) to the cultivation medium has frequently improved biomass formation and 
heterologous protein production by S. cerevisiae, both for the production of 
heterologous xylanase (Donald et al., 1994; Pérez-González et al., 1996; Nuyens et al., 
2001) and other heterologous proteins (Chiruvolu et al., 1996; Choi et al., 1996; 
Hensing et al., 1995b; Vasavada, 1995; Wang and Da Silva, 1993; Castelli et al., 1994; 
Kim et al., 2000; Kapat et al., 2001; Toman et al., 2000; Chauhan et al., 1999; Boze et 
al., 2001; Gupta and Mukherjee, 2002).  [Although the amino acid composition of 
casamino acids (i.e. casein hydrolysate) is frequently known, its complex origin and the 
interaction between different components do not allow for classification as a defined 
medium component.]  In some cases, however, strong increases in biomass yields due 
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to addition of these compounds are accompanied by a decrease in the specific 
productivity (amount of heterologous protein produced per gram of biomass), with 
varying effects on the overall productivity (Vasavada, 1995; Vad et al., 1998).  Gupta 
and Mukherjee (2002) also observed an increase in plasmid stability and productivity 
when the availability of yeast extract was reduced to limit the growth of the production 
strain.  The nature of the complex nitrogen sources may thus influence the metabolic 
flux to the production of the recombinant protein and segregational stability (Mendoza-
Vega et al., 1994a).  The optimal concentration of complex medium components should 
always be determined (Chang et al., 1998). 
 
The concentration of the various components in defined media for the cultivation of 
yeast strains may also influence growth and heterologous protein production of the 
yeast, most notably sources of nitrogen, vitamins and trace elements (Boze et al., 2001; 
Mendoza-Vega et al., 1994a; Blondeau et al., 1994; De Kock et al., 2000; Jung et al., 
1991).  Nitrogen sources most strongly preferred by S. cerevisiae include glutamine, 
asparagine and ammonium (Dubois and Messenguy, 1997), though Wittrup and Benig 
(1994) observed increased production of heterologous proteins due to several amino 
acids.  For the production of heterologous proteins for pharmaceutical use, the addition 
of pure amino acids to increase production levels may provide additional benefits, as it 
avoids the regulatory requirements associated with raw materials from animal origin 
(Mendoza-Vega et al., 1994a).  The beneficial effect of supplementing an existing 
defined medium with individual amino acids on the physiology of the cultivated yeast 
strain has been demonstrated (Toman et al., 2000; Albers et al., 1996; Blechl et al., 
1992).  Although frequently used in defined media, ammonium has been shown to 
inhibit production of α-amylase by S. cerevisiae, whereas its utilisation also results in 
the acidification of the medium (Chen et al., 2000; Hensing et al., 1995b).  Alternative 
nitrogen sources such as urea and asparagine have thus been suggested (Hensing et al., 
1995b; Chen et al., 2000).  Other defined components shown to increase heterologous 
protein production by yeast were succinate (Cha et al., 1998) and oleic acid (Kobayashi 
et al., 2000b). 
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2.9.2. pH and cultivation temperature 
Both the pH and temperature during various stages in the cultivation of a recombinant 
yeast strain can have an effect on the production level of heterologous protein, and 
should thus be optimised to improve physiological conditions for heterologous protein 
production (Kozlov et al., 1995; Kim and Kang, 1996).  The results of such empirical 
optimisations are highly specific to the production system being investigated, due to the 
plethora of cellular processes affected by changes in temperature and pH, besides the 
possible reduction in protease activity.  Blondeau et al. (1994), for example, observed 
separate pH optima for recombinant protein secretion (6.5) and biomass production (pH 
6.0) by K. lactis.   Since the posttranslational modification of a heterologous protein can 
be temperature-dependent, higher secretion rates may also be obtained by lowering the 
cultivation temperature (Ljubijankic et al., 1999; Cassland and Jönsson, 1999; Hong et 
al., 2002; Nagashima et al., 1994). 
 
2.9.3. Aeration 
Supply of oxygen to the growing cell population is the rate-limiting step in many 
aerobic processes, being mostly influenced by the speed of agitation and aeration rate 
(Kapat et al., 2001).  In high cell density bioreactors the oxygen supply towards the end 
of the fermentation may also become limiting and subject recombinant yeast to 
considerable stress, which can affect the quality of the produced protein and lead to 
proteolytic degradation, the incorporation of incorrect amino acids or incorrect 
posttranslational modifications (Roecklin et al., 1997; Rao et al., 1999).  As both 
heterologous protein production and glucose consumption by yeast are generally 
dependent on the level of dissolved oxygen during cultivation, optimal levels should be 
determined empirically for each production system (Alberghina et al., 1993; Calado et 
al., 2002; Blondeau et al., 1994; Pyun et al., 1999).  However, the potential benefits of 
improved oxygenation may not be realisable on large scale, since high oxygen 
consumption will lead to significant metabolic heat generation in bioreactors 
(Rosenfeld, 1999).  The generation of large amounts of heat will escalate the 
operational cost of fermentations due to an increased requirement for cooling. 
 
2.9.4. Feeding profile 
Heterologous protein production on industrial scale is frequently undertaken in fed-
batch cultures, though continuous cultures have also found some application.  The flow 
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rate and composition of the feed to a fed-batch fermentation can have a significant 
effect on the productivity of the bioprocess and selection of an optimal feeding profile is 
thus essential for high levels of heterologous protein production.  The relevant aspects 
of the physiology of the production strain, such as yields, medium requirements, growth 
rates and kinetics, should be determined prior to the design of a large-scale, high cell 
density fed-batch fermentation and can be measured in continuous culture (Alberghina 
et al., 1993; Hensing et al., 1995c; Blondeau et al., 1994; Mendoza-Vega et al., 1994b).  
Feeding should be designed to ensure that the required nutrients are available at optimal 
concentrations, whereas the addition of components that may exhibit a toxic effect due 
to accumulation in fed-batch cultures should be avoided.  Possible changes in the 
physiology of the production strain during the fed-batch fermentation should also be 
accounted for.  For cultures of S. cerevisiae the control of both glucose and ethanol 
levels are essential for high level of heterologous protein, since ethanol formation 
inhibits biomass formation and possibly also heterologous protein production (Shiba et 
al., 1994; Vasavada, 1995; Kapat et al., 1997; Noronha et al., 1999).  The short 
perturbation of cultivation by exposure to high levels of glucose early in the 
fermentation will result in a significant reduction in the biomass yield, due to the long-
term nature of Crabtree effect (Vasavada, 1995).  Multiple production levels may also 
be observed at a single growth rate or dilution rate, whereas repeated fed-batch cultures 
may significantly improve productivity (Da Silva and Bailey, 1991; Ibba et al., 1993).  
For the methylotrophic yeasts, P. pastoris and H. polymorpha the feeding profile of 
glycerol and/or methanol during various phases of a fed-batch cultivation should be 
optimised, and may be complimented by the accurate control of the methanol 
concentration (Loewen et al., 1999; Inan et al., 1999; Hong et al., 2002).  Heterologous 
protein production may also be optimised by using model-based feed control to 
determine the required flow rate.  The model used for control should describe both 
biomass formation and heterologous protein production (Zhang et al., 2000).  The use 
of more complex feeding profiles, such as a cyclic feed, may also improve heterologous 
protein production by yeast (Chang et al., 1998). 
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2.10. COMPARISON OF YEASTS 
 
With regards to the choice of yeast species for production of a foreign protein, S. 
cerevisiae and P. pastoris remain the most frequently used hosts (Cereghino and Cregg, 
1999).  However, public literature on heterologous protein production with yeast is 
increasingly being dominated by reports on the successful production of various foreign 
proteins using the P. pastoris expression system, though this may not necessarily reflect 
the situation in industry (Hodgson, 1993).  Besides having a well-established reputation 
for high-level secretion of foreign proteins, the use of this system is facilitated by the 
commercial availability of suitable expression vectors and strains (Invitrogen) 
(Cereghino and Cregg, 2000; Rosenfeld, 1999; Gellissen and Hollenberg, 1997; 
Buckholtz and Gleeson, 1991).  Examples of low production levels or failure to express 
heterologous proteins with the P. pastoris system are also accumulating, though usually 
not reported (Romanos, 1995).  Despite several reports of “lower production levels,” S. 
cerevisiae is still widely used as host, mostly due to its suitability for the production of 
health care and food grade proteins, its usefulness in industrial biofuel processes, the 
extensive knowledge on its molecular genetics and the ability to manipulate them, and 
the previous establishment of production processes using this organism.  Fundamental 
breakthroughs in understanding the genetic and physiological requirements of a host 
strain for the production of high levels of heterologous protein, may only be possible in 
a host such as S. cerevisiae that facilitates investigations on a genomic, transcriptional, 
metabolite, biochemical and physiological basis.  Despite the problems associated with 
the hyperglycosylation of heterologous proteins and ethanol production during aerobic 
growth on glucose, S. cerevisiae was therefore the preferred for the fundamental studies 
presented in Chapters 4 to 7.  Recent information on the comparative aspects of the 
various yeast species for heterologous protein production (including H. polymorpha, Y. 
lipolytica, Schizosaccharomyces pombe and P. stipitis) is presented below. 
 
2.10.1. S. cerevisiae 
S. cerevisiae was the first yeast to be used for heterologous protein production, mostly 
due to knowledge on its molecular genetics and long-time use in industrial processes 
(Swinkels et al., 1993).  Due to its GRAS status S. cerevisiae remains a favourite for the 
production of health care products, therapeutic proteins and food products (Kleman and 
Strohl, 1994; Vasavada, 1995; De Baetselier and Van Broekhoven, 1998; Romanos et 
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al., 1992).    High cell densities (> 50 g.l-1) can also be obtained with S. cerevisiae when 
cultivated on glucose under optimised conditions (Fieschko et al., 1987; Shiba et al., 
1994; Alberghina et al., 1991; Mendoza-Vega et al., 1994a; Mendoza-Vega et al., 
1994b; Kerry-Williams et al., 1998; Yang et al., 1997).  However, limited oxygen 
availability or too high growth rates may induce ethanol accumulation in these 
fermentations, resulting in a loss of glucose-substrate and a possible repression of 
strong glycolytic promoters (such as PGK1) used to drive heterologous gene expression 
(Kappeli, 1986). Although production levels attainable with S. cerevisiae seldom 
exceed 1-5% to the total cellular protein, a few notable examples of heterologous 
proteins produced to levels above 1 g.l-1 have been reported (Buckholtz and Gleeson, 
1991; Mendoza-Vega et al., 1994a): 
 
• Roecklin et al. (1997):  6 g.l-1 of heterologous glutathione S-transferase 
produced intracellularly during high cell density (78 g.l-1) cultivation 
• De Baetselier et al. (1991): 3 g.l-1 of heterologous glucose oxidase produced 
extracellularly after screening of host strains 
• Lee et al. (1999): 1.3 g.l-1 of extracellular human growth hormone by using an 
optimised, plasmid-based expression system. 
• Fusetti et al. (1996): More than 1 g.l-1 of Candida rugosa Lipase I was 
accumulated in the fermentation medium 
• Alberghina et al. (1993): After optimisation intracellular heterologous protein 
production up to 30% of total cellular protein was attained. 
• Sleep et al., 1991: By screening a number of mutants it was possible to identify 
a transformant in which the heterologous protein constituted 40% of the total 
soluble protein 
 
A significant disadvantage to the use of S. cerevisiae for the production of heterologous 
proteins may be the extensive overglycosylation of secreted proteins, which can reduce 
the binding and activity of heterologous hydrolytic enzymes on crystalline surfaces 
(Boer et al., 2000).  For mammalian proteins, however, glycosylation is often not 
essential for biological activity (Olins, 1996).  An example of therapeutic proteins 
produced with S. cerevisiae, besides those mentioned in the Chapter 1, is recombinant 
human granulocyte colony-stimulating factor (hG-CSF), which has been established by 
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international standard as preferential to products from other yeasts, based on in vitro 
bioassays and immunoassays (Bae et al., 1999). 
 
Limitations in the expression of heterologous proteins by yeast may sometimes be 
overcome by using well advanced molecular techniques to modify the host or the 
expression systems, as has been presented elsewhere in this review.  The completion of 
the Yeast Genome Project (Goffeau et al., 1996) and information furnished by 
Functional Genomics (Kowalczuk et al., 1999) has led to an increased interest in the use 
of S. cerevisiae as host for the production of various recombinant proteins.  Besides the 
frequent direct functionality of S. cerevisiae molecular genetics in alternative yeasts, the 
extensive physiological and genetic knowledge available on this yeast can provide a 
scientific knowledge base for heterologous protein production.  S. cerevisiae may thus 
be considered as a development platform for genetic engineering in yeast. 
 
2.10.2. P. pastoris and H. polymorpha 
Heterologous gene expression in the methyloptrophic yeasts P. pastoris and H. 
polymorpha is based on the utilisation of the promoter of the methanol oxidase gene for 
methanol regulation of gene expression, although alternative promoters have also been 
developed more recently.  Expression of heterologous genes in these hosts occurs 
exclusively by integration of the expression vector into the host genome, resulting in 
stable transformants.  However, methanol induction for heterologous gene expression 
may be problematic on industrial scale, since methanol is a potential fire hazard, 
necessitates the use of expensive explosion proof fermentation equipment and is not 
suitable for the production of food grade products (Cereghino and Cregg, 2000; 
Cereghino and Cregg, 1999; Swinkels et al., 1993).  The major advantages of P. 
pastoris are: The preference for respiratory growth, the proven ability for high cell 
density fermentations, the ease of scale-up and the proven ability for secretion of 
correctly folded proteins (Cereghino and Cregg, 2000; Rosenfeld, 1999; Olins, 1996).  
An impressive list of proteins has been produced to relatively high levels in P. pastoris 
(Cereghino and Cregg, 2000).  Some examples of high levels of recombinant protein 
production by the methylotrophic yeasts are: 
 
• Werten et al. (1999): 14.8 g.l-1 of heterologous gelatin produced extracellularly 
by P. pastoris after inactivation of proteolytic activity. 
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• Clare et al. (1991): 12 g.l-1 tetanus toxin produced by P. pastoris transformants 
containing multiple integrations of the expression cassette 
• Barr et al. (1992): 4 g.l-1 human serum albumin secreted by P. pastoris   
• Mayer et al. (1999): Phytase production levels of 13.5 g.l-1 obtained by 
cultivation of recombinant H. polymorpha  
 
2.10.3. K. lactis 
K. lactis is suited to the production of food grade products due to its GRAS status, and 
is considered to be a major alternative to S. cerevisiae in this regard (Bonekamp and 
Oosterom, 1994; Swinkels et al., 1993).  Accumulation of heterologous protein 
production to levels corresponding to “several gram per litre” (Fleer et al., 1991) and 
30% of the total cellular protein (Faber et al., 1996) have been reported. 
 
2.10.4. Y. lipolytica 
Early development of Y. lipolytica expression systems was based on the use of the 
native XPR2-promoter.  However, production systems suffer from the complexity of 
regulation of this promoter as full induction can only be obtained by the addition 
proteose peptone to the medium (Chang et al., 1997).  Kim et al. (2000) demonstrated 
the ease with which this yeast can be cultivated to cell densities over 100 g.l-1 by using a 
one-step feeding process. 
 
2.10.5 S. pombe 
Next to S. cerevisiae, S. pombe represents the yeast with the best-characterised 
molecular genetics.  However, the potential of this yeast to produce eukaryotic mature 
proteins in a form closer to their natural conformation, due to several characteristics that 
are more similar to mammalian cells than other yeasts, has not been fully utilised due to 
slow progress in the development of an effective foreign-gene expression system (Giga-
Hama and Kumagai, 1999).   
 
2.10.6. P. stipitis 
P. stipitis has seldom been used as a host for the production of heterologous proteins.  
This xylose-fermenting yeast is Crabtree-negative, with ethanol-production induced 
only in response to oxygen limitation (Du Preez et al., 1989).  Growth of the yeast is not 
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inhibited by glucose concentrations of up to 50 g.l-1 (Du Preez et al., 1986).  Production 
of a heterologous cellulase under control of the native XYL1 promoter, and heterologous 
xylanases under control of the native XYL1, TKL and ADH2 promoters, has been 
reported (Piontek et al., 1998; Den Haan and Van Zyl, 2001; Passoth and Hahn-
Hägerdal, 2000). 
 
2.10.7. Experimental comparisons of expression systems 
Conclusions on the suitability of different yeast hosts for the production of a 
heterologous protein should be based on direct experimental comparison of 
transformants for the production of a specific protein, as is presented here.  For the 
production of recombinant single chain Fv (scFv) antibody fragments, P. pastoris was 
long considered to be the only option, since the secretion of scFv fragments in S. 
cerevisiae was hampered by the formation of large intracellular protein aggregates 
(Pennell and Eldin, 1998; Frenken et al., 1998).  However, optimisation of the 
expression system and overproduction of some of the secretory components has led to 
the successful secretion of reasonable amounts of scFv fragments by S. cerevisiae 
(Shusta et al., 1998).  Recombinant P. pastoris has also secreted functional Fab 
fragments at a level of 40 mg.l-1, which is similar to the production levels obtained for 
other heterodimeric biologically active proteins (Lange et al., 2001).  Conversely, 
production levels of heterologous β-glucosidase levels in S. cerevisiae were superior to 
those obtained with P. pastoris, though only a single copy of the expression cassette 
was present in the latter (Skory et al., 1996).  Improved production levels of 
recombinant anticoagulant peptide (AcAP-5) by P. pastoris compared to production by 
S. cerevisiae may also have been an artefact of the adenine-auxotrophic mutation of the 
latter transformant, which can influence heterologous protein production negatively 
(Neeper et al., 1990; Inan et al., 1999). 
 
With regard to the other “alternative” yeasts, a comparison of production levels of six 
fungal proteins by S. cerevisiae, H. polymorpha, K. lactis, S. pombe and Y. lipolytica 
revealed inferior production levels by S. cerevisiae transformants in all cases (Müller et 
al., 1998).  These sentiments were echoed by the increased production levels of 
heterologous β-lactoglobulin (Rocha et al., 1996) and interleukin 1β (Blondeau et al., 
1994) obtained with K. lactis, compared to S. cerevisiae, and improved production of 
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heterologous receptor protein (Sander et al., 1994) and T. reesei endoglucanase (Okada 
et al., 1998) by S. pombe, also compared to S. cerevisiae.  In several additional cases, 
the use of the yeasts K. lactis and H. polymorpha as expression hosts have resulted in 
increased yields of a better-quality product (Gellissen and Hollenberg, 1997).  
 
2.11. CONCLUSIONS 
 
Though by no means extensive, this review has identified potential limitations in most 
of the steps involved in the production of heterologous proteins by yeasts, specifically 
S. cerevisiae.  Though several examples of improved production through the application 
of rational improvements to these limitations were presented, no single limitation could 
be identified as determining production levels of heterologous proteins.  Variations in 
the strains, expression systems, heterologous proteins and media composition render 
such a conclusion impossible in the light of the biological complexity of 
microorganisms.  However, the application of various rational approaches in an 
empirical manner has frequently resulted in significant improvements in heterologous 
protein production, both in terms of quantity and quality of the heterologous protein 
produced.  The nature of the limitations in heterologous protein production is such that 
the task of addressing them lies more strongly in the hands of the molecular biologist, 
since the significant improvements attainable with improved fermentation technology 
are frequently much smaller than the order-of-magnitude improvements observed due to 
changes based on molecular genetics.  The improvement of strains for the production of 
heterologous proteins should be based on rational approaches to molecular genetics and 
selection of transformants with higher production levels, with quantitative microbial 
physiology applied for the rigorous characterisation of improvements. 
 
Most notable among the presented limitations, was firstly the possible effect of 
proteolytic degradation of synthesised products shortly after translation, during 
posttranslational processing or after secretion, which may represent a generic limitation 
in the production of heterologous proteins.  Furthermore, the much emphasised “limited 
secretory capacity” of yeasts, though more specifically S. cerevisiae, also requires the 
optimisation of gene expression and improvement of the secretory machinery via 
rational approaches to obtain improved production levels.  However, vague references 
to the effect of “host strain characteristics” and the “intrinsic protein characteristics” 
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remain to be quantified.  The use of S. cerevisiae as a host strain for heterologous 
protein production also remains advantageous due to the applicability of transformants 
to established processes, such as brewing, baking and wine making, and the production 
of bioethanol.  Basic studies on the molecular genetics of heterologous protein 
production is possible for S. cerevisiae, since it has the most comprehensive yeast 
genetic tool kit available, thus facilitating fundamental breakthroughs (Shusta et al., 
1998). 
 
Three aspects of microbial physiology that may influence heterologous protein 
production levels and are yet to be fully explored are the effect of heterologous gene 
expression on the physiology of the host strain, the uncharacterised effect of 
auxotrophic markers on heterologous protein production and the effect of medium 
composition on the cellular carbon- and nitrogen-metabolism.  Changes in the host 
metabolism and physiology due to the production of a heterologous protein specifically 
may represent an untapped well of information on the limitations in microbial 
metabolism during foreign protein production and secretion, and was further 
investigated in Chapters 4 and 5.  The possible effect of auxotrophic requirements may 
also represent a host strain characteristic that is important for heterologous protein 
production, and was studied in comparison to prototrophic production strains (Chapter 
6), whereas a systematic determination of the effect of medium composition on 
heterologous protein production may reveal limitations in resource availability for 
heterologous protein production (Chapter 7).  The applicability of these results to the 
use of an alternative yeast host (P. stipitis) for heterologous protein production was also 
studied (Chapter 8).  Clarification of these and other fundamental aspects of microbial 
physiology are required prior to scale-up to ensure an optimal production process. 
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Chapter 3 
 
PURIFICATION OF HETEROLOGOUS XYLANASE PRODUCED BY 
S. CEREVISIAE AND ASPERGILLUS NIGER 
 
3.1. INTRODUCTION 
 
A proper investigation of the microbial physiology during heterologous protein 
production required the ability to quantify the mass amount of heterologous xylanase 
produced by S. cerevisiae.  As production levels of recombinant xylanase were 
determined as activity measurements (typically nkat.ml-1) obtained with the DNS-
method (Bailey et al., 1992), it was necessary to determine the specific activity of the 
pure recombinant xylanase (nkat.mg-1), and thereby calculate the amount of 
recombinant protein (e.g. mg.l-1) produced.  The purification of the recombinant 
xylanase was therefore necessary.  Pure recombinant xylanase could also be used for 
raising polyclonal rabbit antibodies, which are useful for detecting small amounts of 
recombinant protein in protein mixtures, using Western blots.   
 
The purification of the β-1,4-xylanase II of T. reesei from a fungal fermentation broth 
was reported previously (Törrönen et al., 1992; Tenkanen et al., 1992).  This 
purification method was selected as a starting point for the purification of recombinant 
xylanase in the present study, by assuming that the recombinant xylanase and the native 
protein would have similar isoelectric characteristics (Henrik Stålbrand; Evodia Setati, 
personal communication).  The basic steps in the purification protocol by Törrönen et 
al. (1992) were empirically optimised for the purification of heterologous xylanase from 
each of the two microbial sources. 
 
3.2.  PRODUCTION OF RECOMBINANT β-XYLANASE 
 
The recombinant T. reesei β-xylanase produced by both S. cerevisiae (La Grange et al., 
1996) and A. niger (Rose and Van Zyl, 2002) was purified, to account for possible 
changes in the specific activity due to the hyperglycosylation of the recombinant 
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xylanase by the former.  Recombinant S. cerevisiae was cultivated in a chemically 
defined medium (Verduyn et al., 1992), supplemented with seven amino acids (Chapter 
4) whereas the recombinant A. niger was cultivated in a semi-defined medium (Rose 
and Van Zyl, 2002).  Cultures were performed in shake-flasks at 30ºC in semi-batch 
mode, with a single addition of fresh medium subsequent to the consumption of the 
glucose in the medium used for inoculation.  The purity of the recombinant xylanase 
samples was determined by silver-staining (Biorad Silverstain Kit) of SDS-PAGE gels 
(Laemmeli, 1970). 
 
3.3. SAMPLE PREPARATION 
 
Approximately 3L of fermentation broth obtained from each of the microbial cultures 
was separated from cells by centrifugation at 4ºC, and the proteins therein precipitated 
by the slow addition of crystalline (NH4)2SO4 to the cooled sample.  To obtain a 
saturated solution,  (NH4)2SO4 was added to a final concentration of approximately 0.57 
g.ml-1.  The samples were incubated overnight at 8ºC to obtain complete precipitation.   
 
The precipitated protein from the two samples were collected separately by 
centrifugation, and re-dissolved in the cation exchange buffer.  Proteins smaller than 14 
kDa were removed by dialysis, using a membrane with a 12-14 kDa cut-off point.  
Precipitation with (NH4)2SO4 resulted in an approximately 30-fold concentration of the 
proteins in the original fermentation broth sample.  The volumetric xylanase activity in 
the A. niger concentrated sample was higher than in the S. cerevisiae sample (Table 
3.1), indicating a significantly higher production level of recombinant xylanase during 
cultivation.  However, the xylanase in the A. niger sample was also less pure than in the 
S. cerevisiae sample, indicating a significantly higher level of native proteins secreted 
by the former. 
 
For S. cerevisiae two dominants forms of the recombinant protein were visible in the 
concentrated sample, i.e. 21 kDa, which is close to the native protein, and a more 
heavily glycosylated form of ≈26 kDa (Fig. 3.1).  For the sample obtained from A. 
niger, only a single glycosylation form was visible, i.e. 21 kDa, and the extracellular 
xylanase protein was thus not hyperglycosylated (Lane 1; Fig. 3.5). 
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Figure 3.1. Concentrated sample from S. cerevisiae fermentation broth (Lanes 1 and 2). 
 
3.4. CATION EXCHANGE  
 
Cation exchange was selected as the first purification step due to the relatively high 
isoelectric point of the native β-xylanase (pI = 9.0; Tenkanen et al., 1992; Törrönen et 
al., 1992).  Sephadex Fast Flow cation exchange gel (Amersham-Pharmacia Biotech, 
Uppsala, Sweden) was therefore used to "capture" the majority of the recombinant 
xylanase from the mixture of native proteins in the concentrated sample.  The most 
effective pH for cation exchange was determined in a small-scale experiment with the 
S. cerevisiae protein sample (Fig. 3.2).  1.0 ml of cation exchange gel was equilibrated 
to different pH values using either a 5 or 50 mM buffer, and loaded with 0.5 ml of 
sample in the same buffer.  The bound xylanase was eluted with a B buffer at the same 
pH and ionic strength, though also containing 1M NaCl.  To cover the range of pH 
values investigated, two different buffers [Tris (pH 7.2-8.0) and phosphate-citrate (pH 
4.0-7.0)] were used. 
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Figure 3.2. Small-scale cation exchange with a S. cerevisiae protein sample. A. 
Percentage of xylanase in the loaded sample bound to the gel. B. Xylanase activity 
eluted from gel during washing with B buffer. (♦) Percentage of xylanase bound when 
using a 5 mM buffer. (?) Percentage of xylanase bound when using 50 mM buffer. (?) 
Xylanase activity eluted from gel after loading using a 50 mM buffer. (g) Xylanase 
activity eluted from gel after loading using a 50 mM buffer. 
 
Although the percentage of the xylanase bound to the cation exchange gel increased 
with a decrease in pH, the most dramatic improvement in the binding was obtained by 
reducing the ionic strength of the buffer from 50 mM to 5 mM (Fig 3.2A).  The 
xylanase bound to the gel could be recovered by eluting the gel with the corresponding 
B buffers (Fig. 3.2B).  The increased concentration of cations in the 50 mM buffers 
apparently out-competed the weak binding of the positively charged xylanase protein to 
the gel.  A large difference in the binding efficiency and eluted activity at pH 7.2 (Tris) 
and pH 7.0 (phosphate-citrate) was observed.  This may have been due to the presence 
of cations in the phosphate-citrate buffer that competed with xylanase for binding to the 
cation exchange gel.  A 5 mM Tris buffer at pH 7.2 was therefore the most efficient for 
cation exchange using the S. cerevisiae protein sample.  A similar small-scale cation 
exchange experiment was performed using the A. niger protein sample, with 
equilibration of the gel over the pH range 7.2-8.0 (Tris) and 4.0-7.0 (phosphate-citrate) 
using only 5 mM buffers (Fig. 3.3).  The 5 mM Tris buffer at pH 7.2, however, poorly 
facilitated cation exchange with the A. niger sample, compared to its performance with 
the S. cerevisiae sample.  The poor binding was also confirmed when loading the A. 
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niger sample to a cation-exchange column equilibrated with the 5 mM Tris buffer at pH 
7.2. The 5 mM phosphate-citrate buffer at pH 7.0 was thus selected for cation exchange 
when using the A. niger sample. 
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Fig. 3.3. Small-scale cation exchange with an A. niger protein sample. The percentage 
of xylanase in the loaded sample bound to the gel at different pH values when using a 5 
mM buffer. (?) Percentage of xylanase from A. niger protein sample bound to gel when 
using 5 mM buffer. (?) Percentage of xylanase from S. cerevisiae sample bound to gel 
when using a 5 mM buffer.  
 
Subsequent cation exchange was performed on a 16 mm diameter column, containing 
140 mm of packed gel (Packing volume: 28 ml gel; Gel capacity: 1.407 g per 28 ml; 
Maximum load: 280 mg protein bound to the gel).  Elution was performed with a B-
buffer containing 2M NaCl, which was applied to the column without a gradient.  For 
the S. cerevisiae sample, the specific xylanase activity was higher in the fractions from 
cation exchange than in the original sample (Table 3.1), indicating that the xylanase 
protein was concentrated during cation exchange.  The recombinant xylanase from S. 
cerevisiae was also visibly cleaner after cation exchange (Figs. 3.1 and 3.4).  Cation 
exchange with the A. niger sample was less efficient.  Despite the optimisation of the 
cation exchange buffer, the proper binding of the recombinant xylanase to the cation 
exchange column could not be obtained.  The cation exchange column instead only 
retarded the movement of the recombinant xylanase through the column, relative to the 
other proteins, and thereby facilitated a partial separation of the xylanase from these 
proteins.  The concentration of xylanase in the resulting eluent was lower than in the 
original sample.  However, a reasonable amount of the xylanase in the original sample 
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was removed during the cation exchange procedure (compare lanes 1 and 2; Fig. 3.5).  
The large increase in the specific activity of the recombinant xylanase sample vouched 
for a significant increase in the purity of the xylanase protein during cation exchange 
(Table 3.1).  The additional difficulties observed during cation exchange using an A. 
niger concentrated sample might be attributed to either the large amount of other 
proteins present in the sample, that could hamper the binding of the recombinant 
xylanase to the column, or a decrease in the binding capacity of the gel due to ageing. 
Mr     1     2     3     4 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Eluent from cation exchange performed with a S. cerevisiae protein sample. 
Lane 1 to 4: Purest fractions collected from cation exchange. Mr: Molecular weight 
marker. 
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Fig 3.5. Eluent from cation exchange performed with A. niger protein sample. Lane 1: 
Concentrated sample. Lane 2: Concentrated sample after cation exchange. Lane 3: 
Eluent from cation exchange (concentrated). Mr: Molecular weight marker. 
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3.5. GELFILTRATION 
 
Gelfiltration was applied as a final purification and "polishing” step, to obtain a pure 
protein.  Gelfiltration was performed on a pre-packed Sephadex 200 HR 16/60 column 
(Amersham-Pharmacia Biotech, Uppsala, Sweden) equilibrated with a 50 mM 
phosphate buffer at pH 6.0.  The cation exchange fractions were concentrated using a 
ultrafiltration membrane device (Amicon Centricon) and applied as a 1 ml sample to the 
gelfiltration column.  For the S. cerevisiae sample a single gelfitration run was 
sufficient to obtain a protein with apparent electrophoretic purity (Fig. 3.6), whereas for 
the A. niger sample two subsequent runs were performed to ensure the purity of the 
final product (Fig. 3.7).  In the final S. cerevisiae sample three distinct glycosylation 
patterns could be identified: 21 kDa, ≈26 kDa and ≈28 kDa, with the latter two 
representing hyperglycosylated versions of the recombinant xylanase.  For the A. niger 
sample only a single 21 kDa form of the protein was observed, corresponding to the 
size of the native xylanase (Törrönen et al., 1992; Tenkanen et al., 1992). 
 
The specific activity of the final S. cerevisiae sample was slightly lower than the sample 
obtained after cation exchange, despite a visible improvement in the electrophoretic 
purity of the protein (compare Figs. 3.4 and 3.6).  This decrease could be attributed 
either to a destabilisation of the xylanase protein due to the removal of other proteins in 
the solution, or xylanase activity present in some of the impurities removed during 
gelfiltration.  However, the specific activities obtained for the pure S. cerevisiae and A. 
niger samples were very similar, indicating that the purification procedures resulted in 
proteins of similar purity, and that these values were reliable for the conversion of 
activity measurements to amount of recombinant protein.  In Table 3.1 the progress in 
the various steps in the purification procedure for recombinant xylanase from S. 
cerevisiae and A. niger respectively, are compared. 
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Mr      1      2      3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Final product from gelfiltration performed with S. cerevisiae sample. Lanes 
1 to 3: Purest fractions.  Mr: Molecular weight marker  
 
 
Table 3.1 Activity measurements from steps in the purification of recombinant xylanase 
Product from => S. cerevisiae A. niger 
 Volumetric* 
nkat.ml-1 
Specific* 
nkat.μgprotein-1 
Volumetric* 
nkat.ml-1 
Specific* 
nkat. μgprotein-1 
Sample Preparation 5450 31.6 30900 14 
Cation Exchange 47200 36.4 1750 30.8 
Gelfiltration 3000 30.2 1460 33.3 
* Activity Measurements 
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Figure 3.7. Final product from gelfiltration performed with A. niger sample. Lanes 1-4 
and 11 to 14: Purest fractions.  Lanes 5 to 10: Less pure fractions. 
 
Both the S. cerevisiae and A. niger pure xylanase protein samples were used for raising 
polyclonal rabbit antibodies.  The antibody obtained from the S. cerevisiae sample 
mostly bound to the ≈26 kDa form of the recombinant protein [visualised with Western 
blot (Fig. 3.8)], indicating that binding might be strongest on the outer mannose 
glycosylation chains.  The A. niger-antibody was also of sufficient quality for use in 
Western blotting (data not shown). 
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Figure 3.8. Western blot with detection of xylanase in a protein mixture using an 
antibody raised against a pure xylanase protein produced by S. cerevisiae. 
 
3.6. CONCLUSIONS 
 
The recombinant xylanases produced by S. cerevisiae and A. niger were purified in two 
steps, resulting in electrophetretically pure proteins.  The specific activities of these 
proteins were very similar, indicating that the expression host had little effect on the 
functionality of the proteins.  These specific activities were subsequently used to 
determine the mass amount of heterologous protein produced by S. cerevisiae during 
physiological studies. 
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Chapter 4 
 
PHYSIOLOGICAL RESPONSE OF S. CEREVISIAE TO 
HETEROLOGOUS XYLANASE PRODUCTION 
 
Published as:  Görgens, J.F., Van Zyl, W.H., Knoetze, J.H., Hahn-Hägerdal, B. (2001) 
The metabolic burden of the PGK1 and ADH2 promoter systems for heterologous 
xylanase production by Saccharomyces cerevisiae in defined medium. Biotechnology 
and Bioengineering 73(3): 238-245. 
 
Please Note:  Although the fermentation work presented in this chapter was completed 
as part of a previous master’s degree, the discussion and interpretation of the data, as 
presented here, was performed as part of the Ph.D. degree. 
 
4.1. INTRODUCTION 
 
An overall theme in the present dissertation is the identification of some of the cellular 
mechanisms that may regulate or limit the production of a heterologous xylanase by S. 
cerevisiae.  The occurrence of an additional “metabolic load” associated with 
heterologous gene expression was therefore investigated by quantifying the physiology 
of isogenic, transformed strains during cultivation under well-controlled conditions.  
The presence of such deleterious physiological effects due to heterologous protein 
production may present a wellspring of information on cellular processes that are 
negatively influenced by heterologous protein production.  The negative effects 
associated with recombinant protein production may also decrease the overall 
productivity of transformed strains.  These investigations also attempted to identify 
regulatory mechanisms that determine the physiological response of the yeast host to 
heterologous protein production.  The identification of such regulatory mechanisms is 
critical for understanding and improving the production of heterologous proteins by 
yeast. 
 
Due to the importance of recombinant gene expression in yeasts and other 
microorganisms for metabolic engineering (Bailey, 1991) and the commercial 
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production of heterologous proteins (Hensing et al., 1995), expression systems for a 
number of yeasts have been developed (Hensing et al., 1995), especially in S. 
cerevisiae, which has served as a host for the production of numerous foreign proteins 
(Hadfield et al., 1993; Heinisch and Hollenberg, 1993).  The presence of a non-specific 
“metabolic burden” (Bentley et al., 1990; Janes et al., 1990) or “protein burden” (Snoep 
et al., 1995) has been observed in numerous host organisms due to the expression of 
foreign genes, affecting the growth thereof negatively.  For recombinant S. cerevisiae 
strains, reductions in the maximum specific growth rate, biomass yield, respiratory 
capacity and stability of the recombinant plasmid, due to heterologous gene expression, 
have been observed (Srienc et al., 1986; Marquet et al., 1987; Sardonini and DiBiasio, 
1987; Gopal et al., 1989; Zurbriggen et al., 1989; Janes et al., 1990; Da Silva and 
Bailey, 1991, Giuseppin et al., 1993; Dequin and Barre, 1994; Nacken et al., 1996).  A 
decrease in the flux through glycolysis of the host strain (Snoep et al., 1995; Van Hoek 
et al., 1998) and an increase in the maintenance energy requirement (Stouthamer and 
Van Verseveld, 1987; Bhattacharya and Dubey, 1995) have also been observed. The 
metabolic burden of recombinant protein production increased with increasing 
production levels, either due to plasmid copy number amplification or an increase in the 
strength of the recombinant promoter (Seo and Bailey, 1985; Srienc et al., 1986; 
Betenbaugh et al., 1989; Bentley et al., 1990; Janes et al., 1990; Ryan and Parulekar, 
1991; Snoep et al., 1995; Gu et al., 1996; Nacken et al., 1996).  This non-specific effect 
can be separated from the catalytic activity of the protein being produced (Snoep et al., 
1995), and is often disregarded in studies concerning heterologous gene expression in S. 
cerevisiae (Romanos et al., 1992).  
 
The metabolic burden of recombinant gene expression has been associated with the 
allocation of cellular resources to plasmid-related activities (Peretti and Bailey, 1987; 
Gopal et al., 1989; Ryan and Parulekar, 1991; Gu et al., 1996), either for plasmid 
replication or the production of the cloned gene product (Bentley et al., 1990; Da Silva 
and Bailey, 1991; Ryan and Parulekar, 1991; Bailey, 1993).  The effect of cloned gene 
expression has been associated with either the energetic cost of extra protein synthesis 
(Gopal et al., 1989; Bailey, 1993; Snoep et al., 1995) or the competitive effect of extra 
protein synthesis (Shuster, 1989; Gopal et al., 1989; Van der Aar et al., 1992; Snoep et 
al., 1995).  The “dilution” of native proteins, i.e. the reduction of the activity of native 
proteins by recombinant gene expression, was also proposed as a major mechanism 
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causing a decrease in the flux through glycolysis and a decrease in the maximum 
specific growth rate of the host organism (Snoep et al., 1995; Van Hoek et al., 1998).  
Other proposed mechanisms are: the effect of foreign DNA synthesis during plasmid 
replication (Ibba et al., 1993; Lang and Looman, 1995; Lopes et al., 1996 and Carlsen et 
al., 1997), the “toxicity” of recombinant proteins to the cell (Ibba et al., 1993) and the 
negative consequences of small amounts of read-through transcripts (Janes et al., 1990). 
 
In the present investigation, the metabolic burden introduced by the individual genetic 
components in a model expression system for heterologous xylanase production in S. 
cerevisiae was quantified, in an effort to identify some of the mechanisms that may 
limit heterologous protein production.  The T. reesei ß-1,4-xylanase II encoding gene, 
XYN2, was expressed from a multicopy, 2μm plasmid under regulation of either the 
yeast glycolytic phosphoglyceratekinase (PGK1) or alcoholdehydrogenase II (ADH2) 
promoters (La Grange et al., 1996).  The two xylanase-producing strains were 
compared quantitatively with three references strains, where either the heterologous 
XYN2 gene, or the heterologous gene and the promoter and terminator were omitted 
from the recombinant plasmid.  The five recombinant yeast strains were cultivated 
under identical conditions in aerobic batch culture.  In batch culture, the PGK1 
promoter is maximally induced by the presence of glucose (Shuster, 1989; Kingsman et 
al., 1990; Romanos et al., 1992), whereas the ADH2 promoter is repressed during 
growth on glucose and derepressed during the transition to growth on ethanol (Shuster, 
1989; Price et al., 1990; Noronha et al., 1998).  As the produced xylanase had no known 
catalytic function in yeast metabolism and was secreted efficiently by the recombinant 
strains, the quantified metabolic burden was strictly related to the presence and activity 
of the recombinant expression system (Van der Aar et al., 1990a; Van der Aar et al., 
1990b; Van Hoek et al., 1998).  Stable maintenance of the recombinant plasmids in 
non-selective cultivation media has been ensured through the inclusion of the fur1 ura3 
autoselective system (Loison et al., 1986) in the recombinant strains (La Grange et al., 
1996). 
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4.2. MATERIALS AND METHODS 
4.2.1. Strains and plasmids 
The S. cerevisiae strains selected for this study are presented in Table 4.1.  For the 
construction of autoselective strains the method of Loison et al. (1986) has been used.  
The strain stocks were stored in a 15% glycerol solution at –80ºC.   
 
Table 4.1. Strains used in this study 
Strain Genotype Source 
S. cerevisiae Y294 ura3, leu2, trp1,his3 La Grange et al. (1996) 
 Plasmid Promoter Gene  
Y294 [Host]* YEp352 - - This study 
Y294 [PGK1]* pJC1 PGK1 - Crous et al. (1995) 
Y294 [PGK1-XYN]* pDLG6 PGK1 XYN2 La Grange et al. (1996) 
Y294 [ADH2]* pDLG1 ADH2 - La Grange et al. (1996) 
Y294 [ADH2-XYN]* pDLG5 ADH2 XYN2 La Grange et al. (1996) 
* [  ] Indicates the content of the recombinant plasmid.   
 
4.2.2. Medium and inoculum 
Batch fermentations were conducted in a defined medium (Verduyn et al., 1992) 
containing 20 g.l-1 glucose as the carbon source.  The medium was also supplemented 
with amino acids, both according to the auxotrophic requirements of the yeast strains 
[histidine (165 mg.l-1), leucine (870 mg.l-1) and tryptophan (664 mg.l-1)] and to enhance 
heterologous enzyme production [aspartate (257 mg.l-1), glutamate (64 mg.l-1), glycine 
(33 mg.l-1) and serine (108 mg.l-1)].  The concentrations of amino acids were calculated 
according to biosynthetic requirements (unpublished results). 
 
A two-step procedure was used for inoculum preparation.  A preculture (5 ml) was 
inoculated with a small amount of cells from a –80ºC culture and grown overnight (12 
h) at 30ºC in a Gallenkamp INR-200 orbital incubator (Leicester, UK) at 150 rpm.  The 
preculture was subsequently transferred to 200 ml of medium in a 1L baffled shake 
flask and grown for 12-15 h (depending on the growth rate of the strain), at 30ºC.  Both 
the preculture and the inoculum were prepared in the same medium as used in the 
fermenter.  Cell densities in all cultures were estimated as absorbance (optical density) 
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measurements at 620 nm (A620) with a Hitachi U-1100 spectrophotometer (Hitachi Ltd., 
Tokyo, Japan).  The volume of shake-flask culture, required to inoculate the fermenter 
to an A620 of 0.5, was centrifuged at 5000 rpm for 6 min in a Beckman J2-21 centrifuge 
(Geneva, Switzerland) and the cells re-suspended in 80 ml of medium, to obtain the 
final inoculum. 
 
4.2.3. Fermentations 
Fully aerobic batch fermentations were conducted in a computer-controlled glass 
fermenter (Belach Bioteknik AB, Stockholm, Sweden) with a total volume of 1000 ml 
and a working volume of 800 ml.  The temperature and pH of the cultures were 
controlled at 30ºC and pH 5.0 (by the addition of 2M NaOH or 2M HCl), respectively.  
The fermentation broth was magnetically agitated in the range of 350 to 450 rpm and 
aerated with a 0.5 l.min-1 airflow (standard conditions).  The level of dissolved oxygen 
was monitored with a dissolved oxygen probe (Belach Bioteknik AB, Stockholm, 
Sweden) and maintained at a minimum of 50% of air saturation by adjusting the 
agitation speed when necessary.  The outlet gas from the fermenter was cooled in a 
condenser, through which a water/methanol mixture at 2ºC was circulated.  Dow 
Corning anti-foam (BDH) was added to the fermenter to control foaming, although this 
was not necessary during batch growth on glucose.  All fermentations were repeated at 
least three times. 
 
4.2.4. Analytical methods 
Samples for the determination of cell density, substrate consumption and product 
formation were taken from fermentations at 45 to 60 min intervals.  Samples for 
substrate and product analysis were centrifuged for 3 min at 14 000 rpm in a Force 14 
microfuge (Denver Instruments, Denver, CO) within 1 min after sampling.  The 
supernatant was collected in microfuge tubes, rapidly frozen at -80ºC and stored at –
20ºC for analysis. 
 
Samples for the determination of cell density were kept on ice during analyses and 
diluted with 9 g.l-1 NaCl into the 0.05 - 0.2 linear absorbance detection range of the 
spectrophotometer.  A620 measurements were completed in duplicate within 4 min of 
sampling.  During the late exponential phase of each fermentation the dry weight 
(Meinander et al., 1996) and absorbance (A620) measurements were also calibrated. 
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The fraction of non-viable cells in each sample was determined using fluorescence 
microscopy (Rapoport and Meysel, 1985).  Samples were first diluted for cell counting 
in a haemocytometer, using 9 g.l-1 NaCl for the initial dilutions and an equal volume of 
a 1 mg.ml-1 primulin dye solution (Sigma) for the final 1:2 dilution.  Primulin dye 
caused fluorescence of the non-viable cells.  Plasmid stability (fraction or percentage of 
plasmid containing cells) was determined throughout a typical fermentation for each 
strain.  Approximately 100 yeast colonies were transferred from a complex medium 
(YPD) plate to a SC-ura-Leu selective plate (Rose et al., 1990), using sterile, dried 
toothpicks and the percentage of colonies that grew on the selective medium was 
determined (Da Silva and Bailey, 1991). 
 
4.2.5. Substrate consumption and product formation 
Glucose, ethanol, glycerol, acetate and succinate concentrations were determined by 
column liquid chromatography (CLC) in a Gilson CLC system (Middletown, WI).  The 
compounds were separated on an HPX87-H column (Biorad, Richmond, CA) at 65ºC, 
with 5 mM H2SO4 at 0.6 ml.min-1 as mobile phase, and detected with a Shimadzu 
RID6A refractive index detector (Kyoto, Japan).  Samples were assayed for xylanase 
activity according to Bailey et al. (1992).  The substrate (1% birchwood xylan [Sigma] 
suspended in 50 mM pH 6.0 citrate buffer) and enzyme (diluted with 50 mM pH 6.0 
citrate buffer) mixtures were incubated for 5 min at 60ºC, and the reducing sugar 
determined (Miller et al., 1960). By diluting the enzyme preparations, xylanase activity 
could be measured within the linear range of the assay.  1 unit of enzyme activity (1 U) 
corresponded to 1 μmole of reducing sugar released per minute.  All enzyme activities 
were converted to protein amounts (mg) by use of the conversion factor 1.812 U.μgpure 
xylanase
-1, obtained by protein purification (Chapter 3).   
 
4.2.6. Calculations 
Specific growth rates were calculated at individual points on the growth curve [ln (cell 
density) vs. time] by using the four surrounding points (two on each side) on the curve 
to determine the slope at the specific point.  The maximum of these specific growth 
rates for each fermentation was selected, and an average calculated for each strain.  The 
specific rates of cell death were also calculated for the fraction of non-viable cells in the 
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population.  These rates were defined as the rate of increase in the density of non-viable 
cells in the culture, and were also estimated from slope determinations in the natural 
logarithmic domain.  The yields of biomass and fermentation products on glucose were 
estimated from the slopes of straight-line sections in the product concentration vs. 
glucose concentration curves.  The rates of glucose consumption and ethanol production 
were calculated by fitting a limited population growth model (Hirsch and Smale, 1974) 
to fermentation data (unpublished results).  Specific substrate consumption and product 
formation rates were calculated from the time-based derivatives of the model.  The 
significance of differences between average values, for all of the reported variables, was 
estimated with Student’s independent T-test, using the SigmaPlot® (© SPSS Inc.) 
software package. 
 
4.3. RESULTS 
 
Two recombinant S. cerevisiae strains, Y294 [PGK1-XYN] and Y294 [ADH2-XYN], 
producing heterologous xylanase from a 2μm plasmid expression system, controlled 
either by the PGK1 or the ADH2 promoters, were characterized quantitatively.  The 
strains were compared with three reference strains, where either the heterologous XYN2 
gene (Y294 [PGK1] and Y294 [ADH2]) or the heterologous gene and the promoter and 
terminator (Y294 [Host]) were omitted from the plasmid (Table 4.1).  The recombinant 
S. cerevisiae Y294 [Host] strain was preferred as a reference strain to the parental S. 
cerevisiae Y294 strain, as the latter did not grow in the defined medium.  The 
quantitative differences between the autoselective, recombinant S. cerevisiae strains in 
aerobic batch culture, were verified statistically. 
 
4.3.1. Substrate consumption and product formation 
During batch cultivation the growth, substrate consumption and product formation of 
the recombinant strains were monitored and typical data for the [PGK1-XYN] and 
[ADH2-XYN] strains are presented in Figure 4.1.  Initial growth on glucose continued 
for 12-14 h, with ethanol and glycerol as the major by-products.  Growth continued 
after glucose depletion with ethanol and glycerol as carbon sources.  
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Figure 4.1. Time course for substrate consumption and product-formation by the Y294 
[ADH2-XYN] (closed symbols) and Y294 [PGK1-XYN] (open symbols) strains during 
batch culture in optimised defined medium. (A) (g,?) Xylanase production 
(mg.gbiomass-1). (B) (♦,◊) biomass formation (absorbance, 620 nm). (C) (n,O) glucose 
concentration (g.l-1) and (?,Δ) ethanol concentration (g.l-1). 
 
4.3.2. Heterologous protein production levels 
Levels of heterologous enzyme production were significantly affected by the 
characteristics of the promoter used.  During exponential growth on glucose and 
ethanol, heterologous enzyme production by the [PGK1-XYN] strain was growth 
associated, whereas during the stationary phase production continued without biomass 
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formation (Fig. 4.1).  For the [ADH2-XYN] strain, heterologous enzyme production as 
fully repressed during growth on glucose and derepressed during the transition to 
growth on ethanol (Fig. 4.1).  Heterologous enzyme production during the stationary 
phase was also observed.   
 
Overall production levels of the [ADH2-XYN] strain were slightly higher than for the 
[PGK1-XYN] strain.  After 80 h of cultivation time, specific xylanase production levels 
of 3.2 and 2.6 mg.gbiomass-1 were obtained with these strains, respectively (Fig. 4.1A), 
based on a specific activity of 1810 U.mg-1 for the pure recombinant xylanase obtained 
during protein purification.  Approximately 2 mgxylanase.gcellular protein-1 xylanase protein 
was produced by the [PGK1-XYN] strain during growth on glucose, assuming a 
biomass composition containing circa 50% cellular protein (Albers et al., 1996).  This 
amount of xylanase production corresponds to maximally 0.2% of the total cellular 
protein produced during this growth phase. 
 
4.3.3. Growth rate 
The maximum specific growth rates of the five recombinant yeast strains during growth 
on glucose, and subsequent growth on ethanol, were compared (Tables 4.2 and 4.5).  
During growth on glucose, the maximum specific growth rate of the Y294 [Host] strain 
was significantly higher than the other strains, also confirmed with hypothesis testing 
(Table 4.5).  The growth rate of the [PGK1] strain was also significantly higher than the 
[PGK1-XYN] strain, whereas the [ADH2] and [ADH2-XYN] strains had similar 
growth rates.  The [PGK1-XYN] strain thus grew significantly slower on glucose than 
the [ADH2-XYN] strain.  During growth on ethanol, the growth rates of all strains were 
approximately 10-fold lower than during growth on glucose.  During this second 
growth phase, the maximum specific growth rate of the [ADH2-XYN] strain was 
significantly lower than the [ADH2] strain, similar to the difference observed between 
the [PGK1-XYN] and [PGK1] strains during growth on glucose.  The [PGK1-XYN] 
and [ADH2-XYN] strains grew at similar growth rates during this growth phase (Table 
4.5).  For all strains, the fraction of plasmid containing cells in the population remained 
at 100% throughout fermentations.  The fractions of non-viable cells for the individual 
strains were also similar (1-5%) and consequently the rates of cellular death were not 
significantly different, irrespective of the content of the recombinant plasmid. 
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Table 4.2. Maximum specific growth rates on glucose and ethanol in defined medium 
Strain μmax on glucose μmax on ethanol 
Y294 [Host] 0.33 ± 0.030 0.026 ± 0.005 
Y294 [PGK1] 0.28 ± 0.010 0.035 ± 0.002 
Y294 [PGK1-XYN] 0.25 ± 0.003 0.030 ± 0.003 
Y294 [ADH2] 0.29 ± 0.004 0.032 ± 0.001 
Y294 [ADH2-XYN] 0.27 ± 0.020 0.028 ± 0.002 
 
4.3.4. Biomass and by-product yields 
The yields of biomass and by-products on glucose were determined during the initial 
exponential growth phase (Tables 4.3 and 4.5).  The biomass yield of the Y294 [Host] 
strain was significantly larger than the other recombinant strains.  However, the 
differences in the biomass yields between the [PGK1-XYN] and [PGK1] strains, and 
the [ADH2] and [ADH2-XYN] strains, respectively, were less significant than the 
differences observed in the maximum specific growth rates between these strains.  
Though the difference between the [ADH2-XYN] and the [PGK1-XYN] strains during 
growth on glucose was not significant, the overall level of biomass formation for the 
[ADH2-XYN] was higher (Fig. 4.1B).  The reduced significance of differences in the 
biomass yields (based on the statistical t-test) was attributed to inaccuracy in the 
estimation of biomass concentrations, leading to large variations in individual values 
between fermentations.  Little difference was observed between the yields of ethanol 
and glycerol on glucose for individual strains whereas the values obtained for succinate 
and acetate were small and therefore not reliable (Appendix A, Table A.1). 
 
Table 4.3. Yields on glucose in defined medium 
Strain Yield on glucose (gproduct.gglucose-1) 
 Biomass Ethanol Glycerol 
Y294 [Host]  0.123 ±0.008 0.37 ±0.04 0.059 ±0.023 
Y294 [PGK1] 0.114 ±0.007 0.40 ±0.02 0.061 ±0.009 
Y294 [PGK1-XYN] 0.109 ±0.008 0.39 ±0.01 0.055 ±0.006 
Y294 [ADH2] 0.110 ±0.004 0.37 ±0.02 0.063 ±0.007 
Y294 [ADH2-XYN] 0.112 ±0.007 0.36 ±0.04 0.047 ±0.008 
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4.3.4. Rates of substrate consumption and product formation 
The specific glucose consumption rate of the Y294 [Host] strain was compared to the 
other recombinant strains (Tables 4.4 and 4.5).  The glucose consumption rates of the 
[PGK1] and [ADH2] strains were decreased compared to the Y294 [Host] strain.  
Further decreases in the maximum specific glucose consumption rates of the [PGK1-
XYN] and [ADH2-XYN] strains, compared to the [PGK1] and [ADH2] strains, 
respectively, were also observed, though the specific glucose consumption rate of the 
[ADH2-XYN] was higher than the [PGK1-XYN] strain.  The specific rates of ethanol 
formation for the recombinant strains were also compared (Table 4.4) and the 
differences between the strains were qualitatively similar to differences in the specific 
glucose consumption rates. 
 
 
Table 4.4. Specific rates of glucose consumption and ethanol formation after 9 h in 
defined medium 
Strain Specific glucose consumption 
rate (gglucose.gbiomass-1.h-1) 
Specific ethanol formation 
rate (gethanol.gbiomass-1.h-1) 
Y294 [Host] 2.34 ±0.23 0.90 ±0.02 
Y294 [PGK1] 2.10 ±0.04 0.86 ±0.04 
Y294 [PGK1-XYN] 1.85 ±0.18 0.72 ±0.06 
Y294 [ADH2] 2.19 ±0.15 0.86 ±0.07 
Y294 [ADH2-XYN] 2.13 ±0.21 0.79 ±0.08 
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Table 4.5. Significance of differences in calculated average values (Tables 4.2 to 4.4) 
according to Student’s T-test. 
Difference tested between Significance (%) ** 
  μmax on 
Glucose 
μmax on 
Ethanol 
Biomass 
Yield 
Ethanol 
Yield 
Glucose 
Consumption 
Rate 
[Host] [PGK1] 93 95 80 82 85 
[PGK1] [PGK1-XYN] 99 95 N. s. 80 94 
[Host] [PGK1-XYN] 99.6 N. s. 93 N. s. 98 
[Host] [ADH2] 89 87 93 N. s. N. s. 
[ADH2] [ADH2-XYN] N. s. 97 N. s. N. s. N. s. 
[Host] [ADH2-XYN] 96 N. s. 87 N. s. 84 
[PGK1] [ADH2] N. s. 96 N. s. 86 N. s. 
[PGK1-XYN] [ADH2-XYN] 94 N. s. N. s. N. s. 89 
** For each of the experimentally measured variables, the significance of the difference 
between the average values, obtained for the strains mentioned on the left, was 
determined. 
N. s. Not significant 
 
4.4. DISCUSSION 
 
Five recombinant S. cerevisiae strains were cultivated under identical conditions to 
quantify the molecular basis of the metabolic burden of heterologous gene expression, 
and to evaluate proposed mechanisms for the metabolic burden.  The study was 
designed to quantitatively estimate the metabolic effect of different genes and 
differently regulated promoters in the heterologous expression system. 
 
4.4.1. Plasmid replication 
The maintenance and replication of multiple copies of the 2μm YEp352 plasmid by the 
Y294 [Host] strain did not affect the growth of the host organism significantly, as the 
maximum specific growth rates of the parental Y294 and Y294 [Host] strains were 
similar in complex medium (Appendix A, Table A.2).  The effect of 2μm plasmid 
replication on growth was previously shown to be too small for experimental 
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observation (Mead et al., 1986; Van Hoek et al., 1998), though simulation studies had 
proposed a 1.5-3% reduction in the maximum specific growth rate due to plasmid 
replication in defined medium (Mead et al., 1986).  Notions toward the effect of foreign 
DNA synthesis during plasmid replication on cellular activities were also disproved by 
similar growth rates and biomass yields for the [ADH2] and [ADH2-XYN] strains 
during growth on glucose. 
 
4.4.2. Plasmid-based glycolytic promoter 
Conversely to plasmid replication, the inclusion of either the PGK1 or ADH2 promoter 
on the recombinant plasmid introduced a significant metabolic burden on the host 
organism.  The observed reductions in the maximum specific growth rate (12-15%), 
biomass yield on glucose (8-11%) and specific glucose consumption rate (6-10%) of the 
[PGK1] and [ADH2] strains, compared to the Y294 [Host] strain (Tables 4.2, 4.3 and 
4.5), were quantitatively more significant than the effect of plasmid replication (Mead et 
al., 1986; Van Hoek et al., 1998).  This effect of a plasmid-based promoter has not been 
reported in S. cerevisiae before. 
 
As the metabolic effect of the plasmid-based PGK1 and ADH2 promoters was not 
influenced by the regulatory characteristics of the promoters, it might be attributed to 
the regulation of transcription, i.e. the synthesis of transcription machinery and 
subsequent binding to the promoter, from a large number of plasmid-based glycolytic 
promoters.  The observed effect may also be caused by significant changes in the 
plasmid copy number and/or read-through transcription. 
 
4.4.3. Heterologous gene expression 
The presence of the heterologous XYN2 gene on the recombinant plasmid introduced a 
metabolic burden in the [PGK1-XYN] and [ADH2-XYN] strains only during active 
gene expression.  During growth on glucose, the maximum specific growth rate (11%), 
biomass yield (4%) and specific glucose consumption rate (12%) of the [PGK1-XYN] 
strain was reduced (Tables 4.2, 4.3 and 4.4), whereas during growth on ethanol the 
maximum specific growth rate (14%) of the [ADH2-XYN] strain was decreased (Table 
4.2); compared to the [PGK1] and [ADH2] strains.  Similar reductions have been 
observed for other foreign gene expression systems in S. cerevisiae (Da Silva and 
Bailey, 1991; Dequin and Barre, 1994).   
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The metabolic burden of heterologous gene expression was disproportionally large with 
respect to the amount of heterologous protein produced, as also noted by Koch (1983).  
The energetic cost for the synthesis of recombinant protein to the equivalent of 0.2% 
cellular protein during growth on glucose could not directly be translated into the 11% 
reduction in the maximum specific growth rate of the [PGK1-XYN] strain (Table 4.2).  
Reduced production levels for heterologous gene expression, compared to homologous 
gene expression, have also been observed for production from the same expression 
system (Chen et al., 1984; Gopal et al., 1989), apparently due to a higher energetic 
demand for heterologous gene expression (Gopal et al., 1989).   
 
Alternatively, the "dilution" of native proteins (Snoep et al., 1995) may have been 
caused by a competition for available transcription factors during active heterologous 
gene expression, as the cells mostly secreted the heterologous xylanase.  For the ADH2 
promoter the availability of the Adr1p transcription factor has become limiting when a 
large number of plasmid-based ADH2 promoters were present in the cell, which 
subsequently reduced the expression levels of the chromosomal ADH2 (Irani et al., 
1987).  As Adr1p is a limiting factor in ADH2 transcription (Kramer et al., 1984; Price 
et al., 1990) the overexpression of ADR1 has improved the expression level of the 
chromosomal ADH2 (Irani et al., 1987) and has also increased the production levels of 
ADH2-regulated recombinant protein production (Price et al., 1990). Similarly, for the 
PGK1 promoter, available evidence indicates that the transcription factor essential for 
the activation of the promoter, Gcr1p, is produced at extremely low levels (Baker, 1986; 
Huie and Baker, 1996).  A limitation in the availability of essential transcription factors 
for both the PGK1 and ADH2 promoters may therefore influence the expression of the 
glycolytic enzymes and thereby affect the growth of the host organism.  The 
disproportionally large effect of foreign gene expression may also be attributed to a 
competition for limiting amounts of translation factors, biosynthetic precursors or 
metabolic energy (Shuster, 1989; Janes et al., 1990; Van der Aar et al., 1992). 
 
Heterologous xylanase production levels by the [ADH2-XYN] and [PGK1-XYN] 
strains during stationary phase were similar and were apparently not affected by the 
regulatory characteristics of the promoters.  Continued heterologous protein production, 
during the post-exponential phase, both by expression systems containing the PGK1 
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and the ADH2 promoter has been reported (Shuster, 1989; Price et al., 1990; Cartwright 
et al., 1994; Dickson and Brown, 1998). Conversely, the regulatory characteristics of 
both promoter systems, associated with their function in primary metabolism, were 
retained during the major growth phases (Shuster, 1989; Kingsman et al., 1990; Price et 
al., 1990; Romanos et al., 1992; Noronha et al., 1998).  The observed metabolic burden 
of heterologous xylanase production was directly related to the induction of gene 
expression by either of these promoters.  Results from this study have quantitatively 
justified the use of a promoter for heterologous protein production in S. cerevisiae that 
is not active during the major growth phase, based on a decreased metabolic burden 
during biomass formation. 
 
4.5. CONCLUSIONS 
The present study has confirmed the presence of a disproportional yeast response to 
heterologous xylanase production.  This was associated with the ability of the cell to 
sense and respond to both the production of a foreign protein and the presence of the 
plasmid-based promoter.  The negative physiological effect of foreign protein synthesis 
may also limit the attainable levels of xylanase production.  Further investigation was 
required to identify the exact cellular processes and regulatory mechanisms involved in 
the observed physiological response. 
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Chapter 5 
 
TRANSCRIPTIONAL RESPONSE OF S. CEREVISIAE TO 
HETEROLOGOUS XYLANASE PRODUCTION 
 
5.1. INTRODUCTION 
 
Low production levels of heterologous proteins secreted by yeasts limit the advantages 
associated with the capacity of these hosts for posttranslational processing and secretion 
of foreign proteins (Hinnen et al., 1995).  Posttranslational processing and secretion of 
foreign proteins allow for correctly folded proteins with full biological activity to be 
produced in the extracellular medium, thus simplifying purification of the product.  
Evidence of possible limitations in the production and secretion of a heterologous 
xylanase by S. cerevisiae was given by the presence of a “metabolic burden” on the host 
physiology due to foreign gene expression (Chapter 4).  In the present chapter the major 
cellular processes and regulatory mechanisms associated with the observed 
physiological response were therefore identified, by using genome-wide transcriptional 
profiling.  Further illumination of a global sensing and regulation mechanism for 
heterologous protein by yeast, representing a possible limitation to the attainable 
production levels, could thus be obtained.  A potential relationship between the 
physiological response and the level of heterologous xylanase production also resulted 
in a general strategy for improving recombinant protein production. 
 
Microarray technology allows for the quantification of the transcriptional response of 
cellular processes to a variety of environmental and genetic changes, such as high 
salinity (Yale and Bohnert, 2001; Posas et al., 2000), aerobic and anaerobic culture (Ter 
Linde et al., 1999), the diauxic shift (DeRisi et al., 1997), progression through the 
mitotic cell cycle (Cho et al., 1998; Chu et al., 1998), different levels of copper 
availability (Gross et al., 2000), rapamycin treatment (Shamji et al., 2000; Cardenas et 
al., 1999), amino acid starvation (Natarajan et al., 2001), treatment with an alkylating 
agent (Jelinsky and Samson, 1999), deletion of the snf/swi complex components, SNF2 
or SWI1 (Sudarsanam et al., 2000), deletion of CDC73 (Kerkmann and Lehming, 2001), 
deletion of the GCR1 transcription factor (Lopez and Baker, 2000), reduced cell wall 
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integrity (Jung and Levin, 1999), aging (Lin et al., 2001), drug treatments and mutations 
affecting ergosterol synthesis (Bammert and Fostel, 2000; DeRisi et al., 2000) and long-
term physiological adaptation (Ferea et al., 1999).  The genes required for meiosis and 
spore formation (Rabitsch et al., 2001) and iron homeostasis (Yun et al., 2000; Foury 
and Talibi, 2001) have also been identified using genome-wide transcription profiling, 
whereas the function of several unclassified genes has been identified (Hughes et al., 
2000).  Microarray technology has also been used to investigate recombinant protein 
production by E. coli, where significant changes in the expression of glycolytic and 
pentose phosphate pathways, biosynthesis, respiration, and heat shock and chaperone 
genes were observed (Oh and Liao, 2000; Gill et al., 2000; Gill et al., 2001). 
 
In the present investigation, the transcriptional response of S. cerevisiae to individual 
genetic components in a model expression system for heterologous xylanase production 
was quantified.  The T. reesei ß-1,4-xylanase II encoding gene, XYN2, was expressed 
from a multicopy, 2μm plasmid under regulation of the yeast glycolytic 
phosphoglyceratekinase (PGK1) promoter (La Grange et al., 1996), which is maximally 
induced in aerobic batch culture by the presence of glucose (Shuster, 1989; Chambers et 
al., 1989; Kingsman et al., 1990; Romanos et al., 1992; Hauf et al., 2000). The 
xylanase-producing strain was compared to two references strains, where either the 
heterologous XYN2 gene, or the heterologous gene and the promoter and terminator 
sequences were omitted from the recombinant plasmid.  As the produced xylanase had 
no known catalytic function in yeast metabolism and was secreted efficiently by the 
recombinant strains, the transcriptional response associated with both the presence of a 
large number of plasmid-based glycolytic PGK1 promoters and the expression of 
heterologous XYN2 gene under control of the PGK1 promoter from the 2μm plasmid 
(Chapter 4), was strictly related to the presence and activity of the recombinant 
expression system (Van der Aar et al., 1990a; Van der Aar et al., 1990b; Van Hoek et 
al., 1998).  Stable maintenance of the recombinant plasmids in non-selective cultivation 
media was ensured through the inclusion of the fur1 ura3 autoselective system in the 
recombinant strains (Loison et al., 1986). 
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5.2. MATERIALS AND METHODS 
5.2.1. Strains and plasmids 
The S. cerevisiae strains selected for this study are presented in Table 5.1.  For the 
construction of autoselective strains the method of Loison et al. (1986) was used (La 
Grange et al., 1996).  The strain stocks were stored at –80ºC in a 15% glycerol solution. 
 
Table 5.1. Strains used in this study 
Strain Genotype Source 
S. cerevisiae Y294 ura3, leu2, trp1,his3 La Grange et al. (1996) 
 Plasmid Promoter Gene  
Y294 [Host]* YEp352 - - Chapter 4 
Y294 [PGK1]* pJC1 PGK1 - Crous et al. (1995) 
Y294 [PGK1-XYN]* pDLG6 PGK1 XYN2 La Grange et al. (1996) 
* [  ] Indicates the content of the recombinant plasmid.   
 
5.2.2. Medium, inoculum and fermentations 
Fully aerobic batch fermentations were conducted in a chemically defined medium 
(Verduyn et al., 1992) supplemented with the amino acids [histidine (165 mg.l-1), 
leucine (870 mg.l-1), tryptophan (664 mg.l-1), aspartate (257 mg.l-1), glutamate (64 mg.l-
1), glycine (33 mg.l-1) and serine (108 mg.l-1)], as described previously (Chapter 4).  
Cultures were inoculated to a low cell density using a 5 ml pre-culture, containing cells 
in the late-exponential phase, which improves the reproducibility of batch fermentations 
(A. Eliasson, personal communication).  Cell densities in all cultures were estimated as 
optical density (absorbance) measurements at 620 nm (A620) with a Hitachi U-1100 
spectrophotometer (Hitachi Ltd., Tokyo, Japan).  The fermentor was controlled at 30ºC 
and pH 5.0.   
 
5.2.3. Analytical methods 
Cultures were sampled regularly and the concentrations of glucose and ethanol, and 
extracellular xylanase activity determined as previously (Chapter 4).  Cell samples for 
the characterisation of the transcriptional profile were taken during mid-exponential 
growth, when the cell density reached an absorbance (620 nm) of 5.0.  75 ml of 
fermentation broth was rapidly cooled by adding approximately 40 ml of ice, 
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centrifuged promptly and washed twice with ice-cold sodium-acetate (NaAc) buffer 
(Schmitt et al., 1990).  The final, concentrated sample was suspended in NaAc buffer, 
flash-frozen and stored at –80ºC until analysis. 
 
5.2.4. Quantification of transcriptional response 
The transcriptional profiles of individual recombinant strains were quantified using the 
Affymetrix GeneChip system for S. cerevisiae.  Total yeast RNA was isolated in 
triplicate according to Schmitt et al. (1990) and these triplicates were pooled according 
to strains, followed by mRNA isolation using the Qiagen mRNA Kit.  Subsequent steps 
in the preparation of a hybridisation mixture were performed according to the 
manufacturer’s protocol, and checked using gel electrophoresis.  The fermentation, 
sample collection and preparation, and hybridisation steps were done in duplicate for 
the [PGK1-XYN] strain, whereas the procedure was completed once for the reference 
strains. 
 
5.2.5. Data processing 
Data sets obtained from the scanning of GeneChips were compared using the 
Affymetrix software package, whereby comparisons of the Y294 [PGK1-XYN] and 
Y294 [PGK1] strains to the reference host strain (Y294 [Host]) could be obtained.  For 
the [PGK1-XYN] strain, the geometric average of the duplicate comparisons to the 
[PGK1] and [Host] strains, obtained from individual hybridisations, were calculated.  
All of the changes in the expression of genes in the [PGK1-XYN] strain mentioned in 
this report were reproducible between the two hybridisations. 
 
5.3. RESULTS 
 
The genome-wide transcriptional profile of a recombinant S. cerevisiae strain (Y294 
[PGK1-XYN]), producing a heterologous xylanase from a 2μm plasmid-based 
expression system controlled by the PGK1 promoter, was generated using Affymetrix 
microarray technology.  The transcriptional profile was compared to the profiles of two 
reference strains where the heterologous XYN2 gene (Y294 [PGK1]) or both the 
heterologous gene and the PGK1 promoter and terminator (Y294 [Host]) were omitted 
from the recombinant plasmid (Table 5.1). 
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5.3.1. Aerobic batch fermentations 
The reproducibility of aerobic batch fermentations and physiological differences 
between these strains were previously demonstrated (Chapter 4), with similar trends in 
the maximum specific growth rates observed during the present cultures (Table 5.2).  
Typical patterns of substrate-consumption, and biomass- and product-formation, during 
batch cultivation on glucose are presented in Figure 5.1.  Samples for transcriptional 
profiling were rapidly removed when the cell density (Absorbance) in the fermentor 
reached A620 = 5.0, which corresponded to mid-exponential growth [A final cell density 
of A620 ≈ 12 was normally reached during growth on glucose (Chapter 4)]. 
 
Table 5.2 – Physiological Comparison of Recombinant Strains 
 
Maximum Specific 
Growth Ratea, μmax, [h-1] 
Glucose Uptake Rateb 
[gglucose.gbiomass.h-1] 
Y294 [Host] 0.43 2.34 ±0.23 
Y294 [PGK1] 0.36 2.10 ±0.04 
Y294 [PGK1-XYN] 0.29 1.85 ±0.18 
a Present study. Similar trend was observed in Chapter 4 
b Chapter 4 
 
5.3.2. Comparison of transcriptional profiles 
Clustering of genes according to similar transcriptional responses and expression 
patterns has shown that genes with similar functionality are usually co-regulated 
(DeRisi et al., 1997; Eisen et al., 1998; Gasch et al., 2000), allowing the global analysis 
of transcription data on the basis of cumulative changes in gene expression in broad 
functional families (Nau et al., 2000).  In the present study a total of 1014 genes 
showing a significant change in their expression level were sorted into functional 
groups according to the MIPS classification (Mewes et al., 2000), and the individual S. 
cerevisiae strains compared on the basis of general trends in the major cellular 
processes/functions (Table 5.3).     
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Figure 5.1. Aerobic batch cultivation of the [PGK1-XYN] strain in defined medium 
prior to final sampling for transcriptional profiling.  (?,O) Cell density in absorbance 
units (620 nm), (?,?) specific xylanase activity, (♦) glucose concentration (g.l-1) and 
(?) ethanol concentration (g.l-1).  Open symbols indicate duplicate fermentations 
 
5.3.2.1. Significant changes in transcription level 
The significance of changes in transcription level was assessed using two criteria.  
Primary selection of genes was based solely on the fold-change in expression level, 
with changes larger than two-fold considered as significant (as suggested by 
Affymetrix).  However, fold-changes larger than two were observed almost exclusively 
for genes with low expression levels, which do not fulfil central functions in 
metabolism.  The tighter regulation of the more central genes in metabolism, which also 
had higher expression levels, apparently resulted in much smaller fold-changes.  To 
include the latter types of genes in the analysis, the significance of smaller changes in 
mRNA levels were evaluated on the basis of a “Significance factor”, defined as the 
[(Absolute value of fold change)-1] multiplied by the average expression level of the 
gene between two strains.  A minimum value of 100 for the Significance factor was 
chosen for this secondary selection criterion, as this represented an inflection point in 
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the plot of Number of genes selected versus Minimum “Significance factor” (Fig. 5.2).  
The number of selected genes increased exponentially when a criteria below 100 was 
used, indicating the selection of the numerous genes in yeast with low expression levels.  
The inflection point in Figure 5.2 at a Significance factor of 100 thus represented the 
transition from highly expressed genes with small fold-changes, to genes with low 
expression levels.   The secondary selection was therefore limited to more highly 
expressed genes. 
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Figure 5.2.  Number of genes in each strain-comparison for which the change in 
expression level satisfied a “Minimum Significance Factor” criterion.  (•,o) Y294 
[PGK1-XYN] vs. Y294 [PGK1] and (?,?) Y294 [PGK1-XYN] vs. Y294 [Host]. 
Closed symbols are genes of known function, and open symbols are genes of unknown 
function. 
 
Overall changes in the individual functional categories were quantified by comparing 
the sum-totals of both the number of genes up- or down-regulated and the sum-totals of 
the “Significance factors,” as presented in Table 5.3.  The “Overall changes” in Table 
5.3 represent the total number of genes with significant changes in expression level in 
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each functional group, either in the [PGK1] or [PGK1-XYN] strain.  The “Magnitude of 
… changes” represents specific data for either the [PGK1] or [PGK1-XYN] strain, with 
the sum totals for up-regulation (“UP”) and down-regulation (“DOWN”) presented 
separately.  Both the total number of genes with changed expression level (“# ORFs”) 
and the sum-total of the “Significance factors” (“Σ Significance”) are presented.  For 
the summation based on the “Significance factor,” negative values were assigned to the 
genes that were down-regulated, resulting in the negative values associated with the “Σ 
Significance” total for down-regulated groups. 
 
In some functional categories, several changes in the expression of genes were observed 
without any clear overall trend.  This “shuffling around” of gene expression was 
associated with the large amount of redundancy present in metabolism, by which it 
obtains robustness (Cornish-Bowden and Cardenas, 2000).  Differential expression of 
isoenzymes, possibly due to differences in the properties of these enzymes, is also 
frequently observed in response to environmental changes (Gasch et al., 2000).  
 
5.3.3. Cellular processes affected by heterologous gene expression 
The cellular functions most strongly affected by changes in the content of the 
recombinant plasmids were:  Metabolism (mostly amino acids and ammonium), energy 
conservation (glycolysis, respiration, TCA cycle), protein synthesis (ribosome 
biogenesis, translation and transcription), transport facilitation (mechanisms, ionic and 
amino acid transport, and cellular import), and cell rescue and virulence.  The 
presentation of the overall changes in cellular processes is based mostly on the results 
presented in Table 5.3, though conclusions were also confirmed by the original data 
presented in Appendix D.  Further data on changes in the expression of individual 
genes, obtained mostly from the results presented in Appendix D, are discussed in some 
of the functional categories to confirm the extent of transcriptional changes. 
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Table 5.3.  Cellular processes significantly changed in the [PGK1] or [PGK1-XYN] strains 
Cellular Process / Function Overall Changesa Magnitude of [PGK1-XYN] Changes Magnitude of [PGK1] Changes 
 # ORFs % ORFs # ORFs Σ Significance # ORFs Σ Significance 
 Changed Total Changed UP DOWN UP DOWN UP DOWN UP DOWN 
A. METABOLISM 360 1219 30 154 136 290358 -13861 122 66 65825 -3606 
A.1. Amino acid metabolism 89 215 41 60 13 274678 -4029 53 5 62569 -729 
Amino acid biosynthesis 53 119 45 31 10 29088 -2583 31 3 12533 -436 
Regulation of AA metabolism 8 33 24 6 2 7236 -286 2 2 1177 -294 
AA Transport 14 32 44 13 0 233410 0 9 0 46586 0 
AA Degradation 14 35 40 10 2 4944 -1161 11 0 2273 0 
A.2. Nitrogen and sulphur utilisation 22 67 33 7 9 3736 -2607 7 2 1493 -105 
A.3. Nucleotide metabolism 52 155 34 10 32 4053 -7225 10 18 1763 -2772 
Purine ribonucleotide metabolism 23 45 51 2 15 566 -2796 8 5 601 -1200 
Pyrimidine ribonucleotide metabolism 10 29 34 4 6 11155 -1942 0 5 0 -603 
Deoxyribonucleotide metabolism 6 11 55 2 4 40 -685 1 2 104 -351 
B. ENERGY CONSERVATION 99 264 38 45 32 16813 -9447 27 29 9267 -4725 
B.1. Glycolysis 17 35 49 1 14 137 -4381 10 4 4661 -724 
B.2. Pentose-phosphate pathway 7 9 78 2 3 99 -500 2 1 219 -47 
B.3. Tricarboxylic-acid pathway (Krebs cycle, TCA cycle) 10 25 40 6 2 914 -741 0 4 0 -600 
B.4. Respiration 39 92 42 25 3 4239 -514 4 13 852 -2139 
B.5. Fermentation 9 33 27 4 4 10283 -1429 6 2 3432 -274 
B.6. Glyoxylate cycle 3 6 50 1 2 310 -1105 0 2 0 -319 
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Table 5.3.  Cellular processes significantly changed in the [PGK1] or [PGK1-XYN] strains (continued) 
Cellular Process / Function Overall Changesa Magnitude of [PGK1-XYN] Changes Magnitude of [PGK1] Changes 
 # ORFs % ORFs # ORFs Σ Significance # ORFs Σ Significance 
  Changed Total Changed UP DOWN UP DOWN UP DOWN UP DOWN 
C. TRANSCRIPTION, PROTEIN SYNTHESIS AND FATE 408 1895 22 122 234 19883 30854 178 60 49955 935 
C.1. Transcription 120 861 14 53 39 6126 6028 39 16 5579 1651 
rRNA transcription 22 113 19 8 7 1061 989 10 1 1578 114 
tRNA transcription 11 84 13 4 5 373 641 4 1 381 142 
mRNA transcription 79 580 14 34 26 3469 4053 25 14 3240 1395 
C.2. Protein Synthesis 175 372 47 23 145 6424 36793 115 18 39257 2810 
Ribosome biogenesis 135 223 61 15 85 4671 27583 85 7 33458 1600 
Translation 22 64 34 3 16 492 3643 6 5 1704 614 
Aminoacyl-tRNA-synthetases 12 37 32 2 7 537 1177 4 2 719 316 
tRNA Expression    0 36 0 4077 19 2 2898 24 
C.3. Protein Fate (folding, modification, destination) 113 662 17 46 50 7333 11967 24 26 5120 5396 
Protein folding and stabilization 15 60 25 6 6 972 1890 1 5 360 1318 
Protein targeting, sorting and translocation 21 147 14 7 12 1157 3369 6 6 1148 1675 
Protein modification 29 188 15 14 10 2656 1548 8 2 1312 306 
Assembly of protein complexes 20 95 21 6 12 914 3345 4 7 1356 1287 
Proteolytic degradation 20 164 12 12 9 1453 1573 5 6 943 810 
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Table 5.3.  Cellular processes significantly changed in the [PGK1] or [PGK1-XYN] strains (continued) 
Cellular Process / Function Overall Changesa Magnitude of [PGK1-XYN] Changes Magnitude of [PGK1] Changes 
 # ORFs % ORFs # ORFs Σ Significance # ORFs Σ Significance 
  Changed Total Changed UP DOWN UP DOWN UP DOWN UP DOWN 
D. CELLULAR TRANSPORT 302 1116 27 154 190 496554 29292 120 85 104349 9919 
D.1. Intracellular Transport and Transport 112 541 21 43 50 222095 12220 36 22 46741 4431 
Nuclear transport 6 59 10 1 4 107 926 1 1 132 867 
Mitochondrial transport 27 81 33 13 5 2572 1323 7 10 1196 1666 
Vesicular transport (Golgi network, etc.) 21 129 16 6 13 575 3214 5 3 568 537 
Vacuolar transport 16 56 29 4 12 732 3157 3 4 641 610 
Cellular import 29 101 29 12 12 218109 3600 15 2 44205 751 
D.2. Transport Facilitation/ Interaction with Environment 190 575 33 111 140 274459 17073 84 63 57608 5488 
D.2.1. Ionic homeostasis 44 137 32 16 19 3943 4412 11 11 2036 1734 
Homeostasis of cations 40 123 33 14 19 3539 4412 9 10 1760 1582 
Homeostasis of metal ions (Na, K, Ca etc.) 20 63 32 13 8 3299 1547 3 1 444 168 
Homeostasis of protons 19 36 53 1 10 241 2865 4 9 1200 1414 
D.2.2. Facilitation of Ion Transport 44 86 51 90 115 270515 12660 71 45 55572 3754 
Cation transporters 34 65 52 12 20 15733 5545 5 5 1816 1038 
Heavy metal ion transporters 14 25 56 10 4 15419 684 1 1 112 168 
Other cation transporters (Na, K, Ca , NH4, etc.) 19 39 49 1 16 215 4861 4 4 1704 871 
Anion transporters (Cl, SO4, PO4, etc.) 10 21 48 6 2 1194 1240 3 1 353 413 
D.2.3. Amino acid transporters 14 25 56 12 1 233362 109 11 0 46770 0 
D.2.4. Drug transporters 10 35 29 9 1 9154 167 6 2 1119 121 
D.2.5. Transport mechanism 29 74 39 4 26 1041 3784 6 11 2027 1513 
Transport ATPases 23 45 51 2 13 376 3411 7 9 1830 1414 
ABC transporters 6 28 21 2 13 665 373 1 2 198 99 
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Table 5.3.  Cellular processes significantly changed in the [PGK1] or [PGK1-XYN] strains (continued) 
Cellular Process / Function Overall Changesa Magnitude of [PGK1-XYN] Changes Magnitude of [PGK1] Changes 
 # ORFs % ORFs # ORFs Σ Significance # ORFs Σ Significance 
  Changed Total Changed UP DOWN UP DOWN UP DOWN UP DOWN 
E. CELL RESCUE, DEFENSE AND VIRULENCE 79 291 27 42 19 36274 4008 24 18 10628 2951 
E.1. Stress response 50 176 28 25 12 25207 2561 14 14 8208 2682 
E.2. Detoxification 28 105 27 17 7 11052 1447 10 4 2421 269 
            
F. CELL FATE, DNA PROCESSING AND CELL CYCLE 191 1347 14 80 64 23738 15073 45 57 13469 7896 
F.1. Cell Fate 100 558 18 42 33 8732 8158 32 29 5963 4461 
Cell growth / morphogenesis 17 96 18 6 9 1393 2012 3 7 692 1390 
(Fungal) Cell differentiation 78 448 17 34 27 6687 6146 27 20 4711 2914 
F.2. DNA Processing and Cell Cycle 91 789 12 38 31 15006 6915 13 28 7506 3435 
DNA processing 26 281 9 6 15 304 2188 1 8 305 1174 
Cell cycle 63 502 13 30 16 4915 4828 11 20 3694 2261 
Mitotic cell cycle and cell cycle control 38 356 11 18 11 3060 3704 9 12 3592 1803 
Meiosis 19 108 18 11 3 1625 625 1 6 103 459 
a Indicates the total number of genes with significant changes in expression levels, either in the [PGK1] or the [PGK1-XYN] strain. 
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5.3.3.1. Metabolism 
Gene expression for various processes in amino acid metabolism (biosynthesis, 
transport and degradation) increased strongly in both the [PGK1-XYN] and [PGK1] 
strains, with 45% of the genes in amino acid biosynthesis affected.  Several changes in 
the utilisation of nitrogenous compounds were also observed.  Though extracellular 
nitrogen availability was identical during the cultivation of the individual strains, 
differences in the physiology of the strain can lead to different transcriptional outputs 
using the same nitrogen sources (Ter Schure et al., 2000). 
 
Aspartate biosynthetic family (Asp, Asn, Thr, Met, Ile) 
In Y294 [PGK1] the availability of asparagine and methionine was apparently limited.  
Expression of the genes for the biosynthesis of asparagine (ASN1, ASN2) and 
methionine (MET6 and MET17) were up-regulated, along with methionine permease 
(MUP1), S-adenosylmethionine (AdoMet, SAM) supply (SAM1, SAM2 and SAM4), 
sulphate uptake and sulphur transfer.  This could be due to decreased intracellular levels 
of S-adenosylmethionine (AdoMet, SAM), induction by the general amino acid control 
(GCN4) system or induction by the Ssy1p extracellular amino acid sensor (Hinnebusch, 
1992; Forsberg et al., 2001).   
 
In Y294 [PGK1-XYN] the systems for asparagine synthesis, sulphur transfer and 
AdoMet supply were additionally up-regulated (ASN1, ASN2, MUP1, SAM4 and the 
genes for sulphate uptake and transfer).  However, methionine biosynthesis was down-
regulated (MET14, MET3, MET6), probably due to a sufficient supply thereof 
(Hinnebusch, 1992), or an improper compartmentalisation of AdoMet to the vacuole 
where it is normally stored (Forsberg et al., 2001).  Decreased expression of thioredoxin 
reductase (TRR1) also indicated a reduction in sulphur utilisation towards methionine 
synthesis by the [PGK1-XYN] strain. 
 
Glutamate biosynthetic family (Glu, Gln, Pro, Arg, Lys) 
An apparent increase in the requirement for arginine in both the [PGK1] and [PGK1-
XYN] strains increased the expression of ARG1 (both strains), and ARG5,6 and CPA2 
([PGK1-XYN] only) (Hilger et al., 1973; Hinnebusch, 1992).  Expression of ARG1 is 
also up-regulated by Ssy1p (Forsberg et al., 2001), whereas CPA2 expression is 
regulated solely by the GCN4-system (Messenguy, 1979).  PRO3 expression, required 
for proline synthesis and arginine degradation (Jones and Fink, 1982), was down-
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regulated in both the [PGK1] and [PGK1-XYN] strains, though more severely in the 
latter.   
 
Gene expression for lysine biosynthesis increased more severely in the [PGK1] strain 
(LYS1, LYS9, LYS12, LYS20 expression increased) than in the [PGK1-XYN] strain 
(LYS1, LYS20 expression increased).  All of the genes involved in lysine biosynthesis 
are regulated by the general amino acid control (Gcn4p) (Hinnebusch, 1992; Natarajan 
et al., 2001), though expression of LYS20 and LYS9 is also up-regulated in response to 
Ssy1p (Forsberg et al., 2001).  Changes in the expression of GLT1, GLN1, GDH1 and 
GDH2 related strongly to the utilisation of ammonium as nitrogen source (discussed 
below). 
 
Aromatic biosynthetic family (Phe, Tyr, Trp) 
Genes in tryptophan biosynthesis (TRP1, TRP3, TRP4, TRP5) and the precursor 
pathway (ARO3) were up-regulated in both the [PGK1] and [PGK1-XYN] strains, with 
an additional increase in expression in the latter.  Biosynthesis of the enzymes required 
for the synthesis of aromatic amino acids is mostly controlled at transcriptional level, 
with the expression of ARO3, TRP3, TRP4 and TRP5 regulated by the Gcn4p activator 
(Braus, 1991).  Both strains apparently experienced a mild increase in the requirement 
for amino acids, as the expression level of ARO3 was not increased under conditions of 
severe intracellular amino acid limitation (Paravicini et al., 1989). 
 
Serine biosynthetic family (Ser, Gly, Cys) 
Expression of genes for cysteine uptake (MUP1), glycine biosynthesis (GLY1), serine 
degradation (SRY1, SDL1, CHA1) and glycine degradation (GCV1, GLY1) was 
increased, with higher expression levels in the [PGK1-XYN] than in the [PGK1] strain. 
 
Pyruvate biosynthetic family (Ala, Val, Leu) 
The biosynthetic genes LEU2 and LEU4, as well as several of the ILV genes were up-
regulated in both the [PGK1] and [PGK1-XYN] strains, with higher expression levels 
in the latter.  Gene expression for branched chain amino acid synthesis is repressed in 
response to leucine availability (Forsberg et al., 2001).  The biosynthesis of leucine, 
valine and isoleucine, also respond to a general amino acid limitation, confirmed by 
patterns of LEU4 expression (Natarajan et al., 2001; Hinnebusch, 1992). 
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Histidine biosynthesis (His) 
Three genes for histidine biosynthesis were up-regulated (HIS3, HIS4, HIS5) to 
approximately equal levels in the [PGK1-XYN] and [PGK1] strains.  Due to the 
absence of histidine-specific transcriptional repression in yeast, these inductions were 
solely due to the action of the GCN4-transcriptional activator (Natarajan et al., 2001). 
 
Amino acid and ammonium transport 
An apparent increase in the requirement for amino acid uptake caused a strong increase 
in the expression of the permeases for Val, Cys, Leu, Ile, Asp, Glu, Met, Gln and Tyr in 
both Y294 [PGK1] and Y294 [PGK1-XYN], though more severely in the latter.  
Expression of the general AGP3 and LYP1 lysine permeases were also up-regulated, 
though to similar levels in the [PGK1-XYN] and [PGK1] strains.  In Y294 [PGK1-
XYN] additional increases in the expression of the permeases for tryptophan (TAT2), 
amino acids in general (AGP1, AGP2) and sulphur amino acids (MMP1) were also 
observed.  Since uptake systems are generally active only when their substrates are both 
available in the medium and useful to the cell, the increased permease expression was 
probably aimed at increasing the uptake of amino acids from the medium (Horák, 1997; 
Sophianopoulou and Diallinas, 1995; Grenson, 1992; Eddy, 1980).  The intracellular 
availability of either individual amino acids or amino acids in general may have been 
limiting, since several of the amino acid permeases (AGP1, BAP2, BAP3, PTR2, DIP5, 
TAT1, TAT2, GNP1, CAR1) are co-ordinately regulated via the Ssy1p transcriptional 
factor (Klasson et al., 1999; Regenberg et al., 1999; Forsberg et al., 2001; Bernard and 
Andre, 2001).  The very strong increase in the expression of the permeases for 
branched-chain amino acids (BAP2, BAP3 and TAT1) indicated the potential utilisation 
of the excess of leucine supplied in the medium.  High concentrations of a particular 
amino acid usually results in it being taken up, deaminated and secreted as fusel oil 
(Cooper, 1982; Grenson, 1992).   
 
A significant down-regulation of the lower affinity, high capacity (MEP1) and high 
affinity, low capacity (MEP2) ammonia transport systems were also observed in the 
[PGK1-XYN] strain, whereas only the expression of MEP2 was slightly down-
regulated in Y294 [PGK1].  Both permeases are repressed in the presence of a good 
nitrogen source (Marini et al., 1997), whereas MEP2 is also involved in the response to 
ammonium limitation (Lorenz and Heitman, 1998).  In the [PGK1-XYN] strain the 
coordination of increased amino permease expression with a deliberate decrease in 
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ammonium uptake corresponded to the repression of amino acid transport by 
ammonium ions (Horák, 1986; Slaughter et al., 1990; Horák, 1997).  Amino acid-
induced signals may cross-talk with signals derived from sensors monitoring other 
nitrogen sources, to co-ordinate gene expression in response to nutrient availability 
(Forsberg et al., 2001). 
 
General regulation of amino acid metabolism 
Gene expression for both the biosynthesis and uptake of amino acids was increased in 
the [PGK1] and [PGK1-XYN] strains, though more severely in the latter.  The 
expression of several important activators of amino acid biosynthesis was increased, 
including ARO9 and SSY1 ([PGK1] and [PGK1-XYN]), and ARG80, ARO8, MET28 
and MCM1 ([PGK1-XYN] only).  The expression of a significant fraction (30/36) of a 
selection of genes known to be controlled by the GCN4-system, was increased in the 
[PGK1] strain, whereas the fraction of up-regulated genes was smaller (22/36) in the 
[PGK1-XYN] strain, though still significant.  The level of GCN4 transcripts was 
unaffected. 
 
Nitrogen utilisation 
Gene expression for ammonium utilisation was strongly altered in the [PGK1-XYN] 
strain, as the expression of GDH1 (NADP-specific glutamate dehydrogenase) was 
down-regulated whilst GDH2 (NAD-specific glutamate dehydrogenase) expression was 
up-regulated.  Expression of the ammonium permeases (MEP1 and MEP2) was also 
decreased.  Decreased GDH1 activity has been associated with carbon or nitrogen 
starvation (Cooper, 1982; Gancedo and Serrano, 1989).  GDH2 expression is also 
derepressed during nitrogen limitation (Cooper, 1982; Coschigano et al., 1991), or 
carbon limitation (See below; Donnini et al., 1990; Coschigano et al., 1991; Ter Schure 
et al., 2000).  Maximal GDH2 derepression also required the catabolic utilisation of 
leucine, serine or valine when ammonia was the primary nitrogen source (Coschigano 
et al., 1991; Forsberg et al., 2001).  Catabolic leucine utilisation was observed during 
chemostat cultivation of an isogenic strain in an identical defined medium (Chapter 6). 
 
Decreased GDH1 expression is also related to the TCA cycle and respiration via its 
control by the HAP system, which is also required for mitochondrial biosynthesis (Dang 
et al., 1996; DeLuna et al., 2001; De Winde and Grivell, 1995) and the activation of 
respiration, e.g. during the diauxic shift (Bourgarel et al., 1999) when GDH1 expression 
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decreases (Dang et al., 1996).  The combined decrease in the expression of GDH1 and 
ACO1 (TCA cycle) may also indicate an overall decrease in the synthesis of glutamate, 
for which α-ketoglutarate is required  (Dang et al., 1996; Forsburg and Guarente, 1989; 
Liu and Butow, 1999; DeLuna et al., 2001).  GDH1 expression is also reduced in the 
presence of leucine due to its relation with branched-chain amino acid synthesis via the 
Leu3p transcription factor (Dang et al., 1996), which corresponds to the increased 
uptake of leucine from the medium (see above).  GDH2 does not have a function in 
carbon metabolism, and expression is not affected by the HAP system (Coschigano et 
al., 1991; Dang et al., 1996).   
 
Up-regulation of GDH2 expression in the presence of decreased GDH1 expression in 
the [PGK1-XYN] strain may thus have been caused by an increase in leucine uptake 
(Dang et al., 1996; Coschigano et al., 1991; Forsberg et al., 2001), an excess of NADH 
in the cell, a limitation in the availability of NADPH for biosynthesis, or a decrease in 
ammonium uptake. Overexpression of GDH2 in a Δgdh1 strain will restore the 
efficiency of ammonium utilisation to that of the parental strain (Roon et al., 1974; 
Miller and Magasanik, 1990; Nissen et al., 2000), and will increase the rate of NADH 
utilisation, the availability of NADPH and the biomass yield of the strain (Nissen et al., 
2000).  Such a strategy may have balanced an increase in NADH production in the cell 
due to the up-regulation of amino acid biosynthesis in the [PGK1-XYN] strain (Albers, 
2000).  Alternatively, the decreased expression of the MEP ammonium permeases may 
have mimicked an increase in the extracellular ammonium concentration, which elicited 
very similar changes in GDH expression during continuous cultivation (Ter Schure et 
al., 1995; Ter Schure et al., 2000).  The down-regulation of GLT1/GLN1 expression in 
[PGK1-XYN] will also decrease ATP-consumption during ammonium utilisation.  
GDH and GLN1/GLT1 activity may therefore have been varied to tune the redox 
balance in the cell (Albers, 2000), as no transhydrogenase activity exists in yeast 
(Gancedo and Serrano, 1989).   
 
Arginase (CAR1) expression was increased in both the [PGK1] and [PGK1-XYN] 
strains (more severely in the latter).  This has been associated with nitrogen limitation 
(Dubois and Messenguy, 1997), or an increase in the availability of either arginine 
(Klasson et al., 1999) or micromolar concentrations of a variety of amino acids (Dubois 
and Wiame, 1976) in the cell.  Arginine, together with allantoin and allantoate, are 
present at high concentrations (1-10 mM) in the vacuole, and may be released during 
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amino acid limitation, causing the induction of cytosolic arginase expression (Cooper, 
1982; Davis, 1986). DAL1 and DAL2 expression for allantoin degradation (Rai et al., 
1999; Cooper, 1982) was also increased in Y294 [PGK1]. 
 
Nucleotide metabolism 
Gene expression for nucleotide biosynthesis was decreased in both the [PGK1-XYN] 
and [PGK1] strains, which corresponded to the observed decreases in growth rate.  The 
expression of URA3 (present on the recombinant plasmid) for pyrimidine biosynthesis 
was decreased in Y294 [PGK1] and Y294 [PGK1-XYN], though more severely in the 
latter and in combination with reduced URA5 expression.  The apparent limitation in 
pyrimidine availability in Y294 [PGK1-XYN] was complimented by a strong up-
regulation of the genes for the supply of uracil (FUR1, FUI1, FUR4 and URA2) 
(Grenson, 1992; Reece, 2000).   
 
5.3.3.2. Energy Conservation 
The conservation of energy was significantly changed in both the [PGK1-XYN] and 
[PGK1] strains, as the rate of glucose uptake was decreased (Chapter 4).  The observed 
physiological change was reflected on a transcriptional level by significant changes in 
glycolysis and the pentose phosphate pathway (strongly up-regulated in [PGK1]; 
strongly down-regulated in [PGK1-XYN]), respiration and the TCA cycle (strongly up-
regulated in [PGK1-XYN] and down-regulated in [PGK1]), the glyoxylate cycle (down 
regulated in both [PGK1-XYN] and [PGK1]) and fermentation (up-regulated in 
[PGK1]).  Patterns of gene expression in glycolysis and respiration were highly 
consistent between the individual genes in the group, indicating the presence of an 
overall regulatory strategy and expression as co-ordinated groups (Eisen et al., 1998; 
Gasch et al., 2000).   
 
Glycolysis and PPP 
The observed decrease in the glucose uptake rate (Table 5.2) and glycolytic gene 
expression in the [PGK1-XYN] strain corresponded to the apparent limitation in 
nitrogen availability, which can cause a reduction in sugar uptake and the glycolytic 
flux (Gancedo and Serrano, 1989).  The reduced glycolytic flux of the [PGK1-XYN] 
strain most likely decreased the proportion of sugars fermented versus respired during 
respirofermentative growth and thus caused respiration to become more important 
(Lagunas, 1986), resulting in its up-regulation.  The down-regulation of hexose 
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transport, and up-regulation of respiration and mitochondrial gene expression strongly 
correlated with the transcription profile of cells undergoing a nutritional (carbon or 
nitrogen) downshift or glucose-deprivation (Shamji et al., 2000).  Decreased sugar 
uptake will also reduce the intracellular glucose concentration, which will diminish the 
repression of respiration by glucose (Alexander and Jeffries, 1990; Meijer et al., 1998).  
Conversely to the situation in the [PGK1-XYN] strain, the decrease in the glucose 
uptake rate (Chapter 4), and apparent limitation in intracellular nitrogen availability of 
the [PGK1] strain (not as severe as in the [PGK1-XYN] strain; see above) was 
associated with an increase in the expression of the glycolytic enzymes, a slightly 
decreased expression of respiration and increased expression of the fermentative 
pathway (ADH1 and ASC1). 
 
The pentose phosphate pathway (PPP) is the major source of NADPH required for 
biosynthesis during growth in defined medium (Gancedo and Serrano, 1989).  In the 
[PGK1-XYN] strain the flux through the PPP was apparently unaltered, as 
transcriptional changes only affected the ratios between constituent enzymes 
(GND1/GND2; RPE1/TAL1).  However, a net increase in the expression of two other 
NADPH-producing reactions was observed: the cytosolic malic enzyme (MDH2) and 
aldehyde dehydrogenase (ALD5/ALD6).  Changes in ammonium assimilation also 
indicated a possible shortage of NADPH in the cell (see above).  Changes in the 
expression of isoenzymes is a frequent response of yeast cells to changes in 
environmental conditions, possibly due to differences in the properties of these enzymes 
(Gasch et al., 2000). The flux through the PPP was apparently changed in the [PGK1] 
strain, as the decreased expression of ZWF1 was complimented by an increase in the 
expression of PGI1 in glycolysis, indicating a strategy for decreasing the fraction of 
carbon shunted to the PPP.  A net increase in the expression of aldehyde dehydrogenase 
(ALD5/ALD6) for additional NADPH generation, along with the increased expression 
of transketolase (TKL1) and RPE1, was also observed. 
 
TCA cycle and respiration 
Expression of ACO1 decreased more severely in the [PGK1-XYN] strain than in the 
[PGK1] strain in the early TCA cycle was mimicked by the decreased expression of 
CIT2 in the glyoxylate cycle.  In the [PGK1-XYN] strain the expression of the genes in 
the latter part of the TCA (SDH2, SDH4, FUM1) was increased, while the ratio between 
the isoenzymes LSC1/LSC2 and MDH1/MDH3 in the glyoxylate cycle was apparently 
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changed.  Gene expression for respiration also increased strongly in this strain, as was 
confirmed by the increase in mitochondrial gene expression and the increased 
expression amino acid permeases, which is related to the respiratory capacity of the 
strain (Horák, 1997).  Respiration is also up-regulated in response to limited nitrogen 
availability, as it seems to conserve nitrogen sources better than fermentative growth 
(Backhus et al., 2001).  Increased respiratory capacity was also evident from the strong 
decrease in CIT2 and DLD3 expression, whose expression levels are sharply increased 
in cells with dysfunctional mitochondria (limited respiratory capacity) (Liu and Butow, 
1999; Robinson and Lopes, 2000) and the induction of HSP26 expression (Meunier and 
Choder, 1999). Changes in ammonium assimilation also indicated a strategy for 
reducing the excess of NADH in the cell (see above), possibly due to increased amino 
acid biosynthesis (Albers, 2000).   The reduced expression of TPI1, TDH and ACO1 
(iron-dependent) in the [PGK1-XYN] strain would slowdown the rate of NADH 
production, while decreasing the glycolytic flux (Krieger and Ernst, 1994).  In the 
[PGK1] strain the decreased expression of ACO1 and CIT2 were accompanied by 
reduced expression of SDH2 and subunits of the alpha-ketoglutarate dehydrogenase 
complex (KGD2 and LPD1) in the latter part of the TCA.  Gene expression in both the 
TCA cycle and respiration thus decreased in this strain, as was confirmed by the 
decrease in mitochondrial gene expression.  The overall decrease in the TCA flux 
indicated either that the increase in glycolytic gene expression (see above) caused the 
decrease expression of respiration and the TCA, or that the imported amino acids were 
directly incorporated into protein and reduced the requirement for TCA metabolites.  
No additional strategy for reducing the NADH level in [PGK1] cells was apparent. 
 
5.3.3.3. Transcription, protein synthesis and protein fate 
Large, overall changes in the expression of genes for protein synthesis, both in the 
[PGK1-XYN] and [PGK1] strains, were complimented by smaller changes in 
transcription and the fate of the synthesised protein. 
 
Transcription 
Changes in the expression of 14% of the genes encoding transcription machinery 
resulted in stronger increases in gene expression in the [PGK1] strain than in the 
[PGK1-XYN] strain.  Stronger up-regulation in the [PGK1] strain was evident for the 
functions rRNA transcription (strongly up-regulated in [PGK1]; unchanged in [PGK1-
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XYN]), tRNA transcription (up-regulated in [PGK1] and slightly down-regulated in 
[PGK1-XYN]) and mRNA transcription (up-regulated in [PGK1] only).  
 
Protein synthesis 
The expression of 47% of the genes involved in the synthesis of proteins was changed 
in either the [PGK1] or the [PGK1-XYN] strain.  Overall, expression was strongly 
down-regulated in the [PGK1-XYN] strain and up-regulated in the [PGK1] strain, as 
was exemplified by the functions of ribosome biogenesis (ribosomal proteins), 
translation (machinery), aminoacyl-tRNA-synthetases and tRNA expression.  
Ribosomal gene expression, ribosomal biogenesis and protein synthesis is regulated 
almost entirely at transcriptional level (Warner, 1989; Tuite, 1989; Planta, 1997; DeRisi 
et al., 1997; Li et al., 1999).  The different ribosomal proteins are transcribed and 
synthesised in approximately equimolar amounts, and transcription is co-ordinately 
regulated to match the synthesis of rRNA and other translational components (Oliver 
and Warmington, 1989; Warner, 1989; Tuite, 1989; Planta, 1997; Li et al., 1999).  Cells 
can adjust the production of all ribosomal proteins in a precise and concerted fashion to 
meet the physiological demands under varying environmental conditions (Galego et al., 
1993; Planta, 1997). 
 
Protein fate (folding, modification, destination) 
Gene expression for the folding, modification and sorting of proteins in the cell were 
not strongly affected in either the [PGK1-XYN] or [PGK1] strains.  Protein folding, 
stabilization, targeting, sorting and translocation was down-regulated in both the 
[PGK1-XYN] and [PGK1] strains, whereas protein modification was up-regulated in 
both.   The assembly of protein complexes was down-regulated in [PGK1-XYN], whilst 
no net change in the expression of genes involved in proteolytic degradation was 
observed.  The composition of the proteasome may therefore have been changed 
without affecting the level of proteases.  A net increase in the expression of the stress 
response in Y294 [PGK1-XYN] may be related to the secretion of the heterologous 
protein, as numerous heat shock proteins (HSPs) and stress response proteins also 
function as molecular chaperones (Morano et al., 1998).  The decrease in UBI4 
expression in Y294 [PGK1] corresponds to the increased in fermentation relative to 
respiration in this strain (Cheng et al., 1994). 
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5.3.3.4. Cellular transport and transport mechanisms, interaction with the cellular 
environment and transport facilitation 
 
Intracellular transport and transport mechanisms 
Intra-organellular transport was up-regulated in both the [PGK1-XYN] and [PGK1] 
strains.  In the [PGK1-XYN] strain nuclear transport, vesicular transport (Golgi 
network, etc.) and vacuolar transport was down-regulated, whereas mitochondrial 
transport was up-regulated.  Cellular import was strongly increased in [PGK1] and 
[PGK1-XYN], mostly due to the large increases in the expression of amino acid 
transporters (BAP3, BAP2, MUP1, TAT1, TAT2 and LYP1), and changes in the ratios 
between hexokinase and glucokinase isoenzymes (carbon uptake).  Virtually no 
decreases in the expression of amino acid transporters were observed. 
 
Transport facilitation and interaction with the cellular environment 
Ionic homeostasis was strongly altered in both the [PGK1-XYN] and [PGK1] strains, 
with the expression of more than 50% of the ion and amino acid transport facilitators 
affected.  In [PGK1-XYN], expression of the ORFs required for the homeostasis of 
metal ions was increased, which was mostly caused by a large increase in the 
expression of the transporters for heavy metals and dominated by altered expression of 
the genes involved in iron transport at the plasma membrane and in vesicles (FIT, FRE, 
FET and ARN) (Georgatsou and Alexandraki, 1994; Yun et al., 2001; Yun et al., 2000).   
Iron and copper transporters are induced during limited metal ion availability, and is 
regulated at transcriptional level (Georgatsou and Alexandraki, 1994; Martins et al., 
1998; Georgatsou and Alexandraki, 1999).  The expression of remaining ORFs for 
cation (Na+, K+, Ca2+, NH4+, etc.) and proton homeostasis was decreased.  In the 
[PGK1] strain, an increase in the expression of ORFs for metal transport was also 
observed, though at lower levels than in Y294 [PGK1-XYN] and without increasing the 
expression of the heavy metal transporters.  Homeostasis of protons was also decreased, 
though the changes were smaller in magnitude than in Y294 [PGK1-XYN].   Changes 
in the expression of anion transporters were insignificant in both strains.  The 
expression of drug transporters was also increased in both Y294 [PGK1] and Y294 
[PGK1-XYN], though more strongly in the latter.  The general transport mechanisms 
(including ATPases and ABC transporters) were down-regulated in both the [PGK1-
XYN] (more strongly) and [PGK1] strains, consistent with the decreased homeostasis 
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of protons, the glucose-dependency thereof (Gancedo and Serrano, 1989) and the 
observed decreases in the glucose uptake rate of these strains (Chapter 4).   
 
5.3.3.5. Cell rescue, defence and virulence 
The expression of 27% of the genes involved in cell rescue, defence and virulence were 
changed in either the [PGK1-XYN] or [PGK1] strains, with Y294 [PGK1-XYN] 
experiencing significantly more stress than Y294 [PGK1].  Some of the genes in 
metabolism that are partially controlled by stress response elements (STREs) were up-
regulated in Y294 [PGK1-XYN] (ACS1, GLC7, GLK1, MDH2, TPS2, SGA1), whereas 
others were down-regulated in Y294 [PGK1] (GAC1, GLK1, HXK1, PGM2) (Moskvina 
et al., 1998).  The induction of the general stress response was apparent in both the 
[PGK1-XYN] and [PGK1] strains, though less obviously in the latter.  Three genes 
involved in the response to nutrient limitation or starvation (SNZ1, SNO1 and YGP1; 
Padilla et al., 1998) were strongly increased in both Y294 [PGK1-XYN] and Y294 
[PGK1].  Detoxification and the expression of various drug resistance genes increased 
in both the [PGK1] and [PGK1-XYN] strains, though more strongly in the latter.  In the 
[PGK1-XYN] strain, strong increases in the expression of the ARN transporters, 
associated with vesicular iron transport, as well as an increase in ATX1 expression, was 
observed as part of this response.  Changes in the glucose and energy metabolism of a 
cell can alter its lifespan, and the shift in the metabolism of the [PGK1-XYN] strain 
away from glycolysis towards a more respiratory metabolism (see above), and 
decreased transcription of tRNAs, partially corresponds to an increase in cellular ageing 
(Lin et al., 2001).   
 
5.3.3.6. Summary 
The presented overall changes in the various metabolic processes are summarised in 
Table 5.4. 
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Table 5.4. Summary of overall changes in cellular processes 
Cellular Process 
[PGK1] vs. 
[Host] 
[PGK1-XYN] vs. 
[Host] 
[PGK1-XYN] vs. 
[PGK1] 
Amino acid requirement ? ?? ? 
NH4+ utilisation -- ? ? 
μmax ? ?? ? 
Glucose uptake rate ? ?? ? 
Glycolysis ? ? ?? 
Respiration and TCA ? ? ? 
Iron uptake -- ? ? 
Fermentation ? -- ? 
Transcription machinery ? ? ? 
Protein synthesis ? ? ?? 
General stress response ? ?? ? 
URA3 expression ? ? ? 
Pyrimidine uptake -- ? ? 
Plasmid copy number ? ? ? 
?, ??: Increased measure of up-regulation of gene expression 
?, ??:  Increased measure of downregulation of gene expression 
?: Slight downregulation of gene expression 
 
5.4. DISCUSSION 
 
Genome-wide transcriptional profiles of three recombinant S. cerevisiae strains were 
compared under identical cultivation conditions, to identify the cellular processes 
involved in the physiological response to foreign protein production.  The 
transcriptional effect of a large number of glycolytic PGK1 promoters, present on the 
recombinant plasmid in the Y294 [PGK1] strain, could also be determined.  An increase 
in the abundance of a particular transcript was interpreted as an increase in the capacity 
of the cell to synthesise the corresponding protein (Backhus et al., 2001; Gasch et al., 
2000).  Though the changes in the transcriptional profiling of S. cerevisiae due to 
various environmental and genetic factors have been reported previously, the present 
investigation is the first to quantify of the transcriptional response to the production of a 
heterologous protein.  
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5.4.1. Data analysis 
The tight regulation of genes with high expression levels resulted in smaller changes 
their expression level. In response to this, a “Significance factor” was defined, which 
afforded significance to these changes.  The reported changes in the expression of 
several genes in glycolysis, respiration and ribosomal protein synthesis would otherwise 
not have been observed, despite the presence of clear regulatory trends in the 
transcriptional response.  The overall regulatory pattern for gene expression in these 
three categories was strongly mimicked by the individual genes.  The changes in 
expression levels observed in the present investigation were generally smaller in 
magnitude than in several previous reports, probably due to the transient nature of the 
transcriptional response (Gasch et al., 2000).  The present cultures were sampled after 
several hours of exponential, balanced growth, and the transcriptional response 
therefore represent quasi-steady-state changes in gene expression, which are typically 
smaller than the changes observed within a short period after a sudden change (Gasch et 
al., 2000).  The physiological changes due to the presence of the heterologous gene 
expression were also marginal, typically smaller than 15% (Chapter 4). 
 
5.4.2. Apparent amino acid limitation 
Although an excess of ammonium and amino acids was available during the course of 
batch fermentations, the transcriptional profiles of both the [PGK1] and [PGK1-XYN] 
strains were similar to cells experiencing nitrogen limitation.  This was indicated by the 
up-regulation of amino acid biosynthesis and uptake from the medium, which was more 
severe in the [PGK1-XYN] than in the [PGK1] strain, and the increased expression of 
the SNZ1, SNO1 and several of the GCN4-regulated genes in both strains (Padilla et al., 
1998; Natarajan et al., 2001).  The expression of the genes in respiration was also up-
regulated in the [PGK1-XYN] strain, whilst glycolytic gene expression was down-
regulated. Both confirmed the increased severity of the apparent nitrogen limitation in 
this strain (Backhus et al., 2001; Gancedo and Serrano, 1989).  The increase in gene 
expression for amino acid uptake in the [PGK1-XYN] strain was complimented by a 
decrease in ammonium uptake, further supporting an apparent increase in the 
dependency on amino acid uptake.  Changes in the expression of the glutamate 
dehydrogenases, GDH1 and GDH2, in the [PGK1-XYN] strain also indicated an 
increase in the intracellular leucine availability. 
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The transcriptional response was similar to that of cells experiencing nitrogen limitation 
despite the various transcriptional strategies aimed at increasing amino acid availability.  
All three of the isogenic transformants compared in the present study, retained the his3 
and trp1 auxotrophic markers, while the leu2 marker was complimented by the 
disruption fur1::LEU2.  Gene expression in the biosynthetic pathways for these three 
amino acids also increased in both the [PGK1] and [PGK1-XYN] strains.  However, 
despite the potential disturbance of amino acid metabolism by the auxotrophic 
mutations, the apparent amino acid limitation in these strains was solely due to changes 
in the content of the recombinant plasmids, as these strains were isogenic to the 
reference strain (Y294 [Host]). 
 
5.4.3. Transcriptional response to plasmid-based PGK1 promoter 
In the [pJC1] plasmid, present in the [PGK1] strain, the site of transcription initiation in 
the PGK1 promoter was separated from the site of transcription termination in the 
PGK1 terminator by 101 base pairs (Crous et al., 1995; Hitzeman et al., 1982).  A large 
number of non-translatable transcripts could therefore have been synthesised without 
subsequent protein production.  The transcriptional response of the [PGK1] strain was 
thus associated with both the presence of a large number of active, plasmid-based 
PGK1 promoters on the recombinant plasmid (50-100; Shuster et al., 1989; Bae et al., 
1998), and the synthesis of small mRNA molecules.   
 
The transcriptional changes observed in response to the addition of the PGK1 promoter 
and terminator to the recombinant plasmid are summarised in Table 5.4.  Most notable 
were the increased expression of the genes in glycolysis, fermentation and protein 
synthesis compared to the [Host] strain, despite the observed decrease in the maximum 
specific growth rate and glucose uptake rate (Table 5.2).  However, decoupling between 
glycolytic enzyme expression and the glycolytic flux has been demonstrated (Hauf et 
al., 2000; Schaaff et al., 1989), probably due to the involvement of the sugar uptake rate 
in high-level glycolytic flux control (Pritchard and Kell, 2002).  Glycolytic and 
fermentative gene expression may rather have been increased in response to the 
presence of numerous transcriptionally active PGK1 promoters in the cell, as 
overproduction of Pgk1p caused a significant increase in the glycolytic flux, 
fermentative activity and respiratory capacity of S. cerevisiae during 
respirofermentative growth (Van der Aar et al., 1990a; Van der Aar et al., 1990b). The 
cell may thus have responded to an apparent increase in the glycolytic flux, indicated by 
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transcription from a large number of PGK1 promoters in the cell.  The down-regulation 
of gene expression in the TCA cycle and respiration, confirmed by the decrease in 
mitochondrial gene expression, further substantiated an apparent increase in the 
glycolytic flux observed by the cell.  Since ribosomal protein synthesis functions as an 
indicator for the potential to grow, rather than the rate of growth itself (Donovan and 
Pearson, 1986; Ju and Warner, 1994; Pernambuco et al., 1996; Crauwels et al., 1997), 
the increase in ribosomal gene expression in the [PGK1] strain may similarly be part of 
a strategy to create spare translational capacity.  This would allow the yeast to increase 
the rate of protein synthesis instantaneously during a nutritional up-shift (Oliver and 
Warmington, 1989; Tuite, 1989).  However, both glycolytic and ribosomal gene 
expression place high demands on the transcriptional apparatus of the host strain.  
Ribosomal protein mRNAs are among the most abundant mRNAs in the cell, despite 
their short half-life, whilst the transcription of rRNA genes represents about 60% of the 
total transcription of a growing cell (Warner, 1989; Planta, 1997; Li et al., 1999).  The 
biosynthetic capacity of S. cerevisiae for the overproduction of glycolytic enzymes is 
also limited (Hauf et al., 2000).  The increased ribosomal and glycolytic gene 
expression, associated with an expected increase in the glycolytic flux, would thus 
occupy a large fraction of the available transcriptional apparatus of the host strain 
(Planta, 1997; Li et al., 1999; Jelinsky and Samson, 1999).  The resulting decrease in 
the availability of transcriptional machinery may therefore have caused a decrease in the 
growth rate and glucose uptake rate of the [PGK1] strain.  The apparent amino acid 
limitation in the [PGK1] strain may also be related to the general stress response to 
foreign gene expression, which is discussed below.  However, the severity of the 
general stress response and the apparent amino acid limitation was insufficient to 
dominate the transcriptional profile of the [PGK1] strain. 
 
5.4.4. Cellular processes affected by foreign protein production 
The transcriptional response to the production of translatable foreign mRNA molecules, 
the synthesis of the foreign protein during translation and the secretion of the produced 
protein was determined in isolation from other metabolic effects, by the comparison of 
the [PGK1-XYN] strain to the [PGK1] and [Host] strains (Table 5.4).  Foreign protein 
production caused an apparent amino acid limitation in the cell, which corresponded to 
the dependency of recombinant protein production on amino acid availability reported 
either in S. cerevisiae (Wittrup and Benig, 1994; Van der Aar et al., 1990a) or bacterial 
systems (E. coli: Ramirez and Bentley, 1993; Bacillus brevis: Park et al. 1996; 
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Staphylococcus: Gupta et al., 1999), where production levels increased significantly by 
the addition of amino acids to the cultivation medium.  Metabolite balancing during 
recombinant protein production has also identified a drain on biosynthetic precursors in 
the TCA cycle during recombinant protein production (Jin et al., 1997).  The increased 
expression level for the general stress response, specifically due to production of the 
foreign protein, indicated a greater severity of stress in the [PGK1-XYN] than in the 
[PGK1] strain (Gasch et al., 2000).  Gene expression for protein synthesis also 
decreased in response to the production of the foreign xylanase protein, which is 
normally associated with general starvation/stress conditions (Cardenas et al., 1999; 
Chu et al., 1998; DeRisi et al., 1997; Jelinsky and Samson, 1999; Natarajan et al., 2001; 
Planta, 1997; Eisen et al., 1998; Planta and Mager, 1998; Li et al., 1999; Gasch et al., 
2000) or nitrogen limitation (Warner and Gorenstein, 1978; Oliver and Warmington, 
1989; Warner, 1989; Moehle and Hinnebusch, 1991; Cardenas et al., 1999).  However, 
the decreased expression of ribosomal proteins may also be a concerted effort to divert 
transcription to the expression of other genes, since gene expression for ribosomal 
protein synthesis places large demands on the transcriptional apparatus of the yeast (see 
above; Jelinsky and Samson, 1999).  A strong correlation between the growth rate of 
the strain and the expression level of the genes for ribosomal proteins also exists (Tuite, 
1989; Lopez and Baker, 2000).  The expression of ribosomal proteins was thus related 
to the decrease in glycolytic gene expression, the glycolytic flux and the maximum 
specific growth rate of the [PGK1-XYN] strain compared to the [PGK1] strain (Tables 
5.2 to 5.4).  The secretory capacity of the host strain was apparently not saturated by 
foreign protein expression (see also Chapter 6), as was reported for other production 
systems (Wittrup et al., 1994; Tuite and Freedman, 1994; Parekh et al., 1995; Parekh 
and Wittrup, 1997), since the expression of the genes that facilitate the sorting, 
degradation and secretion of the proteins in the cell was not significantly changed in the 
[PGK1-XYN] strain.  This also indicated low levels of erroneously translated protein 
production (Kurland and Gallant, 1996).  The up-regulation of respiration in the 
[PGK1-XYN] strain was related to the apparent limitation in amino acid availability, as 
exhibited by other yeast systems (Lagunas, 1986; Shamji et al., 2000; Backhus et al., 
2001).  The increased requirement for iron in the [PGK1-XYN] strain also 
corresponded to the increase in gene expression for respiration and the electron 
transport chain (cytochromes), which are critically dependent on its availability 
(Georgatsou and Alexandraki, 1994; Krieger and Ernst, 1994; Martins et al., 1998; 
Georgatsou and Alexandraki, 1999; Foury and Talibi, 2001).  Decreased levels of 
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URA3 transcripts indicated a reduction in the copy number of the recombinant plasmid 
in the [PGK1-XYN] strain, with the resulting decrease in pyrimidine biosynthesis 
complimented by increasing the expression of the pyrimidine permeases.  The stability 
and copy number of the 2 μm plasmid was previously shown to decrease in response to 
active gene expression (Srienc et al., 1986; Janes et al., 1990; Da Silva and Bailey, 
1991). 
 
The observed transcriptional trends in the [PGK1-XYN] strain were very similar to the 
E. coli stringent response, where nutrient limitation decreased ribosome synthesis and 
increased respiration, amino acid uptake and amino acid biosynthesis (Moehle and 
Hinnebusch, 1991).  Nitrogen limitation and a nutritional downshift was previously 
shown to elicit a similar stringent response in S. cerevisiae (Backhus et al., 2001; Perez-
Ortin, 2002; McEntee et al., 1994; Yang et al., 2000; Natarajan et al., 2001). 
 
To the knowledge of the author no previous study on the transcriptional response of 
yeast to recombinant protein production has been undertaken, though several 
investigators have reported the physiological and transcriptional profiling of 
recombinant E. coli.  Decreases in the growth rate (Oh and Liao, 2000; Dong et al., 
1995) and glucose consumption rates, were complimented by a partial repression of 
glycolytic and PPP gene expression, and the transcriptional induction of respiration (Oh 
and Liao, 2000).  Measured decreases in the levels of ribosomes, the ribosomal proteins 
and those involved in translation and protein folding (Jürgen et al., 2000; Rinas, 1996; 
Dong et al., 1995) reduced the levels of normal cellular protein synthesis, and thereby 
decreasing glycolytic gene expression and activity (Dong et al., 1995; Snoep et al., 
1995).  Increased transcription of various stress-related (heat shock) and chaperone 
genes in response to recombinant protein production has also been reported (Oh and 
Liao, 2000; Dong et al., 1995; Gill et al., 2000; Gill et al., 2001), along with the 
induction of the E. coli stringent response, associated with an increase in intracellular 
proteolytic activity (Harcum and Bentley, 1993).   
 
Although the level of heterologous protein production by S. cerevisiae reported here 
(less than 1% of the total cellular protein production; Chapter 4) was considerably lower 
than typical production levels in bacterial systems (up to 40% of the total cellular 
protein production), very similar physiological and transcriptional responses were 
observed.  The magnitude of these physiological and transcriptional responses to 
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heterologous protein production by yeast was also disproportionate to the amount of 
foreign protein produced (Chapter 4).  Similar observations for recombinant E. coli 
strains overproducing heterologous proteins with no apparent catalytic activity in 
metabolism was associated with a strong decrease in translation due to the coordinate 
reduction in the rate of normal protein synthesis, the accumulation of heat shock 
proteins, and the degradation of rRNA and ribosomes (Kurland and Dong, 1996).  In 
response, the recombinant bacteria behaved as if experiencing amino acid starvation or 
antibiotic inhibition (Kurland and Dong, 1996).  In the present investigation, the 
production of heterologous xylanase by a transformed strain of S. cerevisiae apparently 
resulted in a similar stress response, by which the cells lost the ability to grow in an 
optimal, balanced fashion.  The loss of functionality by the cell due to foreign protein 
production may thus have caused the observed disproportionate metabolic effects.  The 
severity of the stress response to heterologous protein synthesis was sufficient to 
dominate the transcriptional profile of the strain. 
 
5.5. CONCLUSIONS 
 
The physiological response of recombinant S. cerevisiae strains to the presence of an 
expression system for heterologous protein production were related to the presence of 
multiple copies of the glycolytic PGK1-promoter and terminator, which apparently 
caused the cell to increase its biosynthetic capacity at the expense of other processes, 
and the synthesis of the foreign protein, which resulted in a stringent stress response by 
the host strain.  The introduction of physiological stress by heterologous gene 
expression thus caused a loss of functionality in the host strain, causing the 
disproportionate physiological effects of heterologous protein production.  The active 
up-regulation of the stringent stress response due to the synthesis and secretion of a 
foreign protein further confirmed the presence of a global sensing and regulatory 
mechanism, able to sense and respond to heterologous protein production.  The loss of 
biosynthetic capacity associated with the stringent stress response may also have limited 
the ability of the host strain to produce heterologous xylanase, resulting in lower 
production levels.  Reducing the propensity of recombinant gene expression to 
introduce metabolic stress may therefore increase production levels of foreign proteins 
by yeast. 
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5.7 APPENDIX 
 
The classification of the 1014 genes, showing significant change in their expression 
level in either the Y294 [PGK1-XYN] or [Y294 [PGK1] strains, into functional 
categories according the MIPS classification (Mewes et al., 2000) is presented in the 
Appendix D. 
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Chapter 6 
 
COMPARISON OF THREE EXPRESSION SYSTEMS FOR 
HETEROLOGOUS XYLANASE PRODUCTION BY S. CEREVISIAE 
 
6.1. INTRODUCTION 
 
In the previous two chapters the presence of a regulated stress response by the yeast cell 
to heterologous protein production was presented.  However, besides the effect of 
metabolic stress, the production levels of heterologous proteins may also be influenced 
by other genetic and physiological factors.  In the present study, the influence of 
expression vector selection and uncomplimented auxotrophic markers in transformant 
strains on the production levels of a heterologous protein were investigated.  The 
presence of global sensing and regulatory mechanisms, which may determine the 
production level of heterologous xylanase in response to these factors, was thus 
investigated. 
 
Both the copy number and stability of the expression cassette, and the genetic and 
physiological characteristics of the host strain, have been shown to affect the production 
levels of a heterologous protein by S. cerevisiae (Weber et al., 1992; Ljubijankic et al., 
1999; Park et al., 2000; Nacken et al., 1996; Janes et al., 1990; Lopes et al., 1996; Park 
et al., 2000; Eckart and Bussineau, 1996; Fleer, 1992; Schultz et al., 1994; Mendoza-
Vega et al., 1994; Porro et al., 1992).  Two types of expression vectors commonly used 
for heterologous protein production in S. cerevisiae, are the yeast episomal plasmids 
(YEp), based on the endogenous, extra-chromosomal 2 μm plasmid, and yeast 
integrative plasmids (YIp), based on homologous integration at specific chromosomal 
positions.  These vectors represent alternative methods for maintaining foreign DNA 
within a host cell.  With regard to expression level, the former benefits from higher 
copy number (up to 100 copies per cell), resulting in a higher foreign gene dosage, 
whereas the latter provides robust genetic stability.  Disadvantages are the frequent 
segregational instability of YEp vectors, resulting in the loss of the recombinant 
plasmid during cell division despite the presence of selection markers on the 
recombinant plasmid, and the low copy number of YIp vectors, resulting in low levels 
of expression (Harashima, 1998; Mendoza-Vega et al., 1994; Gellissen and Hollenberg, 
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1997; Lopes et al., 1996; Shuster et al., 1989; Bae et al., 1998; Weber et al., 1992; 
Ljubijankic et al., 1999; Park et al., 2000).  To improve the stability of YEp-type 
vectors, several autoselection systems, based on double or triple selection, have been 
developed (Loison et al., 1986; Wang and Da Silva, 1993; Compagno et al., 1993).  
One such system, based on the disruption of the native FUR1-gene in combination with 
insertion of the URA3 gene on the recombinant plasmid, in a host that contains a URA3 
mutation, resulted in excellent genetic stability, also in continuous culture (Loison et al., 
1986; Marquet et al., 1987). 
 
The presence of auxotrophic mutations in host strains for recombinant protein 
production is often essential for obtaining genetically stable transformants, through the 
use of selection strategies such as those presented above.  However, during the early 
studies of yeast genetics and molecular biology, the effect of uncomplimented 
auxotrophic mutations, not complimented by the genetic components in the 
recombinant gene expression system, on the growth and metabolism of laboratory 
strains were disregarded, or considered as insignificant.  This idea has been transferred 
to numerous molecular biologists of today.  Host strains with excessive auxotrophic 
mutations are still frequently used for recombinant protein production, resulting in 
transformant strains containing uncomplimented auxotrophic markers (See Table 2.1).  
The presence of uncomplimented auxotrophic markers in transformant strains requires 
the availability of a sufficient amount of the required metabolite in the complex or 
defined cultivation medium.  Some investigators have observed that such transformants 
may overconsume the required metabolite (amino acid or nucleotide) and can have 
difficulties in growth, protein production and genetic stability (Mendoza-Vega et al., 
1994; VanDusen et al., 1997; Pronk et al., 1996; Chopra et al., 1999; Beretta et al., 
1991; Korogodin et al., 1991; Çakar et al., 1999; Kozlov et al., 1995; L. Gustafsson, 
personal communication).  Auxotrophic strains grown in nutrient supplemented 
medium are thus not necessarily physiologically equivalent to the complemented 
transformants (Pronk et al., 1996; Chopra et al., 1999).   
 
The production of several heterologous xylanases by S. cerevisiae transformants based 
on the YEp-type expression vectors containing auxotrophic markers has been reported, 
though no mention of the effect of host strain genetics and type of expression vector 
was made (La Grange et al., 1996; Ganga et al., 1998; Crous et al., 1995; Nuyens et al., 
2001; Li and Ljungdahl, 1996; Pérez-González et al., 1996).  The effect of expression 
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vector selection and auxotrophic mutations on heterologous xylanase production by S. 
cerevisiae in batch and continuous culture were thus determined.  A trp1 his3 
auxotrophic transformant, expressing T. reesei xylanase II (XYN2) from a YEp 
expression vector, stabilised by the autoselection system of Loison et al. (1986), was 
cultivated in a chemically defined medium containing various concentrations of the 
required amino acids.  Heterologous protein production by this strain was compared to 
two prototrophic transformants, containing either the same autoselection-YEp 
expression system, or an alternative YIp-type of expression vector.  The expression 
cassette construct (promoter-heterologous xylanase-terminator) was identical in these 
strains.  Cultivation of auxotrophic transformants in the presence of an excess of the 
required amino acids resulted in a dramatic increase in levels of recombinant xylanase 
production, comparable to production levels obtained with a similar protrophic 
transformant.  The potential benefits of utilising the autoselective YEp expression 
system in a prototrophic background were thus demonstrated. 
 
6.2. MATERIALS AND METHODS 
6.2.1. Strains and plasmids 
The construction of the recombinant S. cerevisiae Y294 [ura3/URA3, leu2::LEU2, trp1, 
his3] strains producing a heterologous ß-1,4-xylanase, through expression of a plasmid-
based XYN2 gene, was previously reported (La Grange et al., 1996).  Strain stocks were 
stored in a 15% glycerol solution at –80ºC.  Manipulation of plasmid DNA and 
transformation of strains were according to standard protocols.  The genetic stability of 
the transformants were determined by replica plating from complex (YPD) medium to 
selective, defined medium (without the amino acids used for selection) and counting the 
percentage of growing colonies (Da Silva and Bailey, 1991).   
 
6.2.2. Fermentations 
Batch fermentations in a defined medium (Verduyn et al., 1992) containing 20 g.l-1 
glucose as the carbon source and amino acid supplementation as discussed below, were 
conducted in a high performance bioreactor, as previously reported (Chapter 4).  For 
glucose-limited chemostat cultures, new medium was fed to the fermenters at a constant 
rate of 60 ml.h-1 and the working volume maintained at 600 ml by controlling the 
weight of the fermentation set-up.  Glucose-limitation with a defined feed medium 
containing 15 g.l-1 of glucose was ensured by measuring the biomass yield in the same 
medium with 20 or 22 g.l-1 glucose feed.  No apparent decrease in the biomass yield 
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was observed, confirming that biomass production was limited by glucose rather than 
other nutrients.  Fermentations were aerated with oxygen-enriched air at 0.5 l.min-1 
(standard conditions) and the level of dissolved oxygen concentration maintained at a 
minimum of 60% to ensure fully aerobic growth at low dilution rates.  Steady-state 
measurements were taken after the carbon dioxide, biomass and recombinant xylanase 
production level had stabilised; the latter usually after approximately 7-8 residence 
times. 
  
6.2.3. Sampling 
Samples for the determination of cell density, substrate consumption and product 
formation during continuous cultures were removed directly from the fermentation 
broth.  The supernatant was collected by filtration through a 0.2 µm filter before storage 
at -20ºC. Samples for the determination of cell density by absorbance (620 nm) were 
diluted with 9 g.l-1 NaCl into the 0.05 - 0.2 linear absorbance detection range of the 
spectrophotometer. Samples for dry weight measurements, made in parallel to 
absorbance (A620) measurements for all steady-state samples, were taken directly from 
the fermentation broth and kept on ice during the analysis.  For the quantification of 
XYN2 and GCN4 RNA levels, 10 ml of fermentation broth was rapidly sampled, added 
to a tube containing approximately 5 ml of ice, centrifuged for 2 min and washed twice 
with cold Acetate buffer (50 mM NaAc; 10 mM EDTA), before storage at -80ºC.  
Samples for extracellular amino acids were prepared by addition of an equal volume of 
4% Trichloroacetic acid (TCA) to a supernatant sample and storage at -20ºC. Samples 
for the quantification of intracellular xylanase activity were taken from the outlet of the 
cultivation.  Approximately 15 ml of fermentation broth was collected on ice, washed 
twice with 9 g.l-1 NaCl and the cellular protein extracted with Y-PER (Yeast Protein 
Extraction Reagent; Pierce). Samples for the determination of the total cellular content 
of protein were also taken from the outlet.  The cells were collected by centrifugation, 
washed twice with 9 g.l-1 NaCl and resuspended to a final concentration of 5 g.l-1 (dry 
weight). Cell extracts and cell samples were frozen at -80ºC and stored at -20 ºC until 
analysis.  Sampling for cell density, substrate consumption and product formation 
during batch fermentation were similarly performed. 
 
6.2.4. Substrate consumption and product formation 
Glucose, ethanol, glycerol, acetate and succinate concentrations, as well as xylanase 
activity were determined as previously described (Chapter 4).  Xylanase enzyme 
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activities were converted to protein amounts (mg) by use of the conversion factor 1.812 
U.μgpure xylanase-1, obtained for the purified protein (Chapter 3).  The specific intracellular 
xylanase activity (mgactive xylanase.gcell protein-1) was determined by measuring both the 
xylanase activity (U.ml-1; as in Chapter 4) and the total protein concentration, using the 
MicroBCA kit (Pierce), in the cell extract made for this purpose.  Amino acid analyses 
were performed at the Department of Biochemistry and Nutrition, Denmark Technical 
University, Lyngby, Denmark.  Total cellular protein content was determined with the 
modified biuret method (Herbert et al., 1971), whereas total yeast protein secretion was 
measured with the MicroBCA Kit (Pierce), according to manufacturers specifications.  
Due to the potential effect of extracellular free amino acids on total protein 
measurements, samples were first treated by dialysis in pure water using a dialysis 
membrane with a very low molecular weight cut-off (1.5 kDa). 
 
6.2.5. XYN2 and GCN4 expression levels 
Quantitative Reverse-Transcriptase PCR (QRT-PCR) was used for the quantification of 
XYN2 and GCN4 RNA levels.  The total RNA content of cell samples was extracted 
according to Schmitt et al. (1990), with slight modifications to account for volume 
differences.  Extracted total RNA was used as template for cDNA synthesis using the 
Reverse Transcriptase II enzyme (Gibco), according to manufacturer’s specifications.  
Synthesised cDNA was quantified using real-time PCR performed by the LightCycler® 
(Roche).  Levels of XYN2, GCN4 and ACT1 cDNA in each 20 μl sample (containing 4 
μl cDNA mixture) were quantified, with the latter used as standard.  Each measurement 
was repeated at least three times using different dilutions of the cDNA mixture (1:1, 
1:4, 1:16), and the results analysed using the Roche LightCycler® software package. 
 
6.3. RESULTS 
 
Heterologous xylanase production by auxotrophic (trp1 and his3) transformants from a 
YEp expression vector, stabilised by an autoselection system not involving tryptophan 
or histidine (Loison et al., 1986), in a chemically defined medium was compared to 
xylanase production by prototrophic transformants, containing either the same 
autoselection-YEp expression system, or an alternative YIp-type of expression vector.  
The concentrations of amino acids in the defined medium were varied. 
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6.3.1. Construction and screening of prototrophic transformants 
For the construction of prototrophic versions of the recombinant S. cerevisiae strains 
producing heterologous xylanase, the excessive auxotrophic markers were removed 
either from the host strain prior to transformation (YIp-type strains), or directly from the 
corresponding auxotrophic transformants (YEp-type strains; La Grange et al., 1996).  
Functional versions of the LEU2, TRP1 and HIS3 yeast open reading frames were 
isolated from the plasmids, YIplac128, YIplac204 and YDp-H (Berben et al., 1991), 
respectively.  Transformation of either the host strain or the auxotrophic transformants 
with the HIS3 and TRP1 fragments for the removal of his3 and trp1 mutations were 
performed in a single step, with a good success rate.  Removal of the leu2 mutation 
prior to integration required a further transformation of the host strain S. cerevisiae 
Y294 [ura3 leu2] with the LEU2 fragment to obtain the host strain S. cerevisiae Y294 
[ura3]. 
 
6.3.1.1 Construction and screening of prototrophic YEp-based transformants 
Transformation of the two existing auxotrophic, YEp-based recombinant strains (see 
Chapter 4; La Grange et al., 1996) resulted in two prototrophic, xylanase producing 
strains:  Y294 [PGK1-XYN] PlasPro and Y294 [ADH2-XYN] PlasPro.  Additional 
strain selection through the isolation of stable colonies from selective plating was also 
performed, prior to isolation of the final transformants.  Heterologous xylanase 
production and genetic stability of several transformants were tested in two subsequent 
rounds of screening in shake-flask cultures.  Xylanase production by the prototrophic 
YEp-based transformants at similar levels to those obtained with the auxotrophic strains 
in the defined medium supplemented with seven amino acids (see Chapter 4) was 
observed (Fig. 6.1).  Due to the intrinsic lack of reproducibility of shake-flask cultures, 
little significance was associated with the differences in production levels from 
individual transformants (Fig. 6.1). 
 
Although the prototrophic transformants originating from the S. cerevisiae Y294 
[ADH2-XYN] strain was completely stable during the screening procedure, significant 
genetic instability was present in the prototrophic plasmid-based [PGK1-XYN] PlasPro 
transformants.  After 96 hours of cultivation in shake-flasks, a significant percentage 
(10-100%) of the growing transformant colonies had lost their prototrophic 
characteristics, despite two successive rounds of positive selection. 
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Figure 6.1.  Comparison of original auxotrophic strains (closed symbols) with several of 
the generated prototrophic transformants (open symbols).  (A) [PGK1-XYN] PlasPro 
strains and (B) [ADH2-XYN] PlasPro strains. (•,♦) Specific xylanase level (mg.gbiomass-
1). 
 
6.3.1.2. Construction of prototrophic YIp-based transformants 
Prototrophic, integrative transformants, based on a YIp-type expression vector, were 
obtained by rearranging sections of the YEp-expression vector and integration of the 
resulting plasmid into the ura3 locus of the Y294 [ura3] host strain.  These procedures 
are described in detail below. 
 
6.3.1.2.A. Construction of integration cassette 
Rearrangement of both the pDLG5 and pDLG6 YEp-expression vectors (Fig. 6.2) were 
attempted, to provide flanking of the expression cassettes by the URA3 selection 
marker, as depicted in Figure 6.3, and thereby allow for homologous recombination at 
the URA3 locus of the host strain.  Several potential strategies of Polymerase Chain 
Reaction (PCR) amplification were applied, with limited success in some cases. 
 
PCR AMPLIFICATION 
The Expand High Fidelity PCR System (Roche) was used for the amplification of the 
final integrative fragments, as the final fragments were relatively large (approximately 
3800 bp).  The PCR reactions were optimised by varying the annealing temperature 
(formaldehyde addition), the concentration of Mg2+ ions and the template DNA 
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concentration.  Primers for the PCR reactions were designed using the following 
general rules: 
• GC content of the primers should be 40-60%. 
• Melting point (temperature at which binding between the primer and the 
template is disturbed) of the primers used in the same reaction should be similar. 
• The 3’ end of the primer should contain at least 2 G and/or C base pairs to 
facilitate strong binding. 
 
RESTRICTION CUTTING OF PLASMIDS 
The expression cassette and URA3-marker were cut from the original pDLG5 and 
pDLG6 plasmids (La Grange et al., 1996) using the restriction enzymes, NdeI, SmaI 
and Alw44I (Fig. 6.2).  The fragments were purified using gel electroporation.  
 
Figure 6.2. Restriction enzyme digestion of the pDLG5 plasmid.  Fragment containing 
the expression cassette was isolated.  The pDLG6 plasmid was treated in a similar 
manner. 
 
 
 
 
Figure 6.3. Required integrative fragment (pDLG5 shown here) for transformation of 
Y294 [ura3] host. 
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PCR STRATEGY ONE 
The fragments isolated from the pDLG5 and pDLG6 plasmids, containing only the 
expression cassettes and URA3 marker, possessed one blunt end (SmaI) and one sticky 
end (NdeI).  The latter were removed by a blunt ending procedure using T4 DNA 
polymerase (Gibco), followed by ligation of the blunts ends using T4 DNA ligase 
(Gibco).  Hereby the reconstruction of the two “mini-plasmids”, each containing only 
an expression cassette and a URA3 marker, was attempted (Fig. 6.4).  In a final step an 
integrative fragment with URA3 flanking the expression cassettes would then be 
generated using PCR amplification (note arrows in Fig. 6.4).  Primers were designed to 
start amplification in the middle of the URA3 marker, the efficiency of these primers 
was confirmed using plasmid DNA (YIplac211) as template.  Primers binding inside 
the URA3 gene were:  Ura_L: 5’-TGT GGT GGG CCC AGG TAT TGT TAG CGC 
TTT GAA G-3’; Ura_R: 5’-AAT ACC TGC GCC CAC CAC ACC GTG TG-3’.  
However, Strategy One was not successful, most likely because of the inefficiency of 
ligations using two blunt ends.  The low success rate of this procedure apparently 
compromised the rest of the approach. 
 
Figure 6.4. Strategy One for amplification of expression cassette, resulting in an 
integrative fragment.  Ura_R and Ura_L show the binding sites and directions of the 
primers used for PCR. 
 
PCR STRATEGY TWO 
In the second approach, the isolated fragments containing the expression cassettes were 
amplified in two PCR steps, resulting in two primary PCR products:  The Long product 
extended from the middle of the URA3 gene to the end of the expression cassette, 
pDLG5 
ADH2p
XYN2
ADH2t
URA3 (orf) 
Ura_R 
Ura_L 
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whereas the remainder of the URA3 gene was amplified as the Short product.  The same 
URA3 primers as used in Strategy One were employed, though in combination with two 
additional primers, which were designed as follows:  A BamHI restriction site was 
introduced on the 5’ end of the primers which bind to the end of the expression cassette, 
whereas for the new primers binding to the end of the URA3 gene, a 19 bp extension on 
the 5’ end was introduced.  This extension contained a BamHI restriction site, closest to 
the binding region, whereas the base pairs corresponding the end of the expression 
cassette was introduced in the remainder of the 19 bp extension (Fig. 6.5).  The 
additional primers were:  pDLG5: 3’-GCG GAT CCC ATC GTC CAT TC-5’ and 5’-
GAA TGG ACG ATG GGA TCC GAA ACA TGA AAT TGC CCA G-3’ (with 
extension); pDLG6: 5’-GCG GAT CCT TAA CGA ACG CAG AAT TTT CGA G-3’ 
and 5’-CTC GAA AAT TCT GCG TTC GTT AAG GAT CCG CCC AGT ATT CTT 
AAC CC-3’ (with extension). 
 
Figure 6.5.  Primary PCR products obtained with Strategy Two. 
 
Two options for using the two primary (purified) PCR products to generate integrative 
fragments were investigated:  Firstly, the two primary products were used concurrently 
as template DNA in a single PCR reaction with the primers binding in the middle of the 
URA3 gene.  The overlapping regions (19 bp extension) would bind during the 
annealing and elongation steps, and thereby facilitate the generation of a single product 
with URA3 flanking of the expression cassette (See Fig. 6.6A).  Alternatively 
(secondly) the two primary PCR products were first cut with BamHI, producing 
BamHI 
 
BamHI 
 
ADH2p
XYN2
ADH2t
URA3 (orf) 
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compatible sticky ends on both fragments.  Ligation of fragments was attempted, again 
using T4 DNA Ligase, as the probability of a successful sticky end ligation should be 
much higher than that of a blunt end ligation.  Successful PCR amplification of the 
ligation product, also using the primers that bind to the middle of the URA3 gene, would 
produce the required integrative fragments (See Fig. 6.6B). 
 
Figure 6.6. Use of primary PCR products in Strategy Two to obtain integrative 
fragments. 
 
For both the pDLG5 and pDLG6 cassettes the generation of the Short primary PCR 
products were trivial.  However, generation of the Long PCR products (middle of the 
URA3 gene to the end of the expression cassette) was more problematic and required 
much optimisation of the reaction conditions.  The Long product was eventually 
obtained for the pDLG5 cassette ([ADH2-XYN]), though not for the pDLG6 cassette.  
One of the primers in the primary reaction for the pDLG6 cassette was also replaced 
with a primer binding further from the end of the expression cassette: 5’-GCG GAT 
CCA TTA AAA GAT AAA TAA TAG TCT ATA TAT ACG-3’.  The primary PCR 
product could still not be obtained. 
 
The attempted "Overlap PCR" (Fig. 6.6A) with the Long and Short products from the 
pDLG5 cassette produced a smear of amplification products, which indicated improper 
binding in the overlap region resulting in unspecific amplification products.  Further 
optimisation did not improve the product quality.  PCR amplification of the ligated 
pDLG5 fragments was also unsuccessful, despite attempted optimisations.  The reverse 
primer binding to the middle of the URA3 gene was also replaced, though no final  
ADH2p
XYN2
ADH2t
URA3 (frag) 
Ura_R 
Ura_L 
URA3 (frag) 
A 
ADH2p 
XYN2
ADH2t
Ura_R 
Ura_L 
URA3 (frag) 
URA3 (frag) 
B
159
PCR product could be obtained with the new, ligated primary products.  A severe 
limitation in the latter approach was the reliance on ligation products, as the generated 
amount of these products is very small.  It is therefore not possible to determine prior to 
the PCR reaction whether the ligation was successful, which compromises rational 
approaches to optimisation of the procedure. 
 
PCR STRATEGY THREE 
In the final approach for obtaining integrative fragments, a single PCR amplification of 
the original template was performed using two new primers:  The first primer was 
designed to bind 50 bp from the end of the Open Reading Frame (ORF) of the URA3 
gene, whereas the second annealed to the other end of the expression cassette.  The 
latter primer contained the 50 bp between the start of the URA3 ORF and the position 
where the first primer annealed, as an extension on the 5’ end.  A successful PCR 
amplification product would thus contain the expression cassette with 50 bp flanking of 
the URA3 gene ORF on the one side, and the remainder of the URA3 ORF on the other 
side (Fig. 6.7).  The final primers were:  pDLG5: 5’-TGC TGC CAA GCT ATT TAA 
TAT CAT GCA CG-3’ and 5’-ACA GGA CTA GGA TGA GTA GCA GCA CGT 
TCC TTA TAT GTA GCT TTC GAC ATG GAT CCC ATC GTC CAT TC-3’ (with 
50 bp extension); pDLG6:  5’-TGC ACG AGT TAT AAT ATA TCG GGT GAC AC-
3’ and 5’-GCG GAT CCA TTA AAA GAT AAA TAA TAG TCT ATA TAT ACG 
GCA GCA CGT TCC TTA TAT GTA GCT TTC GAC ATG GAT CCC ATC GTC 
CAT TC -3’ (with 50 bp extension). 
 
PCR amplification of the pDLG5 expression cassette with the newly designed primers 
proved trivial, whereas numerous optimisation efforts did not result in a PCR product 
with the pDLG6 cassette.  The pDLG6 plasmid was also sequenced in the areas close to 
the binding sites of the primers, which proved to match the designed primers exactly.  
The addition of "PCR enhancers" such as BSA, DMSO and Tween 20 also did not 
result in the generation of a proper PCR product, and no explanation for the poor 
performance of the pDLG6 plasmid as PCR template could be afforded. 
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Figure 6.7.  Strategy Three to obtain integrative fragments containing an expression 
cassette. 
 
6.3.1.2.B. Transformation of S. cerevisiae Y294 [ura3] 
The S. cerevisiae Y294 [ura3] host strain was transformed with the integrative fragment 
generated by PCR from the pDLG5 expression cassette, containing only DNA from 
yeast origin.  Recombination of the non-functional URA3 gene ORF on the yeast 
chromosome with the functional fragments of the ORF contained in the integrative 
plasmid (double cross-over procedure) resulted in a single functional version of the 
URA3 gene ORF on the chromosome (Fig. 6.8).  Transformants were selected on the 
basis of prototrophy. 
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Figure 6.8. Recombination of chromosomal ura3 ORF with integrative plasmid URA3 
ORF.  Native ura3 promoter was used for regulation of URA3 expression.  Binding sites 
of PCR primers used to verify the presence of the XYN2 expression cassette are 
indicated. 
 
To confirm the presence of the ADH2-XYN expression cassette and the XYN2 gene on 
the chromosome, the transformants were cultivated in shake-flasks and the presence of 
xylanase activity confirmed (Appendix B, Table B.1).  The total genomic DNA content 
of several transformants was also isolated, and the presence of the XYN2 gene 
confirmed with PCR (Fig. 6.9).  The functional version of the URA3 ORF was 
integrated into the chromosome of the S. cerevisiae Y294 [ura3] host strain 
downstream from the original ura3 promoter (Fig. 6.8).  The generation of a PCR 
product using the genomic DNA as template and primers that bind inside the ura3 
promoter and inside the XYN2 gene (indicated by arrows in Fig. 6.8) thus proved that 
the XYN2 gene was present on the chromosome (Fig. 6.9). The resulting strain was 
named [ADH2-XYN] Int. 
Xyn2 ADH2p ADH2t ura3-ORF 
(No function) 
 
   URA3-ORF    ura3p 
  Integrated 
ura3-ORF 
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  Ura3p 
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Figure 6.9. Use of PCR to confirm integration of the ADH2-XYN expression cassette 
(rearranged from plasmid pDLG5) in S. cerevisiae Y294 [ADH2-XYN] Int.  Lane 1: 
Molecular weight marker; Lane 2: Successful integration and PCR, showing a 2.7 kbp 
product; Lane 3: Unsuccessful integration. 
 
6.3.2. Comparison of prototrophic and auxotrophic transformants in batch culture 
Prototrophic and auxotrophic strains were compared in batch culture to determine the 
effect of expression vector selection and auxotrophic requirements on the production 
level of heterologous xylanase and the physiology of the transformant strain. 
 
6.3.2.1. Comparison of prototrophic strains 
The growth and xylanase production of the constructed prototrophic strains ([ADH2-
XYN] Int, [ADH2-XYN] PlasPro, [PGK1-XYN] PlasPro) were first compared in batch 
cultivation in defined medium without amino acids (Fig. 6.10).   
← PCR Product  
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Figure 6.10.  (A) Growth and (B) Specific xylanase production by the prototrophic 
recombinant S. cerevisiae strains in defined medium without amino acids.  (♦) [ADH2-
XYN] PlasPro, (•) [ADH2-XYN] Int, and (?) [PGK1-XYN] PlasPro strains. 
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During the cultivation of the prototrophic transformants, the patterns of heterologous 
xylanase production from the YEp-based expression vectors corresponded to the typical 
characteristics of the PGK1 and ADH2 promoters employed (Fig. 6.10).  The 
characteristics of these promoters were discussed in Chapter 4.  Xylanase production by 
the [PGK1-XYN] PlasPro strain was also inferior to the [ADH2-XYN] PlasPro strain, 
as was observed for the auxotrophic versions of the strains (Chapter 4), although the 
genetic instability of the former may have attributed to this effect.  Though xylanase 
production by the [ADH2-XYN] Int strain was measurable, it was very poor compared 
to the YEp-based prototrophic strains.  The [ADH2-XYN] Int strain apparently grew 
faster and to a higher biomass yield than the other strains, with the [PGK1-XYN] 
PlasPro strain growing the slowest and to the lowest final biomass yield.  Due to the 
presence of genetic instabilities, no further investigation of the [PGK1-XYN] PlasPro 
strain was undertaken, and the comparison of auxotrophic and prototrophic strains was 
thus limited to expression systems regulated by the ADH2 promoter. 
 
6.3.2.2. Comparison of plasmid-based auxotrophic and prototrophic transformants with 
ADH2-regulated expression systems in batch culture 
The auxotrophic and prototrophic versions of the YEp-based [ADH2-XYN] strain were 
also compared in batch culture.  To support the growth of the auxotrophic strain, the 
chemically defined medium was first supplemented only with the amino acids, histidine 
(165 mg.l-1), leucine (870 mg.l-1) and tryptophan (664 mg.l-1).  Whereas histidine and 
tryptophan represent auxotrophic requirements, leucine was added because of the high 
levels of consumption in defined medium previously reported (Albers, 2000; Kozlov et 
al., 1995; L. Gustafsson, personal communication).  The concentrations of these amino 
acids were selected by a rational approach, based on the requirements for biomass 
formation (Greasham and Herber, 1997; unpublished results), with the total amino acid 
concentration in the medium corresponding to 10.8 mM.  During shake-flask cultivation 
a medium with a total amino acid content of 4.3 mM was able to support the maximum 
level of biomass formation by the auxotrophic strain (Appendix B, Fig. B.1).  At a total 
concentration of 10.8 mM, an excess of amino acids were thus available for biomass 
formation and heterologous protein production, justifying its use as the maximum level 
of addition.  The effect of reducing the total amino acid concentration to 4.3 and 1.9 
mM on the general fermentation performance of the strain, while keeping the ratios 
between the individual amino acids constant, was also evaluated.  The influence the 
total auxotrophic amino acid concentration on the maximum specific growth rate of the 
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auxotrophic [ADH2-XYN] strain, compared to the prototrophic strain cultivated in 
defined medium without amino acids, is presented in Table 6.1. 
 
Table 6.1.  Effect of total auxotrophic amino acid concentration on the growth of the 
auxotrophic [ADH2-XYN] strain. 
Total Amino Acid Concentration 
[mM] 
Maximum Specific Growth Rate, μmax 
[h-1] 
10.8 0.22 
4.3 0.30 
1.9 0.41 
0.0** 0.32 
** [ADH2-XYN] PlasPro strain 
 
Decreasing the total amino acid concentration in the defined medium increased the 
growth rate of the auxotrophic strain, resulting in a fairly fast growth rate for the 
auxotrophic strain in a medium containing only 1.9 mM of amino acids.  The substrate 
consumption and product formation during these cultures are presented in Figures 6.11 
and 6.12.  The highest levels of biomass formation, and xylanase production per unit of 
biomass, were observed during cultivation of the auxotrophic strain in a medium 
supplemented with the maximum level of amino acids (10.8 mM).  Growth and 
xylanase production in the latter cultures were comparable to levels obtained with the 
prototrophic strain in the medium without amino acids, and were significantly improved 
compared with cultures with 4.3 or 1.9 mM of amino acids (Fig. 6.11A and B).  The 
increase in biomass and xylanase production in the former two cultures was 
accompanied by a decrease in ethanol formation (Fig. 6.11D) and an increase in CO2 
production (Fig. 6.11E; Fig. 6.12C), though the rate of glucose uptake (i.e. the 
glycolytic flux) was unaffected (Fig. 6.12A).  The decreased biomass yield of the 
auxotrophic strain in the presence of 4.3 mM amino acids thus resulted in increased 
ethanol, carbon dioxide and glycerol formation (Fig. 6.11A, D and E; Fig. 6.12C and 
D). 
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Figure 6.11.  Substrate consumption and production formation by the auxotrophic [ADH2-
XYN] and prototrophic [ADH2-XYN] PlasPro strain during batch cultivation in defined 
medium.  The [ADH2-XYN] PlasPro strain (?) was cultivated in a defined medium without 
amino acids, whereas the auxotrophic strain was cultivated in a medium containing the 
amino acids, histidine, leucine and tryptophan at a total concentration of 10.8 mM (?), 4.3 
mM (?) and 1.9 mM (?). 
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Figure 6.12.  Substrate consumption and production formation by the auxotrophic [ADH2-
XYN] and prototrophic [ADH2-XYN] PlasPro strain during batch cultivation in defined 
medium.  The [ADH2-XYN] PlasPro strain (?) was cultivated in a defined medium without 
amino acids, whereas the auxotrophic strain was cultivated in a medium containing the 
amino acids, histidine, leucine and tryptophan at a total concentration of 10.8 mM (?), 4.3 
mM (?) and 1.9 mM (?). 
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Decreasing the total amino acid concentration below 4.3 mM limited biomass formation 
by the auxotrophic strain, as the final biomass yield in the cultivation with 1.9 mM of 
amino acids was significantly reduced (Fig 6.11A). Severe amino acid limitation 
apparently set in before glucose was completely consumed, resulting in immediate 
cessation of biomass formation (Fig. 6.11 A and C), though ethanol formation may have 
continued for a short while after amino acid depletion.  Despite the severe amino acid 
limitation of biomass formation, the xylanase production levels during cultivation in the 
presence of 1.9 and 4.3 mM of amino acids were approximately equal.  However, these 
levels were significantly lower than those obtained with the prototrophic strain in 
defined medium without amino acids, or with the auxotrophic strain during cultivation 
in the presence of an excess of amino acids (10.8 mM) (Fig. 6.11A and B).  The faster 
growth rate of the auxotrophic strain in the presence of 1.9 mM of amino acids was 
reflected by an increased rate of glucose consumption, and carbon dioxide and ethanol 
formation (Fig. 6.11C, D and E; Fig. 6.12A, B and C).  Ethanol and glycerol 
consumption after the diauxic shift in the presence of severe amino acid limitation (1.9 
mM amino acids) was apparently much reduced, though high levels of carbon dioxide 
formation was observed during this metabolic phase (Fig. 6.11D and E; Fig. 6.12B, C 
and D).  The degree of reduction- and carbon -balances also indicated that evaporation 
contributed significantly to the time-wise decrease in ethanol levels after severe amino 
acid limitation, rather than metabolic consumption (Appendix B, Table B.2).  The level 
of acetate formation was significantly increased during severe amino acid limitation 
(Fig. 6.12E). 
 
6.3.2.3. Effect of amino acid supplementation on the prototrophic YEp- and YIp-
transformants in batch culture 
In an effort to further improve xylanase production by the auxotrophic strain, the amino 
acid content of the defined medium was increased, prior to cultivation in glucose-
limited chemostat, to include the amino acids aspartate (257 mg.l-1), glutamate (64 mg.l-
1), glycine (33 mg.l-1) and serine (108 mg.l-1), in addition to those already present at 
maximum concentration in the defined medium.  These amino acids and their 
concentrations were also selected by considering biosynthetic requirements (suggested 
by Greasham and Herber, 1997; Chapter 4).  The effect on the prototrophic strains of 
supplementing the defined medium with all seven amino acids was tested in batch 
culture (Fig. 6.13). 
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Figure 6.13.  Growth and xylanase production by the prototrophic [ADH2-XYN] 
PlasPro (?,?) and [ADH2-XYN] Int (?,O) strains during batch cultivation in defined 
medium.  Open symbols indicate cultivation in medium with the seven amino acid 
mixture, and closed symbols in the medium without. (A) Biomass formation (g.l-1) and 
(B) specific xylanase production (mg.gcells-1). 
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Addition of the selected amino acid mixture to the defined medium significantly 
inhibited xylanase production by both the [ADH2-XYN] PlasPro and [AND-XYN] Int 
prototrophic strains, though the growth of the strains was not severely affected (Fig. 
6.13).  Xylanase production levels by the [ADH2-XYN] Int strain in defined medium 
without amino acids was measurable, though in the medium with amino acids no 
production could be measured. 
 
6.3.3. Comparison of prototrophic and auxotrophic transformants in glucose-
limited chemostat culture 
The growth and heterologous xylanase production of the prototrophic [ADH2-XYN] 
PlasPro and [ADH2-XYN] Int strains were compared to the performance of two 
auxotrophic strains, [ADH2-XYN] and [PGK1-XYN], in chemostat culture.  
Cultivation of the strains at low dilution rates (0.1 h-1 or below) under aerobic 
conditions resulted in a fully respiratory metabolism, characterised by high levels of 
biomass and CO2 formation with very little ethanol production.  The stabilisation of the 
YEp-expression vector by the ura3 fur1 autoselection system resulted in excellent 
genetic stability in continuous cultivation, with no significant decrease in xylanase 
production or plasmid stability by the auxotrophic [ADH2-XYN] and [PGK1-XYN] 
strains during 1150 hours of growth, corresponding to more than 100 generations. 
 
6.3.3.1. Oscillatory behaviour during fully aerobic, glucose-limited growth in 
chemostat culture 
In some chemostat cultures, the attainment of steady-state levels of carbon dioxide 
production and oxygen consumption was complicated by cell cycle synchronisation in 
the yeast population, resulting in oscillatory changes in the CO2 and O2 concentrations 
in the gas-outlet from the fermenter (Fig. 6.14).  This phenomenon has previously been 
associated with fully aerobic metabolism in chemostat culture (Beuse et al., 1999; Sohn 
et al., 2000; Murray et al., 1998).  The period of the oscillations varied between 4.5h 
([AND2-XYN] Int) and 6-8h ([ADH2-XYN] PlasPro).   
 
Frequent sampling during oscillatory behaviour confirmed that oscillations had no 
measurable effect on the production level of heterologous xylanase, whereas 
representative steady-state values for the CO2 and O2 levels in the outlet during these 
oscillations were obtained by averaging over several residence times.  The effect of 
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oscillations on the steady-state readings could further be minimised by comparing 
HPLC-measured concentrations of glucose and extracellular metabolites in the 
fermenter during the final three residence times prior to steady-state sampling.   
Fermentation Time (h)
380 390 400 410 420
O
2 C
on
te
nt
 o
f G
as
-o
ut
le
t (
%
)
42.2
42.4
42.6
42.8
43.0
43.2
43.4
C
O
2 C
on
te
nt
 o
f G
as
-O
ut
le
t (
%
)
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
 
Figure 6.14.  Oscillatory behaviour of [ADH2-XYN] PlasPro yeast population during 
fully aerobic growth in glucose-limited chemostat culture, maintained at a dilution rate 
of 0.1 (h-1) by feeding of chemically defined medium without amino acids.  Graph 
indicates changes in the O2 (upper, blue line) and CO2 (lower, red line) content (%) of 
the gas-outlet from the fermenter. 
  
6.3.3.2. Comparison of auxotrophic and prototrophic transformants producing 
heterologous xylanase in glucose-limited chemostat culture 
For the cultivation of the auxotrophic strains in glucose-limited chemostat culture, the 
defined feed medium, containing 15 g.l-1 of glucose, was supplemented with seven 
amino acids at the maximum concentrations (see above).  The effect of varying the total 
amino acid concentration in the feed was investigated by reducing the concentration of 
glucose in the feed from 15 to 5 g.l-1, which subsequently decreased the C/N ratio 
(gglucose.mmolfree amino nitrogen-1) of the feed and the concentration of biomass in the 
fermenter, while increasing the total amino acid uptake per gram of biomass (Fig. 6.15).   
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Figure 6.15. Xylanase production, biomass formation and amino acid metabolism of the 
auxotrophic [ADH2-XYN] and [PGK1-XYN] strains in glucose-limited chemostat culture. (?) 
Extracellular xylanase production (mg.gbiomass-1). (A) Consumption of Trp, His and Leu (?,O) 
and (B) consumption of Asp, Glu, Gly and Ser (?,O). (?,?) Total requirement for biomass 
formation and (O,O) actual amino acid consumption. (C) (?) Total amino acid secretion 
(μmol.gbiomass-1). (D) (?) Biomass yield (gbiomass.gglucose consumed-1). (E) For comparison, xylanase 
production by [ADH2-XYN] PlasPro in defined medium with seven amino acids (?) or defined 
medium without amino acids (?). 
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Figure 6.16. Expression and processing of Xyn2p by auxotrophic [ADH2-XYN] in 
glucose-limited chemostat culture.  (?) Extracellular xylanase production (mg.gbiomass-1). 
(A) XYN2 (?) and GCN4 (?) total RNA levels, quantified with RT-PCR. (B) (?) 
Intracellular level of xylanase protein (mg.gprotein-1), based on activity measurements. 
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Heterologous xylanase production levels by both auxotrophic strains were radically 
dependent on the C/N ratio of the feed medium, and thus on the level of amino acid 
uptake per gram of biomass (Fig. 6.15).  The dramatic improvement in specific 
xylanase production demonstrated in Fig. 6.15 (A and B) was caused solely by 
changing the ratio between glucose and amino acids in the feed, since changing the 
concentrations of other defined medium components (ammonium, mineral salts, 
vitamins and trace elements) did not have a similar effect (Appendix B, Table B.3).  
Differences in the xylanase production levels of the [ADH2-XYN] and [PGK1-XYN] 
auxotrophic strains were overshadowed by the dramatic increase in production levels in 
response to high levels of amino acid uptake, indicating that the effect was strongly 
related to the host strain physiology and genetics.  Increased production of xylanase was 
apparently caused by the increased uptake of leucine, histidine and tryptophan, since 
increasing the concentration of the other four amino acids (aspartate, glutamate, glycine 
and serine) did not cause a similar increase in production levels (Fig. 6.15B; C/N ratio ≈ 
0.6).  Levels of leucine, histidine and tryptophan uptake were constantly in excess of the 
stoichiometric requirement for biomass formation (Fig. 6.15A).  Amino acid analysis 
also revealed a low level of secretion of the 13 amino acids not supplemented to the 
defined medium (Fig. 6.15C).  The dramatic increase in extracellular xylanase 
production corresponded to a significant increase in the total amino acid secretion per 
gram of biomass (Fig. 6.15C).  Although the biomass yields of the auxotrophic strains 
increased slightly when the C/N ratio of the feed was reduced from 0.8 to 0.55, no 
further increases were observed during the shift to the lowest C/N ratio (Fig. 6.15D), 
which corresponded to the maximum amino acid uptake and xylanase production.  
Increased amino acid uptake thus did not improve biomass formation.  Changes in the 
extracellular levels of heterologous xylanase were also associated with decreases in the 
total XYN2 and GCN4 RNA-content of the auxotrophic [ADH2-XYN] cells (Fig. 
6.16A).  Fairly significant decreases in the intracellular xylanase level (based on activity 
measurements) were also observed in response to the decrease in the C/N ratio that 
resulted in high levels of extracellular xylanase (Fig. 6.16B).  The dramatic increase in 
the level of extracellular xylanase production was not mimicked by a similar 
improvement in total protein secretion, although accurate measurements of total protein 
secretion was complicated by the low production levels and the dilution of samples 
during dialysis (Appendix B, Fig. B.2). 
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The formation of metabolic products by the auxotrophic [ADH2-XYN] strain was 
analysed by means of a carbon-balance, assisted by a degree of reduction balance 
(Table 6.2).  Due to difficulties with the measurement of the O2-content of the outlet, an 
RQ value of 1.07 (Sonnleitner and Käppeli, 1986) was used to calculate the O2-
consumption.  Since the increase in xylanase production at low C/N ratios was not 
accompanied by a significant increase in the levels of metabolic products, the carbon 
skeletons of the amino acids imported by the cell were most likely not utilised, but 
rather secreted (Cooper, 1982).  The utilisation of carbon skeletons would have resulted 
in a significant increase in ethanol production and evaporation (approximately 0.39 
cmol.cmolglucose consumed-1), which is highly unlikely since the production of biomass and 
other metabolic products were unaffected. 
 
The effect of high levels of amino acids in the defined medium on heterologous 
xylanase production by the prototrophic [ADH2-XYN] PlasPro and [ADH2-XYN] Int 
strains in chemostat cultivation was also determined.  Supplementation of the defined 
medium with all seven amino acids significantly inhibited xylanase production by the 
[ADH2-XYN] PlasPro strain (Fig. 6.15E), similar to the observation made during batch 
cultivation in defined medium (Fig. 6.13).  Xylanase production levels by the [ADH2-
XYN] PlasPro strain during chemostat cultivation in the same defined medium without 
amino acids were very similar to the maximum levels produced by the auxotrophic 
[ADH2-XYN] strain during chemostat cultivation in the defined medium supplemented 
with maximum levels of amino acids.  Although cell cycle synchronisation and 
metabolic oscillations in chemostat was observed more frequently with the prototrophic 
than with the auxotrophic strains, no oscillatory behaviour was observed for the 
[ADH2-XYN] PlasPro strain when cultivated in the presence of all seven amino acids.  
The biomass yield of the [ADH2-XYN] PlasPro strain during fully aerobic cultivation 
was also negatively affected by the presence of these amino acids (Table 6.3).  
Although the levels of xylanase production by the [ADH2-XYN] Int strain in chemostat 
culture were too low for quantification, biomass formation was negatively affected by 
the presence of all seven amino acids (Table 6.3).  Even in the presence of maximum 
amino acid levels, the biomass yield of the auxotrophic strain was lower than for the 
prototrophic strain in defined medium without amino acids (Table 6.3).  For both the 
[ADH2-XYN] PlasPro and [ADH2-XYN] Int strains, no significant genetic instability 
was observed during continuous cultivation up to 690 and 400 hours, respectively. 
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Table 6.2. Carbon-balance* for the auxotrophic [ADH2-XYN] during glucose-limited chemostat cultivation in defined medium. 
Feed Co-substrates Metabolic products [cmol]  Degree of Carbon 
C/N ratioa Glucoseb AA's [cmol] O2 [amol]c Biomass CO2 Glycerol Acetate Succinate Ethanold Xylanase [mg] reduction balance 
0.802 15.9 -0.187 -1.11 0.405 0.592 0.001 0.0 0.006 0.012 0.49 0.0 1.02 
0.793 15.7 -0.188 -1.06 0.413 0.568 0.001 0.001 0.004 0.021 0.13 0.0 1.01 
0.793 15.7 -0.188 -1.16 0.401 0.621 0.008 0.002 0.010 0.008 0.23 0.0 1.02 
0.790 15.7 -0.189 -1.18 0.379 0.630 0.008 0.002 0.011 0.008 0.60 0.0 1.02 
0.775 15.4 -0.188 -1.02 0.445 0.546 0.008 0.0 0.004 0.008 0.23 0.0 1.01 
0.775 15.4 -0.188 -1.03 0.440 0.549 0.009 0.001 0.004 0.009 0.11 0.0 1.01 
0.567 15.6 -0.238 -1.10 0.491 0.589 0.008 0.0 0.003 0.016 1.13 0.0 1.01 
0.552 11.0 -0.261 -1.03 0.441 0.551 0.015 0.0 0.003 0.014 1.71 0.0 1.01 
0.395 7.8 -0.366 -0.90 0.495 0.481 0.016 0.0 0.003 0.008 30.48 0.0 1.00 
0.296 5.9 -0.475 -0.86 0.484 0.462 0.024 0.0 0.003 0.021 37.14 0.0 0.99 
0.291 11.6 -0.495 -0.88 0.452 0.473 0.015 0.0 0.003 0.043 27.61 0.0 0.99 
0.275 5.5 -0.509 -0.97 0.459 0.518 0.029 0.0 0.002 0.001 15.47 0.0 1.01 
0.274 5.4 -0.530 -1.05 0.433 0.563 0.0 0.0 0.003 0.012 13.15 0.0 1.01 
0.273 10.8 -0.529 -1.19 0.470 0.635 0.014 0.0 0.003 0.018 27.69 0.0 1.02 
*Note: Except for Feed Glucose in [g.l-1], the units of measurements are reported on the basis of one cmol of glucose consumed. 
a gglucose.mmolamino N-1   b g.l-1   c Moles of O-atoms   
d Corrected for evaporation, as calculated with degree of reduction balance 
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Table 6.3. Biomass yield of auxotrophic and prototrophic strains in chemostat culture. 
Strain Amino acid supplementation Biomass yield 
[ADH2-XYN] Aux 7 AA’s (Max) 0.42 ± 0.04 
[ADH2-XYN] PlasPro None 0.53 ± 0.04 
[ADH2-XYN] PlasPro 7 AA’s (Max) 0.45 ± 0.03 
[ADH2-XYN] Int 7 AA’s (Low) 0.57 ± 0.02 
[ADH2-XYN] Int 7 AA’s (Max) 0.40 
 
 
6.4. DISCUSSION 
 
The growth and heterologous xylanase production of a trp1 his3 auxotrophic S. 
cerevisiae transformant, from a YEp-based expression vector stabilised by an 
autoselection system (Loison et al., 1986), was characterised in a chemically defined 
medium containing various concentrations of the required amino acids.  The 
performance of the strain was compared to two prototrophic transformants, containing 
either the identical autoselection-YEp expression system, or an alternative YIp-type 
expression vector with the same expression cassette.  The effect of expression vector 
selection and auxotrophic mutations on the growth and heterologous xylanase 
production of recombinant S. cerevisiae in batch and continuous culture could thus be 
determined. 
 
6.4.1. Choice of expression vector 
The choice of expression vector significantly affected production levels of heterologous 
xylanase.  Production levels by the YIp-type expression vector were largely inferior to 
levels obtained with the YEp-type vectors, both in batch and continuous culture.  The 
increased gene dosage obtained with the YEp-type vectors thus dramatically improved 
heterologous xylanase production, as has been reported for other heterologous protein 
production systems (Smith et al., 1985; Bitter et al., 1987; Denis and Drouin, 1987; 
Kaisho et al., 1989; Janes et al., 1990; Weber et al., 1992; Mendoza-Vega et al., 1994; 
Compagno et al., 1996; Lopes et al., 1996; Nacken et al., 1996; Gellissen and 
Hollenberg, 1997; Ljubijankic et al., 1999; Park et al., 2000; Vassileva et al., 2001; Kim 
et al., 2001).  The increase in the growth rate and biomass yield of the [ADH2-XYN] 
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Int strain compared to the YEp-based strains in batch culture (Fig. 6.10) was apparently 
related to the absence of the "metabolic loads" associated with the retention of multiple 
copies of the 2μm plasmid (Mead et al., 1986) and the production of the heterologous 
xylanase (Chapter 4).   
 
The high level of foreign gene expression from the multi-copy YEp-type vector did not 
saturate the secretory capacity of the host strain for proteins, though in other cases 
saturation has been observed for similar expression systems (Wittrup et al., 1994; Tuite 
and Freedman, 1994; Parekh et al., 1995; Parekh and Wittrup, 1997).  The excellent 
genetic stability of the present YEp-based transformants during chemostat cultivation 
demonstrated the ability of the ura3 fur1 autoselection system to stabilise YEp-type 
vectors (Marquet et al., 1987), and cast doubt on the necessity of extending the system 
by inclusion of urid-k disruption (Wang and Da Silva, 1993).  The total xylanase 
production of 24 mg.l-1 by the prototrophic [ADH2-XYN] PlasPro strain at low biomass 
concentration (approximately 5 g.l-1) in batch cultivation was of the same order of 
magnitude as the 60 mg.l-1 of heterologous xylanase obtained with P. pastoris under 
similar conditions (Berrin et al., 2000).  Use of autoselection-YEp-based expression 
vectors may be preferred to multi-copy integration systems, such as the loxP or 
repetitive DNA-targeting methods (Lee and Da Silva, 1996; Güldener et al., 1996; 
Parekh et al., 1996), due to ease of molecular biology techniques (Alberghina et al., 
1993).   
 
6.4.2. Influence of auxotrophic requirements 
The effect of uncomplimented auxotrophic markers on the production levels of 
heterologous proteins by transformed strains remain unclear, since two of the highest 
production levels of heterologous protein reported in S. cerevisiae were obtained by 
cultivating an auxotrophic transformant in complex medium (De Baetselier et al., 1991; 
Lee et al., 1999).  However, despite these examples of high production levels with 
auxotrophic transformants, convincing evidence was given in the present investigation 
of the potential negative effects of these markers. 
 
179
6.4.2.1. Effect on growth 
A limited availability of the required amino acids significantly reduced biomass 
formation by the auxotrophic [ADH2-XYN] strain in batch culture, similar to previous 
observations (Beretta et al., 1991; VanDusen et al., 1997; Shiba et al., 1998; Zigova et 
al., 1999).  Increasing the concentration of these amino acids in the defined medium 
increased the final biomass concentration, until the maximum biomass yield was 
attained, whilst decreasing the growth rate of the transformant strain.  The latter 
observation is consistent with the frequent over-accumulation of amino acids by yeast, 
even to the point of inhibition of its own growth (Eddy, 1982).  Poor growth on ethanol 
during severe amino acid limitation indicated that the activity of the enzymes required 
for gluconeogenesis was also reduced.  
 
6.4.2.2. Effect on heterologous xylanase production 
Supplementation of the defined medium with an excess of leucine, histidine and 
tryptophan, compared to the requirements for biomass formation, dramatically 
increased heterologous xylanase production by the auxotrophic [ADH2-XYN] and 
[PGK1-XYN] strains, both in batch and chemostat cultivation.  Extremely low levels of 
heterologous xylanase production by auxotrophic, YEp-based transformants in defined 
media without amino acid excess, were previously reported (Donald et al., 1994; Pérez-
González et al., 1996; Nuyens et al., 2001), along with increased production of various 
heterologous proteins by auxotrophic transformants due to increased amino acid 
availability (Carty et al. 1987; Wittrup and Benig, 1994; Shiba et al., 1998; Zigova et 
al., 1999; Rao et al., 2000).  Wittrup and Benig (1994) observed a 8-fold increase in 
foreign protein production by a leu2 ura3 auxotrophic transformant in batch cultivation 
due to supplementation with an excess of amino acids.  Surprisingly, the level of total 
free amino nitrogen in the two defined media reportedly supporting higher production 
levels (37 and 19 mM; Wittrup and Benig, 1994) would have resulted in an amino acid 
availability of approximately 15 and 7.9mM.gbiomass-1 in batch culture (assuming a 
biomass yield of 0.12 g.gglucose consumed-1), both of which are larger than the availability of 
7.8 mM.gbiomass-1 required for increased xylanase production in the present glucose-
limited chemostat cultures.  The effect of growth rate changes in chemostat culture on 
the levels of heterologous xylanase production by the auxotrophic strains were marginal 
compared to the effect of amino acid concentration in the feed (Appendix B, Fig. B.3). 
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The observation of the “amino acid effect” for both the ADH2- and PGK1-regulated 
expression systems, indicated a strong relation to the host strain characteristics. 
 
The utilisation of an excess of auxotrophic amino acids, resulting in maximal levels of 
heterologous xylanase production by the auxotrophic strain, did not increase the level of 
biomass formation significantly.  The excess of amino acids was therefore not 
incorporated into cellular protein, as observed in previous reports (Wittrup and Benig, 
1994; Albers et al., 1996).  The excess of amino acids was probably catabolised by de- 
or trans-amination, resulting in the utilisation of the amino groups and secretion of the 
carbon skeleton (Cooper, 1982).  This occurs more readily when the amino acids are 
present at a high concentration (Grenson, 1992), as was the case when the C/N ratio of 
the feed medium was below 0.3 (gglucose.mmolamino N-1) (Fig. 6.15A).  Both metabolite 
balancing using the Metabolic Network Analysis software package (SPAD IT, The 
Netherlands), as well as the carbon- and degree of reduction-balances (Table 6.2), 
indicated that the carbon skeletons of the amino acids were probably not utilised. 
 
The increased xylanase production at a C/N ratio below 0.3 (gglucose.mmolamino N-1) in 
glucose-limited chemostat cultivation was associated with the increased secretion of the 
13 amino acids not supplied in the defined medium, indicating a saturation of the 
auxotrophic yeast cells with amino acids (Fig. 6.15C).  Although uptake and 
accumulation of most amino acids from the external medium seems irreversible, amino 
acids are excreted into the medium whenever available above a given threshold in yeast 
cells (Grenson, 1992).  A saturation of auxotrophic yeast cells by excessive of amino 
acid uptake at low C/N ratio’s was thus required to support maximal production of the 
heterologous xylanase by the auxotrophic strain.  Improved xylanase production at a 
low C/N ratio was reflected in a marginal change of the level of total XYN2 RNA (Fig. 
6.16A), indicating that xylanase production was strongly regulated during 
posttranslational processing and secretion.  Decreased levels of intracellular xylanase 
also indicated an improved secretion of the heterologous protein at a C/N ratio below 
0.3 (gglucose.mmolamino N-1).  In Chapter 5, a significant induction of the S. cerevisiae 
stringent response in reaction to heterologous xylanase production was described, which 
has also been associated with an increase in intracellular proteolytic activity in other 
microorganisms (Harcum and Bentley, 1993).  The increased production of 
heterologous xylanase in response to saturation of the auxotrophic cells with amino 
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acids, would indicate that the inhibition of proteolytic degradation of the foreign protein 
during posttranslational processing, may have caused the increased production levels 
observed for the auxotrophic [ADH2-XYN] strain at lower C/N ratio’s.   
 
Maximum levels of xylanase production obtained with the auxotrophic YEp-based 
strains during amino acid excess, both in chemostat (C/N ratio below 0.3) and batch 
(10.8 mM total amino acid level) cultivation, were similar to production levels obtained 
with the prototrophic YEp-based [ADH2-XYN] PlasPro strain during the same 
cultivation, though in defined medium without amino acids.  The presence of 
auxotrophic mutations in transformants thus caused a physiological defect during the 
cultivation of the recombinant yeast, which severely reduced heterologous protein 
production.  These excessive auxotrophic requirements either made it more difficult for 
the yeast to cope with the additional burden of heterologous protein production, or 
introduced irregularities into the amino acid metabolism. The auxotrophic transformants 
also required significant amino acid overconsumption to stabilise the nitrogen 
metabolism, and were more able to cope with these excessive amounts of extracellular 
amino acids, as was demonstrated by the inhibition of both growth and heterologous 
xylanase production of the prototrophic strains by high amino acid concentrations.  The 
irregularities introduced by the presence of auxotrophic mutations in transformants thus 
reduced heterologous protein production severely, which supported a previous 
suggestion: Completely avoid the use of auxotrophic strains for heterologous protein 
production and metabolic engineering (Çakar et al., 1999). 
 
6.5. CONCLUSIONS 
 
The present investigation has demonstrated the ability of an autoselection-YEp-based 
expression system to support increased levels of heterologous protein production by 
prototrophic transformants.  The deleterious effects of auxotrophic mutations in 
transformants on heterologous xylanase production were also demonstrated, which 
required either the removal of these markers, or supplementation of the cultivation 
medium with an excess of the appropriate amino acids.  The use of auxotrophic strains 
should be completely avoided. 
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Further evidence of the global sensing and regulation of heterologous protein 
production by the cell was presented by the response of auxotrophic recombinant strains 
to amino acid availability below the levels required for saturation of the cell, which 
resulted in a posttranscriptional down-regulation of production levels.  The general 
physiological state of the yeast host and the availability of nutrients thus affected the 
biosynthetic capacity of S. cerevisiae towards the production of a heterologous protein. 
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Chapter 7 
 
DEFINED MEDIUM REQUIREMENTS FOR IMPROVED 
HETEROLOGOUS XYLANASE PRODUCTION BY A 
PROTOTROPHIC TRANSFORMANT OF S. CEREVISIAE 
 
7.1. INTRODUCTION 
 
Although the use of a defined medium in processes for heterologous protein production 
is popular, due to easier purification of the product and the propensity towards rapid 
scale-up (Greasham and Herber, 1997), very low production levels of heterologous 
xylanases compared to complex medium have been reported (Donald et al., 1994; 
Pérez-González et al., 1996; Nuyens et al., 2001; unpublished results).  The 
experimental results presented in Chapter 6 also indicated that the saturation of 
auxotrophic transformants with amino acids could dramatically improve heterologous 
xylanase production levels.  In the present work, the existence of an increased 
requirement for amino acid and/or carbon metabolite availability during heterologous 
xylanase production by a prototrophic transformant was thus investigated.  The possible 
use of all 20 amino acids or succinate, as an additional carbon source, for the 
enhancement of heterologous xylanase production by the prototrophic [ADH2-XYN] 
PlasPro strain (see Chapter 6) in defined medium, was investigated.  
 
Supplementation of defined medium with exogenous nitrogen sources may improve the 
general physiology of yeast strains, specifically during fully respirative growth on 
ethanol in batch culture after the diauxic shift, which is not supported by some defined 
media (Chen et al., 1993; Gu et al., 1991).  Supplementation of a defined medium with 
a mixture of amino acids has increased the level of biomass formation, the maximum 
specific growth rate and the glucose uptake rate by S. cerevisiae, due to direct 
incorporation of the consumed amino acids into biomass (Albers et al., 1996).  Similar 
positive effects on growth and fermentation by S. cerevisiae due to amino acid 
supplementation has been reported elsewhere (Thomas and Ingledew, 1990; Thomas 
and Ingledew, 1992).  Imbalances and deficiencies in the supply of assimilable nitrogen 
compounds are also the most common causes of fermentation faults in the wine 
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industry (Jiranek et al., 1995).  Nitrogen sources most strongly preferred by S. 
cerevisiae include glutamine, asparagine and ammonium.  These nitrogen sources lead 
to higher growth rates, when present in cultivation medium as the sole nitrogen source, 
than less preferred nitrogen sources and can prevent other nitrogen sources from being 
utilised (Ter Schure et al., 2000; Dubois and Messenguy, 1997; Wiame et al., 1985; 
Cooper, 1982).   
 
The availability of amino acids may also limit the production of heterologous proteins, 
as the transcriptional profile of a recombinant S. cerevisiae strain producing 
heterologous xylanase is very similar to yeast experiencing amino acid limitation 
(Chapter 5).  Nitrogen sources such as amino acids are also known to improve 
production levels of heterologous proteins (Mendoza-Vega et al., 1994), as has been 
demonstrated in several studies (Wittrup and Benig, 1994; Toman et al., 2000; Blechl et 
al., 1992).  Supplementation of a defined medium with amino acids may also reduce the 
proteolytic degradation of the heterologous protein product, which is a frequent 
limitation in the attainment of high production levels by yeast (Chapter 2).  Addition of 
the amino acids arginine and lysine to cultures of S. cerevisiae has decreased proteolysis 
of the extracellular recombinant protein, probably due to inhibition of the proteolytic 
enzymes targeted to basic amino acid sites in the protein (Choi et al., 2000; Kang et al., 
2000; Chung and Park, 1998).  Supplementation of defined media with casein 
hydrolysate (casamino acids) has frequently inhibited extracellular proteolysis of 
heterologous protein products by yeast (Coppella and Dhurjati, 1989; Boze et al., 2001; 
Werten et al., 1999; Goodrick et al., 2001; Sreekrishna et al., 1997), although it was 
excluded from the present study due to its complex origin (Mendoza-Vega et al., 1994).  
Metabolite balancing during recombinant protein production has also identified a drain 
on amino acids and biosynthetic precursors from the TCA cycle during recombinant 
protein production (Jin et al., 1997).  The addition of succinate was previously shown to 
increase levels of recombinant glucoamylse production in this manner, though possibly 
in part due to the improved buffering of the defined medium (Cha et al., 1998).   
 
In the present investigation, the effect of supplementation with amino acids and 
succinate on the production of heterologous xylanase by a prototrophic S. cerevisiae 
transformant was determined.  The T. reesei ß-1,4-xylanase II encoding gene, XYN2, 
was expressed from a multicopy, 2μm plasmid under regulation of the yeast glycolytic 
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alcoholdehydrogenase II (ADH2) promoter by the prototrophic [ADH2-XYN] PlasPro 
transformant (Chapter 6).  Due to the derepression of heterologous xylanase production 
by this strain during growth on ethanol (Chapters 4 and 6), the additional medium 
components were added at a time close to that of glucose depletion.  Supplementation 
was thus aimed at stimulating the TCA cycle through succinate addition, which 
provides the cell with precursors for biosynthesis, or increasing the availability of 
complete amino acids for biosynthesis.  The aim of these experiments was to identify 
possible limitations in the availability of metabolic nutrients for the synthesis of 
heterologous xylanase. 
 
7.2 MATERIALS AND METHODS 
7.2.1. Strains and plasmids 
Construction of the prototrophic recombinant S. cerevisiae Y294 [ura3/URA3, 
leu2::LEU2] strain, [ADH2-XYN] PlasPro, producing a heterologous ß-1,4-xylanase 
through expression of a plasmid-based XYN2 gene under control of the native ADH2-
promoter, and verification of its genetic stability were previously described (Chapter 6).  
Strain stocks were stored in a 15% glycerol solution at –80ºC.   
 
7.2.2. Shake-flasks screening of medium components 
The screening of potential medium components was performed in shake-flask cultures.  
The prototrophic yeast strain was cultivated in baffled shake-flasks, using a defined 
medium (Verduyn et al., 1992) containing 20 g.l-1 glucose as the carbon source until 
glucose depletion.  Supplementary medium components were added to individual 
shake-flask cultures at the start of the subsequent diauxic shift, thus increasing the 
availability of the components during growth on ethanol and the production phase for 
heterologous xylanase (Chapter 4).  Growth on ethanol in shake-flask cultures was 
performed at either pH 5.0, by using a 50 mM citrate buffer, or at pH 3.0, by allowing 
the acidity of the broth to increase during growth on glucose in unbuffered defined 
medium, due to ammonium utilisation (Hensing et al., 1995; Greasham and Herber, 
1997).  Amino acids were added to the cultures in powder form without sterilisation, 
though no subsequent contamination was observed, probably due to the purity of 
individual amino acid preparations. 
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7.2.3. Fermentations 
Batch and continuous cultivation in the defined medium, with supplementation as 
presented below, were performed as previously (Chapter 6).  The pH of the 
fermentations was controlled at 5.0, unless otherwise specified. 
  
7.2.4. Sampling and analytical methods 
Sampling for both batch and continuous cultures, and the analytical methods employed, 
were previously described (Chapter 6).  Ammonium concentration was determined 
using the Boehringer Mannheim Ammonia test kit (Cat. Nr. 1112732) adapted for use 
with the Cobas Mira autoanalyser.   
 
7.3. RESULTS 
 
The effect of various potential medium supplements on the production of heterologous 
xylanase and biomass by recombinant S. cerevisiae in shake-flask, batch and 
continuous cultivation was determined.  Because of the relatively large number of 
experiments required, medium optimisation was mostly done in shake-flask cultivation 
(Greasham and Herber, 1997), with final quantification performed in controlled 
fermentation equipment. 
 
7.3.1. Supplementation with amino acids 
7.3.1.1. Shake-flask cultivation 
All 20 amino acids were initially screened in shake-flask cultivation, to identify those 
that either had a positive effect on yeast growth and/or xylanase production, or did not 
influence metabolism negatively.  The aim was to select a small number of amino acids 
that may be added as mixtures to the defined medium, and thereby obtain an improved 
defined medium.  The individual amino acids were added to shake-flask cultures at a 
time close to that of glucose depletion to maximise their availability during the xylanase 
production phase of the [ADH2-XYN] PlasPro strain.  During the screening of amino 
acids the effect of supplementation at a concentration of approximately 4 mM was 
determined at both pH 3.0 and 5.0. 
 
Supplementation of the defined medium with individual amino acids during cultivation 
at pH 3.0 resulted in dramatic differences in the production levels of heterologous 
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xylanase (Fig. 7.1).  Under these cultivation conditions, a significant time-wise loss of 
xylanase activity in the extracellular medium was observed, probably due to the activity 
of acidic proteases.  The addition of some of the amino acids, most notably Arg, Ala, 
Asn, Glu, Gln and Gly, significantly retarded the extracellular proteolytic degradation 
of the xylanase protein and thus improved the stability of the heterologous protein (Fig. 
7.1). 
 
The overall effect of individual amino acids on the extracellular xylanase production 
was quantified by means of a single parameter, defined as the “Relative xylanase 
productivity” (see Tables 7.1 and 7.2).  During the course of a particular cultivation, the 
maximum volumetric xylanase activity (nkat.ml-1) and the maximum specific xylanase 
activity (nkat.gcells-1) were estimated.  The time-wise integrals of the specific xylanase 
activity and the cell density were also determined for each shake-flask culture.  The 
quantitative influence of each amino acid on the overall productivity was thus 
represented by these four parameters.  Each of the parameters was subsequently scaled, 
with an arbitrary value of 100 assigned to the maximum value among the 20 different 
amino acids, and a value of zero to the control cultivation.  The “Relative xylanase 
productivity” for a specific amino acid was calculated by summing the four productivity 
parameters. 
 
The scaled results obtained during growth on ethanol at pH 3.0 are presented in Table 
7.1, which confirmed the efficiency of Arg, Ala, Asn, Glu, Gln and Gly for improving 
the xylanase productivity (Table 7.1; “Relative productivity”).  Of specific interest was 
arginine, which was the most efficient amino for improving xylanase production at pH 
3.0 on all accounts.  Some of the amino acids significantly inhibited biomass formation 
during growth on ethanol, most notably Ile, Trp, Met, Cys, Phe, Thr, Leu and Tyr 
(Table 7.1; “Cell density integral”).  Supplementation of the defined medium with 
several of the amino acids, including Cys, His, Ile, Leu, Lys, Met, Phe, Thr, Trp, Tyr 
and Val, inhibited xylanase production by the prototrophic [ADH2-XYN] strain under 
these conditions (Table 7.1). 
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Figure 7.1. Effect of individual amino acids on xylanase production in shake-flask 
culture during growth on ethanol at pH 3.0 and pH 5.0.  (O) Control without amino acid 
addition, (?) glutamine, (?) asparagine, (?) arginine, (?) alanine and (+) glycine. (?) 
Glutamate (pH 3.0) or aspartate (pH 5.0). 
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Table 7.1. Effect of individual amino acids on the xylanase productivity of the 
prototrophic [ADH2-XYN] PlasPro strain at pH 3.0 in shake flask culture. 
Amino acid a 
Cell density 
integral 
Volumetric 
activity 
Specific 
activity 
Specific activity 
integral 
Relative 
productivity b 
Alanine 29 54 64 60 207 
Arginine 100 100 100 100 400 
Asparagine 45 85 88 90 308 
Aspartate 3 -21 8 7 -4 
Cysteine -74 -94 -80 -34 -282 
Glutamate 40 54 71 82 246 
Glutamine 64 96 98 91 349 
Glycine 25 30 44 25 124 
Histidine -1 -36 -3 -6 -46 
Isoleucine -132 -105 -99 -71 -407 
Leucine -28 -68 -49 -26 -171 
Lysine -4 -47 -19 -17 -86 
Methionine -110 -103 -83 -41 -338 
Phenylalanine -69 -85 -56 -34 -244 
Proline 21 -8 27 15 55 
Serine 14 -11 16 12 31 
Threonine -50 -77 -54 -32 -212 
Tryptophan -116 -104 -85 -45 -350 
Tyrosine -22 -64 -37 -23 -146 
Valine -6 -53 -27 -18 -104 
a Amino acids were added to a final concentration of approximately 4 mM. 
b The maximum value corresponds to a 2-5 fold increase in the specific xylanase 
activity (U.mgbiomass-1). 
 
The effect of amino acid supplementation on extracellular xylanase levels was less 
dramatic during cultivation at pH 5.0, with relatively small improvements in the 
production levels due to addition of the individual amino acids (Fig. 7.1).  However, the 
overall levels of heterologous xylanase production at pH 5.0 were noticeably higher 
than at pH 3.0, as extracellular xylanase was significantly more stable (Fig. 7.1).  The 
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effect of interaction between amino acids and extracellular proteases on the production 
of heterologous xylanase was thus much less pronounced at pH 5.0.  Similar to 
observations during cultivation at pH 3.0, several of the amino acids significantly 
inhibited biomass formation at pH 5.0 (Cys, His, Ile, Leu, Met, Phe, Ser, Thr, Trp, Tyr 
and Val; Table 7.2).  However, very few of the amino acids, namely Cys, Ile, Trp, Tyr 
and Val, inhibited xylanase production in the defined medium during cultivation at pH 
5.0 (Table 7.2).  The amino acids that improved xylanase production by the [ADH2-
XYN] PlasPro strain under these cultivation conditions, without inhibiting biomass 
formation, were Ala, Arg, Asn, Asp, Gln, Gly and Lys (Table 7.2). 
 
Table 7.2. Effect of individual amino acids on the xylanase productivity of the 
prototrophic [ADH2-XYN] PlasPro strain at pH 5.0 in shake flask culture. 
Amino acid a 
Cell density 
integral 
Volumetric 
activity 
Specific 
activity 
Specific activity 
integral 
Relative 
productivity 
Alanine 54 44 -4 4 98 
Arginine 46 83 10 27 165 
Asparagine 42 67 39 45 193 
Aspartate 66 100 23 36 226 
Cysteine -477 -213 -12 -213 -916 
Glutamate 34 -4 7 0 37 
Glutamine 100 26 5 2 133 
Glycine 11 81 28 50 170 
Histidine -282 53 69 84 -76 
Isoleucine -430 -261 -59 -292 -1042 
Leucine -83 18 17 11 -37 
Lysine 15 73 19 22 128 
Methionine -308 33 80 25 -170 
Phenylalanine -75 53 29 -8 0 
Proline 92 60 2 -10 145 
Serine -47 27 38 76 94 
Threonine -389 61 100 94 -135 
Tryptophan -172 -54 4 -1 -223 
Tyrosine -116 -36 26 21 -104 
Valine -276 -9 51 100 -134 
a Amino acids were added to a final concentration of approximately 4 mM. 
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The effect of individual amino acids at pH 3.0 and 5.0 on the relative xylanase 
productivity are summarised in Table 7.3.  The amino acids were differentiated 
according to their influence on productivity under both conditions, resulting in the 
selection of Ala, Arg, Asn, Glu, Gln and Gly for further testing during cultivation of the 
[ADH2-XYN] PlasPro strain under controlled conditions in defined medium. 
 
Table 7.3. Summary of relative xylanase productivity of the [ADH2-XYN] PlasPro 
strain at pH 3.0 and 5.0. 
Relative xylanase productivity 
Amino acid a 
pH 3.0 pH 5.0 Total 
Arginine 400 165 565 
Asparagine 308 193 501 
Glutamine 349 133 482 
Alanine 207 98 305 
Glycine 124 170 294 
Glutamate 246 37 284 
Aspartate -4 226 222 
Proline 55 145 199 
Serine 31 94 125 
Lysine -86 128 42 
Histidine -46 -76 -123 
Leucine -171 -37 -208 
Valine -104 -134 -238 
Phenylalanine -244 0 -244 
Tyrosine -146 -104 -251 
Threonine -212 -135 -347 
Methionine -338 -170 -508 
Tryptophan -350 -223 -573 
Cysteine -282 -916 -1198 
Isoleucine -407 -1042 -1449 
a Amino acids were added to a final concentration of approximately 4 mM. 
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7.3.1.2. Quantification in batch culture 
The influence of the selected amino acids on growth and xylanase production by the 
[ADH2-XYN] PlasPro strain was tested during growth on ethanol in batch cultivation.  
Cultures were supplemented either with arginine (40 mM), a four amino acid mixture 
(Arg, Asn, Ala, Gly; 20 mM) or a six amino acid mixture (Arg, Asn, Gly, Ala, Gln, 
Glu; 20 mM) after the diauxic shift, during the onset of ethanol consumption.  The 
concentrations in brackets indicate the total free amino nitrogen content of the medium 
after supplementation (Fig. 7.2; Table 7.4).  The product yields presented in Table 7.4 
were calculated for the duration of growth on ethanol. 
 
Definite increases in the levels of biomass formation, xylanase production, and 
ammonium consumption were observed due to supplementation of the defined medium 
with the four or six amino acid mixtures (Fig. 7.2A, B and E).  The complete 
consumption of the available ethanol during the first 33 hours after the diauxic shift in 
these supplemented cultures also indicated that the rate of carbon consumption was 
increased (Fig. 7.2C and D).  The final levels of biomass and xylanase production in the 
medium supplemented with the four and six amino acid mixtures were comparable to 
those observed during cultivation in complex medium (Fig. 7.2A and B).  
Supplementation of the medium with arginine did not affect the yeast physiology 
significantly, whereas biomass and xylanase production were inhibited during 
cultivation at pH 3.0 (Fig. 7.2A and B), as was observed in shake-flask cultures (Fig. 
7.1). 
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Figure 7.2. Effect of defined medium supplementation with amino acids (at different total free 
amino nitrogen concentrations) during growth on ethanol in batch culture on (A) biomass, (B) 
xylanase and (C and D) ethanol production, (E) ammonium consumption and (F) total protein 
secretion. (O) pH 5.0 and (?) pH 3.0 controls without amino acid addition, (?) Arg, Asn, Ala, 
Gly mixture (20 mM) (?) arginine (40 mM), (?) Arg, Asn, Gly, Ala, Gln, Glu mixture (20 
mM), and (+) complex (YPD) medium control. 
200
Table 7.4. Product yields during growth on ethanol after the diauxic shift in batch culture (cmolproduct.cmolethanol consumed-1)Ψ 
Supplementation Maximum specific growth rate [h-1] Biomass Glycerol Acetate CO2 Total amino acids a 
No amino acids, pH 5.0 0.025 0.50 -0.18 -0.07 0.75 0.00 
No amino acids, pH 3.0 0.019 0.49 -0.24 -- 0.75 0.00 
Arginine (40 mM) 0.020 0.59 -0.20 -0.10 0.84 -0.13 
Arg, Asn, Ala, Gly (20 mM) 0.038 0.62 -0.04 -0.05 0.66 -0.09 
Arg, Asn, Gly, Ala, Gln, Glu (20 mM) 0.043 0.71 -0.04 -0.18 0.64 -0.13 
Complex medium (YPD) 0.049 0.81 -0.04 -0.45 1.09 -0.40 
Ψ Yields were corrected for ethanol evaporation, which was calculated from the degree of reduction balance 
a Total co-consumption of amino acids (cmolamino acid consumed.cmolethanol consumed-1). 
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Addition of the four or six amino acid mixture also increased the growth rate of the 
recombinant S. cerevisiae strain during ethanol consumption (Table 7.4).  The co-
consumption of glycerol during growth on ethanol was reduced by supplementation of 
the four or six amino acid mixtures and was similar to levels observed during growth on 
complex medium.  Accurate measurement of the total protein secretion by the yeast was 
not possible due low production levels (Fig. 7.2 F), and no conclusion with regards to 
the effect of amino acid supplementation on the total protein secretion by the [ADH2-
XYN] PlasPro strain could thus be made.  The effect of amino acid supplementation on 
the intracellular levels of xylanase was determined in samples taken from the respective 
cultures at a single time point, corresponding to 20h after the depletion of glucose and 
supplementation of the defined medium (Table 7.5).  The intracellular xylanase activity 
increased in response to supplementation of the defined medium with the four and six 
amino acid mixtures. 
 
Table 7.5. Specific intracellular xylanase activity 20h after supplementation 
Supplementation Specific intracellular xylanase activity 
(mgactive xylanase.gcell protein-1) 
No amino acids, pH 5.0 2.49 
Arginine (40 mM) 2.46 
Arg, Asn, Ala, Gly (20 mM) 3.49 
Arg, Asn, Gly, Ala, Gln, Glu (20 mM) 3.80 
 
7.3.1.3. Quantification in continuous culture 
The effect of various amino acid mixtures on heterologous xylanase production was 
also investigated during steady-state growth in glucose-limited chemostat culture (Table 
7.7).  Supplementation of defined medium with two mixtures of pure amino acids, 
“Casamino acids” and “SD-Optimised”, previously enhanced heterologous protein 
production by S. cerevisiae (defined and tested by Wittrup and Benig, 1994).  The effect 
of these mixtures on heterologous xylanase production in continuous culture were 
compared to the seven amino acid mixture (see Chapters 4 and 6) and various mixtures 
of the six amino acids selected from shake-flask screening.  In some chemostat cultures, 
the level of amino acid consumption at steady-state was measured (Table 7.7; “Amino 
acid uptake”). 
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Surprisingly, supplementation of the feed medium with the “Casamino acids” and “SD-
Optimised” mixtures significantly inhibited xylanase production by the prototrophic 
strain, despite the positive effect of “Casamino acids” on biomass formation.  The 
similar negative effect of the seven amino acid mixture for the auxotrophic [ADH2-
XYN] strain on xylanase and biomass production by the prototrophic [ADH2-XYN] 
PlasPro strain was also observed in Chapter 6.  Addition of arginine by itself to the 
defined medium at 8 and 20 mM free amino nitrogen concentration did not affect 
xylanase production by the prototrophic strain, although at 40 mM xylanase production 
was inhibited.  Biomass formation was slightly improved by arginine supplementation, 
as was also observed during the screening of amino acids in shake-flasks at pH 5.0 (see 
above).    The combination of arginine with asparagine or glutamine also resulted in 
some inhibition of xylanase production at 20 mM level, though the arginine-asparagine 
mixture at 40mM stimulated both biomass and xylanase production.  Addition of the 
four amino acid mixture improved heterologous xylanase production, despite the low 
level of supplementation, as was also observed during batch cultivation.  
Supplementation with the six amino acid mixture significantly improved both biomass 
and xylanase production during growth on glucose. Consumption of arginine was 
relatively poor when added as a single amino acid, or in a bi-component mixture.  
However, in the six amino acid mixture all of the amino acids were utilised effectively 
by the prototrophic strain (Table 7.6). 
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Table 7.6. Effect of amino acid supplementation of the feed to glucose-limited chemostat cultures on product yields (cmolproduct.cmolglucose consumed-1) 
Amino acid supplementation § Total amino-N (mM) § Amino acid uptake Biomass CO2 Ethanol evaporation XylanaseΨ 
None 0 0 0.55 0.35 0.055 31.86 
Casamino acids a 20 -- 0.74 0.39 0.054 12.23 
SD-optimised a 20 -- 0.59 0.42 0.054 3.81 
Auxotrophic 7 AA mixture b 20 -- 0.43 0.59 0.035 0.23 
Auxotrophic 7 AA mixture b,c 20 -- 0.40 0.55 0.030 3.42 
Arginine 8 -- 0.58 0.38 0.028 32.93 
Arginine  (59.1) d 20 0.051 0.63 0.37 0.025 31.97 
Arginine 40 -- 0.63 0.46 0.047 22.14 
Arg (48.1), Asn (99.8) d 20 0.069 0.63 0.48 0.00 24.85 
Arg (59.1), Gln (97.9) d 20 0.081 0.60 0.38 0.054 29.31 
Arg, Asn 40 -- 0.66 0.51 0 38.07 
Arg, Asn, Ala, Gly 2.5 -- 0.56 0.34 0.064 37.22 
Arg (99.4), Asn (99.8), Gly (95.1), 
Ala (82.7), Gln (99.1), Glu (99.1) d 
20 0.132 0.68 0.41 0.016 49.29 
§ Different amino acid mixtures added to a feed medium containing 10 g.l-1 of glucose as carbon source. 
Ψ (mgxylanase.cmolglucose consumed-1) 
a Pure amino acids added according to Wittrup and Benig (1994)      b Chapter 6       c Feed medium contained only 5 g.l-1 of glucose 
d Values in brackets indicate the percentage of the amino acid supply in feed that was utilised by the yeast. 
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Fig. 7.3. Effect of succinate addition and consumption (F) on the production of (A) biomass, (B) 
xylanase and (C and D) ethanol, and the consumption of (E) ammonium. (O) Defined medium 
without supplementation. Succinate was supplemented at a concentration of (?) 9 g.l-1 or (?) 
11 g.l-1.  (C) Dotted line represents the Specific Ethanol level (gEtOH.gcells-1). 
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Table 7.7. Product yields during growth on ethanol after the diauxic shift in batch culture (cmolproduct.cmolethanol consumed-1)Ψ 
Supplementation Maximum specific growth rate (h-1) Biomass Glycerol Acetate Succinate CO2 
Defined only 0.025 0.50 -0.18 -0.07 0.00 0.75 
Low succinate 0.045 0.67 -0.12 -0.11 -0.14 0.69 
High succinate 0.043 0.73 -0.25 -0.05 -0.14 0.70 
Ψ Yields were corrected for ethanol evaporation, which was calculated from the degree of reduction balance 
 
Table 7.8. Specific intracellular xylanase activity 20h after supplementation 
Supplementation Specific intracellular xylanase activity (mgactive xylanase.gcell protein-1) 
Defined only 2.49 
Low succinate 4.91 
High succinate 2.93 
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7.3.2. Addition of succinate 
The effect of succinate addition on biomass formation and xylanase production in 
defined medium during growth on ethanol in batch culture was also tested (Fig. 7.3 and 
Table 7.7).  The defined medium was supplemented with succinate after the diauxic 
shift to final levels of 9 and 11 g.l-1. The majority of the added succinate was consumed 
during approximately 32 hours of growth on ethanol (Fig. 7.3F), although the rate of 
ethanol consumption was not significantly affected by the consumption of succinate.  
Succinate consumption resulted in a higher final level of biomass formation, and 
increased xylanase production and ammonium consumption (Fig. 7.3A, B and E).  The 
increase in xylanase production was partly due to a decrease in the lag phase after 
derepression of the ADH2-promoter, whereas the increase in the biomass yield during 
growth on ethanol due to succinate consumption was accompanied by an increase in the 
maximum specific growth rate (Table 7.7).  The improvement in extracellular xylanase 
production due to supplementation with succinate was apparently associated with an 
increase in the intracellular xylanase activity (Table 7.8).   
 
7.4 DISCUSSION 
 
The influence of supplementing a chemically defined medium with individual amino 
acids, mixtures of selected amino acids or succinate, on the production of heterologous 
xylanase by the prototrophic, recombinant S. cerevisiae strain, [ADH2-XYN] PlasPro 
via native ADH2-regulation, was investigated.  Amino acids were first screened in 
shake-flask culture, prior to the combination of potential medium components in 
mixtures.  The aim of these experiments was to determine whether limitations in the 
availability of metabolic precursors in both the carbon- and nitrogen metabolism 
affected the production of heterologous xylanase. 
 
7.4.1. Effect of amino acids 
7.4.1.1. Screening of amino acids 
Six amino acids (Arg, Asn, Gly, Ala, Gln and Glu) were selected on the basis of 
improved xylanase production and/or biomass formation during growth on ethanol in 
shake-flask culture at pH 3.0 and 5.0.  The effects of these amino acids on metabolism, 
whether individually or in mixtures, were observed in the presence of an excess 
ammonium in the defined medium, which is a general inhibitor of amino acid uptake in 
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yeast (Slaughter et al., 1990; Jiranek et al., 1995).  The positive effect of the preferred 
nitrogen sources Gln and Asn on heterologous xylanase production may thus be related 
to the ability of yeast to utilise these compounds in the presence of ammonium 
(Slaughter et al., 1990; Jiranek et al., 1995; Ter Schure et al., 2000; Wiame et al., 1985; 
Cooper, 1982).  The presence of ammonium in the defined medium was advantageous, 
however, as it may prevent the induction of catabolic enzymes for amino acid 
utilisation, thus allowing for anabolic assimilation of amino acids (Cooper, 1982; 
Stanbrough and Magasanik, 1995). 
 
One of the reasons for the “Preferred Nitrogen Source” status of some of the amino 
acids is their relative richness in amino nitrogen – one mol of asparagine or glutamine 
contains twice the amount of amino nitrogen than most of the other amino acids.  The 
high nitrogen content of arginine and glutamate may similarly be responsible for their 
preferential utilisation from amino acid mixtures (Jiranek et al., 1995; Herriaz and 
Ough, 1993), and ability to improve heterologous xylanase and biomass production.  
The effects of glutamate addition may be related to its central role in nitrogen 
metabolism (Watson, 1976).  The positive effects of glycine and alanine observed 
during amino acid screening could not be explained similarly, since neither contains 
large amounts of amino nitrogen, whilst glycine is poorly metabolised from amino acid 
mixtures (Jiranek et al., 1995; Herriaz and Ough, 1993). 
 
The beneficial effect of the selected amino acids may also be related to the inhibition of 
extracellular proteases, which dominated the screening of amino acids in shake-flasks at 
pH 3.0, while also having some effect at pH 5.0 (Fig. 7.1).  The ability of arginine to 
improve heterologous protein production in such a manner has been demonstrated, 
either when added as a single amino acid to defined medium (Kang et al., 2000), or 
along with glycine and glutamate in casamino acid mixtures (Coppella and Dhurjati, 
1989; Boze et al., 2001; Werten et al., 1999; Goodrick et al., 2001; Sreekrishna et al., 
1997).  As the stability of extracellular xylanase was significantly improved by 
increasing the cultivation pH to 5.0, the effect of the amino acid addition in the latter 
cultures were most strongly related to their utilisation in metabolism. 
 
Growth and heterologous xylanase production by recombinant S. cerevisiae was 
improved by supplementation of the defined medium with the amino acids 
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preferentially stored in the vacuole after utilisation.  The basic amino acids (Arg and 
Lys) are strongly preferred for storage in the vacuole due to their richness in nitrogen, 
along with Gly, Ala, Asn and Gln (Messenguy et al., 1980; Wiame et al., 1985; 
Grenson, 1992; Horàk, 1997).  Free amino acids accumulated in this manner may be 
stored either in the cytoplasm, where it is rapidly utilised for protein synthesis, or in the 
vacuole, where it can remain for longer periods (Messenguy et al., 1980).  The acidic 
amino acids (aspartate and glutamate) are not accumulated in the vacuole (Grenson, 
1992).   
 
7.4.1.2. Supplementation with amino acid mixtures 
The supplementation of defined medium with amino acids in controlled batch and 
continuous cultures were investigated at a cultivation pH of 5.0.  The addition of the 
four and six amino acid mixtures during batch growth on ethanol improved the yield of 
biomass and heterologous xylanase, with ethanol and ammonium consumption rates 
increased as a result of the higher growth rate.  Improved biomass formation due to 
amino acid supplementation was previously observed (Albers et al., 1996).  The 
availability of nitrogen apparently limited protein production and biomass formation 
during growth on ethanol, as has been reported in other defined media (Chen et al., 
1993; Gu et al., 1991).  The positive effect of amino acid addition of xylanase 
production was thus dependent on a balance in the availability of preferred nitrogen 
sources.  During chemostat cultivation the amino acids arginine, asparagine and 
glutamine also did not have a positive effect on heterologous xylanase production if not 
present in the mixture of at least four amino acids.  The synergism between the 
individual amino acids in these two mixtures was therefore essential for the 
improvement of heterologous xylanase and biomass production. 
 
During growth on glucose in continuous culture, the presence of the amino acids, His, 
Ile, Leu, Met, Phe, Ser, Thr, Tyr and Val in the seven amino acid, “Casamino acid” and 
“SD-Optimised” mixtures apparently reduced xylanase production levels (Table 7.6; 
see above).  The disparity between the reported stimulation of heterologous protein 
production by the latter two mixtures (Wittrup and Benig, 1994) and the inhibition of 
xylanase production observed in the present study, emphasised the need for the 
empirical optimisation of defined medium for each production system. The negative 
effect of the seven amino acid mixture on biomass formation in the medium containing 
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only 5 g.l-1 of glucose (Table 7.7) may further be related to the inability of the yeast to 
utilise the carbon-skeletons derived from the respective amino acids (Thomas and 
Ingledew, 1990).  No further rational origins for the inhibition of xylanase production 
by individual amino acids were evident from the analysis. 
 
7.4.2. Supplementation with succinate 
The majority of the succinate supplemented to the defined medium was consumed 
during batch growth on ethanol (Fig. 7.3F), despite previous reports that extracellular 
TCA intermediates cannot support the growth on S. cerevisiae (Kaclikova et al., 1992).  
Succinate consumption increased the final levels of biomass formation and stimulated 
heterologous xylanase production, which identified a limitation in the availability of 
TCA cycle intermediates during growth on ethanol.  The addition of succinate 
apparently improved the synthesis and intracellular level of heterologous xylanase 
(Table 7.8).  Improvement of heterologous protein production by succinate addition was 
previously reported (Cha et al., 1998), though the capacity of succinate to buffer the 
defined medium (Adams et al., 1989) may have dominated the reported observation.  In 
the present investigation, however, heterologous xylanase production by recombinant S. 
cerevisiae was improved by consumption of succinate as an additional carbon-source 
alone. 
 
7.5 CONCLUSIONS 
 
Heterologous xylanase production by S. cerevisiae in defined medium was partially 
limited by the availability of metabolic precursors for protein synthesis, since both the 
addition of suitable amino acid mixtures and succinate improved heterologous xylanase 
production.  This supports the notion that foreign protein production may drain 
metabolic resources from the central pathways (Jin et al., 1997; Ramirez and Bentley, 
1993).  The biosynthetic capacity of a recombinant yeast strains for heterologous 
protein production may thus be regulated actively in response to the availability of 
sufficient resources for protein synthesis.  However, the improvements in xylanase 
production due to medium supplementation observed in the present study were typically 
smaller than two-fold, indicating that heterologous protein production may also limited 
by other factors besides the availability of amino nitrogen and TCA metabolites. 
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Chapter 8 
 
EFFECT OF OXYGENATION AND AMINO ACID 
SUPPLEMENTATION ON HETEROLOGOUS XYLANASE 
PRODUCTION BY P. STIPITIS 
 
 
8.1. INTRODUCTION 
 
Limitations in the attainable production levels of heterologous protein by yeasts 
represent a major hurdle in the application of these hosts in industrial processes 
(Ljubijankic et al., 1999).  In the previous chapters the influence of the regulatory 
characteristics of the promoter (Chapter 4), the presence of auxotrophic markers 
(Chapter 6) and the availability of sufficient nutrients (Chapter 7) on the production of a 
heterologous xylanase by recombinant S. cerevisiae was demonstrated.  In the present 
study, the presence of similar limitations during heterologous xylanase production by an 
alternative yeast, P. stipitis, was investigated.  A strong influence of the cultivation 
conditions, promoter induction and supplementation of the medium with amino acids 
would heterologous protein production by a his3 auxotrophic transformant would 
confirm the generic nature of the limitations previously observed in S. cerevisiae.  
Finally, the characteristics of the selected yeast host strain is known to influence the 
levels of foreign gene transcription, translation and secretory efficiency, protein 
quantity and quality, plasmid stability and plasmid copy number (Park et al., 2000; 
Eckart and Bussineau, 1996; Mendoza-Vega et al., 1994).  The development of P. 
stipitis as an alternative host for heterologous xylanase production is therefore of 
interest for further elucidating the relationship between yeast host and expression level. 
 
P. stipitis is a xylose-fermenting yeast for which the production of heterologous 
proteins (one cellulase and two xylanases) under control of the native XYL1, TKL and 
ADH2 promoters has been reported (Den Haan and Van Zyl, 2001; Passoth and Hahn-
Hägerdal, 2000; Piontek et al., 1998; Morosoli et al., 1992; Moreau et al., 1992).  A 
major advantage of this yeast is its preference for respiratory growth due to Crabtree-
negative status; with ethanol formation induced strongly by oxygen-limited conditions 
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and not in response to high glucose concentrations during aerobic conditions (Skoog 
and Hahn-Hägerdal, 1990; Du Preez, 1994; Cho and Jeffries, 1999; Passoth et al., 
1996).  No fermentation will thus occur under fully aerobic conditions in the presence 
of high glucose concentrations, resulting in high growth rates and high biomass yields 
in the presence of glucose levels up to 50 g.l-1 (Passoth et al., 1996; Skoog and Hahn-
Hägerdal, 1990; Du Preez, 1994; Du Preez et al., 1989).  These characteristics make P. 
stipitis ideal for large-scale fermentations, where high levels of biomass production can 
be obtained in the presence of excess glucose in batch culture, without the need for 
stringent feed control to avoid ethanol formation.  Although P. stipitis produces ethanol 
from glucose or xylose at low dissolved oxygen concentrations, it is also able to re-
assimilate ethanol under the same conditions, depending on the levels of sugar depletion 
and ethanol formation (Passoth et al., 1998; Du Preez et al., 1989).  The ability to grow 
on xylose is also advantageous since D-xylose is the most predominant pentose sugar in 
hemicellulose, which is an abundant renewable carbon source (Jeffries and Jin, 2000; 
Piontek et al., 1998).   
 
Due to the deleterious effects of heterologous protein production on the yeast 
metabolism, the use of inducible promoters is often preferred (Romanos et al., 1992).  
Cloning and use of the inducible, native ADH2-promoter for heterologous xylanase 
production by P. stipitis was previously reported (Passoth and Hahn-Hägerdal, 2000).  
The C. albidus XLN-gene was chosen to demonstrate the function of this promoter for 
heterologous gene expression, as the efficient production and secretion of the encoded 
xylanase by P. stipitis had been demonstrated (Morosoli et al., 1992; Moreau et al., 
1992; Morosoli et al., 1993).  There has been some confusion with regards to the 
appropriate nomenclature of the ADH2 gene (Passoth et al., 1998; Cho and Jeffries, 
1999), although in the present report the naming suggested by Passoth et al. (1998) is 
used.  The native ADH2 gene codes for one of the alcohol dehydrogenases in P. stipitis, 
which catalyses both the formation and assimilation of ethanol under oxygen-limited 
conditions (Passoth et al., 1998; Cho and Jeffries, 1998).  ADH2 expression is induced 
either in response to a change in the dissolved oxygen concentration, or a complete shift 
to oxygen-limited conditions (Passoth et al., 1998; Cho and Jeffries, 1998).  Marginal 
levels of ADH activity and ADH2 mRNA levels were detected during fully aerobic 
conditions (Passoth et al., 1996; Cho and Jeffries, 1998), whereas P. stipitis responded 
to a shift in the dissolved oxygen tension (DOT) from 80% to 20% with a rapid but 
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transient induction of ADH activity (Passoth et al., 1996).  During a shift from aerobic 
to oxygen-limited (0% DOT) conditions, a more permanent induction of ADH2 
expression was observed, with a large increase in ADH2 mRNA (Passoth et al., 1998; 
Cho and Jeffries, 1999).  Effective induction of ADH2-regulated heterologous xylanase 
expression, during a shift from aerobic to oxygen-limited conditions, was previously 
demonstrated for a low cell density culture of recombinant P. stipitis (Passoth and 
Hahn-Hägerdal, 2000).  Although P. stipitis grows reasonably quickly under aerobic 
conditions, growth is severely retarded during oxygen-limited growth (Du Preez et al., 
1989; Skoog and Hahn-Hägerdal, 1990; Du Preez, 1994; Passoth et al., 1996; Passoth 
and Hahn-Hägerdal, 2000; Rizzi et al., 1989).  However, low growth rates during the 
production phase of cultures producing heterologous proteins are preferred, due to the 
decrease in substrate consumption.  The level of oxygenation and the oxygen transfer 
rate during oxygen-limited conditions strongly influence the rate of ethanol production 
(Du Preez, 1994) and therefore possibly also the expression level of the ADH2-gene.  
As the extent of oxygen limitation increases, the level of ethanol production increases 
with a concomitant decrease in the cell yield, growth rate, and sugar uptake rate (Skoog 
and Hahn-Hägerdal, 1990; Du Preez, 1994), and P. stipitis therefore needs a minimum 
low aeration rate to sustain growth (Rizzi et al., 1989; Du Preez, 1994).  Consumption 
of amino acids from the cultivation medium has also decreased ethanol formation 
during oxygen-limited conditions (Guebel et al., 1992). 
 
In the present investigation, P. stipitis was grown to higher cell densities than 
previously employed (Passoth and Hahn-Hägerdal, 2000) in the presence of excess 
glucose, prior to induction of heterologous xylanase production.  The proper control of 
promoter induction, the level of oxygenation and the medium composition during the 
oxygen-limited production phase significantly improved production levels of the 
heterologous xylanase. 
 
8.2. MATERIALS AND METHODS 
8.2.1. Strains and medium 
Transformation of the P. stipitis PJH53 [trp5-10, his3-1] strain with the pVPA2CaXLN 
episomal plasmid, containing the Cryptococcus albidus XLN-gene under control of the 
P. stipitis ADH2-promoter and the P. stipitis HIS3 gene as selection marker, was 
previously reported (Passoth and Hahn-Hägerdal, 2000).  Growth medium for the 
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plating of the recombinant strain contained glucose (20 g.l-1), yeast nitrogen base 
without amino acids (YNB; 6.7 g.l-1), tryptophan (120 mg.l-1) and agar (20 g.l-1).  
Glucose and agar were autoclaved together, whereas YNB and tryptophan were filter-
sterilised separately and added to the medium once the autoclaved solution had cooled 
down sufficiently.  The basic growth medium for liquid cultivation was similarly 
prepared and contained: KH2PO4 (18.75 g.l-1), (NH4)2HPO4 (6 g.l-1), MgSO4*7H2O 
(1.13 g.l-1), YNB without amino acids (6.5 g.l-1), tryptophan (400 mg.l-1) and glucose 30 
g.l-1.  The pH of the medium was adjusted to 5.0 prior to sterilisation (Dellweg et al., 
1984; Passoth and Hahn-Hägerdal, 2000).  The growth medium was also supplemented 
with an amino acid mixture during the course of the fermentation, as discussed below. 
 
8.2.2. Batch fermentations 
Batch fermentations were conducted in a Braun Biotech Biostat® fermenter with a total 
volume of 2000 ml and a working volume of 1500 ml.  Fermenters contained 1350 ml 
of Millipore water during autoclaving, with 150 ml of a 10-fold concentrate of the 
liquid cultivation medium added during inoculation.  The temperature and pH of the 
cultures were controlled at 30ºC and pH 5.0 (by the addition of 2M NaOH or 2M HCl), 
respectively.  The fermentation broth was agitated in the range of 350 to 600 rpm and 
aerated with a 0.5 l.min-1 airflow (standard conditions).  The level of dissolved oxygen 
was monitored with a dissolved oxygen probe (Braun Biotech) and controlled by 
manual adjustment of the agitation speed and level of oxygen-enrichment of the inlet 
gas flow.  The outlet gas from the fermenter was cooled in a condenser, through which 
cold tap water was circulated.  Dow Corning anti-foam (BDH) was added to the 
fermenter to control foaming, since excessive foaming removed the relatively small 
yeast cells from the fermentation broth. 
 
The transformant strain was cultivated on solid medium prior to inoculation of a 5 ml 
liquid pre-culture.  The pre-culture was grown overnight at 30ºC in a Gallenkamp INR-
200 orbital incubator (Leicester, UK) at 150 rpm and transferred to 200 ml of liquid 
medium in a 1l baffled shake-flask, which was similarly incubated until a sufficient cell 
density was reached.  Both the pre-culture and inoculum were prepared in the same 
medium as used in the fermenter.  Cell densities in all cultures were estimated as 
absorbance (optical density) measurements at 620 nm (A620) with a Hitachi U-1100 
spectrophotometer (Hitachi Ltd., Tokyo, Japan).  The volume of shake-flask culture, 
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required to inoculate the fermenter to an A620 of 0.5, was centrifuged at 5000 rpm for 6 
min in a Beckman J2-21 centrifuge (Geneva, Switzerland) and the cells re-suspended in 
150 ml of the 10-fold medium concentrate, which was rapidly used to inoculate the 
fermenter. 
 
The basic batch cultivation proceeded in at least two steps (Table 8.1).  During the 
aerobic growth phase, the dissolved oxygen tension was maintained at 100% by manual 
adjustment of the level of oxygen-enrichment in the airflow and the agitation speed 
during the first 31 hours of fermentation.  Approximately 150 ml of sample was 
removed during fully aerobic conditions.  Prior to the transfer to oxygen limitation, to 
induce heterologous gene expression, a further 150 ml of the 10-fold concentrate of the 
liquid medium was added to the fermenter, to ensure sufficient nutrient availability 
during heterologous protein production.  A rapid transfer from fully aerobic conditions 
in the fermenter to oxygen-limitation was undertaken once the cell density reached a 
level of A620 = 30, at which time most of the glucose in the cultivation medium had 
been utilised.  The fermenter was first sparged with 100% N2, until the dissolved 
oxygen level had decreased to 0%, with the airflow subsequently re-admitted to 
fermenter either containing the normal level of oxygen (21%), resulting in the “High 
oxygenation” condition, or containing a significantly lower percentage of oxygen, 
resulting in the (very) “Low oxygenation” condition.  The level of dissolved oxygen 
was kept at 0% for the remainder of both types of culture, despite the differences in the 
oxygen transfer rate, thus ensuring that oxygen-limited conditions were maintained.  
After 43h of cultivation two of the cultures, one with “High” and one with “Low” 
oxygenation were also supplemented with a mixture of amino acids (see below).  
During one of the cultures, supplied with both a higher level of oxygenation and amino 
acid addition, a shift from oxygen-limited conditions back to fully aerobic conditions 
was performed once the glucose was completely consumed. 
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Table 8.1. Modes of batch fermentation by recombinant P. stipitis in YNB medium 
Time Oxygenation 
Oxygen content of 
gas inlet 
Nutrients / 
Supplements 
0 – 31 h Fully aerobic 21 – 27% Glucose 
31h Anaerobic 0% Glucose added 
31h – end Oxygen limited, “High” 21% Glucose 
31h – end Oxygen limited, “Low” 5 to 0.5% Glucose 
43h – end a Oxygen limited 21 – 0.5% b Glucose/Ethanol + Amino acid mixture 
63h – end c Fully aerobic 34% Ethanol 
a Amino acid mixtures were added to one of the “High” and one of the “Low” 
oxygenation cultures. 
b Depending on whether “High” or “Low” oxygenation was maintained 
c Only one of the “High oxygenation” cultures with amino acid addition was shifted 
back to fully aerobic growth after glucose consumption. 
 
8.2.3. Analytical methods 
Samples for the determination of cell density, substrate consumption and product 
formation were removed regularly from fermentations, as described previously (Chapter 
4).  Samples for the determination of cell density (Absorbance at 620 nm) were diluted 
with 9 g.l-1 NaCl into the 0.05 - 0.2 linear absorbance detection range of the 
spectrophotometer.  A calibration of the dry weight measurements (Meinander et al., 
1996) to absorbance (A620) was employed to calculate levels of biomass formation 
during the various stages of cultivation. 
 
8.2.4. Substrate consumption and product formation 
Glucose, ethanol, glycerol, acetate and succinate concentrations were determined as 
previously (Chapter 4).  To circumvent the problems associated with the presence of 
excess amounts of a reducing sugar (glucose) in the cultivation medium, samples were 
assayed for xylanase activity by using RBB-dyed xylan (Remazol brilliant blue) 
dissolved in acetate buffer (50mM; pH 5.4) as substrate, as described by Biely et al. 
(1985).  Samples were incubated for 2-6 hours at 30ºC, precipitated with 2 volumes of 
96% ethanol, and the absorbance (595 nm) measured.  Enzyme activity was calculated 
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by multiplying the rate of change in Ab595 (dAb595/dt) by the number of RBB molecules 
per xylan unit (20) and dividing by the molar extinction coefficient (9.25 mM-1.cm-1). 
 
8.3. RESULTS 
 
The relationship between the metabolic state of recombinant P. stipitis and the level of 
heterologous xylanase production, regulated by the native ADH2 promoter, was 
investigated in batch culture.  Biomass formation, substrate consumption and product 
formation by the recombinant strain are presented in Figure 8.1 and Tables 8.2 and 8.3.  
Levels of biomass formation during fully aerobic cultivation were approximately 15-
fold higher than those obtained in previous cultures with the same strain (Passoth and 
Hahn-Hägerdal, 2000), without measurable ethanol formation (Fig. 8.1A and E; Table 
8.2).  The maximum specific growth rate of the transformant during this growth phase 
was 0.154 ±0.013 (h-1). 
 
A rapid induction of heterologous xylanase production by the ADH2-promoter was 
obtained by changing the conditions the fermenter from fully aerobic to oxygen-limited 
conditions after 31 hours of cultivation (Fig. 8.1B).  In contrast to results with lower cell 
densities reported previously (Passoth and Hahn-Hägerdal, 2000), no apparent delay in 
the secretion of the foreign protein occurred (Fig. 8.1C and D).  Biomass formation 
significantly decreased during oxygen-limited conditions, as evident from a 
significantly reduced biomass yield (Fig. 8.1A; Table 8.2).  The consumption of glucose 
during oxygen-limitation resulted mostly in ethanol and carbon dioxide formation, with 
the latter calculated by assuming that 1 mole of CO2 was formed for each mole of 
ethanol or acetic acid formed (Skoog and Hahn-Hägerdal, 1990).  This approach 
resulted in the closure of the carbon balance during oxygen-limited growth (Table 8.2).   
 
Aeration is a critical variable for the cultivation of P. stipitis, due to the dependency of 
glucose fermentation on the oxygen transfer rate (Laplace et al., 1991; Guebel et al., 
1992; Du Preez et al., 1989; Du Preez, 1994).  However, the estimation of the effect of 
oxygenation on yeast physiology is hampered by the difficulty controlling oxygen 
consumption accurately, due to the poor sensitivity of dissolved oxygen probes (Du 
Preez, 1994) and the need for on-line estimation and control of the rate of O2-
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consumption per unit of biomass.  In the present investigation two constant oxygen 
transfer rates were employed during oxygen-limited conditions, with an inevitable 
decrease in the oxygen-consumption per gram biomass during the course of the 
fermentation, to determine the effect of host physiology and heterologous protein 
production.   
 
The different oxygenation strategies during oxygen-limited conditions resulted in two 
different levels of oxygen uptake by the recombinant yeast, as was confirmed by 
significant differences in the yeast physiology: Increased oxygenation resulted in 
increased biomass formation (Fig. 8.1A; Table 8.2), an increased rate of glucose 
consumption (Table 8.3), a decrease in CO2 production (Table 8.2), decreased glycerol 
formation (Fig 8.1F). Ethanol consumption during oxygen-limited conditions was not 
observed when the recombinant strain was cultivated with the lower level of 
oxygenation (Fig. 8.1E).  However, no clear effect on the level of recombinant xylanase 
production due to increased oxygenation by itself was observed, as was particularly 
evident for the cultures not supplemented with amino acids (Fig. 8.1C and D).  
However, for the culture supplemented with amino acids the increased oxygenation 
under oxygen-limited conditions resulted in approximately 3 times more heterologous 
xylanase production. 
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Figure 8.1. Biomass, xylanase, ethanol and glycerol production in batch cultivation of 
recombinant P. stipitis, switched from fully aerobic conditions to oxygen-limitation after 31h.  
“Low” (?,O) or “High” (?,?) oxygenation was supplied during oxygen limitation.  The 
amino acid mixture was added after 43h to the cultures represented by the closed symbols. The 
culture with high oxygenation and amino acid addition was shifted to fully aerobic growth after 
63h. 
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Table 8.2. Product formation during growth of recombinant P. stipitis on glucose under fully aerobic and oxygen-limited conditions 
Level of Yields on glucose (cmolproduct formed.cmolglucose consumed-1) 
oxygenation Biomass Ethanol Carbon dioxide (calculated) Carbon balance 
 Aerobica O2-limb +AA'sc Aerobic O2-lim +AA's Aerobic O2-lim +AA's Aerobic O2-lim +AA's 
Low 0.71 0.07 -- 0.00 0.48 -- 0.02 0.49 -- 0.74 1.06 -- 
High 0.61 0.19 -- 0.00 0.40 -- 0.02 0.42 -- 0.64 1.02 -- 
Low +AA's 0.45 0.09 0.12 0.00 0.44 0.41 0.05 0.45 0.41 0.55 1.01 0.96 
High +AA's 0.50 0.23 0.00 0.00 0.34 0.41 0.00 0.35 0.42 0.51 0.94 0.85 
a Fully aerobic growth on glucose prior to the induction of heterologous xylanase production (0 – 31h; Table 8.1) 
b Cultivation under oxygen-limited conditions after the induction of heterologous xylanase production, prior to amino acid addition (31-43h; Table 
8.1). 
c Cultivation under oxygen-limited conditions after amino acid addition (43h – 63h; Table 8.1) 
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Table 8.3. Rate of glucose consumption during oxygen-limited cultivation 
Rate of glucose consumption (gglucose.l-1.h-1) Level of oxygenation 
O2-lima +AA'sb 
Low 0.52 -- 
High 1.53 -- 
Low +AA's 0.78 0.77 
High +AA's 1.48 1.61 
a Cultivation under oxygen-limited conditions after the induction of heterologous 
xylanase production, prior to amino acid addition (31-43h; Table 8.1). 
b Cultivation under oxygen-limited conditions after amino acid addition (43h – 63h; 
Table 8.1) 
 
The addition of an amino acid mixture to the cultivation medium during oxygen-limited 
conditions had positive effects on the productivity of the recombinant strain (Fig. 8.1 
and Table 8.2).  The composition of the amino acid mixture was designed on the basis 
of a rational approach, whereby a 40-60% of the amino acids required for biosynthesis 
were supplied exogenously (Table 8.4; Greasham and Herber, 1997).  The amino acids 
were selected to ensure representation of all the amino acid groups in yeast biosynthesis 
(Jones and Fink, 1982), and did not contain histidine due to its use as selection marker 
for plasmid maintenance.  The amino acid mixture was added as a concentrate to the 
cultures after 43 hours of cultivation, and resulted in a significant increase in biomass 
formation during both low and high oxygenation (Fig. 8.1A).  The rate of glucose 
consumption during oxygen-limited conditions was not affected by the amino acid 
addition (Table 8.3). The specific level of heterologous xylanase production was 
significantly improved by the synergistic action of increased oxygenation and amino 
acid addition in the 43-63h window (Fig. 8.1D), whereas the overall production level 
also benefited from the additional biomass formation (Fig. 8.1C).  Amino acid 
consumption had variable effects on ethanol formation (Fig. 8.1E). 
 
Ethanol consumption after glucose depletion in oxygen-limited cultivation was 
observed only when the higher level of oxygenation was supplied, though no biomass 
formation due to ethanol consumption was evident.  Shifting back from oxygen-limited 
to fully aerobic conditions after glucose depletion did not increase biomass formation or 
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ethanol consumption appreciably, although heterologous xylanase production 
substantially increased (Fig. 8.1 A, C, D and E).  Consumption of ethanol was 
accompanied by a small measure of glycerol (Fig. 8.1 E-F), acetate and succinate co-
consumption (Appendix C, Fig. C.1). 
 
Table 8.4. Amino acid mixtures added to some cultures during oxygen limitation 
Amino acid Final concentrations (mg.l-1) 
 Low oxygenation High oxygenation 
Alanine 679 971 
Asparagine 590 842 
Glutamine 744 1116 
Arginine 296 443 
Glycine 338 507 
 
 
8.4. DISCUSSION 
 
Heterologous protein production under control of the oxygen regulated ADH2-promoter 
was successfully demonstrated in P. stipitis (Passoth and Hahn-Hägerdal, 2000).  In an 
attempt to improve production levels of heterologous xylanase, the effect of 
oxygenation, amino acid supplementation and high cell density was determined.  The 
presence of generic limitations in the production of heterologous proteins, similar to 
those observed with recombinant S. cerevisiae (Chapters 4 to 7), could thus be 
investigated. 
 
The ability of P. stipitis to grow to high cell densities in aerobic culture the presence of 
excess glucose, without measurable ethanol formation, was demonstrated (Fig. 8.1A, B 
and E).  The maximum specific growth rate of the transformant during fully aerobic 
growth was significantly lower than the μmax of 0.3 (h-1) previously reported for a wild-
type P. stipitis strain under similar conditions (Laplace et al., 1991).  The reduction in 
growth rate may have been caused by the loss of the recombinant plasmid during fully 
aerobic growth, or the negative effect of the auxotrophic trp5 marker.  A general 
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reduction in the metabolic activity of a P. stipitis strain due production of the present 
heterologous xylanase was also reported (Morosoli et al., 1992).  
 
In the present investigation, the induction of heterologous xylanase production by the 
transfer from fully aerobic conditions to oxygen limitation was almost immediate, 
compared to the 6-8 h lag phase prior to the detection of extracellular xylanase 
previously reported (Fig. 8.1C and D; Passoth and Hahn-Hägerdal, 2000).  The increase 
in cell density prior to induction, or the accuracy of dissolved oxygen control, may have 
contributed to this observation.  Heterologous xylanase production continued for up to 
70h after the shift to oxygen-limited conditions in the cultures supplemented with 
amino acids (Fig. 8.1C and D), indicating that the induction of the ADH2-promoter 
under these conditions were reasonably constant, despite the transient reduction in 
native ADH2 mRNA-levels previously reported (Cho and Jeffries, 1999).  The 
quantification of XLN mRNA levels is required to confirm the maintenance of 
heterologous gene transcription during oxygen-limited cultivation. 
 
Increased oxygenation during oxygen-limited conditions improved the general 
physiology of the host strain, resulting in more biomass formation, decreased CO2 
production, decreased glycerol formation and ethanol consumption after glucose 
depletion during oxygen-limitation (Fig. 8.1 and Table 8.2), corresponding to previous 
reports on the dependency of the growth and physiology on the aeration rate (Du Preez 
et al., 1989; Skoog and Hahn-Hägerdal, 1990; Du Preez, 1994; Passoth and Hahn-
Hägerdal, 2000).  However, the observed increase in the rate of glucose consumption 
and biomass formation due to higher oxygenation may not be beneficial in heterologous 
protein production processes, since the amount of substrate required to sustain the 
culture during the production phase is significantly increased.  The onset of ethanol re-
assimilation under oxygen-limited conditions in high aeration cultures also coincided 
with glucose depletion, as was previously reported (Fig. 8.1B and E; Passoth et al., 
1998).  The inability of low oxygenation cultures to consume ethanol may therefore 
have been an artefact of the retardation of glucose consumption.  Increased oxygenation 
did not have a significant effect on heterologous xylanase production in cultures 
without amino acid supplementation (Fig. 8.1C and D).  The level of heterologous gene 
expression directed by the plasmid-based ADH2-promoter was apparently unaffected by 
the increase in oxygen consumption during oxygen-limited conditions, despite 
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substantial improvements in the rate of carbon utilisation and biomass formation by the 
recombinant strain. 
 
The availability of exogenous amino acids for the enhancement of heterologous protein 
synthesis was critical at both oxygenation rates, since xylanase production was only 
observed during the 40-100 h window in cultures supplemented with the amino acid 
mixture (Fig. 8.1C and D).  Either the severe effect of oxygen limitation on yeast 
growth and biosynthesis (Fig. 8.1A; Table 8.2; Du Preez et al., 1989; Skoog and Hahn-
Hägerdal, 1990; Du Preez, 1994; Passoth et al., 1996; Passoth et al., 1998), or the 
aforementioned presence of the trp5 auxotrophic marker, apparently limited the 
biosynthetic capacity of the transformant substantially, as was also evident from the 
inability to produce biomass from consumed ethanol.  Auxotrophic yeast transformants 
were also shown to require excess amounts of exogenous amino acids to stabilise 
metabolism and to allow for high levels of heterologous protein production (Chapter 6).  
The increased production of heterologous xylanase by the combined effect of higher 
oxygenation and amino acid supplementation, both of which also increased biomass 
formation, thus indicated the requirement for improved resource availability and 
biosynthetic capacity to support heterologous protein production (Fig. 8.1C and D).  
The positive effect of amino acids on heterologous protein production was probably not 
related to the presence of extracellular proteolytic activity, as reported by Den Haan and 
Van Zyl (2001), since no degradation of extracellular xylanase between 40-100 hours of 
cultivation was observed in cultures not supplemented with amino acids (Fig. 8.1C and 
D). 
 
Heterologous xylanase production under regulation of the oxygen-sensitive ADH2 
promoter was also improved by a shift from oxygen-limited to fully aerobic growth 
during ethanol assimilation, though no additional biomass formation or ethanol 
consumption was observed (Fig. 8.1 C-E).  The induction of the ADH2 promoter of P. 
stipitis under these conditions, known to be required for both ethanol production and 
assimilation (Passoth et al., 1998; Cho and Jeffries, 1999), has not been reported 
previously.   
 
Ethanol production during the induction phase (i.e. oxygen-limitation) of cultures based 
on the present transformant seems inevitable.  However, adequate control of ethanol 
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formation and consumption for maximal heterologous protein production by S. 
cerevisiae has been demonstrated (Badziong et al., 1999; Noronha et al., 1998; Noronha 
et al., 1999).  Although the current low production levels of C. albidus xylanase by the 
ADH2-based expression system could not be compared directly to production by P. 
stipitis via XYL1-regulation (Morosoli et al., 1992; Morosoli et al., 1993), or by S. 
cerevisiae (Moreau et al., 1992), due to different enzyme assays, the levels obtained 
with S. cerevisiae were fairly poor, and corresponded to approximately 1% of the total 
secreted protein (Moreau et al., 1992; Morosoli et al., 1992; Morosoli et al., 1993).  In 
defined medium the production levels of the T. reesei xylanase II by P. stipitis 
compared favourably to levels obtained with S. cerevisiae (Den Haan and Van Zyl, 
2001; La Grange et al., 1996).  P. stipitis may therefore represent a viable alternative to 
the more traditional yeasts for heterologous xylanase production. 
 
8.5. CONCLUSIONS 
 
In the present investigation the production of heterologous xylanase by recombinant P. 
stipitis, under regulation of the native ADH2 promoter, could be improved by 
cultivating the yeast to higher cell densities, increasing the level of oxygenation under 
oxygen-limited conditions, supplementing the defined medium with amino acids and 
reverting to fully aerobic conditions during ethanol consumption.  The production level 
of heterologous xylanase was strongly influenced by the level of induction from the 
ADH2 promoter, as was also observed during the cultivation of recombinant S. 
cerevisiae (Chapter 4).  The requirement for exogenous amino acids to improve 
heterologous xylanase production by an auxotrophic transformant was demonstrated in 
both P. stipitis and S. cerevisiae (Chapter 6).  The general physiological state of the 
yeast host and the availability of nutrients affected the biosynthetic capacity of both S. 
cerevisiae and P. stipitis for the production of a heterologous protein (Chapter 6 and 7).  
The active regulation of heterologous xylanase production by both yeasts was thus 
demonstrated. 
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Chapter 9 
 
CONCLUSIONS ON YEAST PHYSIOLOGY AND NITROGEN 
METABOLISM DURING HETEROLOGOUS PROTEIN 
PRODUCTION 
 
9.1. INTRODUCTION 
 
The low yields of heterologous xylanase production observed with an S. cerevisiae 
expression system prompted an investigation into the factors that may limit 
heterologous protein production by yeast.  Several experimental strategies were 
therefore designed to identify specific aspects of yeast genetics, physiology and 
nitrogen metabolism that may negatively influence yeast productivity in bioprocesses.  
The experimental data were also interpreted in terms of a possible global sensing and 
regulatory mechanism, whereby the yeasts were able to actively regulate the production 
level of heterologous xylanase in response to physiological and environmental factors.  
The identification of general regulatory mechanisms is of importance for the rational 
improvement of heterologous protein production by yeast. 
 
9.2. FACTORS THAT MAY LIMIT YEAST PRODUCTIVITY 
 
In the previous chapters, the negative effect of several factors on the productivity of 
recombinant yeast for heterologous protein production was demonstrated.  The 
disproportionate “metabolic burden” of heterologous protein production may affect 
yields in a bioprocess negatively by reducing biomass formation and increasing the 
fermentation time (Chapter 4).  The additional metabolic “load” of foreign protein 
production was strongly related to induction of the yeast stringent stress response 
(Chapter 5).  The corresponding loss of metabolic functionality, due to the 
downregulation of glycolysis, translation and protein synthesis, the apparent nitrogen 
limitation and the up-regulation of respiration, resulted in the disproportionate 
physiological effects of foreign protein production.  The loss of biosynthetic capacity 
associated with the stringent stress response may therefore have limited the ability of 
the host strain to produce heterologous xylanase, resulting in lower production levels.  
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The ability of the yeast strain to cope with the metabolic stress associated with the 
production of a heterologous protein may thus be crucial for obtaining a high level of 
foreign protein production.  The production level of a particular protein could be linked 
to its propensity to introduce metabolic stress when expressed in a heterologous host 
organism, which may explain the large variation in production of various heterologous 
proteins in a particular organism (Chapter 2).   
 
The production levels of heterologous xylanase were significantly influenced by 
expression vector selection and the presence of auxotrophic mutations in transformed 
strains of S. cerevisiae (Chapter 6).  Increasing the gene dosage of the heterologous 
xylanase with the multicopy YEp-type expression system, dramatically improved 
xylanase production compared to the integrative, low copy number YIp-type expression 
system.  The level of foreign gene transcription in the cell thus limited heterologous 
xylanase production, whereas the secretory capacity of the host strain was not saturated.  
The genetic stability of the autoselective YEp-type expression system in long-term 
chemostat culture was also demonstrated, as is required for repetitive cultivation in 
bioprocesses.  The autoselection-YEp-based expression system was able to support high 
levels of heterologous protein production by prototrophic transformants.   
 
The presence of auxotrophic requirements in the transformed S. cerevisiae strains 
substantially reduced heterologous xylanase production (Chapter 6).  The retention of 
uncomplimented auxotrophic markers in transformants required the stabilisation of 
nitrogen metabolism via the saturation of yeast cells with imported amino acids, to 
allow for high levels of heterologous xylanase production.  The addition of amino acids 
to the cultivation medium also improved heterologous xylanase production by an 
auxotrophic P. stipitis transformant (Chapter 8).  The presence of excessive auxotrophic 
mutations apparently caused a physiological defect in transformants that severely 
reduced production levels of heterologous xylanase.  The auxotrophic requirements 
either made it more difficult for the yeast to cope with the additional burden of 
heterologous protein production, or introduced irregularities into the amino acid 
metabolism.  The removal of excessive auxotrophic markers resulted in high levels of 
xylanase production by a prototrophic transformant in defined medium without amino 
acid addition.  As the irregularities introduced by the presence of auxotrophic mutations 
in transformants may cripple the productivity of a bioprocess for heterologous protein 
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production severely, the use of auxotrophic strains should be avoided completely 
(Çakar et al., 1999). 
 
Heterologous xylanase production by S. cerevisiae in defined medium was partially 
limited by the availability of metabolic precursors for protein synthesis, since both the 
addition of suitable amino acid mixtures and succinate improved heterologous xylanase 
production (Chapter 7).  This supported the notion that foreign protein production may 
drain metabolic resources from the central pathways (Jin et al., 1997; Ramirez and 
Bentley, 1993).  An additional requirement for metabolic precursors and building 
blocks may thus exist in cellular metabolism for the synthesis of a foreign protein. 
Although the addition of these components to the defined medium may increase the 
productivity of a bioprocess, the magnitude of improvements were typically smaller 
than two-fold, indicating the presence of other limiting factors besides the availability 
of amino nitrogen and TCA metabolites.  The order of magnitude improvement 
obtained by the removal of the auxotrophic requirements from the transformed strains 
indicated that molecular genetics and the adaptation of the expression system has a 
superior potential for increasing the production levels of heterologous proteins, rather 
than the simple optimisation of cultivation conditions. 
 
The production of heterologous xylanase by recombinant P. stipitis, under regulation of 
the native ADH2 promoter, could be improved by cultivating the yeast to high cell 
densities, increasing the level of oxygenation under oxygen-limited conditions, 
supplementing the defined medium with amino acids and reverting to fully aerobic 
conditions during ethanol consumption (Chapter 8).  The production level of 
heterologous xylanase was thus strongly influenced by the level of induction from the 
oxygen-sensitive ADH2 promoter, similar to observations during the cultivation of 
recombinant S. cerevisiae (Chapter 4).  The requirement for exogenous amino acids to 
improve heterologous xylanase production by auxotrophic transformants of both S. 
cerevisiae (Chapter 6) and P. stipitis (Chapter 8) was also demonstrated.  Changes in 
the general physiological state of the yeast host and nutrient availability influenced the 
total biosynthetic capacity of both S. cerevisiae and P. stipitis and thus affected 
production levels of heterologous xylanase (Chapters 6 to 8).  The presence of several 
generic limitations in the production of heterologous xylanase by the yeasts, S. 
cerevisiae and P. stipitis, was therefore identified, including transcription level, nutrient 
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availability, the metabolic vitality of the host and the biosynthetic capacity.  Due to 
ability to grow to high cell density in the presence of excess glucose in batch culture 
without the formation of ethanol, P. stipitis remains an attractive host for the 
development of bioprocesses for heterologous protein production. 
 
9.3. THE DESIGN OF LIFE 
 
The present investigations have provided proof for the existence of global sensing and 
regulatory mechanisms whereby the yeast may actively regulate both the production of 
heterologous proteins and the physiological response to this process.  Yeast cells were 
able to down-regulate biomass formation in response to heterologous protein 
production, indicating the presence of cellular mechanisms able to sense and respond to 
the production of a foreign protein (Chapter 4).  Yeast also responded actively to the 
production of heterologous xylanase by inducing the stringent stress response, which 
dominated the physiology and transcriptional profile of S. cerevisiae during foreign 
protein production.  The active induction of the stringent stress response due to the 
synthesis and secretion of a foreign protein confirmed the presence of a global sensing 
and regulatory mechanism, similar to a virtual “cellular intelligence,” that determined 
the response to heterologous protein production.  The production levels of heterologous 
xylanase may also be down-regulated by the loss of functionality (biosynthetic 
capacity) associated with the stringent response. 
 
The global and apparently “intelligent” regulation of heterologous protein production 
by the yeast cell was also demonstrated by the response of auxotrophic S. cerevisiae 
strains to a limited availability of amino acids, below the levels required for the 
saturation of the cell.  The production level of the foreign protein was actively down-
regulated without reducing the level of xylanase transcripts in the cell (Chapter 6).  A 
strong relationship between the availability of resources in nitrogen metabolism and the 
willingness of the yeast to produce a foreign protein was thus demonstrated.  The 
general physiological state of the yeast host and the availability of nutrients also 
affected the biosynthetic capacity of both prototrophic S. cerevisiae and auxotrophic P. 
stipitis for the production of a heterologous protein (Chapters 6 to 8).  The biosynthetic 
capacity of a recombinant yeast strain for heterologous protein production may thus be 
actively regulated in response to the availability of sufficient resources for protein 
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synthesis.   The heterologous protein production from a plasmid-based expression 
system was thus subjected to a number of regulatory mechanisms in the yeast cell, 
which complicated the manipulation of the cellular biosynthesis of a foreign protein at 
will. 
 
9.4. RECOMMENDATIONS 
 
Two aspects of yeast expression systems for heterologous protein production that 
require extensive clarification are the influence of host strain and foreign protein 
characteristics on the attainable production levels.  In the present dissertation, the 
influence of host strain characteristics on heterologous xylanase was demonstrated by 
the large difference in production levels obtained with the auxotrophic and prototrophic 
transformants of S. cerevisiae.  However, the specific characteristics of different yeast 
strains that determine the levels of foreign gene transcription, translation and secretory 
efficiency, protein quantity and quality, plasmid stability and plasmid copy number 
(Park et al., 2000; Eckart and Bussineau, 1996; Mendoza-Vega et al., 1994) have not 
been identified, despite numerous published references to their influence (see Chapter 
2).  Such characteristics may be identified by first developing and/or selecting improved 
host strains, followed by rigorous characterisation. 
 
Several investigations have also referred to the influence of the biochemical 
characteristics of a specific recombinant protein on the attainable production levels (see 
Chapter 2).  In the present dissertation reference was made to the potential relationship 
between the measure of metabolic stress introduced by the production of a particular 
protein, and the final production level (Chapter 5).   The measurement of the 
intracellular proteolytic activity towards various heterologous proteins may thus be 
useful for determining the relevance of the stringent proteolytic response in 
heterologous protein production.  The magnitude of the stringent stress response by a 
particular host strain towards various heterologous proteins may also be compared via 
transcriptional profiling, whereby a possible relationship between the biochemical 
characteristics of a protein and the corresponding levels of stress response and 
extracellular protein production can be established.  Furthermore, the elucidation of the 
specific characteristics of recombinant proteins that may limit their production in 
heterologous hosts will provide valuable information on the most suitable host for the 
237
production of a particular protein. A systematic investigation of the influence of host 
strains and recombinant protein characteristics that determine production levels will 
allow for the rational, rather than empirical, design of future production systems.  
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Appendix A 
 
Additional results from Chapter 4 
 
Table A.1 Product yields on glucose during batch cultivation of auxotrophic strains in 
defined medium 
Strain Yield on glucose (gproduct.gglucose-1) 
 Acetate Succinate 
[Host] 0.012 ±0.004 0.0015 ±0.0001 
[PGK1] 0.012 ±0.004 0.0019 ±0.0004 
[PGK1-XYN] 0.014 ±0.006 0.0013 ±0.0003 
[ADH2] 0.008 ±0.001 0.0011 ±0.0005 
[ADH2-XYN] 0.011 ±0.001 0.0011 ±0.0002 
 
Table A.2 Maximum specific growth rate (μmax, h-1) during growth on glucose in 
complex medium (YPD) 
Strain Maximum specific growth rate (μmax, h-1) 
Sc Y294 0.37 ± 0.04 
Sc Y294 [Host] 0.38 ± 0.03 
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Appendix B 
 
Additional results from Chapter 6 
 
Table B.1 Xylanase production by the prototrophic [ADH2-XYN] Int transformants 
during shake-flask cultivation in defined medium  
Transformant # Xylanase production (μg.l-1) 
 3 days cultivation 5 days cultivation 
2 98 91 
7 10 77 
8 16 96 
10 27 21 
13 23 110 
19 28 85 
20 38 44 
23 127 0 
25 42 99 
31 22 68 
37 19 122 
40 0 132 
45 29 65 
46 111 78 
56 25 84 
57 85 120 
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Figure B.1. Biomass formation by the auxotrophic [ADH2-XYN] strain during shake-
flask cultivation in defined medium, supplemented with His, Trp and Leu at different 
total concentrations. (♦) Final level of biomass formation (Absorbance, 620 nm) and 
(•) maximum specific growth rate (μmax, h-1). 
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Table B.2. Carbon- and degree of reduction balance during batch cultivation of the auxotrophic [ADH2-XYN] strain in defined medium containing 
different total levels of amino acids 
Product formation or substrate consumption (cmol.cmolethanol consumed-1) Total AA 
Concentration 
[mM] Biomass Glycerol Acetate Succinate CO2 O2 * Amino acids 
EtOH 
Evaporated 
Degree of 
Reduction
C-balance 
10.8 0.24 -0.05 -0.02 0.00 0.47 -1.50 -0.12 0.48 0.00 1.00 
4.3 0.28 -0.05 -0.04 0.00 0.76 -2.38 -0.10 0.15 0.00 1.00 
1.9 0.05 -0.03 -0.05 0.01 0.72 -2.10 0.00 0.32 0.00 1.00 
0.0 ** 0.34 -0.12 0.00 0.00 0.45 -1.30 0.00 0.33 0.00 1.00 
* Reported as amol.cmolethanol consumed-1 
** [ADH2-XYN] PlasPro strain 
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Table B.3.  Effect of components besides amino acids in the defined medium on 
xylanase production by the auxotrophic [ADH2-XYN] strain in chemostat culture 
Changes in medium components Feed C/N Ratio 
(gglucose.mmolamino N-1) NH4+ and Salts Vitamins and Trace Elements 
Xylanase 
[mg.l-1] 
0.25 1 1 8.3 
0.25 ½ 1 10.6 
0.25 ½ ½ 9.8 
 
Time Ferm 96 vs O2 Outlet Ferm 96 
Time (Ferm 96) vs CO2 out Ferm 96 
Feed C/N Ratio (ggluc.mmolamino N-1)
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Figure B.2. Total extracellular protein production by the auxotrophic [ADH2-XYN] 
strain during chemistat cultivation in defined medium containing seven amino acids. (•) 
Total extracellular protein production (mg.l-1). 
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Figure B.3. No clear correlation between dilution rate and xylanase production by the 
auxotrophic [ADH2-XYN] strain during chemistat cultivation in defined medium 
containing seven amino acids. Outliers of high xylanase production correspond to 
media with low C/N ratio’s. (•) Extracellular xylanase production (mg.gbiomass-1). 
 
 
245
Appendix C 
 
Additional results from Chapter 8 
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Figure C.1. Acetate and succinate production in batch cultivation of recombinant P. 
stipitis, switched from fully aerobic conditions to oxygen-limitation after 31h.  “Low” 
(?,O) or “High” (?,?) oxygenation was supplied during oxygen limitation.  The 
amino acid mixture was added after 43h to the cultures represented by the closed 
symbols. The culture with high oxygenation and amino acid addition was shifted to 
fully aerobic growth after 63h. 
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Appendix D 
 
Functional classification of the gene expression data from Chapter 5. 
 
The classification of the 1014 genes, with a significant change in their expression level 
in either the S. cerevisiae Y294 [PGK1-XYN] or Y294 [PGK1] strains, into the MIPS 
functional categories (Mewes et al., 2000) is presented below. 
 
Mewes, H. W., Frishman, D., Gruber, C., Geier, B., Haase, D., Kaps, A., Lemcke, K., 
Mannhaupt, G., Pfeiffer, F., Schueller, C., Stocker, S. & Weil, B. (2000). MIPS: a database 
for genomes and protein sequences. Nucleic Acids Research 28, 37-40. 
e m s
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All Genes showing Significant Change (1014), sorted into MIPS categories
Information presented in the Sequence: ORF Nam Gene Na Gene Alia Identifier Function pDLG6 vs pJC1 Comparison pDLG6 vs YEp352 Comparison pJC1 vs pDLG6 Comparison pJC1 vs YEp352 Co
Signific. Signific. Signific.
Expr Leve Fold Chng Factor Expr Leve Fold Chng Factor Expr LevelFold Chng Factor Expr LevelFold Chng
METABOLISM
amino acid metabolism
amino acid biosynthesis
Glutamate Family (Glut, Glum, Pro, Arg, Lys)
YOL058W ARG1 ARG10 8593_at YOL058W 1917.4 1.1 191.7 1917.4 1.6 1150.4 1715.0 -1.1 171.5 1715.0 1.5
YDL182W LYS20 6683_g_at YDL182W 2082.9 -1.0 101.7 2082.9 1.1 310.2 2189.0 1.0 106.8 2189.0 1.2
YIR034C LYS1 4070_at YIR034C s 1335.0 -1.0 65.2 1335.0 1.2 332.4 1385.0 1.0 67.6 1385.0 1.3
YNR050C LYS9 LYS13 8808_at YNR050C S 0.0 0.0 0.0 0.0 0.0 0.0 1516.0 1.1 151.6 1516.0 1.2
YIL094C LYS12 4172_at YIL094C H 1052.7 -1.2 206.1 1052.7 -1.0 0.0 1219.6 1.2 238.8 1219.6 1.2
YJR109C CPA2 10902_at YJR109C 778.2 1.1 115.9 778.2 1.2 193.8 0.0 0.0 0.0 0.0 0.0
YER069W ARG5,6 5642_at YER069W 592.0 1.2 118.4 592.0 1.0 28.9 499.6 -1.2 99.9 499.6 -1.1
YDL171C GLT1 6649_at YDL171C 204.4 -1.7 142.5 204.4 -2.2 244.8 344.1 1.7 239.9 344.1 -1.3
YPR035W GLN1 7698_at YPR035W 1270.0 -1.4 508.0 1270.0 -1.2 316.2 1721.7 1.4 688.7 1721.7 1.1
YER023W PRO3 ORE2 5678_at YER023W 771.7 -1.2 192.1 771.7 -1.4 346.6 961.5 1.2 239.4 961.5 -1.2
Aromatic Family (Phen, Tyr, Tryp)
YDR035W ARO3 6450_at YDR035W 1396.4 1.1 139.6 1396.4 1.3 418.9 1273.6 -1.1 127.4 1273.6 1.2
YKL211C TRP3 10801_at YKL211C 465.6 1.2 115.9 465.6 1.7 348.9 337.3 -1.2 84.0 337.3 1.4
YDR354W TRP4 6095_at YDR354W 321.6 1.2 80.1 321.6 1.5 176.6 0.0 0.0 0.0 0.0 0.0
YGL026C TRP5 5036_at YGL026C 1026.9 -1.2 201.1 1026.9 -1.1 98.0 1215.8 1.2 238.1 1215.8 1.1
YDR007W TRP1 6468_at YDR007W 233.8 1.4 105.0 233.8 1.1 34.8 0.0 0.0 0.0 0.0 0.0
Serine Family (Ser, Gly, Cys)
YGR055W MUP1 4936_at High affinity 968.3 2.0 968.3 968.3 9.0 7745.5 486.4 -2.0 486.4 486.4 4.5
YEL046C GLY1 5789_at Threonine A 560.0 2.2 699.6 560.0 3.1 1175.9 248.0 -2.2 309.9 248.0 1.4
YGR155W CYS4 NHS5, ST 4856_at YGR155W 911.2 1.1 135.7 911.2 1.3 273.3 789.1 -1.1 117.5 789.1 1.1
YFL018C LPD1 HPD1 5367_at YFL018C 871.1 1.2 216.9 871.1 -1.0 0.0 700.8 -1.2 174.5 700.8 -1.2
Aspartate Family (Asp, Asgn, Thr, Meth, Ileu)
YGR055W MUP1 4936_at High affinity 968.3 2.0 968.3 968.3 9.0 7745.5 486.4 -2.0 486.4 486.4 4.5
YPR145W ASN1 7588_at YPR145W 1054.4 1.3 368.1 1054.4 2.6 1685.0 757.0 -1.3 264.2 757.0 1.9
YPL273W SAM4 8022_at YPL273W A 1143.8 1.4 457.5 1143.8 1.7 800.6 810.0 -1.4 324.0 810.0 1.2
YGR124W ASN2 4869_at YGR124W 938.4 1.3 281.5 938.4 1.5 469.2 735.3 -1.3 220.6 735.3 1.2
YBR294W SUL1 7067_at Putative s 97.3 1.3 33.9 97.3 4.0 291.6 70.8 -1.3 24.7 70.8 2.9
YJR130C STR2 10878_at YJR130C 347.7 1.2 86.6 347.7 1.7 260.5 272.6 -1.2 67.9 272.6 1.4
YGL184C STR3 5196_at YGL184C 243.4 1.3 72.1 243.4 1.9 229.8 0.0 0.0 0.0 0.0 0.0
YGL125W MET13 MET11 5117_at YGL125W 579.3 1.1 86.3 579.3 1.3 173.8 0.0 0.0 0.0 0.0 0.0
YLR092W SUL2 10256_at YLR092W 560.9 1.1 56.1 560.9 1.2 112.2 545.7 -1.1 54.6 545.7 1.1
YDR158W HOM2 6304_at YDR158W 1615.5 -1.1 240.6 1615.5 1.0 78.9 1816.5 1.1 270.5 1816.5 1.1
YJR148W BAT2 TWT2, EC 10896_at YJR148W 0.0 0.0 0.0 0.0 0.0 0.0 204.4 -2.0 214.5 204.4 1.7
YER052C HOM3 BOR1, SIL45664_at YER052C A 0.0 0.0 0.0 0.0 0.0 0.0 821.6 1.1 82.2 821.6 1.2
YLR303W MET17 MET15, M 10018_at YLR303W 2391.4 -1.1 356.1 2391.4 -1.0 0.0 2776.8 1.1 413.5 2776.8 1.2
YCR053W THR4 6841_at YCR053W 0.0 0.0 0.0 0.0 0.0 0.0 802.0 1.1 80.2 802.0 1.3
YER091C MET6 5620_at YER091C v 966.8 -1.2 240.7 966.8 -1.1 96.7 1207.0 1.2 300.5 1207.0 1.1
YLR180W SAM1 ETH10 10161_g_ YLR180W 3444.8 -1.2 689.0 3444.8 -1.0 168.1 4328.7 1.2 865.7 4328.7 1.2
YJR010W MET3 11032_at YJR010W A 902.1 -1.2 180.4 902.1 -1.2 180.4 1098.4 1.2 219.7 1098.4 1.0
a
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YKL001C MET14 10563_at YKL001C 1314.9 -1.2 327.4 1314.9 -1.1 195.8 1620.4 1.2 403.5 1620.4 1.0
YLR027C AAT2 ASP5 10323_at YLR027C 1551.3 -1.1 231.0 1551.3 -1.1 231.0 1722.6 1.1 256.5 1722.6 -1.0
YJR139C HOM6 10887_at YJR139C 2306.2 -1.2 461.2 2306.2 -1.1 343.4 2917.6 1.2 583.5 2917.6 1.0
Pyruvate Family (Ala, Val, Leu)
YNL104C LEU4 8973_at YNL104C 1720.8 1.1 172.1 1720.8 2.0 1720.8 1616.3 -1.1 161.6 1616.3 1.8
YLR089C 10253_at YLR089C 820.2 2.2 984.2 820.2 2.5 1230.2 348.3 -2.2 418.0 348.3 1.1
YLR355C ILV5 9979_at YLR355C 1911.6 1.0 93.3 1911.6 1.1 284.7 0.0 0.0 0.0 0.0 0.0
YJR016C ILV3 10993_at YJR016C 1257.3 1.1 125.7 1257.3 1.2 251.5 0.0 0.0 0.0 0.0 0.0
YMR108W ILV2 SMR1, TH 9550_at YMR108W 502.3 1.1 74.8 502.3 1.4 225.6 448.3 -1.1 66.8 448.3 1.3
YCL018W LEU2 6909_at YCL018W 1041.6 1.3 312.5 1041.6 1.2 208.3 805.3 -1.3 241.6 805.3 -1.0
YJR148W BAT2 TWT2, EC 10896_at YJR148W 0.0 0.0 0.0 0.0 0.0 0.0 204.4 -2.0 214.5 204.4 1.7
YCL009C ILV6 6871_at YCL009C 1187.4 -1.1 176.8 1187.4 -1.0 0.0 1351.5 1.1 201.3 1351.5 1.1
YER086W ILV1 ISO1 5614_at YER086W 655.1 -1.0 0.0 655.1 1.2 131.0 0.0 0.0 0.0 0.0 0.0
Histidine (His)
YCL030C HIS4 6902_at YCL030C 1793.9 -1.1 179.4 1793.9 1.2 358.8 1904.8 1.1 190.5 1904.8 1.3
YIL116W HIS5 4195_at YIL116W 582.6 1.2 145.1 582.6 1.6 378.2 441.8 -1.2 110.0 441.8 1.4
YOR202W HIS3 8359_at YOR202W 673.6 1.1 67.4 673.6 1.1 100.3 0.0 0.0 0.0 0.0 0.0
YGR204W ADE3 4814_at YGR204W 724.6 -1.2 144.9 724.6 -1.2 180.4 901.8 1.2 180.4 901.8 -1.0
General
YPR074C TKL1 7694_at YPR074C T 1097.1 -1.1 163.4 1097.1 -1.0 53.5 1280.0 1.1 190.6 1280.0 1.1
YMR250W GAD1 9388_at YMR250W 67.9 2.2 81.3 67.9 1.7 50.9 31.1 -2.2 37.2 31.1 -1.2
YHR068W DYS1 4449_at YHR068W 603.4 -1.4 241.4 603.4 -1.3 181.0 781.4 1.4 312.6 781.4 1.1
regulation of amino acid metabolism
YHR137W ARO9 4386_at Aromatic a 1112.7 2.2 1332.6 1112.7 6.9 6610.5 513.9 -2.2 615.5 513.9 3.2
YDR160W SSY1 SHR10 6306_at YDR160W 35.6 1.1 3.6 35.6 2.5 55.2 33.2 -1.1 3.3 33.2 2.4
YMR043W MCM1 FUN80 9576_at Putative tr 90.2 1.6 58.6 90.2 2.0 94.7 54.3 -1.6 35.3 54.3 1.2
YGL202W ARO8 5223_at YGL202W 1059.9 1.2 263.9 1059.9 1.3 318.0 843.6 -1.2 210.1 843.6 1.0
YIR017C MET28 4098_at YIR017C 353.7 1.2 88.1 353.7 1.3 106.1 0.0 0.0 0.0 0.0 0.0
YMR042W ARG80 ARGR1 9575_at Regulator 57.3 1.8 45.8 57.3 1.9 51.5 31.3 -1.8 25.0 31.3 1.0
YCR028C FEN2 6863_at YCR028C 375.2 -1.2 93.4 375.2 -1.4 148.7 465.8 1.2 116.0 465.8 -1.1
YEL009C GCN4 AAS3, AR 5737_at 1433.2 1.0 70.0 1433.2 -1.1 136.8 1390.5 -1.0 67.9 1390.5 -1.1
YDR328C SKP1 MGO1 6160_at YDR328C 487.2 1.2 121.3 487.2 -1.1 48.7 386.5 -1.2 96.2 386.5 -1.4
amino acid transport
YDR046C BAP3 6415_at Valine trans 670.0 2.6 1072.0 670.0 178.1 118656.5 297.2 -2.6 475.5 297.2 81.3
YBR068C BAP2 7291_at Major AA 646.7 2.3 839.2 646.7 133.8 85884.2 280.3 -2.3 363.8 280.3 58.7
YPL265W DIP5 8030_at Dicarboxyli 911.4 2.2 1085.3 911.4 18.4 15885.5 416.4 -2.2 495.9 416.4 8.5
YGR055W MUP1 4936_at High affinity 968.3 2.0 968.3 968.3 9.0 7745.5 486.4 -2.0 486.4 486.4 4.5
YNL268W LYP1 9126_at YNL268W 580.1 -1.0 0.0 580.1 2.3 782.8 570.8 -1.0 0.0 570.8 2.3
YDR508C GNP1 5977_at High-affinity 434.0 1.7 302.5 434.0 5.8 2102.6 256.4 -1.7 178.7 256.4 3.5
YBR069C TAT1 VAP1, WAK7292_at Amino aci 164.5 3.1 345.1 164.5 11.2 1685.2 53.1 -3.1 111.4 53.1 4.1
YKR039W GAP1 10511_at YKR039W 46.7 -2.4 65.2 46.7 -1.4 21.0 110.8 2.4 154.9 110.8 1.7
YCL025C AGP1 YCC5 6907_at YCL025C 249.7 1.3 87.2 249.7 1.8 212.1 186.9 -1.3 65.2 186.9 1.4
YOL020W TAT2 LTG3, SA 8587_at YOL020W 216.0 1.7 151.2 216.0 2.3 291.5 127.2 -1.7 89.0 127.2 1.4
YFL055W AGP3 5425_at General a 16.0 1.6 10.4 16.0 4.8 61.6 9.6 -1.6 6.2 9.6 3.0
YKL124W SSH4 MLF4 10704_at YKL124W s 28.2 2.2 33.4 28.2 2.7 47.9 13.1 -2.2 15.5 13.1 1.5
YBR132C AGP2 7223_at Amino aci 13.8 3.5 34.3 13.8 3.5 34.4 4.0 -3.5 9.9 4.0 -1.2
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YLL061W MMP1 10415_at YLL061W 16.8 2.5 25.1 16.8 2.2 20.1 6.6 -2.5 9.9 6.6 -1.2
amino acid degradation (catabolism) 
Glutamate Family (Glut, Glum, Pro, Arg, Lys)
YPL111W CAR1 LPH15 7869_at Arginase / S 304.8 2.1 350.3 304.8 3.8 853.4 142.4 -2.1 163.7 142.4 1.9
YDL215C GDH2 6693_at YDL215C 199.9 1.8 169.7 199.9 2.2 249.7 107.7 -1.8 91.5 107.7 1.2
YOR375C GDH1 URE1 8174_at YOR375C 662.8 -2.4 927.9 662.8 -2.5 994.1 1441.3 2.4 2017.8 1441.3 -1.0
Aromatic Family (Phen, Tyr, Tryp)
Serine Family (Ser, Gly, Cys)
YEL046C GLY1 5789_at Threonine A 560.0 2.2 699.6 560.0 3.1 1175.9 248.0 -2.2 309.9 248.0 1.4
YKL218C SRY1 10794_at YKL218C 517.3 1.6 335.8 517.3 2.7 878.4 307.0 -1.6 199.3 307.0 1.6
YDR019C GCV1 GSD1 6480_at YDR019C g 443.3 1.4 199.1 443.3 1.2 86.8 318.4 -1.4 143.0 318.4 -1.2
YIL167W SDL1 4284_at Serine deh 13.4 4.2 42.7 13.4 3.8 37.9 1.6 -4.2 5.1 1.6 -1.5
YCL064C CHA1 6915_at YCL064C 14.8 -1.1 2.1 14.8 2.3 19.0 16.6 1.1 2.3 16.6 2.6
Aspartate Family (Asp, Asgn, Thr, Meth, Ileu)
YLR180W SAM1 ETH10 10161_g_ YLR180W 3444.8 -1.2 689.0 3444.8 -1.0 168.1 4328.7 1.2 865.7 4328.7 1.2
YPL273W SAM4 8022_at YPL273W A 1143.8 1.4 457.5 1143.8 1.7 800.6 810.0 -1.4 324.0 810.0 1.2
YJR148W BAT2 TWT2, EC 10896_at YJR148W 0.0 0.0 0.0 0.0 0.0 0.0 204.4 -2.0 214.5 204.4 1.7
YDR502C SAM2 ETH2 5971_at YDR502C S 988.2 -1.2 197.6 988.2 -1.0 48.2 1185.2 1.2 237.0 1185.2 1.1
YCL064C CHA1 6915_at YCL064C 14.8 -1.1 2.1 14.8 2.3 19.0 16.6 1.1 2.3 16.6 2.6
YDR321W ASP1 6152_at YDR321W 670.4 -1.3 234.0 670.4 -1.2 166.9 901.4 1.3 314.7 901.4 1.1
Pyruvate Family (Ala, Val, Leu)
YJR148W BAT2 TWT2, EC 10896_at YJR148W 0.0 0.0 0.0 0.0 0.0 0.0 204.4 -2.0 214.5 204.4 1.7
Histidine (His)
General
YJR025C BNA1 HAD1 11003_at YJR025C 1095.0 1.1 163.1 1095.0 1.6 710.9 940.5 -1.1 140.1 940.5 1.4
nitrogen and sulfur metabolism
nitrogen and sulfur utilization
YOL058W ARG1 ARG10 8593_at YOL058W 1917.4 1.1 191.7 1917.4 1.6 1150.4 1715.0 -1.1 171.5 1715.0 1.5 857.5
YPR035W GLN1 7698_at YPR035W 1270.0 -1.4 508.0 1270.0 -1.2 316.2 1721.7 1.4 688.7 1721.7 1.1 172.2
YDR353W TRR1 6139_at YDR353W 869.2 -1.2 173.8 869.2 -1.1 129.4 1042.3 1.2 208.5 1042.3 1.1 104.2
YIR029W DAL2 ALC1 4065_at Allantoicas 2.1 -3.1 4.3 2.1 -1.2 0.4 22.3 3.1 46.2 22.3 3.0 44.6
YLR089C 10253_at YLR089C 820.2 2.2 984.2 820.2 2.5 1230.2 348.3 -2.2 418.0 348.3 1.1 34.8
YDL215C GDH2 6693_at YDL215C 199.9 1.8 169.7 199.9 2.2 249.7 107.7 -1.8 91.5 107.7 1.2 21.5
YIR027C DAL1 4063_at Allantoina -2.7 -3.1 -5.5 -2.7 1.3 -0.9 1.4 3.1 2.9 1.4 2.6 2.2
YJR010W MET3 11032_at YJR010W A 902.1 -1.2 180.4 902.1 -1.2 180.4 1098.4 1.2 219.7 1098.4 1.0 0.0
YKL001C MET14 10563_at YKL001C 1314.9 -1.2 327.4 1314.9 -1.1 195.8 1620.4 1.2 403.5 1620.4 1.0 0.0
YLR027C AAT2 ASP5 10323_at YLR027C 1551.3 -1.1 231.0 1551.3 -1.1 231.0 1722.6 1.1 256.5 1722.6 -1.0 0.0
YOR375C GDH1 URE1 8174_at YOR375C 662.8 -2.4 927.9 662.8 -2.5 994.1 1441.3 2.4 2017.8 1441.3 -1.0 0.0
YIR032C DAL3 4068_at Ureidoglyco 27.7 -5.8 132.3 27.7 -7.0 166.2 143.8 5.8 686.9 143.8 -1.2 28.8
YDL171C GLT1 6649_at YDL171C 204.4 -1.7 142.5 204.4 -2.2 244.8 344.1 1.7 239.9 344.1 -1.3 103.2
regulation of nitrogen and sulphur utilization
YPL111W CAR1 LPH15 7869_at Arginase / S 304.8 2.1 350.3 304.8 3.8 853.4 142.4 -2.1 163.7 142.4 1.9 128.2
YFL021W GAT1 NIL1 5409_at YFL021W t 52.6 -2.5 81.2 52.6 -2.1 60.2 119.0 2.5 183.9 119.0 1.2 23.8
YMR043W MCM1 FUN80 9576_at Putative tr 90.2 1.6 58.6 90.2 2.0 94.7 54.3 -1.6 35.3 54.3 1.2 10.9
YIR017C MET28 4098_at YIR017C 353.7 1.2 88.1 353.7 1.3 106.1 0.0 0.0 0.0 0.0 0.0 0.0
YMR042W ARG80 ARGR1 9575_at Regulator 57.3 1.8 45.8 57.3 1.9 51.5 31.3 -1.8 25.0 31.3 1.0 0.0
YKR034W DAL80 UGA43 10551_at YKR034W 0.0 0.0 0.0 0.0 0.0 0.0 1.8 2.0 1.9 1.8 -2.0 1.8
YCR028C FEN2 6863_at YCR028C 375.2 -1.2 93.4 375.2 -1.4 148.7 465.8 1.2 116.0 465.8 -1.1 46.6
nucleotide metabolism
purine ribonucleotide metabolism
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YMR120C ADE17 9519_at YMR120C 1034.4 -1.3 361.1 1034.4 -1.1 103.4 1366.7 1.3 477.1 1366.7 1.2 273.3
YMR300C ADE4 9306_at YMR300C 0.0 0.0 0.0 0.0 0.0 0.0 183.2 1.3 62.6 183.2 1.8 146.6
YNL220W ADE12 BRA9 9083_at YNL220W 1163.7 -1.1 173.3 1163.7 -1.0 0.0 1347.0 1.1 200.6 1347.0 1.1 134.7
YML056C IMD4 9700_at YML056C s 602.7 1.5 331.0 602.7 1.7 451.6 360.6 -1.5 198.0 360.6 1.2 72.1
YIR029W DAL2 ALC1 4065_at Allantoicas 2.1 -3.1 4.3 2.1 -1.2 0.4 22.3 3.1 46.2 22.3 3.0 44.6
YIR027C DAL1 4063_at Allantoina -2.7 -3.1 -5.5 -2.7 1.3 -0.9 1.4 3.1 2.9 1.4 2.6 2.2
YAR073W IMD1 11263_f_atYAR073W 255.3 1.3 89.1 255.3 1.4 114.7 0.0 0.0 0.0 0.0 0.0 0.0
YNL141W AAH1 9027_at YNL141W 190.1 -1.2 38.0 190.1 -1.5 104.4 0.0 0.0 0.0 0.0 0.0 0.0
YDR399W HPT1 BRA6 6050_at YDR399W 662.7 -1.1 98.7 662.7 -1.2 132.5 810.6 1.1 120.7 810.6 -1.0 0.0
YGL234W ADE5,7 5234_at YGL234W 946.7 -1.2 235.7 946.7 -1.1 141.0 1163.0 1.2 289.6 1163.0 1.0 0.0
YAR015W ADE1 11330_at YAR015W 804.0 -1.1 119.7 804.0 -1.2 160.8 952.4 1.1 141.8 952.4 -1.0 0.0
YGR204W ADE3 4814_at YGR204W 724.6 -1.2 144.9 724.6 -1.2 180.4 901.8 1.2 180.4 901.8 -1.0 0.0
YLR058C SHM2 SHMT2 10267_at YLR058C 1548.0 -1.1 230.5 1548.0 -1.1 230.5 1780.5 1.1 265.1 1780.5 -1.0 0.0
YML035C AMD1 AMD3 9674_at YML035C  0.0 0.0 0.0 0.0 0.0 0.0 5.9 -1.3 1.9 5.9 -2.4 8.3
YIR032C DAL3 4068_at Ureidoglyco 27.7 -5.8 132.3 27.7 -7.0 166.2 143.8 5.8 686.9 143.8 -1.2 28.8
YBR263W SHM1 SHMT1, T 7083_at YBR263W 338.5 -1.2 84.3 338.5 -1.5 169.2 423.2 1.2 105.4 423.2 -1.2 84.6
YMR217W GUA1 9399_at YMR217W 937.7 -1.1 139.6 937.7 -1.2 233.5 1069.8 1.1 159.3 1069.8 -1.1 107.0
YLR028C ADE16 10324_at YLR028C 511.1 1.4 229.5 511.1 1.0 24.9 345.5 -1.4 155.2 345.5 -1.4 138.2
YOR128C ADE2 8420_at YOR128C 752.3 -1.0 0.0 752.3 -1.2 150.5 778.8 -1.0 0.0 778.8 -1.2 155.8
YHR216W IMD2 PUR5 4323_f_at YHR216W 765.5 -1.0 37.4 765.5 -1.2 149.9 797.7 1.0 38.9 797.7 -1.2 159.5
YGR061C ADE6 4942_at YGR061C 543.9 -1.1 81.0 543.9 -1.5 298.7 604.9 1.1 90.1 604.9 -1.3 181.5
YML022W APT1 9688_at YML022W 901.0 -1.0 0.0 901.0 -1.2 224.3 928.0 -1.0 0.0 928.0 -1.2 185.6
YJR105W ADO1 10898_at YJR105W a 2356.6 -1.1 350.9 2356.6 -1.1 350.9 2638.0 1.1 392.8 2638.0 -1.1 263.8
pyrimidine ribonucleotide metabolism
YBR021W FUR4 7334_at Uracil per 208.8 4.1 656.1 208.8 6.4 1124.9 41.4 -4.1 130.1 41.4 1.5 20.7
YBL042C FUI1 7410_at High affinity 254.7 7.2 1578.8 254.7 7.4 1629.8 31.8 -7.2 197.2 31.8 1.0 0.0
YJL130C URA2 11165_at YJL130C 1459.3 1.4 655.4 1459.3 1.3 509.4 928.3 -1.4 416.9 928.3 -1.0 0.0
YPR062W FCY1 7682_at YPR062W 1068.9 -1.1 106.9 1068.9 -1.2 213.8 0.0 0.0 0.0 0.0 0.0 0.0
YML106W URA5 PYR5 9736_at YML106W 1266.1 -1.3 375.0 1266.1 -1.3 442.0 1643.2 1.3 486.6 1643.2 -1.0 0.0
YHR128W FUR1 4422_at Uracil pho 441.7 48.6 21042.7 441.7 18.9 7891.4 9.1 -48.6 433.6 9.1 -2.8 16.4
YKL024C URA6 10583_at YKL024C 314.8 1.1 30.0 314.8 -1.3 93.2 273.6 -1.1 26.1 273.6 -1.4 109.4
YJR133W XPT1 10881_at YJR133W X 632.7 -1.0 30.9 632.7 -1.3 189.8 671.5 1.0 32.8 671.5 -1.2 134.3
YEL021W URA3 5724_at Orotidine- 1100.9 -1.5 604.6 1100.9 -1.7 767.4 1703.4 1.5 935.5 1703.4 -1.1 170.3
YBR252W DUT1 7117_at YBR252W 525.9 -1.1 52.6 525.9 -1.4 236.2 574.6 1.1 57.5 574.6 -1.3 172.4
deoxyribonucleotide metabolism
YDR353W TRR1 6139_at YDR353W 869.2 -1.2 173.8 869.2 -1.1 129.4 1042.3 1.2 208.5 1042.3 1.1 104.2
YOR074C CDC21 CRT9, TM 8152_f_at YOR074C 29.7 1.1 4.0 29.7 2.0 31.0 29.4 -1.1 3.9 29.4 1.8 23.2
YGR180C RNR4 4835_at YGR180C 942.0 -1.0 46.0 942.0 -1.1 140.3 0.0 0.0 0.0 0.0 0.0 0.0
YIL066C RNR3 DIN1, RIR 4045_s_at YIL066C 7.3 2.2 8.5 7.3 -1.1 1.0 2.2 -2.2 2.6 2.2 -1.2 0.4
YJL026W RNR2 CRT6 11041_at YJL026W 665.7 -1.1 66.6 665.7 -1.3 232.4 774.7 1.1 77.5 774.7 -1.2 154.9
YER070W RNR1 CRT7, RI 5643_at YER070W 457.9 1.0 22.3 457.9 -1.4 183.1 391.7 -1.0 19.1 391.7 -1.5 195.9
regulation of nucleotide metabolism
YER056C FCY2 BRA7 5668_at YER056C p 1819.5 -1.1 238.3 1819.5 1.0 19.9 2117.5 1.1 277.4 2117.5 1.1 311.1
YIR023W DAL81 UGA35 4059_at YIR023W 21.9 -1.0 0.0 21.9 1.3 6.6 21.4 -1.0 0.0 21.4 1.2 4.3
YLR014C PPR1 10310_at YLR014C 34.7 1.1 5.2 34.7 1.2 6.9 30.4 -1.1 4.5 30.4 1.0 0.0
YNL098C RAS2 8979_at YNL098C 0.0 0.0 0.0 0.0 0.0 0.0 478.7 -1.1 47.9 478.7 -1.3 143.6
polynucleotide degradation
YKL009W MRT4 10598_at YKL009W 766.7 -1.1 76.7 766.7 -1.2 153.3 0.0 0.0 0.0 0.0 0.0 0.0
YIL078W THS1 4186_at YIL078W 799.3 -1.1 79.9 799.3 -1.1 119.0 0.0 0.0 0.0 0.0 0.0 0.0
YEL034W HYP2 TIF51A 5756_at YEL034W T 2636.4 -1.2 656.5 2636.4 -1.1 392.6 3320.4 1.2 826.8 3320.4 1.1 332.0
nucleotide transport
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YBR085W AAC3 ANC3 7263_at YBR085W 47.0 -2.0 48.6 47.0 -1.9 43.8 99.8 2.0 103.3 99.8 1.1 10.0
YER056C FCY2 BRA7 5668_at YER056C p 1819.5 -1.1 238.3 1819.5 1.0 19.9 2117.5 1.1 277.4 2117.5 1.1 311.1
YOR222W ODC2 8334_at YOR222W 506.1 -1.3 149.9 506.1 -1.5 274.6 689.7 1.3 204.3 689.7 -1.2 137.9
other nucleotide-metabolism activities
YKL067W YNK1 NDK1 10629_at YKL067W 846.5 1.1 126.1 846.5 -1.0 0.0 677.9 -1.1 100.9 677.9 -1.1 67.8
YKR091W SRL3 10470_at YKR091W 39.2 2.4 56.8 39.2 1.9 35.3 15.7 -2.4 22.8 15.7 -1.4 6.3
YDR226W ADK1 6237_at YDR226W 1116.1 -1.1 166.2 1116.1 -1.1 166.2 1457.8 1.1 217.1 1457.8 1.0 0.0
YDL125C HNT1 6605_at YDL125C 1355.2 -1.1 135.5 1355.2 -1.1 201.8 0.0 0.0 0.0 0.0 0.0 0.0
YDR454C GUK1 PUR5 6013_at YDR454C g 909.7 -1.2 178.1 909.7 -1.5 493.7 1122.7 1.2 219.9 1122.7 -1.3 336.8
phosphate metabolism
phosphate utilization
YBR092C PHO3 7273_at Acid phos 356.2 1.4 141.2 356.2 4.4 1226.2 257.9 -1.4 102.2 257.9 3.2 567.4
YBR011C IPP1 7370_at YBR011C I 1251.3 -1.2 250.3 1251.3 -1.2 250.3 1505.0 1.2 301.0 1505.0 1.0 0.0
regulation of phosphate utilization 
YFR034C PHO4 5333_at YFR034C 9.9 2.3 12.4 9.9 1.4 4.0 3.3 -2.3 4.1 3.3 -1.2 0.7
YBR106W PHO88 7242_at YBR106W 1301.9 -1.2 260.4 1301.9 -1.2 324.2 1545.7 1.2 309.1 1545.7 -1.0 0.0
phosphate transport
YJL117W PHO86 11132_at YJL117W 0.0 0.0 0.0 0.0 0.0 0.0 473.2 1.0 23.1 473.2 1.3 142.0
YER053C ?? 5665_at YER053C i 227.7 1.6 136.6 227.7 1.3 79.5 141.7 -1.6 85.0 141.7 -1.2 28.3
YLR348C DIC1 9972_at YLR348C 231.9 1.5 115.9 231.9 1.3 69.6 0.0 0.0 0.0 0.0 0.0 0.0
YJR077C MIR1 10961_at YJR077C i 1731.2 1.1 257.8 1731.2 1.0 84.5 1524.8 -1.1 227.1 1524.8 -1.1 152.5
YBR106W PHO88 7242_at YBR106W 1301.9 -1.2 260.4 1301.9 -1.2 324.2 1545.7 1.2 309.1 1545.7 -1.0 0.0
C-compound and carbohydrate metabolism
C-compound and carbohydrate utilization
YDR380W ARO10 6077_at Similarity t 883.1 2.3 1191.7 883.1 11.5 9314.3 375.6 -2.3 506.9 375.6 5.0 1502.4
YGR192C TDH3 GLD1, HS 4802_i_at Glyceralde 3727.1 -1.2 898.1 3727.1 -1.0 165.7 4578.3 1.2 1103.2 4578.3 1.2 915.7
YJR009C TDH2 GLD2 11031_s_ YJR009C 3547.9 -1.1 528.3 3547.9 -1.0 0.0 4151.9 1.1 618.3 4151.9 1.2 830.4
YHR174W ENO2 4334_i_at YHR174W 2988.8 -1.3 1043.3 2988.8 -1.1 445.1 4037.7 1.3 1409.5 4037.7 1.2 807.5
YLR044C PDC1 10296_at YLR044C 2283.0 -1.2 456.6 2283.0 -1.0 0.0 2763.9 1.2 552.8 2763.9 1.2 552.8
YDL182W LYS20 6683_g_at YDL182W 2082.9 -1.0 101.7 2082.9 1.1 310.2 2189.0 1.0 106.8 2189.0 1.2 437.8
YBR145W ADH5 7236_at YBR145W 1213.1 1.0 59.2 1213.1 1.3 423.4 1149.0 -1.0 56.1 1149.0 1.3 344.7
YBR196C PGI1 CDC30 7152_at Glucose-6 1683.3 -1.2 419.1 1683.3 -1.0 82.2 2100.2 1.2 522.9 2100.2 1.2 420.0
YAL023C PMT2 FUN25 11344_at YAL023C 1047.0 1.1 104.7 1047.0 1.3 365.5 859.8 -1.1 86.0 859.8 1.2 172.0
YCR012W PGK1 6890_at 3-Phospho 3009.0 -1.2 589.2 3009.0 -1.1 287.2 3629.6 1.2 710.8 3629.6 1.1 363.0
YKL152C GPM1 10721_at Phosphogly 3118.6 -1.1 464.4 3118.6 -1.0 152.2 3538.3 1.1 526.9 3538.3 1.1 353.8
YOL126C MDH2 8663_at Cytosolic 126.7 1.9 113.7 126.7 3.4 309.9 66.1 -1.9 59.3 66.1 1.8 52.9
YKL085W MDH1 10654_at YKL085W 1063.9 1.1 158.4 1063.9 1.2 264.9 866.5 -1.1 129.0 866.5 1.1 86.7
YKL104C GFA1 10680_at YKL104C 276.7 1.6 179.6 276.7 1.9 262.6 169.2 -1.6 109.9 169.2 1.1 16.9
YLR300W EXG1 BGL1 10015_at YLR300W 1585.6 1.0 77.4 1585.6 1.1 236.1 0.0 0.0 0.0 0.0 0.0 0.0
YDL095W PMT1 6591_at YDL095W 415.6 1.4 166.2 415.6 1.4 166.2 299.5 -1.4 119.8 299.5 1.0 0.0
YJL174W KRE9 11209_at YJL174W 643.5 1.2 128.7 643.5 1.2 160.2 581.8 -1.2 116.4 581.8 1.0 0.0
YGR282C BGL2 4712_at YGR282C 1370.4 -1.1 204.1 1370.4 -1.0 66.9 1589.9 1.1 236.8 1589.9 1.1 159.0
YOR067C ALG8 8495_at YOR067C 598.7 -1.2 149.1 598.7 -1.0 0.0 730.4 1.2 181.9 730.4 1.2 146.1
YMR083W ADH3 9569_at YMR083W 1156.0 -1.2 231.2 1156.0 -1.0 56.4 1403.8 1.2 280.8 1403.8 1.1 140.4
YCL040W GLK1 HOR3 6937_at YCL040W 686.5 1.6 411.9 686.5 1.2 137.3 437.3 -1.6 262.4 437.3 -1.3 131.2
YOL059W GPD2 GPD3 8592_at YOL059W 166.1 1.7 115.8 166.1 1.8 132.4 98.2 -1.7 68.5 98.2 1.1 9.8
YGR244C LSC2 4764_at YGR244C 330.9 1.5 164.3 330.9 1.4 131.2 0.0 0.0 0.0 0.0 0.0 0.0
YPR074C TKL1 7694_at YPR074C T 1097.1 -1.1 163.4 1097.1 -1.0 53.5 1280.0 1.1 190.6 1280.0 1.1 128.0
YAL054C ACS1 11356_at YAL054C i 350.3 1.2 87.2 350.3 1.3 122.3 0.0 0.0 0.0 0.0 0.0 0.0
YGL156W AMS1 5179_at Alpha man 58.3 4.3 192.3 58.3 2.7 102.0 12.2 -4.3 40.2 12.2 -1.6 7.3
YGR143W SKN1 4843_at YGR143W 145.7 1.8 123.7 145.7 1.7 102.0 79.0 -1.8 67.1 79.0 -1.1 7.9
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YOR377W ATF1 8176_at YOR377W 98.6 2.0 103.5 98.6 1.8 83.7 44.1 -2.0 46.3 44.1 -1.1 4.4
YGR043C ?? 4969_at Transaldol 42.7 2.6 70.2 42.7 2.9 80.7 16.0 -2.6 26.3 16.0 1.1 1.6
YIL099W SGA1 4212_g_at Intracellula 40.4 2.4 56.6 40.4 2.3 52.4 25.6 -2.4 35.8 25.6 -1.0 1.1
YKR061W KTR2 10532_at YKR061W 52.6 2.3 70.7 52.6 1.9 49.6 22.7 -2.3 30.5 22.7 -1.2 4.5
YPL053C KTR6 MNN6 7790_at YPL053C 0.0 0.0 0.0 0.0 0.0 0.0 406.6 1.2 101.2 406.6 1.1 40.7
YGR256W GND2 4732_at YGR256W 12.0 2.4 17.3 12.0 2.5 18.5 0.0 0.0 0.0 0.0 0.0 0.0
YPR001W CIT3 7753_at YPR001W 11.9 2.6 18.9 11.9 1.4 5.3 5.5 -2.6 8.8 5.5 -1.8 4.4
MEL1 MEL1 3933_s_at MEL1 Requ 0.0 0.0 0.0 0.0 0.0 0.0 3.7 2.0 3.7 3.7 2.1 4.1
YFL056C AAD6 5424_at YFL056C 4.7 2.1 5.2 4.7 1.5 2.5 2.3 -2.1 2.6 2.3 -1.5 1.2
YHR104W GRE3 4442_at YHR104W 279.7 1.4 111.9 279.7 -1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
YMR306W FKS3 9313_at 1,3-Beta-gl -11.2 5.3 -47.9 -11.2 3.7 -30.7 -19.1 -5.3 -82.1 19.1 -2.7 32.5
YNL241C ZWF1 MET19, P 9108_at Glucose-6 206.9 1.3 62.1 206.9 -1.0 0.0 157.1 -1.3 47.1 157.1 -1.3 47.1
YML054C CYB2 9702_at YML054C C 95.6 2.7 166.8 95.6 1.2 18.7 37.7 -2.7 65.8 37.7 -2.4 52.8
YDR178W SDH4 6279_at YDR178W 695.1 1.2 139.0 695.1 1.0 33.9 586.8 -1.2 117.4 586.8 -1.1 58.7
YDR074W TPS2 HOG2, PF 6398_at YDR074W 224.7 1.5 111.6 224.7 -1.0 11.0 140.6 -1.5 69.8 140.6 -1.6 84.4
YMR105C PGM2 9547_at YMR105C 0.0 0.0 0.0 0.0 0.0 0.0 157.8 -1.3 55.1 157.8 -1.6 94.7
YDR148C KGD2 6339_at YDR148C d 0.0 0.0 0.0 0.0 0.0 0.0 206.5 -1.2 41.3 206.5 -1.5 103.3
YDR368W YPR1 6110_at YDR368W 0.0 0.0 0.0 0.0 0.0 0.0 260.2 -1.0 12.7 260.2 -1.4 104.1
YOR142W LSC1 8389_at YOR142W 701.9 -1.0 34.3 701.9 -1.1 104.5 0.0 0.0 0.0 0.0 0.0 0.0
YJL002C OST1 NLT1 11019_at YJL002C 1148.9 -1.1 171.1 1148.9 -1.1 114.9 1315.8 1.1 195.9 1315.8 1.0 0.0
YDL078C MDH3 6565_at YDL078C 270.4 -1.0 13.2 270.4 -1.4 121.4 258.3 1.0 12.6 258.3 -1.4 103.3
YAL060W BDH1 11388_at YAL060W 844.2 -1.1 84.4 844.2 -1.1 125.7 0.0 0.0 0.0 0.0 0.0 0.0
YDL022W GPD1 DAR1, HO 6485_at YDL022W 763.2 1.1 113.7 763.2 -1.0 0.0 647.3 -1.1 96.4 647.3 -1.2 129.5
YJL052W TDH1 GLD3 11061_g_ YJL052W 1811.4 -1.0 77.3 1811.4 -1.1 134.2 2067.3 -1.0 88.2 2067.3 1.0 0.0
YJL121C RPE1 EPI1, POS 11128_at YJL121C 688.8 -1.3 240.4 688.8 -1.2 137.8 905.1 1.3 315.9 905.1 1.1 90.5
YLR354C TAL1 9978_at YLR354C 946.7 -1.0 46.2 946.7 -1.1 141.0 0.0 0.0 0.0 0.0 0.0 0.0
YEL002C WBP1 5744_at YEL002C 953.0 -1.0 46.5 953.0 -1.1 141.9 0.0 0.0 0.0 0.0 0.0 0.0
YCR034W FEN1 ELO2, GN 6869_at YCR034W 728.3 -1.1 72.8 728.3 -1.2 145.7 0.0 0.0 0.0 0.0 0.0 0.0
YGL253W HXK2 HEX1, HK 5260_at YGL253W 751.4 -1.3 262.3 751.4 -1.2 150.3 981.0 1.3 342.4 981.0 1.1 98.1
YMR149W SWP1 9504_at YMR149W 783.3 -1.1 116.6 783.3 -1.2 153.4 883.5 1.1 131.6 883.5 -1.1 88.4
YJR143C PMT4 10891_at YJR143C 771.0 -1.1 77.1 771.0 -1.2 154.2 0.0 0.0 0.0 0.0 0.0 0.0
YFR053C HXK1 5307_at YFR053C 271.0 1.0 13.2 271.0 -1.5 135.5 259.3 -1.0 12.7 259.3 -1.6 155.6
YER003C PMI40 PMI 5702_at YER003C m 630.6 -1.1 63.1 630.6 -1.2 157.0 694.4 1.1 69.4 694.4 -1.2 138.9
YGL062W PYC1 5090_at YGL062W 142.4 -1.7 106.7 142.4 -2.3 185.1 291.0 1.7 218.0 291.0 -1.3 87.3
YFL045C SEC53 ALG4 5435_at YFL045C 1356.7 -1.1 202.0 1356.7 -1.1 202.0 1549.8 1.1 230.8 1549.8 -1.0 0.0
YHR183W GND1 4343_at YHR183W 1485.6 -1.1 221.2 1485.6 -1.1 221.2 1682.4 1.1 250.5 1682.4 1.0 0.0
YLR342W FKS1 9966_at YLR342W 726.7 -1.1 69.4 726.7 -1.3 253.7 861.6 1.1 82.2 861.6 -1.2 172.3
YGR240C PFK1 4760_at Phosphofr 1005.6 -1.2 250.4 1005.6 -1.3 301.7 1258.0 1.2 313.2 1258.0 -1.1 125.8
YLR286C CTS1 10045_at YLR286C 2323.9 -1.1 346.1 2323.9 -1.1 346.1 2400.2 1.1 357.4 2400.2 -1.1 240.0
YDR050C TPI1 6419_at Triosepho 2559.9 -1.2 637.4 2559.9 -1.1 381.2 3338.3 1.2 831.2 3338.3 1.1 333.8
YFL014W HSP12 5372_at YFL014W 625.4 1.8 493.3 625.4 -1.2 122.5 350.2 -1.8 276.3 350.2 -2.1 385.2
YKL060C FBA1 10636_at Aldolase 3014.1 -1.2 750.5 3014.1 -1.1 448.8 3801.9 1.2 946.7 3801.9 1.1 380.2
YCR005C CIT2 6883_at YCR005C 1341.0 -1.1 199.7 1341.0 -1.3 468.1 1588.0 1.1 236.5 1588.0 -1.1 158.8
YDL055C PSA1 MPG1, VI 6543_at YDL055C 1894.9 -1.2 471.8 1894.9 -1.2 471.8 2378.1 1.2 592.1 2378.1 1.0 0.0
YGR254W ENO1 HSP48 4730_s_at Enolase I 2833.6 -1.2 493.5 2833.6 -1.2 493.5 3244.5 1.2 565.1 3244.5 1.0 158.4
YMR205C PFK2 9432_at YMR205C 1287.5 -1.2 252.1 1287.5 -1.4 510.4 1558.7 1.2 305.2 1558.7 -1.2 311.7
YOL086C ADH1 ADC1 8657_at YOL086C 3553.5 -1.2 695.9 3553.5 -1.1 529.2 4293.4 1.2 840.8 4293.4 1.1 429.3
YAL038W CDC19 PYK1 11371_at Pyruvate ki 3016.0 -1.2 751.0 3016.0 -1.2 590.6 3721.2 1.2 926.6 3721.2 1.0 0.0
YLR304C ACO1 GLU1 10019_at YLR304C 1066.5 -1.4 479.0 1066.5 -1.6 636.6 1602.0 1.4 719.5 1602.0 -1.1 160.2
regulation of C-compound and carbohydrate utilization
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YLR094C GIS3 10258_at Cyclin C a 40.0 3.8 111.6 40.0 6.0 199.5 9.8 -3.8 27.4 9.8 1.6 5.9
YOR344C TYE7 SGC1 8188_at 33 kDa se 66.1 2.8 121.6 66.1 3.6 174.1 23.0 -2.8 42.3 23.0 1.3 6.9
YGR288W MAL13 4718_at YGR288W 60.3 1.7 45.1 60.3 2.7 105.4 30.5 -1.7 22.9 30.5 1.6 18.3
YMR043W MCM1 FUN80 9576_at Putative tr 90.2 1.6 58.6 90.2 2.0 94.7 54.3 -1.6 35.3 54.3 1.2 10.9
YGL066W SGF73 5086_at YGL066W 60.2 1.4 23.8 60.2 2.4 86.4 0.0 0.0 0.0 0.0 0.0 0.0
YER133W GLC7 CID1, DIS 5573_at protein ph 242.7 1.2 40.7 242.7 1.3 84.2 217.2 -1.2 36.4 217.2 1.1 30.4
YGL209W MIG2 MLZ1 5216_at YGL209W 54.7 2.0 54.5 54.7 2.3 73.5 0.0 0.0 0.0 0.0 0.0 0.0
YML048W GSF2 ECM6 9709_at YML048W 0.0 0.0 0.0 0.0 0.0 0.0 33.1 1.3 9.2 33.1 2.2 39.7
YDR216W ADR1 6273_at YDR216W 13.6 1.5 7.4 13.6 2.7 23.0 8.6 -1.5 4.7 8.6 1.8 6.9
YOL067C RTG1 8630_at YOL067C 11.2 1.1 1.7 11.2 2.7 19.5 9.6 -1.1 1.4 9.6 2.4 13.4
YCL010C SGF29 6870_at YCL010C 11.0 2.0 11.1 11.0 1.5 5.7 5.6 -2.0 5.7 5.6 -1.3 1.7
YOR178C GAC1 8380_at YOR178C 5.2 1.7 3.5 5.2 -1.3 1.8 3.1 -1.7 2.1 3.1 -2.1 3.4
YNL098C RAS2 8979_at YNL098C 0.0 0.0 0.0 0.0 0.0 0.0 478.7 -1.1 47.9 478.7 -1.3 143.6
YCR028C FEN2 6863_at YCR028C 375.2 -1.2 93.4 375.2 -1.4 148.7 465.8 1.2 116.0 465.8 -1.1 46.6
YGL253W HXK2 HEX1, HK 5260_at YGL253W 751.4 -1.3 262.3 751.4 -1.2 150.3 981.0 1.3 342.4 981.0 1.1 98.1
YDR328C SKP1 MGO1 6160_at YDR328C 487.2 1.2 121.3 487.2 -1.1 48.7 386.5 -1.2 96.2 386.5 -1.4 154.6
YPR165W RHO1 7563_at Ras homolo 819.3 -1.0 0.0 819.3 -1.2 163.9 828.3 -1.0 0.0 828.3 -1.2 165.7
YHR193C EGD2 4353_at YHR193C c 1137.1 -1.1 169.3 1137.1 -1.2 283.1 1294.9 1.1 192.8 1294.9 -1.1 129.5
YGR240C PFK1 4760_at Phosphofr 1005.6 -1.2 250.4 1005.6 -1.3 301.7 1258.0 1.2 313.2 1258.0 -1.1 125.8
YMR205C PFK2 9432_at YMR205C 1287.5 -1.2 252.1 1287.5 -1.4 510.4 1558.7 1.2 305.2 1558.7 -1.2 311.7
YPL037C EGD1 7806_at YPL037C 1962.5 -1.2 392.5 1962.5 -1.3 588.8 2272.2 1.2 454.4 2272.2 -1.1 227.2
C-compound, carbohydrate transport
YDR497C ITR1 5966_at Myo-inosit 1187.5 -1.2 237.5 1187.5 -1.0 0.0 1358.0 1.2 271.6 1358.0 1.2 271.6
YMR011W HXT2 9633_at YMR011W 809.5 -1.3 242.8 809.5 -1.0 0.0 1029.2 1.3 308.8 1029.2 1.2 205.8
YHR094C HXT1 HOR4 4430_at YHR094C 540.4 -1.0 0.0 540.4 1.3 162.1 525.9 -1.0 0.0 525.9 1.3 157.8
YDR345C HXT3 6131_at YDR345C 1351.7 -1.2 264.7 1351.7 -1.1 129.0 1606.0 1.2 314.5 1606.0 1.1 160.6
YCL040W GLK1 HOR3 6937_at YCL040W 686.5 1.6 411.9 686.5 1.2 137.3 437.3 -1.6 262.4 437.3 -1.3 131.2
YLR348C DIC1 9972_at YLR348C 231.9 1.5 115.9 231.9 1.3 69.6 0.0 0.0 0.0 0.0 0.0 0.0
YFL011W HXT10 5377_at YFL011W H 4.7 -1.9 4.1 4.7 1.1 0.6 10.8 1.9 9.4 10.8 2.0 10.8
YDL247W ?? 6709_i_at YDL247W 2.0 2.3 2.6 2.0 -1.0 0.1 -2.2 -2.3 2.9 -2.2 -2.1 2.4
YDR342C HXT7 6128_f_at YDR342C 1141.2 -1.1 114.1 1141.2 -1.2 228.2 0.0 0.0 0.0 0.0 0.0 0.0
YDR343C HXT6 6129_f_at YDR343C 1105.6 -1.1 110.6 1105.6 -1.4 442.2 1197.1 1.1 119.7 1197.1 -1.3 359.1
lipid, fatty-acid and isoprenoid metabolism
lipid, fatty-acid and isoprenoid biosynthesis
YLR372W SUR4 ELO3, SR 9953_at YLR372W 1590.9 -1.2 318.2 1590.9 -1.0 0.0 1910.0 1.2 382.0 1910.0 1.2 382.0
YMR272C SCS7 FAH1 9366_at YMR272C 774.6 -1.0 37.8 774.6 1.2 151.7 845.3 1.0 41.3 845.3 1.3 253.6
YHR007C ERG11 4525_at YHR007C c 0.0 0.0 0.0 0.0 0.0 0.0 1087.9 1.0 53.1 1087.9 1.2 217.6
YNL280C ERG24 9159_at YNL280C 0.0 0.0 0.0 0.0 0.0 0.0 400.7 1.4 180.0 400.7 1.4 160.3
YOR221C MCT1 8332_at YOR221C 88.7 2.0 88.7 88.7 2.8 159.7 55.8 -2.0 55.8 55.8 1.5 27.9
YKL004W AUR1 10560_at YKL004W 618.5 -1.2 123.7 618.5 -1.0 0.0 749.2 1.2 149.8 749.2 1.2 149.8
YDR062W LCB2 SCS1, TS 6431_at YDR062W 668.6 -1.1 99.6 668.6 1.0 32.6 730.5 1.1 108.8 730.5 1.2 146.1
YGR187C HGH1 4797_at YGR187C 238.6 1.1 35.5 238.6 1.5 119.3 0.0 0.0 0.0 0.0 0.0 0.0
YMR246W FAA4 9386_at YMR246W 383.4 1.3 115.0 383.4 1.3 115.0 0.0 0.0 0.0 0.0 0.0 0.0
YLR100W ERG27 10219_at YLR100W 555.6 1.3 166.7 555.6 1.2 111.1 433.9 -1.3 130.2 433.9 -1.1 43.4
YCR048W ARE1 SAT2 6837_at YCR048W 178.6 1.3 62.3 178.6 1.6 107.2 0.0 0.0 0.0 0.0 0.0 0.0
YMR296C LCB1 END8, TS 9347_at YMR296C 0.0 0.0 0.0 0.0 0.0 0.0 262.5 1.0 12.8 262.5 1.4 105.0
YHR190W ERG9 4350_at YHR190W 534.8 1.1 79.6 534.8 1.2 104.7 390.9 -1.1 58.2 390.9 1.0 0.0
YPL145C KES1 LPI3, OSH47880_at YPL145C 405.0 1.2 100.8 405.0 -1.0 19.8 0.0 0.0 0.0 0.0 0.0 0.0
YGR175C ERG1 4830_at YGR175C 828.8 -1.1 123.4 828.8 -1.0 40.5 926.4 1.1 138.0 926.4 1.1 92.6
YCL004W PGS1 PEL1 6875_at 17-kDa Pho 6.6 3.2 14.7 6.6 1.4 2.5 0.0 -3.2 0.0 0.0 -2.4 0.0
YNR019W ARE2 SAT1 8867_at YNR019W 2.1 -2.1 2.4 2.1 -1.7 1.6 8.4 2.1 9.6 8.4 1.2 1.7
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YDL015C TSC13 6492_at YDL015C 641.7 -1.2 128.3 641.7 -1.1 95.5 767.0 1.2 153.4 767.0 1.1 76.7
YGR157W CHO2 PEM1 4858_at Phosphati 579.5 -1.1 86.3 579.5 -1.1 57.9 665.4 1.1 99.1 665.4 1.0 0.0
YGL001C ERG26 5016_at YGL001C 333.4 -1.0 16.3 333.4 -1.3 100.0 0.0 0.0 0.0 0.0 0.0 0.0
YBR265W TSC10 7085_at YBR265W 220.6 -1.0 10.8 220.6 -1.5 109.6 0.0 0.0 0.0 0.0 0.0 0.0
YBR177C EHT1 7179_at YBR177C l 369.1 -1.0 0.0 369.1 -1.3 110.7 335.1 -1.0 0.0 335.1 -1.3 100.5
YML075C HMG1 9724_at YML075C 3 412.1 -1.1 39.3 412.1 -1.3 122.0 0.0 0.0 0.0 0.0 0.0 0.0
YPR113W PIS1 7645_at YPR113W 962.8 -1.1 143.4 962.8 -1.1 143.4 1132.6 1.1 168.7 1132.6 1.0 0.0
YCR034W FEN1 ELO2, GN 6869_at YCR034W 728.3 -1.1 72.8 728.3 -1.2 145.7 0.0 0.0 0.0 0.0 0.0 0.0
YBR263W SHM1 SHMT1, T 7083_at YBR263W 338.5 -1.2 84.3 338.5 -1.5 169.2 423.2 1.2 105.4 423.2 -1.2 84.6
YGR037C ACB1 4963_at YGR037C 0.0 0.0 0.0 0.0 0.0 0.0 923.3 -1.0 45.1 923.3 -1.2 184.7
YPL028W ERG10 LPB3, TS 7770_at YPL028W a 1419.8 -1.1 211.4 1419.8 -1.1 211.4 1632.9 1.1 243.2 1632.9 -1.0 0.0
YNL130C CPT1 8992_at YNL130C 553.9 -1.4 221.6 553.9 -1.4 221.6 791.4 1.4 316.6 791.4 1.0 0.0
YLR058C SHM2 SHMT2 10267_at YLR058C 1548.0 -1.1 230.5 1548.0 -1.1 230.5 1780.5 1.1 265.1 1780.5 -1.0 0.0
YKL182W FAS1 10781_at YKL182W  802.1 -1.0 39.1 802.1 -1.3 237.5 931.3 1.0 45.5 931.3 -1.2 186.3
YGL012W ERG4 5005_at YGL012W 985.3 -1.1 98.5 985.3 -1.2 245.3 1049.9 1.1 105.0 1049.9 -1.2 210.0
YJL196C ELO1 11230_at YJL196C 1330.9 -1.2 331.4 1330.9 -1.2 266.2 1651.1 1.2 411.1 1651.1 1.0 0.0
YPL231W FAS2 7973_at YPL231W a 396.9 1.0 19.4 396.9 -1.7 297.4 377.5 -1.0 18.4 377.5 -1.8 302.0
YMR202W ERG2 9429_at YMR202W 1288.1 -1.1 191.8 1288.1 -1.3 449.6 1456.0 1.1 216.8 1456.0 -1.2 291.2
YNR016C ACC1 8864_at YNR016C a 893.1 -1.2 178.6 893.1 -1.5 490.5 1077.2 1.2 215.4 1077.2 -1.3 323.2
YJR073C OPI3 PEM2 10957_at Methylene 1629.4 -1.3 568.8 1629.4 -1.4 651.8 2223.8 1.3 776.3 2223.8 -1.0 0.0
breakdown of lipids, fatty acids and isoprenoids 4
YMR008C PLB1 9630_at YMR008C 605.9 1.4 272.1 605.9 1.2 150.9 379.7 -1.4 170.5 379.7 -1.1 38.0
YNL012W SPO1 8883_at YNL012W 10.8 2.2 13.1 10.8 1.3 3.2 4.3 -2.2 5.3 4.3 -1.8 3.4
YDR281C PHM6 6201_at Phosphate 6.4 -2.4 9.0 6.4 -3.3 14.7 16.9 2.4 23.7 16.9 -1.2 3.4
YER037W PHM8 5692_at YER037W 31.7 -1.3 11.1 31.7 -2.3 41.1 0.0 0.0 0.0 0.0 0.0 0.0
lipid, fatty-acid and isoprenoid utilization
YMR246W FAA4 9386_at YMR246W 383.4 1.3 115.0 383.4 1.3 115.0 0.0 0.0 0.0 0.0 0.0 0.0
YDL078C MDH3 6565_at YDL078C 270.4 -1.0 13.2 270.4 -1.4 121.4 258.3 1.0 12.6 258.3 -1.4 103.3
YDR410C STE14 6061_at YDR410C f 325.8 -1.4 130.3 325.8 -1.2 81.1 459.0 1.4 183.6 459.0 1.1 45.9
YFL014W HSP12 5372_at YFL014W 625.4 1.8 493.3 625.4 -1.2 122.5 350.2 -1.8 276.3 350.2 -2.1 385.2
regulation of lipid, fatty-acid and isoprenoid metabolism
YNL038W GPI15 8903_at Glysosyl Ph 112.7 1.1 16.8 112.7 6.8 658.5 83.4 -1.1 12.4 83.4 5.9 408.7
YFL031W HAC1 ERN4, IR 5318_s_at bZIP Tran 398.7 1.9 355.4 398.7 2.2 484.5 284.7 -1.9 253.8 284.7 1.2 53.7
YNL231C PDR16 9117_at YNL231C i 264.8 1.4 105.9 264.8 1.6 158.9 0.0 0.0 0.0 0.0 0.0 0.0
YDR123C INO2 DIE1, SCS 6358_at Transcripti 18.7 2.4 26.3 18.7 8.1 132.6 9.1 -2.4 12.8 9.1 4.9 35.5
YMR043W MCM1 FUN80 9576_at Putative tr 90.2 1.6 58.6 90.2 2.0 94.7 54.3 -1.6 35.3 54.3 1.2 10.9
YHR079C IRE1 ERN1 4461_r_at Ire1p, is im 6.0 1.3 1.8 6.0 1.3 1.5 3.9 -1.3 1.2 3.9 -1.0 0.1
YCR028C FEN2 6863_at YCR028C 375.2 -1.2 93.4 375.2 -1.4 148.7 465.8 1.2 116.0 465.8 -1.1 46.6
YDR284C DPP1 6204_at YDR284C 276.7 -1.2 55.3 276.7 -1.5 151.9 0.0 0.0 0.0 0.0 0.0 0.0
lipid and fatty-acid transport
YDR497C ITR1 5966_at Myo-inosit 1187.5 -1.2 237.5 1187.5 -1.0 0.0 1358.0 1.2 271.6 1358.0 1.2 271.6
YNL231C PDR16 9117_at YNL231C i 264.8 1.4 105.9 264.8 1.6 158.9 0.0 0.0 0.0 0.0 0.0 0.0
YMR246W FAA4 9386_at YMR246W 383.4 1.3 115.0 383.4 1.3 115.0 0.0 0.0 0.0 0.0 0.0 0.0
YGR037C ACB1 4963_at YGR037C 0.0 0.0 0.0 0.0 0.0 0.0 923.3 -1.0 45.1 923.3 -1.2 184.7
YOR153W PDR5 LEM1, YD 8400_at Multidrug re 707.7 -1.3 209.6 707.7 -1.3 209.6 916.0 1.3 271.3 916.0 1.0 0.0
other lipid, fatty-acid and isoprenoid metabolism activities
YKL055C OAR1 10641_at YKL055C 27.3 2.6 43.5 27.3 1.8 21.8 7.8 -2.6 12.5 7.8 -1.4 3.1
YNL106C INP52 SJL2 8971_at Inositol poly 15.3 1.3 4.6 15.3 3.1 32.9 11.8 -1.3 3.5 11.8 2.4 16.5
YDR213W UPC2 MOX4 6270_at YDR213W 4.0 -1.1 0.4 4.0 -2.5 6.0 4.5 1.1 0.4 4.5 -2.2 5.4
YBR067C TIP1 7290_at YBR067C c 1652.2 -1.1 246.0 1652.2 -1.2 411.4 1934.7 1.1 288.1 1934.7 -1.1 193.5
YMR307W GAS1 CWH52, G 9315_at YMR307W 2126.2 -1.2 425.2 2126.2 -1.2 425.2 2549.2 1.2 509.8 2549.2 -1.0 0.0
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metabolism of vitamins, cofactors, and prosthetic groups
biosynthesis of vitamins, cofactors, and prosthetic groups
YJR025C BNA1 HAD1 11003_at YJR025C 1095.0 1.1 163.1 1095.0 1.6 710.9 940.5 -1.1 140.1 940.5 1.4 376.2
YOL143C RIB4 8691_at YOL143C 566.7 -1.0 0.0 566.7 1.4 226.7 547.7 -1.0 0.0 547.7 1.3 164.3
YGL125W MET13 MET11 5117_at YGL125W 579.3 1.1 86.3 579.3 1.3 173.8 0.0 0.0 0.0 0.0 0.0 0.0
YDR487C RIB3 6001_at YDR487C 3 662.0 1.1 66.2 662.0 1.2 164.8 537.7 -1.1 53.8 537.7 1.2 107.5
YKR069W MET1 MET20 10494_at YKR069W 506.9 1.3 152.1 506.9 1.3 152.1 382.0 -1.3 114.6 382.0 -1.0 0.0
YNL333W SNZ2 9198_s_at YNL333W 159.9 1.9 143.4 159.9 1.8 134.9 86.0 -1.9 77.2 86.0 -1.1 8.6
YBR256C RIB5 7121_at YBR256C R 221.1 1.4 88.4 221.1 1.5 121.4 0.0 0.0 0.0 0.0 0.0 0.0
YBR153W RIB7 7199_at YBR153W 219.2 1.5 120.4 219.2 1.3 65.8 125.2 -1.5 68.8 125.2 -1.1 12.5
YBL033C RIB1 7419_at YBL033C 196.2 1.6 117.7 196.2 1.4 78.5 122.3 -1.6 73.4 122.3 -1.1 12.2
YGR010W NMA2 4982_at YGR010W 34.6 2.1 39.7 34.6 1.3 12.1 14.4 -2.1 16.6 14.4 -1.6 8.6
YDR044W HEM13 6413_at YDR044W 202.2 -1.2 50.3 202.2 -1.5 101.1 0.0 0.0 0.0 0.0 0.0 0.0
YML110C COQ5 DBI56 9777_at YML110C D 0.0 0.0 0.0 0.0 0.0 0.0 729.9 1.1 108.7 729.9 1.1 73.0
YGR286C BIO2 4716_at YGR286C 182.3 -1.3 63.6 182.3 -1.7 127.1 0.0 0.0 0.0 0.0 0.0 0.0
YGR204W ADE3 4814_at YGR204W 724.6 -1.2 144.9 724.6 -1.2 180.4 901.8 1.2 180.4 901.8 -1.0 0.0
YGL037C PNC1 5025_at YGL037C 732.7 1.3 255.7 732.7 -1.2 182.4 0.0 0.0 0.0 0.0 0.0 0.0
YER043C SAH1 5698_at YER043C p 774.2 -1.1 115.3 774.2 -1.2 192.8 893.0 1.1 133.0 893.0 -1.1 89.3
utilization of vitamins, cofactors, and prosthetic groups
YBR092C PHO3 7273_at Acid phos 356.2 1.4 141.2 356.2 4.4 1226.2 257.9 -1.4 102.2 257.9 3.2 567.4
secondary metabolism
biosynthesis of secondary products derived from primary amino acids
biosynthesis of amines
YKL184W SPE1 ORD1, SP 10779_at YKL184W 159.9 1.8 127.9 159.9 2.4 231.8 89.2 -1.8 71.4 89.2 1.4
YPR069C SPE3 7689_at YPR069C p 167.8 -1.4 75.4 167.8 -1.6 100.2 242.2 1.4 108.8 242.2 -1.1
ENERGY CONSERVATION
glycolysis and gluconeogenesis
YGR192C TDH3 GLD1, HS 4802_i_at Glyceralde 3727.1 -1.2 898.1 3727.1 -1.0 165.7 4578.3 1.2 1103.2 4578.3 1.2 915.7
YJR009C TDH2 GLD2 11031_s_ YJR009C 3547.9 -1.1 528.3 3547.9 -1.0 0.0 4151.9 1.1 618.3 4151.9 1.2 830.4
YHR174W ENO2 4334_i_at YHR174W 2988.8 -1.3 1043.3 2988.8 -1.1 445.1 4037.7 1.3 1409.5 4037.7 1.2 807.5
YBR196C PGI1 CDC30 7152_at Glucose-6 1683.3 -1.2 419.1 1683.3 -1.0 82.2 2100.2 1.2 522.9 2100.2 1.2 420.0
YKL060C FBA1 10636_at Aldolase 3014.1 -1.2 750.5 3014.1 -1.1 448.8 3801.9 1.2 946.7 3801.9 1.1 380.2
YCR012W PGK1 6890_at 3-Phospho 3009.0 -1.2 589.2 3009.0 -1.1 287.2 3629.6 1.2 710.8 3629.6 1.1 363.0
YKL152C GPM1 10721_at Phosphogly 3118.6 -1.1 464.4 3118.6 -1.0 152.2 3538.3 1.1 526.9 3538.3 1.1 353.8
YDR050C TPI1 6419_at Triosepho 2559.9 -1.2 637.4 2559.9 -1.1 381.2 3338.3 1.2 831.2 3338.3 1.1 333.8
YGR254W ENO1 HSP48 4730_s_at Enolase I 2833.6 -1.2 493.5 2833.6 -1.2 493.5 3244.5 1.2 565.1 3244.5 1.0 158.4
YGL253W HXK2 HEX1, HK 5260_at YGL253W 751.4 -1.3 262.3 751.4 -1.2 150.3 981.0 1.3 342.4 981.0 1.1 98.1
YJL052W TDH1 GLD3 11061_g_ YJL052W 1811.4 -1.0 77.3 1811.4 -1.1 134.2 2067.3 -1.0 88.2 2067.3 1.0 0.0
YAL038W CDC19 PYK1 11371_at Pyruvate ki 3016.0 -1.2 751.0 3016.0 -1.2 590.6 3721.2 1.2 926.6 3721.2 1.0 0.0
YGL062W PYC1 5090_at YGL062W 142.4 -1.7 106.7 142.4 -2.3 185.1 291.0 1.7 218.0 291.0 -1.3 87.3
YGR240C PFK1 4760_at Phosphofr 1005.6 -1.2 250.4 1005.6 -1.3 301.7 1258.0 1.2 313.2 1258.0 -1.1 125.8
YCL040W GLK1 HOR3 6937_at YCL040W 686.5 1.6 411.9 686.5 1.2 137.3 437.3 -1.6 262.4 437.3 -1.3 131.2
YFR053C HXK1 5307_at YFR053C 271.0 1.0 13.2 271.0 -1.5 135.5 259.3 -1.0 12.7 259.3 -1.6 155.6
YMR205C PFK2 9432_at YMR205C 1287.5 -1.2 252.1 1287.5 -1.4 510.4 1558.7 1.2 305.2 1558.7 -1.2 311.7
pentose-phosphate pathway
YPR074C TKL1 7694_at YPR074C T 1097.1 -1.1 163.4 1097.1 -1.0 53.5 1280.0 1.1 190.6 1280.0 1.1 128.0
YJL121C RPE1 EPI1, POS 11128_at YJL121C 688.8 -1.3 240.4 688.8 -1.2 137.8 905.1 1.3 315.9 905.1 1.1 90.5
YGR043C ?? 4969_at Transaldol 42.7 2.6 70.2 42.7 2.9 80.7 16.0 -2.6 26.3 16.0 1.1 1.6
YGR256W GND2 4732_at YGR256W 12.0 2.4 17.3 12.0 2.5 18.5 0.0 0.0 0.0 0.0 0.0 0.0
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YLR354C TAL1 9978_at YLR354C 946.7 -1.0 46.2 946.7 -1.1 141.0 0.0 0.0 0.0 0.0 0.0 0.0
YHR183W GND1 4343_at YHR183W 1485.6 -1.1 221.2 1485.6 -1.1 221.2 1682.4 1.1 250.5 1682.4 1.0 0.0
YNL241C ZWF1 MET19, P 9108_at Glucose-6 206.9 1.3 62.1 206.9 -1.0 0.0 157.1 -1.3 47.1 157.1 -1.3 47.1
tricarboxylic-acid pathway (citrate cycle, Krebs cycle, TCA cycle)
YKL085W MDH1 10654_at YKL085W 1063.9 1.1 158.4 1063.9 1.2 264.9 866.5 -1.1 129.0 866.5 1.1 86.7
YGR244C LSC2 4764_at YGR244C 330.9 1.5 164.3 330.9 1.4 131.2 0.0 0.0 0.0 0.0 0.0 0.0
YOR142W LSC1 8389_at YOR142W 701.9 -1.0 34.3 701.9 -1.1 104.5 0.0 0.0 0.0 0.0 0.0 0.0
YPR001W CIT3 7753_at YPR001W 11.9 2.6 18.9 11.9 1.4 5.3 5.5 -2.6 8.8 5.5 -1.8 4.4
YDR178W SDH4 6279_at YDR178W 695.1 1.2 139.0 695.1 1.0 33.9 586.8 -1.2 117.4 586.8 -1.1 58.7
YPL262W FUM1 8033_at YPL262W 770.2 1.2 150.8 770.2 1.1 73.5 627.8 -1.2 122.9 627.8 -1.1 62.8
YDR148C KGD2 6339_at YDR148C d 0.0 0.0 0.0 0.0 0.0 0.0 206.5 -1.2 41.3 206.5 -1.5 103.3
YFL018C LPD1 HPD1 5367_at YFL018C 871.1 1.2 216.9 871.1 -1.0 0.0 700.8 -1.2 174.5 700.8 -1.2 140.2
YLR304C ACO1 GLU1 10019_at YLR304C 1066.5 -1.4 479.0 1066.5 -1.6 636.6 1602.0 1.4 719.5 1602.0 -1.1 160.2
YLL041C SDH2 10390_at YLL041C 1047.5 1.6 628.5 1047.5 1.2 209.5 654.7 -1.6 392.8 654.7 -1.3 196.4
respiration
YLR044C PDC1 10296_at YLR044C 2283.0 -1.2 456.6 2283.0 -1.0 0.0 2763.9 1.2 552.8 2763.9 1.2 552.8
YDL130W STF1 6600_at YDL130W 1812.2 -1.0 89.9 1812.2 -1.0 11.0 2258.3 1.3 635.7 2258.3 1.1 148.1
YBL099W ATP1 7487_at YBL099W 1009.5 -1.1 150.3 1009.5 -1.0 0.0 1258.4 1.1 187.4 1258.4 1.1 125.8
YKL016C ATP7 10591_at YKL016C 689.5 1.2 171.7 689.5 1.3 240.7 546.0 -1.2 136.0 546.0 1.1 54.6
YOR221C MCT1 8332_at YOR221C 88.7 2.0 88.7 88.7 2.8 159.7 55.8 -2.0 55.8 55.8 1.5 27.9
YNL237W YTP1 9111_at Yeast putat 28.1 2.5 41.9 28.1 8.2 201.5 11.1 -2.5 16.6 11.1 3.3 25.5
YBR046C ZTA1 7314_at Homolog t 129.6 2.6 207.0 129.6 3.3 297.8 49.3 -2.6 78.8 49.3 1.3 14.8
YMR145C NDE1 NDH1 9500_at YMR145C 1003.9 1.5 502.0 1003.9 1.5 551.3 664.3 -1.5 332.2 664.3 1.0 0.0
YMR256C COX7 9350_at YMR256C 1167.2 1.1 116.7 1167.2 1.2 233.4 0.0 0.0 0.0 0.0 0.0 0.0
YLR038C COX12 10290_at YLR038C 1869.2 1.1 278.3 1869.2 1.1 186.9 1626.8 -1.1 242.3 1626.8 -1.0 0.0
YOR065W CYT1 CTC1 8493_at YOR065W 269.6 1.5 133.9 269.6 1.5 148.0 0.0 0.0 0.0 0.0 0.0 0.0
YLR395C COX8 9930_at YLR395C 1205.1 1.1 179.5 1205.1 1.1 115.0 1054.3 -1.1 157.0 1054.3 -1.0 0.0
YLL009C COX17 10334_at YLL009C i 551.2 1.2 110.2 551.2 1.1 82.1 0.0 0.0 0.0 0.0 0.0 0.0
YLR205C HMX1 10143_at YLR205C 53.9 1.7 40.3 53.9 2.1 61.9 0.0 0.0 0.0 0.0 0.0 0.0
YFR033C QCR6 COR3, UCR5332_at YFR033C 563.1 1.2 112.6 563.1 -1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Q0185 ?? 4001_at Cytochrom 22.9 2.3 30.5 22.9 2.2 28.1 10.6 -2.3 14.1 10.6 -1.0 0.2
YKL055C OAR1 10641_at YKL055C 27.3 2.6 43.5 27.3 1.8 21.8 7.8 -2.6 12.5 7.8 -1.4 3.1
YKL150W MCR1 10723_at YKL150W 476.9 1.6 286.1 476.9 1.5 238.4 291.2 -1.6 174.7 291.2 -1.1 29.1
YBL045C COR1 QCR1 7407_at YBL045C 624.4 1.3 184.9 624.4 1.1 93.0 476.8 -1.3 141.2 476.8 -1.1 47.7
YPR191W QCR2 COR2, UCR7543_at YPR191W 497.9 1.9 448.1 497.9 1.5 273.4 238.5 -1.9 214.7 238.5 -1.2 47.7
YML054C CYB2 9702_at YML054C C 95.6 2.7 166.8 95.6 1.2 18.7 37.7 -2.7 65.8 37.7 -2.4 52.8
YDR178W SDH4 6279_at YDR178W 695.1 1.2 139.0 695.1 1.0 33.9 586.8 -1.2 117.4 586.8 -1.1 58.7
YGR008C STF2 4980_at YGR008C 783.8 1.3 235.1 783.8 1.1 116.7 605.4 -1.3 181.6 605.4 -1.1 60.5
YML120C NDI1 9765_at YML120C m 207.2 1.9 186.5 207.2 1.2 41.4 108.0 -1.9 97.2 108.0 -1.6 64.8
YGR183C QCR9 UCR9 4838_at YGR183C 1046.0 1.1 155.8 1046.0 1.0 51.1 903.1 -1.1 134.5 903.1 -1.1 90.3
YBR039W ATP3 7307_at YBR039W 630.5 1.2 126.1 630.5 -1.0 0.0 526.3 -1.2 105.3 526.3 -1.2 105.3
YGL191W COX13 5188_at YGL191W 0.0 0.0 0.0 0.0 0.0 0.0 560.7 -1.1 83.5 560.7 -1.2 112.1
YEL024W RIP1 5766_at YEL024W 767.0 1.4 344.5 767.0 1.2 191.0 600.6 -1.4 269.8 600.6 -1.2 120.1
YHR051W COX6 4481_at YHR051W 904.0 1.3 271.2 904.0 1.1 90.4 652.9 -1.3 195.9 652.9 -1.2 130.6
YER141W COX15 5581_at YER141W 491.1 -1.0 0.0 491.1 -1.2 122.3 484.7 -1.0 0.0 484.7 -1.3 145.4
YNL052W COX5A 8935_at YNL052W 606.5 1.2 121.3 606.5 -1.0 29.6 501.4 -1.2 100.3 501.4 -1.3 150.4
YLR295C ATP14 10010_at YLR295C 630.6 1.6 376.4 630.6 1.1 93.9 394.9 -1.6 235.7 394.9 -1.4 158.0
YDR322C TIM11 6154_at YDR322C s 975.4 1.2 195.1 975.4 1.1 97.5 799.4 -1.2 159.9 799.4 -1.2 159.9
YDL004W ATP16 6503_at YDL004W 720.0 1.2 179.3 720.0 1.0 35.1 558.7 -1.2 139.1 558.7 -1.3 167.6
YPL271W ATP15 ATPEPSIL 8024_at YPL271W 1021.8 1.1 152.2 1021.8 -1.0 49.9 899.9 -1.1 134.0 899.9 -1.2 180.0
Q0310 3976_at F1F0-ATP 804.9 1.2 200.4 804.9 -1.0 39.3 644.5 -1.2 160.5 644.5 -1.3 193.4
sS
o
p
A
a
S h
2 o
P
K
m
A
o
d
m
N G
3 R
R
s
m
YGL187C COX4 5193_at YGL187C 759.1 1.1 75.9 759.1 -1.2 151.8 691.0 -1.1 69.1 691.0 -1.3 207.3
YJR048W CYC1 10977_at YJR048W 827.3 1.1 123.2 827.3 -1.1 79.0 697.0 -1.1 103.8 697.0 -1.3 209.1
YDL067C COX9 6531_at YDL067C 687.3 -1.0 33.5 687.3 -1.3 239.9 707.7 1.0 34.5 707.7 -1.3 212.3
fermentation
YDR380W ARO10 6077_at Similarity t 883.1 2.3 1191.7 883.1 11.5 9314.3 375.6 -2.3 506.9 375.6 5.0 1502.4
YLR044C PDC1 10296_at YLR044C 2283.0 -1.2 456.6 2283.0 -1.0 0.0 2763.9 1.2 552.8 2763.9 1.2 552.8
YOL086C ADH1 ADC1 8657_at YOL086C 3553.5 -1.2 695.9 3553.5 -1.1 529.2 4293.4 1.2 840.8 4293.4 1.1 429.3
YMR116C ASC1 CPC2 9512_at YMR116C 2863.4 -1.2 572.7 2863.4 -1.1 286.3 3505.4 1.2 701.1 3505.4 1.1 350.5
YBR145W ADH5 7236_at YBR145W 1213.1 1.0 59.2 1213.1 1.3 423.4 1149.0 -1.0 56.1 1149.0 1.3 344.7
YER073W ALD5 5646_at YER073W 453.5 1.2 109.3 453.5 2.2 540.1 360.2 -1.2 86.8 360.2 1.7 252.1
YFL056C AAD6 5424_at YFL056C 4.7 2.1 5.2 4.7 1.5 2.5 2.3 -2.1 2.6 2.3 -1.5 1.2
YHR039C MSC7 VMA10 4514_at YHR039C 783.6 -1.3 235.1 783.6 -1.4 351.9 1017.3 1.3 305.2 1017.3 -1.1 101.7
YPL061W ALD6 7828_at YPL061W c 750.5 -1.1 111.8 750.5 -1.3 262.0 859.1 1.1 127.9 859.1 -1.2 171.8
metabolism of energy reserves (glycogen, trehalose)
YPL240C HSP82 HSP83, H 8010_i_at YPL240C 0.0 0.0 0.0 0.0 0.0 0.0 514.6 -1.0 0.0 514.6 1.2 102.9
YER133W GLC7 CID1, DIS 5573_at protein ph 242.7 1.2 40.7 242.7 1.3 84.2 217.2 -1.2 36.4 217.2 1.1 30.4
YKL128C PMU1 10700_at YKL128C 585.1 1.3 175.5 585.1 1.3 175.5 0.0 0.0 0.0 0.0 0.0 0.0
YOR178C GAC1 8380_at YOR178C 5.2 1.7 3.5 5.2 -1.3 1.8 3.1 -1.7 2.1 3.1 -2.1 3.4
YDR074W TPS2 HOG2, PF 6398_at YDR074W 224.7 1.5 111.6 224.7 -1.0 11.0 140.6 -1.5 69.8 140.6 -1.6 84.4
YMR105C PGM2 9547_at YMR105C 0.0 0.0 0.0 0.0 0.0 0.0 157.8 -1.3 55.1 157.8 -1.6 94.7
YDR214W AHA1 6271_at YDR214W 0.0 0.0 0.0 0.0 0.0 0.0 295.8 -1.1 28.2 295.8 -1.4 118.3
glyoxylate cycle
YOL126C MDH2 8663_at Cytosolic 126.7 1.9 113.7 126.7 3.4 309.9 66.1 -1.9 59.3 66.1 1.8 52.9
YCR005C CIT2 6883_at YCR005C 1341.0 -1.1 199.7 1341.0 -1.3 468.1 1588.0 1.1 236.5 1588.0 -1.1 158.8
YLR304C ACO1 GLU1 10019_at YLR304C 1066.5 -1.4 479.0 1066.5 -1.6 636.6 1602.0 1.4 719.5 1602.0 -1.1 160.2
oxidation of fatty acids
YBR046C ZTA1 7314_at Homolog t 129.6 2.6 207.0 129.6 3.3 297.8 49.3 -2.6 78.8 49.3 1.3 14.8
other energy generation activities 6 16
YAL054C ACS1 11356_at YAL054C i 350.3 1.2 87.2 350.3 1.3 122.3 0.0 0.0 0.0 0.0 0.0 0.0
YPL171C OYE3 ZRG6 7944_at NAD(P)H 23.0 3.4 54.7 23.0 2.7 38.7 6.8 -3.4 16.2 6.8 -1.3 2.0
YML035C AMD1 AMD3 9674_at YML035C  0.0 0.0 0.0 0.0 0.0 0.0 5.9 -1.3 1.9 5.9 -2.4 8.3
YDL078C MDH3 6565_at YDL078C 270.4 -1.0 13.2 270.4 -1.4 121.4 258.3 1.0 12.6 258.3 -1.4 103.3
YEL071W DLD3 5813_at YEL071W 934.3 -1.4 419.6 934.3 -1.5 513.1 1352.6 1.4 607.5 1352.6 -1.1 135.3
YDL181W INH1 6684_at YDL181W 140.3 1.2 28.1 140.3 -2.0 140.3 113.1 -1.2 22.6 113.1 -2.4 158.3
CELL CYCLE AND DNA PROCESSING
DNA processing
DNA synthesis and replication
YAL040C CLN3 DAF1, FU 11369_at YAL040C 188.8 1.2 37.8 188.8 1.7 132.1 0.0 0.0 0.0 0.0 0.0 0.0
YIL066C RNR3 DIN1, RIR 4045_s_at YIL066C 7.3 2.2 8.5 7.3 -1.1 1.0 2.2 -2.2 2.6 2.2 -1.2 0.4
YAL033W POP5 FUN53 11333_at YAL033W A 232.6 -1.3 69.8 232.6 -1.4 104.5 0.0 0.0 0.0 0.0 0.0 0.0
YBR088C POL30 7266_at YBR088C p 191.6 -1.2 38.3 191.6 -1.6 115.0 0.0 0.0 0.0 0.0 0.0 0.0
YGR180C RNR4 4835_at YGR180C 942.0 -1.0 46.0 942.0 -1.1 140.3 0.0 0.0 0.0 0.0 0.0 0.0
YCR028C FEN2 6863_at YCR028C 375.2 -1.2 93.4 375.2 -1.4 148.7 465.8 1.2 116.0 465.8 -1.1 46.6
YER070W RNR1 CRT7, RI 5643_at YER070W 457.9 1.0 22.3 457.9 -1.4 183.1 391.7 -1.0 19.1 391.7 -1.5 195.9
YMR241W YHM2 9380_at YMR241W 739.4 -1.3 221.8 739.4 -1.3 221.8 974.2 1.3 292.3 974.2 1.0 0.0
YJL026W RNR2 CRT6 11041_at YJL026W 665.7 -1.1 66.6 665.7 -1.3 232.4 774.7 1.1 77.5 774.7 -1.2 154.9
DNA recombination
YCR014C POL4 POLX 6891_at DNA poly 15.3 -3.0 30.5 15.3 1.4 6.1 67.8 3.0 135.1 67.8 5.5 305.1
YMR167W MLH1 PMS2 9479_at YMR167W 10.2 2.7 17.6 10.2 1.2 2.4 3.0 -2.7 5.2 3.0 -2.1 3.3
YMR190C SGS1 9461_at YMR190C 0.0 0.0 0.0 0.0 0.0 0.0 11.3 -1.4 4.5 11.3 -2.1 12.4
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YLR466W YRF1-4 YRF1 3735_f_at YLR466W 437.7 -1.3 131.3 437.7 -1.6 262.6 635.6 1.3 190.7 635.6 -1.3 190.7
YFL003C MSH4 5385_at YFL003C 5.6 2.2 6.9 5.6 -1.2 0.9 0.0 0.0 0.0 0.0 0.0 0.0
YJR021C REC107 MER2 10999_at YJR021C 2.3 2.0 2.4 2.3 2.4 3.2 0.0 0.0 0.0 0.0 0.0 0.0
YGR063C SPT4 4944_at YGR063C 239.6 -1.2 59.6 239.6 -1.4 107.6 0.0 0.0 0.0 0.0 0.0 0.0
YBR088C POL30 7266_at YBR088C p 191.6 -1.2 38.3 191.6 -1.6 115.0 0.0 0.0 0.0 0.0 0.0 0.0
DNA repair
YAL015C NTG1 FUN33 11352_at YAL015C 144.8 1.7 108.5 144.8 2.0 144.4 82.6 -1.7 61.9 82.6 1.1 8.3
YIL066C RNR3 DIN1, RIR 4045_s_at YIL066C 7.3 2.2 8.5 7.3 -1.1 1.0 2.2 -2.2 2.6 2.2 -1.2 0.4
YFL014W HSP12 5372_at YFL014W 625.4 1.8 493.3 625.4 -1.2 122.5 350.2 -1.8 276.3 350.2 -2.1 385.2
YGR180C RNR4 4835_at YGR180C 942.0 -1.0 46.0 942.0 -1.1 140.3 0.0 0.0 0.0 0.0 0.0 0.0
YOL053C ?? 8599_at YOL053C 0.0 0.0 0.0 0.0 0.0 0.0 206.7 -2.3 268.3 206.7 -2.1 227.4
DNA restriction or modification
YOR144C ELG1 RTT110 8391_at YOR144C 40.1 -1.1 6.0 40.1 -2.0 42.1 0.0 0.0 0.0 0.0 0.0 0.0
YPR204W ?? 3542_f_at YPR204W 374.9 -1.3 128.1 374.9 -1.4 144.6 0.0 0.0 0.0 0.0 0.0 0.0
chromatin modification
YGR063C SPT4 4944_at YGR063C 239.6 -1.2 59.6 239.6 -1.4 107.6 0.0 0.0 0.0 0.0 0.0
YML010W SPT5 9655_at YML010W 15.2 2.9 29.0 15.2 1.6 9.6 3.0 -2.9 5.7 3.0 -2.3
cell cycle
mitotic cell cycle and cell cycle control
YLR075W 10239_at YLR075W 2845.6 -1.2 708.6 2845.6 -1.0 138.9 3518.0 1.2 876.0 3518.0 1.2 703.6
YDR524C AGE1 SAT1 5926_g_at YDR524C A 3729.0 -1.3 1015.6 3729.0 -1.1 539.0 4720.7 1.3 1285.7 4720.7 1.1 703.0
YKR042W UTH1 10514_at YKR042W 1982.9 -1.0 0.0 1982.9 1.2 396.6 2155.3 -1.0 0.0 2155.3 1.2 431.1
YFR031C SMC2 5329_s_at YFR031C 3309.1 -1.2 824.0 3309.1 -1.1 492.8 4068.5 1.2 1013.1 4068.5 1.1 406.9
YJL034W KAR2 BIP, GRP 11078_at Homologu 1978.5 1.1 188.8 1978.5 1.2 492.6 1802.2 -1.1 172.0 1802.2 1.2 360.4
YLR175W CBF5 10155_at YLR175W 795.5 -1.0 0.0 795.5 1.4 318.2 829.9 -1.0 0.0 829.9 1.4 332.0
YHR071W PCL5 4452_at YHR071W 0.0 0.0 0.0 0.0 0.0 0.0 251.9 -1.6 151.1 251.9 2.1 277.1
YDL155W CLB3 6620_at G(sub)2-s 84.2 1.0 4.1 84.2 3.1 180.9 79.0 -1.0 3.9 79.0 2.9 150.1
YGL215W CLG1 5210_at YGL215W 190.2 1.0 9.3 190.2 2.1 208.7 136.2 -1.0 6.6 136.2 1.9 122.6
YMR094W CTF13 CBF3C 9536_at 58 kd com 30.0 1.4 12.0 30.0 8.2 215.6 21.4 -1.4 8.6 21.4 5.9 104.9
YCL004W PGS1 PEL1 6875_at 17-kDa Pho 6.6 3.2 14.7 6.6 1.4 2.5 0.0 -3.2 0.0 0.0 -2.4 0.0
YCL024W KCC4 6762_s_at YCL024W 12.4 2.4 17.2 12.4 1.2 2.4 5.1 -2.4 7.1 5.1 -2.0 5.1
YPL255W BBP1 7994_at YPL255W 0.0 0.0 0.0 0.0 0.0 0.0 4.1 -1.5 2.0 4.1 -2.4 5.7
YJL157C FAR1 11181_at YJL157C 346.1 -1.3 120.8 346.1 -1.6 206.5 476.4 1.3 166.3 476.4 -1.2 95.3
YNL307C MCK1 9177_at YNL307C 624.7 -1.1 93.0 624.7 -1.3 218.1 701.8 1.1 104.5 701.8 -1.2 140.4
YJL080C SCP160 11122_at YJL080C 403.0 -1.1 60.0 403.0 -1.5 221.3 472.9 1.1 70.4 472.9 -1.3 141.9
YNL098C RAS2 8979_at YNL098C 0.0 0.0 0.0 0.0 0.0 0.0 478.7 -1.1 47.9 478.7 -1.3 143.6
YGL048C RPT6 CIM3, CR 5059_at YGL048C 697.5 -1.0 0.0 697.5 -1.1 103.9 734.5 -1.0 0.0 734.5 -1.2 146.9
YDR328C SKP1 MGO1 6160_at YDR328C 487.2 1.2 121.3 487.2 -1.1 48.7 386.5 -1.2 96.2 386.5 -1.4 154.6
YNL064C YDJ1 MAS5 8924_at YNL064C 979.7 1.0 47.8 979.7 -1.1 145.9 959.6 -1.0 46.8 959.6 -1.2 191.9
YDL126C CDC48 6604_at YDL126C 655.9 -1.1 65.6 655.9 -1.3 229.0 652.5 1.1 65.3 652.5 -1.3 195.8
YLR229C CDC42 10121_at Member of 1147.0 -1.0 56.0 1147.0 -1.3 400.4 1103.3 1.0 53.9 1103.3 -1.3 331.0
YFL037W TUB2 ARM10, S 5394_at YFL037W b 727.1 1.1 108.3 727.1 1.3 218.1 0.0 0.0 0.0 0.0 0.0 0.0
YMR200W ROT1 9427_at YMR200W 276.0 1.5 138.0 276.0 1.5 151.6 0.0 0.0 0.0 0.0 0.0 0.0
YAL040C CLN3 DAF1, FU 11369_at YAL040C 188.8 1.2 37.8 188.8 1.7 132.1 0.0 0.0 0.0 0.0 0.0 0.0
YGR029W ERV1 3946_at YGR029W 370.4 1.2 82.3 370.4 1.3 129.3 307.9 -1.2 68.4 307.9 1.1 30.8
YNL007C SIS1 8888_at YNL007C 635.8 1.2 127.2 635.8 1.1 63.6 519.0 -1.2 103.8 519.0 -1.1 51.9
YHR030C SLT2 BYC2, MP 4504_at YHR030C 187.6 1.6 111.9 187.6 1.6 121.8 118.8 -1.6 70.9 118.8 1.1 11.9
YNL172W APC1 9041_at YNL172W 102.1 1.3 34.9 102.1 2.2 121.6 76.1 -1.3 26.0 76.1 1.6 45.7
YMR043W MCM1 FUN80 9576_at Putative tr 90.2 1.6 58.6 90.2 2.0 94.7 54.3 -1.6 35.3 54.3 1.2 10.9
YER133W GLC7 CID1, DIS 5573_at protein ph 242.7 1.2 40.7 242.7 1.3 84.2 217.2 -1.2 36.4 217.2 1.1 30.4
YER123W YCK3 CKI3 5608_at YER123W 35.8 1.4 16.1 35.8 2.3 48.2 0.0 0.0 0.0 0.0 0.0 0.0
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YNL012W SPO1 8883_at YNL012W 10.8 2.2 13.1 10.8 1.3 3.2 4.3 -2.2 5.3 4.3 -1.8 3.4
YCR091W KIN82 6786_at YCR091W 5.7 1.4 2.3 5.7 2.0 5.8 0.0 0.0 0.0 0.0 0.0 0.0
YBR109C CMD1 7245_at YBR109C c 758.7 -1.1 75.9 758.7 -1.2 151.7 0.0 0.0 0.0 0.0 0.0 0.0
YLR043C TRX1 LMA1 10295_at YLR043C 1339.6 -1.2 267.9 1339.6 -1.1 199.5 1597.3 1.2 319.5 1597.3 1.0 0.0
YFL039C ACT1 ABY1, EN 5392_at YFL039C 2061.4 -1.2 403.7 2061.4 -1.2 403.7 2477.1 1.2 485.1 2477.1 1.0 0.0
cell cycle checkpoints (checkpoints of morphogenesis, DNA-damage,-replication, mitotic phase and spindle) 1 27 ORFs
YER177W BMH1 5525_at YER177W 1125.3 -1.1 112.5 1125.3 -1.3 392.8 1252.2 1.1 125.2 1252.2 -1.2
meiosis
YPL240C HSP82 HSP83, H 8010_i_at YPL240C 0.0 0.0 0.0 0.0 0.0 0.0 514.6 -1.0 0.0 514.6 1.2 102.9
YDR523C SPS1 5947_at YDR523C d 5.0 2.0 5.2 5.0 -1.2 0.9 2.0 -2.0 2.1 2.0 -2.3 2.6
YMR167W MLH1 PMS2 9479_at YMR167W 10.2 2.7 17.6 10.2 1.2 2.4 3.0 -2.7 5.2 3.0 -2.1 3.3
YPL255W BBP1 7994_at YPL255W 0.0 0.0 0.0 0.0 0.0 0.0 4.1 -1.5 2.0 4.1 -2.4 5.7
YDR214W AHA1 6271_at YDR214W 0.0 0.0 0.0 0.0 0.0 0.0 295.8 -1.1 28.2 295.8 -1.4 118.3
YNL307C MCK1 9177_at YNL307C 624.7 -1.1 93.0 624.7 -1.3 218.1 701.8 1.1 104.5 701.8 -1.2 140.4
YBR078W ECM33 7302_at YBR078W 1606.6 -1.2 321.3 1606.6 -1.2 400.0 1885.9 1.2 377.2 1885.9 -1.1 188.6
YER175C TMT1 TAM1 5523_at Trans-aco 320.3 2.5 477.9 320.3 3.9 925.2 107.8 -2.5 160.8 107.8 1.5 53.9
YFL037W TUB2 ARM10, S 5394_at YFL037W b 727.1 1.1 108.3 727.1 1.3 218.1 0.0 0.0 0.0 0.0 0.0 0.0
YLR094C GIS3 10258_at Cyclin C a 40.0 3.8 111.6 40.0 6.0 199.5 9.8 -3.8 27.4 9.8 1.6 5.9
YHL027W RIM101 4581_at YHL027W 326.7 1.2 65.3 326.7 1.4 130.7 0.0 0.0 0.0 0.0 0.0 0.0
YER133W GLC7 CID1, DIS 5573_at protein ph 242.7 1.2 40.7 242.7 1.3 84.2 217.2 -1.2 36.4 217.2 1.1 30.4
YDL154W MSH5 6621_at YDL154W 20.5 1.7 15.2 20.5 2.1 23.3 0.0 0.0 0.0 0.0 0.0 0.0
YHR124W NDT80 4418_at YHR124W 11.8 1.3 4.1 11.8 2.2 14.7 0.0 0.0 0.0 0.0 0.0 0.0
YLL005C SPO75 10338_at YLL005C 6.0 2.3 8.0 6.0 2.7 9.8 1.8 -2.3 2.4 1.8 1.4 0.7
YOL091W SPO21 MPC70 8652_at YOL091W 5.1 1.4 2.0 5.1 2.9 9.4 0.0 0.0 0.0 0.0 0.0 0.0
YFL003C MSH4 5385_at YFL003C 5.6 2.2 6.9 5.6 -1.2 0.9 0.0 0.0 0.0 0.0 0.0 0.0
YJR021C REC107 MER2 10999_at YJR021C 2.3 2.0 2.4 2.3 2.4 3.2 0.0 0.0 0.0 0.0 0.0 0.0
YNL204C SPS18 SPX18 9055_at YNL204C 4.2 -1.8 3.4 4.2 -2.7 7.2 0.0 0.0 0.0 0.0 0.0 0.0
cytokinesis (cell division)
YNL271C BNI1 PPF3 9123_at Cytoskelet 94.5 1.3 28.0 94.5 3.4 229.7 108.6 -1.3 32.2 108.6 2.1 119.5
YPL255W BBP1 7994_at YPL255W 0.0 0.0 0.0 0.0 0.0 0.0 4.1 -1.5 2.0 4.1 -2.4 5.7
YDR284C DPP1 6204_at YDR284C 276.7 -1.2 55.3 276.7 -1.5 151.9 0.0 0.0 0.0 0.0 0.0 0.0
YLR286C CTS1 10045_at YLR286C 2323.9 -1.1 346.1 2323.9 -1.1 346.1 2400.2 1.1 357.4 2400.2 -1.1 240.0
nuclear and chromosomal cycle
chromosome segregation
YJR135C MCM22 10883_at YJR135C 0.0 0.0 0.0 0.0 0.0 0.0 6.5 -1.8 5.2 6.5 -2.4
other cell division and DNA synthesis activities
YMR096W SNZ1 9538_at Encodes hi 1883.5 1.5 941.7 1883.5 6.2 9787.9 1095.7 -1.5 547.9 1095.7 4.2 3506.2
YFL034C 5396_at YFL034C 503.0 1.2 100.6 503.0 1.2 100.6 0.0 0.0 0.0 0.0 0.0 0.0
TRANSCRIPTION
rRNA transcription
rRNA synthesis
YNL039W BDP1 TFC5 8902_at Subunit of 62.2 1.2 15.5 62.2 3.2 136.5 56.3 -1.2 14.0 56.3 2.5 84.5
YOR224C RPB8 8336_at YOR224C 710.6 -1.1 105.8 710.6 -1.1 105.8 816.1 1.1 121.5 816.1 -1.0 0.0
YOR341W RPA190 RRN1 8185_at YOR341W 328.5 -1.1 48.9 328.5 -1.4 130.2 383.7 1.1 57.1 383.7 -1.2 76.7
YPR187W RPO26 RPB6 7539_at YPR187W 335.7 -1.2 83.6 335.7 -1.4 150.8 429.1 1.2 106.8 429.1 -1.2 85.8
YPR010C RPA135 RPA2, RR 7762_at YPR010C R 352.9 -1.0 17.2 352.9 -1.4 139.9 379.1 1.0 18.5 379.1 -1.3 113.7
rRNA processing
SNR73 9193_at SNR73 S 36.6 -1.8 28.8 36.6 4.0 110.9 63.4 1.8 50.0 63.4 7.3 399.4
YLR175W CBF5 10155_at YLR175W 795.5 -1.0 0.0 795.5 1.4 318.2 829.9 -1.0 0.0 829.9 1.4 332.0
YOR310C NOP58 NOP5 8247_at YOR310C 757.9 -1.2 151.6 757.9 -1.0 37.0 888.7 1.2 177.7 888.7 1.1 88.9
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YHR089C GAR1 4425_at YHR089C s 1304.6 -1.1 194.3 1304.6 -1.0 63.7 1525.6 1.1 227.2 1525.6 1.1 152.6
RPR1 5413_at RPR1 RN 0.0 0.0 0.0 0.0 0.0 0.0 155.0 1.9 139.1 155.0 1.2 31.0
YLR197W SIK1 10132_at YLR197W 0.0 0.0 0.0 0.0 0.0 0.0 402.0 1.1 40.2 402.0 1.3 120.6
YHL034C SBP1 SSBR1 4574_at YHL034C 0.0 0.0 0.0 0.0 0.0 0.0 743.6 1.1 110.7 743.6 -1.1 74.4
SNR36 8059_at SNR36 sn 14.4 -1.2 3.5 14.4 3.0 29.4 18.5 1.2 4.5 18.5 3.9 53.7
YCR018C SRD1 6755_i_at YCR018C 1.6 -2.4 2.2 1.6 -1.7 1.2 5.7 2.4 8.0 5.7 1.3 1.7
YNL282W POP3 9157_at Structural 21.9 1.4 9.4 21.9 5.6 101.6 20.1 -1.4 8.6 20.1 3.5 50.3
YNR053C NOG2 8812_at YNR053C 66.8 2.0 66.8 66.8 2.6 106.8 0.0 0.0 0.0 0.0 0.0 0.0
YAL033W POP5 FUN53 11333_at YAL033W A 232.6 -1.3 69.8 232.6 -1.4 104.5 0.0 0.0 0.0 0.0 0.0 0.0
YDR432W NPL3 MTR13, M 6039_g_at YDR432W 442.1 1.2 106.8 442.1 1.1 53.2 326.8 -1.2 78.9 326.8 -1.2 54.8
YNL112W DBP2 8965_at YNL112W 510.9 -1.2 102.2 510.9 -1.3 153.3 604.6 1.2 120.9 604.6 -1.1 60.5
YDL208W NHP2 6700_at YDL208W 821.0 -1.1 122.3 821.0 -1.2 204.4 930.8 1.1 138.6 930.8 -1.1 93.1
other rRNA-transcription activities 1 6
YMR131C RRB1 9484_at YMR131C 431.3 1.3 150.6 431.3 1.1 64.2 322.8 -1.3 112.7 322.8 -1.2 64.6
tRNA transcription
tRNA synthesis
YNL039W BDP1 TFC5 8902_at Subunit of 62.2 1.2 15.5 62.2 3.2 136.5 56.3 -1.2 14.0 56.3 2.5 84.5
YOR224C RPB8 8336_at YOR224C 710.6 -1.1 105.8 710.6 -1.1 105.8 816.1 1.1 121.5 816.1 -1.0 0.0
YPR187W RPO26 RPB6 7539_at YPR187W 335.7 -1.2 83.6 335.7 -1.4 150.8 429.1 1.2 106.8 429.1 -1.2 85.8
tRNA processing
YIL075C RPN2 SEN3 4189_at YIL075C 0.0 0.0 0.0 0.0 0.0 0.0 385.5 1.2 77.1 385.5 1.4 154.2
RPR1 5413_at RPR1 RN 0.0 0.0 0.0 0.0 0.0 0.0 155.0 1.9 139.1 155.0 1.2 31.0
YDR381W YRA1 SHE11 6078_at YDR381W 400.7 1.1 59.7 400.7 -1.2 99.8 355.9 -1.1 53.0 355.9 -1.4 142.4
YNL282W POP3 9157_at Structural 21.9 1.4 9.4 21.9 5.6 101.6 20.1 -1.4 8.6 20.1 3.5 50.3
YML091C RPM2 9754_at Rpm2p is 187.9 1.7 131.5 187.9 1.4 75.1 120.0 -1.7 84.0 120.0 -1.2 24.0
YAL033W POP5 FUN53 11333_at YAL033W A 232.6 -1.3 69.8 232.6 -1.4 104.5 0.0 0.0 0.0 0.0 0.0 0.0
tRNA modification
YBL013W FMT1 7394_at YBL013W 2.8 1.1 0.3 2.8 2.3 3.6 2.6 -1.1 0.3 2.6 2.2 3.1
YGR204W ADE3 4814_at YGR204W 724.6 -1.2 144.9 724.6 -1.2 180.4 901.8 1.2 180.4 901.8 -1.0 0.0
mRNA transcription
mRNA synthesis
general transcription activities
YCR042C TSM1 TAF150 6830_at "Essential 31.2 -1.0 0.0 31.2 6.3 165.3 34.4 -1.0 0.0 34.4 6.1
YML010W SPT5 9655_at YML010W 15.2 2.9 29.0 15.2 1.6 9.6 3.0 -2.9 5.7 3.0 -2.3
YOR151C RPB2 RPB150, 8398_at YOR151C 378.0 1.2 74.0 378.0 -1.1 56.3 281.6 -1.2 55.1 281.6 -1.4
YLR094C GIS3 10258_at Cyclin C a 40.0 3.8 111.6 40.0 6.0 199.5 9.8 -3.8 27.4 9.8 1.6
YDL140C RPO21 RPB1, RP 6635_at YDL140C 247.9 1.2 61.7 247.9 1.5 123.1 0.0 0.0 0.0 0.0 0.0
YOR224C RPB8 8336_at YOR224C 710.6 -1.1 105.8 710.6 -1.1 105.8 816.1 1.1 121.5 816.1 -1.0
YGR063C SPT4 4944_at YGR063C 239.6 -1.2 59.6 239.6 -1.4 107.6 0.0 0.0 0.0 0.0 0.0
YHR041C SRB2 HRS2 4470_at YHR041C 188.0 -1.6 112.2 188.0 -1.6 112.2 343.7 1.6 205.1 343.7 1.0
YDR404C RPB7 6055_at YDR404C d 422.4 -1.1 42.2 422.4 -1.3 126.7 0.0 0.0 0.0 0.0 0.0
YPR187W RPO26 RPB6 7539_at YPR187W 335.7 -1.2 83.6 335.7 -1.4 150.8 429.1 1.2 106.8 429.1 -1.2
transcriptional control
YDR225W HTA1 H2A1, SP 6236_i_at YDR225W 1800.8 -1.1 268.2 1800.8 1.1 268.2 2018.3 1.1 300.6 2018.3 1.3
YNL031C HHT2 8910_at YNL031C 2640.6 -1.1 393.2 2640.6 -1.0 128.9 3123.3 1.1 465.1 3123.3 1.1
YNL030W HHF2 8911_s_at YNL030W 0.0 0.0 0.0 0.0 0.0 0.0 1477.0 1.1 147.7 1477.0 1.2
YFL021W GAT1 NIL1 5409_at YFL021W t 52.6 -2.5 81.2 52.6 -2.1 60.2 119.0 2.5 183.9 119.0 1.2
YCR042C TSM1 TAF150 6830_at "Essential 31.2 -1.0 0.0 31.2 6.3 165.3 34.4 -1.0 0.0 34.4 6.1
YDR224C HTB1 SPT12 6235_at YDR224C 0.0 0.0 0.0 0.0 0.0 0.0 839.3 1.1 83.9 839.3 1.2
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YKL190W CNB1 10772_at YKL190W T 0.0 0.0 0.0 0.0 0.0 0.0 575.0 1.1 57.5 575.0 1.2
YJR147W HMS2 10895_at Heat shoc 8.6 -2.0 9.0 8.6 2.0 8.7 16.7 2.0 17.5 16.7 4.2
YDR160W SSY1 SHR10 6306_at YDR160W 35.6 1.1 3.6 35.6 2.5 55.2 33.2 -1.1 3.3 33.2 2.4
YDR123C INO2 DIE1, SCS 6358_at Transcripti 18.7 2.4 26.3 18.7 8.1 132.6 9.1 -2.4 12.8 9.1 4.9
YMR182C RGM1 9452_at Putative tr 14.8 1.9 12.9 14.8 6.1 75.1 7.3 -1.9 6.4 7.3 4.1
YOL067C RTG1 8630_at YOL067C 11.2 1.1 1.7 11.2 2.7 19.5 9.6 -1.1 1.4 9.6 2.4
YDR216W ADR1 6273_at YDR216W 13.6 1.5 7.4 13.6 2.7 23.0 8.6 -1.5 4.7 8.6 1.8
YKR034W DAL80 UGA43 10551_at YKR034W 0.0 0.0 0.0 0.0 0.0 0.0 1.8 2.0 1.9 1.8 -2.0
YDR213W UPC2 MOX4 6270_at YDR213W 4.0 -1.1 0.4 4.0 -2.5 6.0 4.5 1.1 0.4 4.5 -2.2
YDR213W UPC2 MOX4 6270_at YDR213W 4.0 -1.1 0.4 4.0 -2.5 6.0 4.5 1.1 0.4 4.5 -2.2
YBL066C SEF1 7430_at Putative tr 9.5 4.0 28.5 9.5 1.8 7.6 5.2 -4.0 15.6 5.2 -2.2
YHR193C EGD2 4353_at YHR193C c 1137.1 -1.1 169.3 1137.1 -1.2 283.1 1294.9 1.1 192.8 1294.9 -1.1
YEL009C GCN4 AAS3, AR 5737_at 1433.2 1.0 70.0 1433.2 -1.1 136.8 1390.5 -1.0 67.9 1390.5 -1.1
YBL002W HTB2 7359_at YBL002W 541.0 -1.1 54.1 541.0 -1.5 270.5 614.9 1.1 61.5 614.9 -1.3
YPL037C EGD1 7806_at YPL037C 1962.5 -1.2 392.5 1962.5 -1.3 588.8 2272.2 1.2 454.4 2272.2 -1.1
YFL031W HAC1 ERN4, IR 5318_s_at bZIP Tran 398.7 1.9 355.4 398.7 2.2 484.5 284.7 -1.9 253.8 284.7 1.2
YOR344C TYE7 SGC1 8188_at 33 kDa se 66.1 2.8 121.6 66.1 3.6 174.1 23.0 -2.8 42.3 23.0 1.3
YMR039C SUB1 TSP1 9617_at YMR039C 306.3 1.1 29.2 306.3 1.4 137.6 0.0 0.0 0.0 0.0 0.0
YHL027W RIM101 4581_at YHL027W 326.7 1.2 65.3 326.7 1.4 130.7 0.0 0.0 0.0 0.0 0.0
YIR017C MET28 4098_at YIR017C 353.7 1.2 88.1 353.7 1.3 106.1 0.0 0.0 0.0 0.0 0.0
YGR288W MAL13 4718_at YGR288W 60.3 1.7 45.1 60.3 2.7 105.4 30.5 -1.7 22.9 30.5 1.6
YKL109W HAP4 10675_at YKL109W t 192.2 1.8 153.2 192.2 1.5 95.4 106.7 -1.8 85.1 106.7 -1.2
YMR043W MCM1 FUN80 9576_at Putative tr 90.2 1.6 58.6 90.2 2.0 94.7 54.3 -1.6 35.3 54.3 1.2
YGL066W SGF73 5086_at YGL066W 60.2 1.4 23.8 60.2 2.4 86.4 0.0 0.0 0.0 0.0 0.0
YGL209W MIG2 MLZ1 5216_at YGL209W 54.7 2.0 54.5 54.7 2.3 73.5 0.0 0.0 0.0 0.0 0.0
YMR042W ARG80 ARGR1 9575_at Regulator 57.3 1.8 45.8 57.3 1.9 51.5 31.3 -1.8 25.0 31.3 1.0
YPR168W NUT2 MED10 7566_at YPR168W 14.1 2.2 17.6 14.1 2.0 14.7 6.3 -2.2 7.9 6.3 -1.1
YCL010C SGF29 6870_at YCL010C 11.0 2.0 11.1 11.0 1.5 5.7 5.6 -2.0 5.7 5.6 -1.3
YFR034C PHO4 5333_at YFR034C 9.9 2.3 12.4 9.9 1.4 4.0 3.3 -2.3 4.1 3.3 -1.2
YNL012W SPO1 8883_at YNL012W 10.8 2.2 13.1 10.8 1.3 3.2 4.3 -2.2 5.3 4.3 -1.8
YLR055C SPT8 10264_at YLR055C 0.0 0.0 0.0 0.0 0.0 0.0 22.9 -2.0 22.7 22.9 -1.7
YIL084C SDS3 4182_at YIL084C F 4.6 2.0 4.8 4.6 -1.2 0.9 0.0 0.0 0.0 0.0 0.0
YNL204C SPS18 SPX18 9055_at YNL204C 4.2 -1.8 3.4 4.2 -2.7 7.2 0.0 0.0 0.0 0.0 0.0
YJL206C ?? 11221_at YJL206C i 427.0 -1.1 63.6 427.0 -1.2 106.3 0.0 0.0 0.0 0.0 0.0
YBL003C HTA2 H2A2 7358_s_at YBL003C 1320.7 -1.2 258.6 1320.7 -1.2 328.9 1555.2 1.2 304.5 1555.2 -1.0
YBR010W HHT1 BUR5, SI 7368_i_at YBR010W 2568.7 -1.1 382.5 2568.7 -1.1 382.5 2912.9 1.1 433.8 2912.9 -1.0
mRNA processing (splicing, 5'-, 3'-end processing)
YKL009W MRT4 10598_at YKL009W mRNA turn -1.2 153.33 D6 766.65 -1.1 76.665 766.65 -1.2 153.33
splicing
SNR128 10782_at SNR128 s 133.2 -1.8 113.1 133.2 -1.5 73.1 246.2 1.8 209.1 246.2 1.3
SNR56 6950_at SNR56 sn 67.6 -2.1 74.3 67.6 -1.9 60.8 141.5 2.1 155.7 141.5 1.1
SNR13 5807_at SNR13 sn 0.0 0.0 0.0 0.0 0.0 0.0 278.5 1.5 153.0 278.5 1.3
YEL026W SNU13 5764_at YEL026W 1087.2 -1.2 270.7 1087.2 -1.1 161.9 1391.4 1.2 346.5 1391.4 1.1
SNR68 4031_at SNR68 sn 0.0 0.0 0.0 0.0 0.0 0.0 172.7 1.1 17.3 172.7 1.7
SNR63 5804_at SNR63 sn 0.0 0.0 0.0 0.0 0.0 0.0 145.2 1.7 108.0 145.2 -1.0
SNR4 5417_at SNR4 snRN 182.7 -1.7 127.9 182.7 -1.3 54.8 316.8 1.7 221.8 316.8 1.3
SNR62 8058_r_at SNR62 sn 16.7 -1.2 2.8 16.7 2.6 26.0 17.9 1.2 3.0 17.9 3.0
YBL026W LSM2 SMX5, SN 7380_f_at YBL026W s 6.6 1.2 1.0 6.6 2.8 12.1 5.5 -1.2 0.9 5.5 2.6
SNR190 10783_at SNR190 s 0.0 0.0 0.0 0.0 0.0 0.0 3.7 2.4 5.1 3.7 -1.3
YDR378C LSM6 6075_at YDR378C S 285.1 -1.1 42.4 285.1 -1.3 99.5 333.1 1.1 49.6 333.1 -1.1
YGR222W PET54 4788_at YGR222W 0.0 0.0 0.0 0.0 0.0 0.0 136.2 -1.4 54.0 136.2 -1.7
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YPR182W SMX3 7580_at YPR182W 0.0 0.0 0.0 0.0 0.0 0.0 206.3 -1.0 10.1 206.3 -1.5
SNR67 5448_at SNR67 sn 0.0 0.0 0.0 0.0 0.0 0.0 182.1 1.8 145.7 182.1 -1.9
YER146W LSM5 5586_at YER146W 523.1 -1.1 77.9 523.1 -1.6 312.2 612.3 1.1 91.2 612.3 -1.3
YOR204W DED1 SPP81 8361_at YOR204W 325.4 1.8 260.3 325.4 1.3 97.6 169.7 -1.8 135.8 169.7 -1.3
YDL087C LUC7 6554_at YDL087C 14.4 2.0 15.0 14.4 1.7 10.8 8.2 -2.0 8.6 8.2 -1.1
SNR64 10407_at SNR64 sn 9.7 -1.4 3.5 9.7 -2.0 9.8 0.0 0.0 0.0 0.0 0.0
SNR74 9192_at SNR74 sn 14.6 -2.0 15.3 14.6 -2.5 22.5 29.3 2.0 30.7 29.3 -1.3
SNR17a 8061_at snr17a sn 26.1 -2.2 32.4 26.1 -2.1 29.8 52.0 2.2 64.7 52.0 1.0
SNR6 9794_at SNR6 snRN 27.4 -1.9 24.4 27.4 -2.5 40.6 51.4 1.9 45.7 51.4 -1.3
SNR75 9191_at SNR75 sn 62.7 -1.4 25.1 62.7 -2.1 68.9 0.0 0.0 0.0 0.0 0.0
SNR70 7475_at SNR70 sn 293.8 -1.5 145.9 293.8 -1.3 102.5 443.7 1.5 220.4 443.7 1.1
YDL084W SUB2 6557_at YDL084W 678.8 -1.2 135.8 678.8 -1.3 203.6 823.9 1.2 164.8 823.9 -1.1
other mRNA-transcription activities
YNL016W PUB1 8879_at YNL016W 329.2 1.6 197.5 329.2 1.9 296.2 203.9 -1.6 122.3 203.9 1.2 40.8
Q0205 4004_at probable 3.9 2.3 5.0 3.9 1.8 3.0 0.0 0.0 0.0 0.0 0.0 0.0
RNA transport
YDR432W NPL3 MTR13, M 6039_g_at YDR432W 442.1 1.2 106.8 442.1 1.1 53.2 326.8 -1.2 78.9 326.8 -1.2 54.8
YDR002W YRB1 CST20, H 6463_at YDR002W 912.6 -1.2 182.5 912.6 -1.2 227.2 0.0 0.0 0.0 0.0 0.0 0.0
other transcription activities 6 57 ORFs
YNL004W HRB1 TOM34 8845_at Heterogen 232.1 1.3 69.6 232.1 3.6 614.9 160.5 -1.3 48.2 160.5 2.7 272.9
YOL010W RCL1 8552_at YOL010W 220.6 1.2 54.9 220.6 1.9 208.2 178.3 -1.2 44.4 178.3 1.6 107.0
YCL033C ?? 6899_at YCL033C 256.1 1.3 76.8 256.1 1.6 166.2 0.0 0.0 0.0 0.0 0.0 0.0
YOR230W WTM1 8342_at YOR230W 812.5 1.0 39.7 812.5 1.1 121.0 0.0 0.0 0.0 0.0 0.0 0.0
YPL230W ?? 7974_at YPL230W 4.2 2.5 6.2 4.2 1.1 0.2 1.8 -2.5 2.6 1.8 -1.8 1.4
YNL255C GIS2 9139_at YNL255C 604.0 -1.1 57.6 604.0 -1.2 118.3 0.0 0.0 0.0 0.0 0.0 0.0
PROTEIN SYNTHESIS
ribosome biogenesis
RDN5-1 3768_i_at RDN5-1 5 633.1 -4.4 2165.4 633.1 -2.8 1137.0 2544.8 4.4 8703.9 2544.8 1.5 1397.6
YJR145C 10893_s_ YJR145C 2528.9 -1.2 505.8 2528.9 1.1 376.6 3067.1 1.2 613.4 3067.1 1.4 1226.8
YPL079W 7811_at YPL079W 3889.3 -1.2 968.4 3889.3 -1.0 189.8 4786.7 1.2 1191.9 4786.7 1.2 957.3
YLR344W 9968_s_at YLR344W 3362.5 -1.2 837.2 3362.5 -1.0 164.1 4066.5 1.2 1012.6 4066.5 1.2 813.3
YNL137C NAM9 MNA6 8985_at Structural 251.5 1.2 49.3 251.5 4.9 990.3 215.5 -1.2 42.2 215.5 4.3 711.2
YLR075W 10239_at YLR075W 2845.6 -1.2 708.6 2845.6 -1.0 138.9 3518.0 1.2 876.0 3518.0 1.2 703.6
YKL180W 10738_i_a YKL180W 2817.6 -1.2 563.5 2817.6 -1.0 0.0 3486.2 1.2 697.2 3486.2 1.2 697.2
YNL005C MRP7 8890_at Peptidyltran 200.5 1.3 70.0 200.5 7.0 1212.7 151.3 -1.3 52.8 151.3 5.4 665.7
YHR021C 4494_at YHR021C 4 2555.9 -1.2 636.4 2555.9 -1.0 124.7 3188.4 1.2 793.9 3188.4 1.2 637.7
YLR340W 9964_at YLR340W 2536.8 -1.2 631.6 2536.8 -1.0 123.8 3106.9 1.2 773.6 3106.9 1.2 621.4
YDR382W 6080_at YDR382W 2413.6 -1.3 714.8 2413.6 -1.1 230.4 3071.7 1.3 909.7 3071.7 1.2 614.3
YJL136C 11158_i_a YJL136C 3299.5 -1.2 808.3 3299.5 -1.0 79.6 4054.7 1.2 993.3 4054.7 1.1 603.8
YGL189C 5191_f_at YGL189C 2355.7 -1.3 636.4 2355.7 -1.1 230.2 2883.3 1.3 778.9 2883.3 1.2 564.6
YDL075W 6569_at YDL075W 1960.6 -1.4 777.2 1960.6 -1.1 283.4 2750.1 1.4 1090.2 2750.1 1.2 550.0
YOR293W 8269_f_at YOR293W 1286.0 -1.2 320.2 1286.0 1.1 122.7 1609.6 1.2 400.8 1609.6 1.3 549.9
YPR043W 7708_f_at YPR043W 1791.2 -1.2 446.0 1791.2 -1.1 44.6 2186.7 1.2 544.5 2186.7 1.1 54.4
YMR143W 9497_i_at YMR143W 849.7 -1.2 211.6 849.7 1.2 175.1 1025.4 1.2 255.3 1025.4 1.5 533.1
YIL052C 4165_i_at YIL052C 2049.3 -1.3 606.9 2049.3 -1.0 0.0 2582.5 1.3 764.8 2582.5 1.2 516.5
YLR441C 9890_s_at YLR441C 2182.4 -1.2 431.9 2182.4 -1.1 42.2 2569.5 1.2 508.5 2569.5 1.1 48.5
YMR242C 9381_s_at YMR242C 1408.7 -1.2 281.7 1408.7 1.0 68.8 1685.4 1.2 337.1 1685.4 1.3 505.6
YGL147C 5142_i_at YGL147C 472.5 -1.4 173.6 472.5 1.4 173.6 629.9 1.4 231.5 629.9 1.8 503.9
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YNL301C 9183_s_at YNL301C 1971.2 -1.2 490.8 1971.2 -1.0 47.5 2419.5 1.2 602.5 2419.5 1.2 483.9
YEL054C 5781_i_at YEL054C 1913.3 -1.2 476.4 1913.3 -1.0 93.4 2365.3 1.2 589.0 2365.3 1.2 473.1
YHL001W 4515_i_at YHL001W 1047.4 -1.3 285.3 1047.4 1.1 65.1 1278.9 1.3 348.3 1278.9 1.4 470.0
YMR230W 9413_f_at YMR230W 798.7 -1.2 126.4 798.7 1.3 219.4 958.6 1.2 151.7 958.6 1.5 450.2
YML063W 9691_i_at YML063W 1232.7 -1.2 306.9 1232.7 1.0 60.2 1493.1 1.2 371.8 1493.1 1.3 447.9
YLR333C 10002_i_a YLR333C 1534.6 -1.2 267.3 1534.6 1.0 65.4 1832.1 1.2 319.1 1832.1 1.2 441.5
YGL031C 5031_at YGL031C 1705.7 -1.3 505.1 1705.7 -1.1 162.8 2163.7 1.3 640.8 2163.7 1.2 432.7
YGR148C 4848_at YGR148C 3354.9 -1.2 835.4 3354.9 -1.1 499.6 4259.1 1.2 1060.5 4259.1 1.1 425.9
YGL030W 5032_at YGL030W 1709.5 -1.2 411.9 1709.5 -1.0 0.0 2125.5 1.2 512.2 2125.5 1.2 425.1
YKL006W 10558_s_ YKL006W 2624.3 -1.3 687.1 2624.3 -1.1 293.1 3341.8 1.3 874.9 3341.8 1.1 423.1
YGR027C 5001_f_at YGR027C 1532.4 -1.2 340.4 1532.4 -1.1 24.5 1862.8 1.2 413.8 1862.8 1.1 61.6
YLR061W 10270_at YLR061W 3375.8 -1.2 840.6 3375.8 -1.1 337.6 4118.2 1.2 1025.4 4118.2 1.1 411.8
YFR031C 5329_s_at YFR031C 3309.1 -1.2 824.0 3309.1 -1.1 492.8 4068.5 1.2 1013.1 4068.5 1.1 406.9
YHR010W 4528_i_at YHR010W 1525.0 -1.2 332.7 1525.0 -1.1 23.9 1850.0 1.2 403.6 1850.0 1.2 79.0
YBR031W 7344_i_at YBR031W 903.3 -1.5 411.8 903.3 -1.2 172.4 1175.7 1.5 536.0 1175.7 1.3 401.6
YLR048W 10301_at YLR048W 2484.7 -1.2 533.5 2484.7 -1.1 159.3 3017.4 1.2 647.8 3017.4 1.1 399.4
YNL162W 9006_s_at YNL162W 1629.0 -1.2 325.8 1629.0 -1.0 79.5 1986.6 1.2 397.3 1986.6 1.2 397.3
YLR287C 10047_f_a YLR287C 3167.8 -1.2 788.8 3167.8 -1.0 154.6 3855.8 1.2 960.1 3855.8 1.1 385.6
YML073C 9726_at YML073C R 1002.1 -1.2 249.5 1002.1 1.0 48.9 1281.1 1.2 319.0 1281.1 1.3 384.3
YLR406C 9897_f_at YLR406C 1821.9 -1.2 453.6 1821.9 -1.1 147.9 2302.1 1.2 573.2 2302.1 1.2 381.4
YDR418W 6069_i_at YDR418W 1443.6 -1.4 524.7 1443.6 -1.1 199.9 1942.5 1.4 706.0 1942.5 1.2 380.4
YDL083C 6559_f_at YDL083C 1335.4 -1.2 299.5 1335.4 -1.1 44.6 1641.7 1.2 368.2 1641.7 1.0 18.0
YOR182C 8384_f_at YOR182C 2871.4 -1.2 715.0 2871.4 -1.1 274.1 3570.6 1.2 889.1 3570.6 1.1 357.1
YMR116C ASC1 CPC2 9512_at YMR116C 2863.4 -1.2 572.7 2863.4 -1.1 286.3 3505.4 1.2 701.1 3505.4 1.1 350.5
YLR388W 9923_f_at YLR388W 2857.6 -1.1 425.5 2857.6 -1.0 139.5 3370.6 1.1 501.9 3370.6 1.1 337.1
YDR012W 6473_i_at YDR012W 1178.7 -1.4 529.4 1178.7 -1.2 293.5 1664.0 1.4 747.4 1664.0 1.2 332.8
YNL069C 8918_at YNL069C 2660.9 -1.2 662.6 2660.9 -1.1 396.2 3325.4 1.2 828.0 3325.4 1.1 332.5
YLL045C 10386_s_ YLL045C 1659.8 -1.2 289.1 1659.8 -1.1 26.4 1906.1 1.2 332.0 1906.1 1.0 14.8
YBR191W 7147_at YBR191W 2492.3 -1.3 738.1 2492.3 -1.2 488.1 3246.8 1.3 961.5 3246.8 1.1 324.7
YER074W 5647_s_at YER074W 1173.0 -1.3 409.4 1173.0 -1.1 174.7 1562.3 1.3 545.4 1562.3 1.2 312.5
YER056C FCY2 BRA7 5668_at YER056C p 1819.5 -1.1 238.3 1819.5 1.0 19.9 2117.5 1.1 277.4 2117.5 1.1 311.1
YOL039W 8613_at YOL039W 2361.0 -1.2 587.9 2361.0 -1.2 472.2 2988.9 1.2 744.2 2988.9 1.1 298.9
YDR500C 5969_at YDR500C 6 2208.7 -1.3 654.1 2208.7 -1.1 328.9 2914.7 1.3 863.2 2914.7 1.1 291.5
YML024W 9686_s_at YML024W 2444.4 -1.1 364.0 2444.4 -1.0 119.3 2901.7 1.1 432.1 2901.7 1.1 290.2
YBL072C 7425_s_at YBL072C 2290.7 -1.2 570.4 2290.7 -1.1 341.1 2779.9 1.2 692.2 2779.9 1.1 278.0
YOR369C 8168_at YOR369C 2272.3 -1.2 445.0 2272.3 -1.0 110.9 2671.6 1.2 523.2 2671.6 1.1 267.2
YGL123W 5119_at YGL123W 2085.1 -1.2 519.2 2085.1 -1.1 310.5 2617.9 1.2 651.9 2617.9 1.1 261.8
YMR194W 9420_i_at YMR194W 2154.9 -1.2 527.9 2154.9 -1.2 375.3 2714.2 1.2 664.9 2714.2 1.1 259.1
YNL302C 9182_s_at YNL302C 2205.2 -1.1 328.4 2205.2 -1.0 107.6 2531.0 1.1 376.9 2531.0 1.1 253.1
YNL096C 8981_at YNL096C 1165.4 -1.0 56.9 1165.4 1.1 173.5 1260.1 1.0 61.5 1260.1 1.2 252.0
YLR185W 10166_at YLR185W 1831.8 -1.3 639.4 1831.8 -1.2 366.4 2462.9 1.3 859.7 2462.9 1.1 246.3
YPL220W 7984_s_at YPL220W 2002.5 -1.2 498.6 2002.5 -1.1 298.2 2442.9 1.2 608.3 2442.9 1.1 244.3
RDN5-3 3770_i_at RDN5-3 5 99.6 -5.9 485.9 99.6 -4.2 322.3 580.0 5.9 2829.7 580.0 1.4 232.0
YOL120C 8668_at YOL120C 1845.5 -1.2 459.5 1845.5 -1.2 361.4 2308.9 1.2 574.9 2308.9 1.1 230.9
YMR286W 9335_at YMR286W 496.5 1.0 24.2 496.5 1.6 296.3 456.1 -1.0 22.3 456.1 1.5 228.1
YPL143W 7882_f_at YPL143W 1752.7 -1.2 436.4 1752.7 -1.1 261.0 2153.6 1.2 536.2 2153.6 1.1 215.4
YKR094C 10474_s_ YKR094C R 1812.2 -1.2 358.7 1812.2 -1.1 266.2 2208.2 1.2 437.0 2208.2 1.1 210.8
YIL148W 4253_i_at YIL148W 822.0 -1.2 198.1 822.0 -1.0 0.0 1017.9 1.2 245.3 1017.9 1.2 203.6
YOR167C 8369_f_at YOR167C 1763.8 -1.2 352.8 1763.8 -1.0 38.8 2079.9 1.2 416.0 2079.9 1.1 198.5
YJL189W 11237_at YJL189W 1683.5 -1.2 336.7 1683.5 -1.1 168.3 1974.3 1.2 394.9 1974.3 1.1 197.4
YGL103W 5094_at YGL103W 1673.9 -1.2 334.8 1673.9 -1.1 167.4 1962.7 1.2 392.5 1962.7 1.1 196.3
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YOR096W 8479_at YOR096W 1643.4 -1.1 244.7 1643.4 -1.0 80.2 1915.7 1.1 285.3 1915.7 1.1 191.6
YPR102C 7632_i_at YPR102C R 1550.4 -1.2 310.1 1550.4 -1.1 155.0 1849.3 1.2 369.9 1849.3 1.1 184.9
YCR031C 6866_at YCR031C 1455.3 -1.2 362.4 1455.3 -1.1 216.7 1839.9 1.2 458.1 1839.9 1.1 184.0
YOL127W 8662_at YOL127W 1394.8 -1.2 347.3 1394.8 -1.1 139.5 1828.8 1.2 455.4 1828.8 1.1 182.9
YPL090C 7845_s_at YPL090C 1431.8 -1.2 286.4 1431.8 -1.1 143.2 1768.0 1.2 353.6 1768.0 1.1 176.8
YFR032C 5331_at YFR032C 1564.0 -1.2 389.4 1564.0 -1.1 232.9 1715.2 1.2 427.1 1715.2 1.1 171.5
YMR142C 9496_at YMR142C 1229.5 -1.3 429.2 1229.5 -1.2 306.1 1708.6 1.3 596.4 1708.6 1.1 170.9
YDR471W 5985_at YDR471W 1396.6 -1.2 279.3 1396.6 -1.1 208.0 1697.3 1.2 339.5 1697.3 1.1 169.7
YGR214W 4780_at YGR214W 1457.7 -1.2 285.4 1457.7 -1.1 217.1 1570.5 1.2 307.5 1570.5 1.1 157.1
YDL130W RPP1B RPL44', R 6600_at YDL130W 1812.2 -1.0 89.9 1812.2 -1.0 11.0 2258.3 1.3 635.7 2258.3 1.1 148.1
YDL184C 6680_s_at YDL184C 1060.2 -1.3 318.1 1060.2 -1.2 212.0 1389.1 1.3 416.7 1389.1 1.1 138.9
YOL077C BRX1 8621_at YOL077C 485.6 -1.0 0.0 485.6 1.1 48.6 508.0 -1.0 0.0 508.0 1.2 101.6
Q0325 3979_i_at mitochond 2.4 1.5 1.1 2.4 -2.4 3.4 0.8 -1.5 0.4 0.8 -2.9 1.5
YGL068W 5084_at YGL068W 0.0 0.0 0.0 0.0 0.0 0.0 283.9 -1.2 56.8 283.9 -1.4 113.6
YNR036C 8839_at YNR036C s 0.0 0.0 0.0 0.0 0.0 0.0 590.3 -1.1 87.9 590.3 -1.3 177.1
YGL076C 5075_i_at YGL076C 1397.4 -1.0 68.2 1397.4 -1.3 380.6 1462.8 1.0 71.4 1462.8 -1.1 217.8
YBL087C 7454_s_at YBL087C 2647.6 -1.1 394.3 2647.6 -1.2 659.3 2964.6 1.1 441.5 2964.6 -1.1 296.5
YML026C 9684_s_at YML026C R 2948.1 -1.1 439.0 2948.1 -1.2 734.1 3458.0 1.1 514.9 3458.0 -1.1 345.8
YBL027W 7378_s_at YBL027W 1885.8 -1.2 377.2 1885.8 -1.3 658.3 2238.6 1.2 447.7 2238.6 -1.2 447.7
YGL224C SDT1 SSM1 5246_at YGL224C 264.2 1.5 131.2 264.2 2.0 263.5 0.0 0.0 0.0 0.0 0.0 0.0
YGL125W MET13 MET11 5117_at YGL125W 579.3 1.1 86.3 579.3 1.3 173.8 0.0 0.0 0.0 0.0 0.0 0.0
YBR282W 7100_at YBR282W 266.4 1.3 91.0 266.4 1.5 144.6 0.0 0.0 0.0 0.0 0.0 0.0
YBR146W 7237_at YBR146W 214.7 1.2 42.9 214.7 1.5 107.3 0.0 0.0 0.0 0.0 0.0 0.0
YOR158W PET123 8405_at YOR158W 210.3 1.2 42.1 210.3 1.5 105.2 0.0 0.0 0.0 0.0 0.0 0.0
YFL034C 5396_at YFL034C 503.0 1.2 100.6 503.0 1.2 100.6 0.0 0.0 0.0 0.0 0.0 0.0
YDR405W 6056_at YDR405W 27.5 1.3 9.6 27.5 2.3 35.5 0.0 0.0 0.0 0.0 0.0 0.0
RDN18-1 3767_s_at RDN18-1 1 0.8 -21.7 16.5 0.8 -13.4 10.0 61.1 21.7 1263.5 61.1 1.6 36.7
YBR189W 7191_f_at YBR189W 1255.6 -1.2 312.6 1255.6 -1.1 46.6 1693.8 1.2 421.8 1693.8 1.1 42.2
YKL156W 10717_at YKL156W 4 1167.3 -1.1 173.8 1167.3 -1.1 116.7 1337.0 1.1 199.1 1337.0 1.0 0.0
YNL255C GIS2 9139_at YNL255C 604.0 -1.1 57.6 604.0 -1.2 118.3 0.0 0.0 0.0 0.0 0.0 0.0
YER131W 5571_at YER131W 475.1 -1.2 93.0 475.1 -1.3 135.2 563.2 1.2 110.3 563.2 -1.0 0.0
YKL009W MRT4 10598_at YKL009W 766.7 -1.1 76.7 766.7 -1.2 153.3 0.0 0.0 0.0 0.0 0.0 0.0
YPL081W 7854_i_at YPL081W 563.9 -1.3 163.7 563.9 -1.3 176.7 717.0 1.3 208.2 717.0 -1.0 35.0
YBR048W 7316_s_at YBR048W 1977.1 -1.1 294.4 1977.1 -1.1 188.7 2248.8 1.1 334.9 2248.8 1.0 0.0
YHL015W 4547_at YHL015W 1285.1 -1.2 251.7 1285.1 -1.1 191.4 1504.1 1.2 294.5 1504.1 1.0 0.0
YPR132W 7619_s_at YPR132W 2790.2 -1.1 415.5 2790.2 -1.1 200.5 3197.7 1.1 476.2 3197.7 1.0 156.1
YOR234C 8300_f_at YOR234C 1443.6 -1.2 288.7 1443.6 -1.1 215.0 1742.0 1.2 348.4 1742.0 1.0 0.0
YJR123W 10916_at YJR123W 2208.1 -1.1 328.8 2208.1 -1.1 220.8 2589.4 1.1 385.6 2589.4 1.0 0.0
YDL061C 6537_f_at YDL061C 1608.4 -1.2 321.7 1608.4 -1.1 239.5 2021.8 1.2 404.4 2021.8 1.0 0.0
YLR325C 9994_at YLR325C 2428.1 -1.1 361.6 2428.1 -1.1 242.8 2763.9 1.1 411.6 2763.9 1.0 0.0
YLR264W 10068_i_a YLR264W 2584.2 -1.1 384.8 2584.2 -1.1 252.5 2952.9 1.1 439.7 2952.9 1.0 144.1
YNL067W 8921_s_at YNL067W 1726.3 -1.0 84.3 1726.3 -1.1 257.1 0.0 0.0 0.0 0.0 0.0 0.0
YOR063W 8491_at YOR063W 1309.3 -1.1 130.9 1309.3 -1.2 261.9 0.0 0.0 0.0 0.0 0.0 0.0
YPL249C 8000_i_at YPL249C 907.7 -1.3 268.8 907.7 -1.3 268.8 1184.0 1.3 350.6 1184.0 1.0 0.0
YJL191W 11235_at YJL191W 642.2 -1.4 288.4 642.2 -1.4 288.4 945.5 1.4 424.7 945.5 1.0 0.0
YLR448W 9852_at YLR448W 1941.5 -1.1 194.2 1941.5 -1.1 289.1 0.0 0.0 0.0 0.0 0.0 0.0
YBL092W 7448_at YBL092W 1463.1 -1.2 292.6 1463.1 -1.2 292.6 1879.3 1.2 375.9 1879.3 1.0 0.0
YDL191W 6672_s_at YDL191W 1556.5 -1.2 304.8 1556.5 -1.2 304.8 1877.9 1.2 367.7 1877.9 -1.0 0.0
RDN37-1 3807_s_at RDN37-1 89.7 -5.0 356.7 89.7 -4.5 309.7 238.4 5.0 947.9 238.4 1.2 36.4
YGR118W 4909_f_at YGR118W 2127.7 -1.1 316.8 2127.7 -1.1 316.8 2514.3 1.1 374.4 2514.3 1.0 0.0
YDR064W 6433_at YDR064W 1722.3 -1.2 344.5 1722.3 -1.2 344.5 2085.3 1.2 417.1 2085.3 1.0 0.0
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YOL040C 8612_at YOL040C 1952.9 -1.2 390.6 1952.9 -1.2 390.6 2270.9 1.2 454.2 2270.9 -1.0 0.0
YHL033C 4575_i_at YHL033C 1955.4 -1.1 195.5 1955.4 -1.2 391.1 0.0 0.0 0.0 0.0 0.0 0.0
YPL131W 7894_at YPL131W 2684.5 -1.2 536.9 2684.5 -1.1 399.7 3209.3 1.2 641.9 3209.3 1.0 0.0
YDL081C 6561_at YDL081C 2074.7 -1.2 499.9 2074.7 -1.2 406.3 2727.7 1.2 657.3 2727.7 1.0 0.0
YJL177W 11205_i_a YJL177W 2100.3 -1.2 523.0 2100.3 -1.2 420.1 2639.5 -1.2 657.2 2639.5 1.0 128.8
YDL082W 6560_at YDL082W 1468.9 -1.2 365.8 1468.9 -1.3 435.0 1816.6 1.2 452.3 1816.6 -1.0 0.0
YLR029C 10325_at YLR029C 1856.7 -1.2 416.4 1856.7 -1.3 505.7 2276.3 1.2 510.5 2276.3 -1.0 111.1
YIL133C 4223_at YIL133C 2311.2 -1.2 575.5 2311.2 -1.2 575.5 2889.0 1.2 719.4 2889.0 1.0 0.0
YJL190C 11236_at YJL190C 3932.3 -1.1 585.6 3932.3 -1.1 585.6 4680.2 1.1 696.9 4680.2 1.0 0.0
YKR057W 10529_i_a YKR057W 4839.1 -1.2 947.6 4839.1 -1.2 947.6 5831.4 1.2 1141.9 5831.4 1.0 0.0
RDN25-1 3765_s_at RDN25-1 1 58.5 -17.2 946.6 58.5 -19.2 1062.1 602.7 17.2 9755.3 602.7 -1.0 22.0
YGR085C 4921_i_at YGR085C 3199.3 -1.2 796.6 3199.3 -1.4 1268.3 3846.1 1.2 957.7 3846.1 -1.2 769.2
translation
YPR080W TEF1 7656_s_at YPR080W 2055.9 -1.3 608.9 2055.9 -1.1 196.2 2619.5 1.3 775.8 2619.5 1.2 523.9
YMR116C ASC1 CPC2 9512_at YMR116C 2863.4 -1.2 572.7 2863.4 -1.1 286.3 3505.4 1.2 701.1 3505.4 1.1 350.5
YEL034W HYP2 TIF51A 5756_at YEL034W T 2636.4 -1.2 656.5 2636.4 -1.1 392.6 3320.4 1.2 826.8 3320.4 1.1 332.0
YJL138C TIF2 11156_s_ YJL138C t 1972.0 -1.1 293.7 1972.0 -1.0 96.3 2291.9 1.1 341.3 2291.9 1.1 229.2
YKL081W TEF4 EFC1 10658_at YKL081W T 389.0 -1.3 130.3 389.0 1.2 74.6 471.5 1.3 157.9 471.5 1.3 134.1
YJR047C ANB1 HYP1, TIF 10976_at YJR047C 180.8 -1.8 153.6 180.8 -1.6 108.5 332.5 1.8 282.4 332.5 1.2 66.5
YNL014W HEF3 ZRG7 8881_at Translatio 3.5 1.5 1.8 3.5 -2.4 4.9 -1.9 -1.5 -1.0 -1.9 -3.7 -5.1
YPL226W NEW1 7978_at YPL226W s 453.2 -1.1 67.5 453.2 -1.3 158.2 519.5 1.1 77.4 519.5 -1.2 103.9
YOR187W TUF1 8343_at YOR187W 687.5 1.2 137.5 687.5 -1.0 0.0 586.9 -1.2 117.4 586.9 -1.2 117.4
YMR146C TIF34 9501_at YMR146C 380.6 -1.0 18.6 380.6 -1.4 170.9 385.5 1.0 18.8 385.5 -1.4 154.2
YBR143C SUP45 SAL4, SU 7234_at YBR143C T 569.1 -1.0 0.0 569.1 -1.4 227.6 583.2 -1.0 0.0 583.2 -1.4 233.3
YOR204W DED1 SPP81 8361_at YOR204W 325.4 1.8 260.3 325.4 1.3 97.6 169.7 -1.8 135.8 169.7 -1.3 50.9
YNL007C SIS1 8888_at YNL007C 635.8 1.2 127.2 635.8 1.1 63.6 519.0 -1.2 103.8 519.0 -1.1 51.9
YMR260C TIF11 9354_at YMR260C 392.1 -1.3 136.9 392.1 -1.2 97.6 539.5 1.3 188.3 539.5 1.1 54.0
YOR276W CAF20 CAF2, CA 8252_at YOR276W 722.3 -1.1 72.2 722.3 -1.2 179.8 0.0 0.0 0.0 0.0 0.0 0.0
YNL244C SUI1 MOF2, RF 9105_at YNL244C 939.7 -1.1 94.0 939.7 -1.2 187.9 0.0 0.0 0.0 0.0 0.0 0.0
YOL139C CDC33 TIF45 8695_at YOL139C 1080.1 -1.1 108.0 1080.1 -1.2 216.0 0.0 0.0 0.0 0.0 0.0 0.0
YOR133W EFT1 8425_s_at YOR133W 1558.5 -1.1 232.1 1558.5 -1.2 388.1 1852.7 1.1 275.9 1852.7 -1.0 0.0
YDL081C 6561_at YDL081C 2074.7 -1.2 499.9 2074.7 -1.2 406.3 2727.7 1.2 657.3 2727.7 1.0 0.0
YLR249W YEF3 TEF3 10097_at YLR249W 2805.7 -1.1 417.8 2805.7 -1.1 417.8 3188.9 1.1 474.9 3188.9 1.0 0.0
initiation
YKL204W EAP1 10762_at YKL204W a 56.4 1.1 7.9 56.4 2.9 104.7 48.1 -1.1 6.7 48.1 2.4 67.3
elongation
YAL003W EFB1 TEF5 11320_at YAL003W T 1673.1 -1.2 331.1 1673.1 -1.1 203.9 2018.1 1.2 399.4 2018.1 1.0 98.5
translational control
YLR203C MSS51 10141_at YLR203C 244.8 1.7 171.3 244.8 1.3 85.4 144.6 -1.7 101.2 144.6 -1.3 43.4
YER133W GLC7 CID1, DIS 5573_at protein ph 242.7 1.2 40.7 242.7 1.3 84.2 217.2 -1.2 36.4 217.2 1.1 30.4
YGR222W PET54 4788_at YGR222W 0.0 0.0 0.0 0.0 0.0 0.0 136.2 -1.4 54.0 136.2 -1.7 95.3
aminoacyl-tRNA-synthetases
YCR024C PMP1 6858_f_at YCR024C a 897.8 -1.3 313.4 897.8 -1.0 0.0 1190.8 1.3 415.7 1190.8 1.3 357.2
YHR020W ?? 4493_at YHR020W 644.3 -1.2 160.4 644.3 -1.1 64.4 807.4 1.2 201.0 807.4 1.1 80.7
YDR037W KRS1 GCD5 6452_at YDR037W 756.0 -1.2 148.0 756.0 -1.0 36.9 901.7 1.2 176.6 901.7 1.1 90.2
YNL073W MSK1 8914_at YNL073W 54.4 1.2 10.9 54.4 2.9 103.3 50.6 -1.2 10.1 50.6 2.4 70.8
YLR060W FRS1 10269_at YLR060W 1379.2 -1.1 205.4 1379.2 -1.2 275.8 1572.9 1.1 234.2 1572.9 -1.1 157.3
YPR033C HTS1 TSM4572 7741_at YPR033C c 720.9 -1.1 72.1 720.9 -1.3 216.3 795.2 1.1 79.5 795.2 -1.2 159.0
YLL018C DPS1 9868_at YLL018C 496.3 1.7 328.2 496.3 1.9 433.5 408.8 -1.7 270.3 408.8 1.1 60.9
YBL076C ILS1 7421_at YBL076C 367.9 -1.1 35.1 367.9 -1.3 109.0 0.0 0.0 0.0 0.0 0.0 0.0
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YIL078W THS1 4186_at YIL078W 799.3 -1.1 79.9 799.3 -1.1 119.0 0.0 0.0 0.0 0.0 0.0 0.0
YBR121C GRS1 7257_at YBR121C G 709.4 -1.2 141.9 709.4 -1.2 141.9 776.5 1.2 155.3 776.5 1.0 0.0
YOR335C ALA1 8225_at YOR335C 579.8 -1.2 144.4 579.8 -1.2 144.4 722.2 1.2 179.8 722.2 -1.0 0.0
YGL245W ?? 5268_at YGL245W 569.8 -1.2 114.0 569.8 -1.3 170.9 669.4 1.2 133.9 669.4 -1.1 66.9
tRNAs
TQ(UUG)D1 3436_f_at TQ(UUG) 204.9 -1.7 153.5 204.9 -1.4 92.0 360.4 1.7 270.0 360.4 1.2 72.1
TQ(UUG)E1 3376_f_at TQ(UUG) 270.3 -1.6 162.2 270.3 -1.5 135.1 431.0 1.6 258.6 431.0 1.1 43.1
TQ(UUG)D2 3439_f_at TQ(UUG) 225.3 -1.6 146.2 225.3 -1.3 78.6 373.1 1.6 242.2 373.1 1.2 74.6
TA(AGC)D 3473_f_at TA(AGC)D 245.5 -1.6 147.3 245.5 -1.3 73.6 373.8 1.6 224.3 373.8 1.2 74.8
TS(UGA)E 3378_f_at TS(UGA)E 99.4 -2.2 119.7 99.4 -1.4 42.6 178.0 2.2 214.4 178.0 1.5 89.0
TA(AGC)J 3885_f_at TA(AGC)J 234.2 -1.6 140.5 234.2 -1.3 70.3 352.3 1.6 211.4 352.3 1.2 70.5
TA(AGC)K2 3830_f_at TA(AGC)K2 289.6 -1.4 130.0 289.6 -1.2 72.1 412.7 1.4 185.4 412.7 1.2 82.5
TG(GCC)D2 3382_f_at TG(GCC) 0.0 0.0 0.0 0.0 0.0 0.0 105.4 2.5 158.5 105.4 1.5 52.7
TA(AGC)M2 3688_f_at TA(AGC) 290.1 -1.4 116.0 290.1 -1.2 58.0 369.4 1.4 147.8 369.4 1.1 36.9
TG(GCC)E 3358_f_at TG(GCC) 0.0 0.0 0.0 0.0 0.0 0.0 93.1 2.5 143.3 93.1 1.1 9.3
TA(AGC)P 3537_f_at TA(AGC)P 273.5 -1.5 150.2 273.5 -1.1 40.7 418.5 1.5 229.8 418.5 1.3 125.6
TA(AGC)L 3743_f_at TA(AGC)L 0.0 0.0 0.0 0.0 0.0 0.0 350.1 1.3 122.2 350.1 1.2 70.0
TA(AGC)M1 3710_f_at TA(AGC) 241.3 -1.6 144.8 241.3 -1.2 60.1 355.7 1.6 213.4 355.7 1.3 106.7
TA(AGC)K1 3819_f_at TA(AGC)K 236.6 -1.5 129.9 236.6 -1.2 47.3 344.3 1.5 189.1 344.3 1.3 103.3
TA(UGC)L 3796_f_at TA(UGC)L 0.0 0.0 0.0 0.0 0.0 0.0 144.9 1.7 101.4 144.9 1.3 43.5
TA(UGC)O 3574_f_at TA(UGC) 0.0 0.0 0.0 0.0 0.0 0.0 150.5 1.6 90.3 150.5 1.4 60.2
TG(UCC)O 3633_f_at TG(UCC) 0.0 0.0 0.0 0.0 0.0 0.0 87.2 1.8 73.6 87.2 1.2 17.4
TR(CCG)L 3760_at TR(CCG)L 0.0 0.0 0.0 0.0 0.0 0.0 69.9 1.9 61.2 69.9 1.9 62.9
TP(AGG)C 3451_f_at tRNA-Pro 4.3 -9.6 36.8 4.3 -4.6 15.6 50.6 9.6 433.5 50.6 2.1 55.7
TG(CCC)D 3397_f_at TG(CCC) 8.1 -1.3 2.7 8.1 -2.4 11.5 5.6 1.3 1.8 5.6 -2.7 9.5
TG(CCC)O 3604_f_at TG(CCC) 10.1 -1.1 1.1 10.1 -2.9 19.6 10.8 1.1 1.2 10.8 -2.3 14.0
TI(AAU)L1 3753_s_at TI(AAU)L1 9.4 -2.3 12.4 9.4 -2.0 9.6 21.6 2.3 28.6 21.6 1.1 2.2
TT(AGU)J 3929_s_at TT(AGU)J 6.6 -1.9 5.8 6.6 -2.6 10.6 0.0 0.0 0.0 0.0 0.0 0.0
TP(AGG)N 3668_f_at tRNA-Pro 7.6 -8.9 59.8 7.6 -5.0 30.5 64.9 8.9 510.3 64.9 1.8 51.9
TG(GCC)O2 3645_f_at tRNA-Gly 9.9 -2.1 11.4 9.9 -4.1 30.6 73.7 2.1 84.7 73.7 -1.1 7.4
TG(GCC)B 3508_f_at tRNA-Gly 17.8 -5.5 80.5 17.8 -2.9 34.4 58.5 5.5 265.4 58.5 1.9 52.7
TG(GCC)O1 3640_f_at TG(GCC) 42.3 -1.9 38.4 42.3 -2.1 46.4 130.0 1.9 118.0 130.0 1.3 39.0
TG(GCC)J2 3842_f_at TG(GCC)J2 30.3 -1.7 20.4 30.3 -2.9 57.8 135.3 1.7 91.1 135.3 1.2 27.1
TG(GCC)J1 3869_f_at tRNA-Gly 27.5 -2.2 34.2 27.5 -3.3 63.7 111.5 2.2 138.8 111.5 1.4 44.6
TS(UGA)P 3562_f_at TS(UGA)P 65.9 -2.8 118.1 65.9 -2.0 66.9 172.3 2.8 308.9 172.3 1.4 68.9
TL(UAA)J SUP51 SUP52 3878_s_at tRNA-Leu 31.2 -3.3 71.3 31.2 -3.3 72.4 90.2 3.3 206.2 90.2 -1.1 9.0
TG(GCC)D1 3472_f_at TG(GCC) 47.7 -1.8 40.0 47.7 -2.5 72.9 119.5 1.8 100.2 119.5 1.4 47.8
TL(GAG)G 3243_at TL(GAG)G 84.4 -2.0 87.3 84.4 -2.0 87.3 171.0 2.0 176.9 171.0 1.0 0.0
TQ(UUG)E2 3364_f_at TQ(UUG) 235.6 -1.7 164.2 235.6 -1.4 93.4 395.0 1.7 275.3 395.0 1.2 79.0
TQ(UUG)L 3804_f_at TQ(UUG)L 217.0 -1.6 140.9 217.0 -1.5 108.5 350.4 1.6 227.5 350.4 1.1 35.0
TG(GCC)P1 3561_f_at tRNA-Gly 32.7 -2.0 33.4 32.7 -4.4 111.9 119.9 2.0 122.3 119.9 1.2 24.0
TD(GUC)J1 3905_s_at TD(GUC)J 235.1 -1.4 105.6 235.1 -1.5 129.1 338.7 1.4 152.1 338.7 -1.1 33.9
TE(CUC)D 3383_f_at TE(CUC)D 176.7 -1.6 114.7 176.7 -1.7 132.4 285.4 1.6 185.3 285.4 -1.1 28.5
TQ(UUG)C 3462_f_at TQ(UUG) 272.7 -1.6 163.6 272.7 -1.5 136.3 432.5 1.6 259.5 432.5 1.1 43.3
TQ(UUG)B 3478_f_at TQ(UUG) 328.3 -1.6 213.1 328.3 -1.4 147.5 531.9 1.6 345.3 531.9 1.1 53.2
TQ(UUG)D3 3405_f_at TQ(UUG) 302.1 -1.5 165.9 302.1 -1.5 151.0 472.8 1.5 259.7 472.8 1.0 0.0
TE(UUC)K 3813_f_at TE(UUC)K 362.8 -1.5 199.2 362.8 -1.4 162.9 559.5 1.5 307.3 559.5 1.0 0.0
TE(UUC)P 3594_f_at TE(UUC)P 418.9 -1.5 208.0 418.9 -1.4 166.0 621.0 1.5 308.4 621.0 1.1 62.1
TR(ACG)O 3598_f_at TR(ACG) 95.7 -2.4 138.6 95.7 -2.7 167.3 261.5 2.4 379.0 261.5 -1.1 26.2
TR(ACG)L 3803_f_at TR(ACG)L 93.8 -2.6 150.1 93.8 -2.9 178.2 266.1 2.6 425.8 266.1 -1.1 26.6
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TR(ACG)D 3438_f_at TR(ACG) 98.0 -2.3 131.8 98.0 -2.8 180.9 257.2 2.3 346.0 257.2 -1.2 51.4
TR(ACG)J 3906_f_at tRNA-Arg 85.0 -2.8 157.1 85.0 -3.1 182.6 240.8 2.8 445.4 240.8 -1.1 24.1
TE(UUC)J 3884_f_at TE(UUC)J 375.0 -1.5 205.9 375.0 -1.5 187.5 578.6 1.5 317.8 578.6 1.0 0.0
TE(UUC)C 3491_f_at TE(UUC)C 383.3 -1.6 230.0 383.3 -1.5 191.7 605.3 1.6 363.2 605.3 1.0 0.0
TE(UUC)L 3758_f_at TE(UUC)L 437.9 -1.4 193.6 437.9 -1.4 193.6 629.7 1.4 278.5 629.7 1.0 0.0
TE(UUC)E1 3371_f_at TE(UUC)E 400.5 -1.4 177.1 400.5 -1.5 198.9 577.7 1.4 255.5 577.7 -1.0 0.0
TE(UUC)B 3482_f_at TE(UUC)B 414.4 -1.6 248.6 414.4 -1.5 207.2 659.3 1.6 395.6 659.3 1.1 65.9
TR(ACG)K 3827_f_at TR(ACG)K 124.2 -2.3 160.3 124.2 -2.7 209.0 285.9 2.3 369.2 285.9 -1.2 57.2
TE(UUC)M 3709_f_at TE(UUC) 384.2 -1.5 211.0 384.2 -1.5 211.0 598.0 1.5 328.4 598.0 1.0 0.0
other protein-synthesis activities
YDL219W DTD1 6689_at YDL219W 284.5 -1.1 21.1 284.5 2.4 395.4 309.6 1.1 22.9 309.6 2.5 478.4
YLL039C UBI4 SCD2 10392_at YLL039C 432.6 1.3 151.0 432.6 -1.1 64.4 321.2 -1.3 112.1 321.2 -1.5 160.6
YNL209W SSB2 9094_s_at YNL209W 2100.0 -1.1 312.7 2100.0 -1.1 312.7 2488.7 1.1 370.6 2488.7 1.0 0.0
PROTEIN FATE (folding, modification, destination)
protein folding and stabilization
YJL034W KAR2 BIP, GRP 11078_at Homologu 1978.5 1.1 188.8 1978.5 1.2 492.6 1802.2 -1.1 172.0 1802.2 1.2 360.4
YDR188W CCT6 HTR3, TC 6290_at YDR188W 379.4 1.3 132.4 379.4 1.2 75.9 0.0 0.0 0.0 0.0 0.0 0.0
YLR090W XDJ1 10254_at YLR090W 106.3 1.5 53.2 106.3 2.2 132.3 0.0 0.0 0.0 0.0 0.0 0.0
YFL016C MDJ1 5370_at YFL016C 158.6 1.6 95.2 158.6 1.7 111.0 108.1 -1.6 64.9 108.1 1.1 10.8
YKL073W LHS1 CER1, SS 10668_at YKL073W 144.8 1.6 94.0 144.8 1.2 36.0 77.9 -1.6 50.6 77.9 -1.3 23.4
YMR154C RIM13 CPL1 9465_at YMR154C 8.5 2.1 9.5 8.5 -1.0 0.0 2.7 -2.1 3.0 2.7 -1.9 2.4
YNL328C MDJ2 9202_at YNL328C 0.0 0.0 0.0 0.0 0.0 0.0 4.5 -1.7 3.3 4.5 -2.5 6.8
YMR161W HLJ1 9473_at YMR161W 124.7 2.0 126.6 124.7 1.2 22.8 96.8 -2.0 98.2 96.8 -2.1 106.5
YDR214W AHA1 6271_at YDR214W 0.0 0.0 0.0 0.0 0.0 0.0 295.8 -1.1 28.2 295.8 -1.4 118.3
YDR304C CPR5 CYP5 6178_at YDR304C 962.7 -1.1 96.3 962.7 -1.1 143.4 0.0 0.0 0.0 0.0 0.0 0.0
YDR155C CPR1 CYP1, CP 6301_at YDR155C c 1671.5 -1.2 327.3 1671.5 -1.1 159.5 0.0 0.0 0.0 0.0 0.0 0.0
YDR212W TCP1 CCT1 6269_at YDR212W 560.2 -1.2 112.0 560.2 -1.4 224.1 677.8 1.2 135.6 677.8 -1.1 67.8
YLR259C HSP60 CPN60, M 10061_at YLR259C 1822.6 -1.1 182.3 1822.6 -1.1 271.4 0.0 0.0 0.0 0.0 0.0 0.0
YLL024C SSA2 10362_at YLL024C 1750.5 -1.3 525.2 1750.5 -1.4 700.2 2199.2 1.3 659.8 2199.2 -1.1 219.9
YAL005C SSA1 YG100 11315_i_a YAL005C 2682.4 -1.0 127.0 2682.4 -1.1 391.6 2804.4 1.0 132.8 2804.4 -1.3 866.8
protein targeting, sorting and translocation
YJL034W KAR2 BIP, GRP 11078_at Homologu 1978.5 1.1 188.8 1978.5 1.2 492.6 1802.2 -1.1 172.0 1802.2 1.2 360.4
YNL070W TOM7 MOM7, Y 8917_at YNL070W 828.9 -1.1 123.4 828.9 1.1 123.4 927.8 1.1 138.2 927.8 1.3 278.3
YOR045W TOM6 ISP6, MO 8518_at YOR045W 1407.9 -1.1 209.6 1407.9 -1.1 140.8 1605.3 1.1 239.0 1605.3 1.1 160.5
YDR086C SSS1 6410_at YDR086C 557.7 -1.3 165.2 557.7 -1.1 83.0 727.0 1.3 215.3 727.0 1.2 145.4
YGR028W MSP1 YTA4 4956_at YGR028W 231.7 1.5 127.2 231.7 1.2 46.3 147.3 -1.5 80.9 147.3 -1.3 44.2
YLR168C MSF1 10148_at YLR168C 269.3 1.4 107.7 269.3 1.4 107.7 0.0 0.0 0.0 0.0 0.0 0.0
YDR432W NPL3 MTR13, M 6039_g_at YDR432W 442.1 1.2 106.8 442.1 1.1 53.2 326.8 -1.2 78.9 326.8 -1.2 54.8
YJL054W TIM54 11058_at YJL054W 105.3 1.4 41.7 105.3 2.0 105.0 0.0 0.0 0.0 0.0 0.0 0.0
YKL073W LHS1 CER1, SS 10668_at YKL073W 144.8 1.6 94.0 144.8 1.2 36.0 77.9 -1.6 50.6 77.9 -1.3 23.4
YLL040C VPS13 SOI1, VPT 10391_at YLL040C 0.0 0.0 0.0 0.0 0.0 0.0 61.3 -1.3 18.4 61.3 -2.0 61.3
YOR327C SNC2 8217_at YOR327C 431.6 -1.1 64.3 431.6 -1.2 107.5 0.0 0.0 0.0 0.0 0.0 0.0
YGR181W TIM13 4836_at YGR181W 412.8 1.0 20.1 412.8 -1.2 102.8 359.6 -1.0 17.6 359.6 -1.3 107.9
YDL212W SHR3 APF1 6696_at YDL212W 1059.4 -1.2 211.9 1059.4 -1.1 157.8 1263.7 1.2 252.7 1263.7 1.0 0.0
YCR075C ERS1 6816_at YCR075C 185.0 -1.2 33.9 185.0 -1.9 162.0 0.0 0.0 0.0 0.0 0.0 0.0
YBR283C SSH1 7101_at YBR283C p 700.9 -1.3 244.7 700.9 -1.2 174.5 938.8 1.3 327.7 938.8 1.1 93.9
YNL064C YDJ1 MAS5 8924_at YNL064C 979.7 1.0 47.8 979.7 -1.1 145.9 959.6 -1.0 46.8 959.6 -1.2 191.9
YMR292W GOT1 9342_at YMR292W 760.7 -1.4 341.6 760.7 -1.3 228.2 1098.6 1.4 493.4 1098.6 1.1 109.9
YOR270C VPH1 8291_at YOR270C 1344.7 -1.3 403.4 1344.7 -1.3 469.4 1771.5 1.3 531.5 1771.5 -1.0 0.0
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YPL037C EGD1 7806_at YPL037C 1962.5 -1.2 392.5 1962.5 -1.3 588.8 2272.2 1.2 454.4 2272.2 -1.1 227.2
YLL024C SSA2 10362_at YLL024C 1750.5 -1.3 525.2 1750.5 -1.4 700.2 2199.2 1.3 659.8 2199.2 -1.1 219.9
YAL005C SSA1 YG100 11315_i_a YAL005C 2682.4 -1.0 127.0 2682.4 -1.1 391.6 2804.4 1.0 132.8 2804.4 -1.3 866.8
protein modification
YBR082C UBC4 7260_at YBR082C u 946.7 1.1 94.7 946.7 1.5 473.3 840.4 -1.1 84.0 840.4 1.3 252.1
YNL238W KEX2 QDS1, VMA9110_at Ca2+-dep 189.7 1.2 37.1 189.7 3.0 385.1 156.4 -1.2 30.6 156.4 2.5 234.6
YAL023C PMT2 FUN25 11344_at YAL023C 1047.0 1.1 104.7 1047.0 1.3 365.5 859.8 -1.1 86.0 859.8 1.2 172.0
YML130C ERO1 9802_at YML130C r 365.0 2.0 383.0 365.0 1.8 292.0 129.8 -2.0 136.2 129.8 -1.1 13.0
YLR120C YPS1 10193_at YLR120C 331.0 1.8 281.1 331.0 1.8 281.1 178.2 -1.8 151.3 178.2 -1.0 0.0
YIR039C YPS6 4075_at YIR039C 112.8 1.9 107.0 112.8 2.6 186.0 58.1 -1.9 55.2 58.1 1.4 23.2
YDL095W PMT1 6591_at YDL095W 415.6 1.4 166.2 415.6 1.4 166.2 299.5 -1.4 119.8 299.5 1.0 0.0
YOR067C ALG8 8495_at YOR067C 598.7 -1.2 149.1 598.7 -1.0 0.0 730.4 1.2 181.9 730.4 1.2 146.1
YPL154C PEP4 PHO9, PR 7916_at YPL154C 1033.3 -1.2 206.7 1033.3 -1.1 103.3 1221.5 1.2 244.3 1221.5 1.1 122.2
YNL172W APC1 9041_at YNL172W 102.1 1.3 34.9 102.1 2.2 121.6 76.1 -1.3 26.0 76.1 1.6 45.7
YLR163C MAS1 MIF1 10188_at YLR163C 166.2 1.7 115.8 166.2 1.2 41.4 85.4 -1.7 59.5 85.4 -1.3 25.6
YMR246W FAA4 9386_at YMR246W 383.4 1.3 115.0 383.4 1.3 115.0 0.0 0.0 0.0 0.0 0.0 0.0
YBR034C HMT1 7348_at YBR034C n 340.4 1.3 100.8 340.4 1.2 84.8 0.0 0.0 0.0 0.0 0.0 0.0
YKL201C MNN4 10445_s_ YKL201C 0.0 0.0 0.0 0.0 0.0 0.0 251.0 1.2 50.2 251.0 1.4 100.4
YGL259W YPS5 5253_g_at YGL259W 39.2 1.3 13.4 39.2 2.1 41.3 18.8 -1.3 6.4 18.8 1.6 11.0
YOL141W PPM2 8693_at YOL141W 9.5 1.3 3.1 9.5 2.3 12.8 0.0 0.0 0.0 0.0 0.0 0.0
YMR154C RIM13 CPL1 9465_at YMR154C 8.5 2.1 9.5 8.5 -1.0 0.0 2.7 -2.1 3.0 2.7 -1.9 2.4
YPL053C KTR6 MNN6 7790_at YPL053C 0.0 0.0 0.0 0.0 0.0 0.0 406.6 1.2 101.2 406.6 1.1 40.7
YEL042W GDA1 5748_at YEL042W 223.0 -1.1 33.2 223.0 -1.5 111.5 0.0 0.0 0.0 0.0 0.0 0.0
YJL002C OST1 NLT1 11019_at YJL002C 1148.9 -1.1 171.1 1148.9 -1.1 114.9 1315.8 1.1 195.9 1315.8 1.0 0.0
YDR410C STE14 6061_at YDR410C f 325.8 -1.4 130.3 325.8 -1.2 81.1 459.0 1.4 183.6 459.0 1.1 45.9
YEL002C WBP1 5744_at YEL002C 953.0 -1.0 46.5 953.0 -1.1 141.9 0.0 0.0 0.0 0.0 0.0 0.0
YMR149W SWP1 9504_at YMR149W 783.3 -1.1 116.6 783.3 -1.2 153.4 883.5 1.1 131.6 883.5 -1.1 88.4
YJR143C PMT4 10891_at YJR143C 771.0 -1.1 77.1 771.0 -1.2 154.2 0.0 0.0 0.0 0.0 0.0 0.0
YDR328C SKP1 MGO1 6160_at YDR328C 487.2 1.2 121.3 487.2 -1.1 48.7 386.5 -1.2 96.2 386.5 -1.4 154.6
YDL212W SHR3 APF1 6696_at YDL212W 1059.4 -1.2 211.9 1059.4 -1.1 157.8 1263.7 1.2 252.7 1263.7 1.0 0.0
YLR043C TRX1 LMA1 10295_at YLR043C 1339.6 -1.2 267.9 1339.6 -1.1 199.5 1597.3 1.2 319.5 1597.3 1.0 0.0
YFL045C SEC53 ALG4 5435_at YFL045C 1356.7 -1.1 202.0 1356.7 -1.1 202.0 1549.8 1.1 230.8 1549.8 -1.0 0.0
YDR139C RUB1 6329_at YDR139C 465.7 -1.0 22.7 465.7 -1.4 209.1 503.7 1.0 24.6 503.7 -1.3 151.1
assembly of protein complexes
YLR075W ?? 10239_at YLR075W 2845.6 -1.2 708.6 2845.6 -1.0 138.9 3518.0 1.2 876.0 3518.0 1.2 703.6
YLR048W ?? 10301_at YLR048W 2484.7 -1.2 533.5 2484.7 -1.1 159.3 3017.4 1.2 647.8 3017.4 1.1 399.4
YPR191W QCR2 COR2, UCR7543_at YPR191W 497.9 1.9 448.1 497.9 1.5 273.4 238.5 -1.9 214.7 238.5 -1.2 47.7
YMR256C COX7 9350_at YMR256C 1167.2 1.1 116.7 1167.2 1.2 233.4 0.0 0.0 0.0 0.0 0.0 0.0
YLR038C COX12 10290_at YLR038C 1869.2 1.1 278.3 1869.2 1.1 186.9 1626.8 -1.1 242.3 1626.8 -1.0 0.0
YLL009C COX17 10334_at YLL009C i 551.2 1.2 110.2 551.2 1.1 82.1 0.0 0.0 0.0 0.0 0.0 0.0
YLR393W ATP10 9928_at YLR393W 8.6 1.9 8.1 8.6 2.5 12.8 0.0 0.0 0.0 0.0 0.0 0.0
YER141W COX15 5581_at YER141W 491.1 -1.0 0.0 491.1 -1.2 122.3 484.7 -1.0 0.0 484.7 -1.3 145.4
YLR447C VMA6 9851_at YLR447C 508.6 -1.0 24.8 508.6 -1.3 150.6 518.0 1.0 25.3 518.0 -1.3 155.4
YDR322C TIM11 6154_at YDR322C s 975.4 1.2 195.1 975.4 1.1 97.5 799.4 -1.2 159.9 799.4 -1.2 159.9
YLL039C UBI4 SCD2 10392_at YLL039C 432.6 1.3 151.0 432.6 -1.1 64.4 321.2 -1.3 112.1 321.2 -1.5 160.6
YKL080W VMA5 CSL5, VA 10660_at YKL080W V 713.6 -1.3 249.1 713.6 -1.2 177.7 957.0 1.3 334.1 957.0 1.1 95.7
YGR214W 4780_at YGR214W 1457.7 -1.2 285.4 1457.7 -1.1 217.1 1570.5 1.2 307.5 1570.5 1.1 157.1
YDL067C COX9 6531_at YDL067C 687.3 -1.0 33.5 687.3 -1.3 239.9 707.7 1.0 34.5 707.7 -1.3 212.3
YPL231W FAS2 7973_at YPL231W a 396.9 1.0 19.4 396.9 -1.7 297.4 377.5 -1.0 18.4 377.5 -1.8 302.0
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YOR332W VMA4 8222_at YOR332W 978.3 -1.3 341.5 978.3 -1.3 341.5 1290.1 1.3 450.3 1290.1 -1.0 0.0
YPL234C TFP3 CLS9, VM 7970_at YPL234C 1186.4 -1.3 355.9 1186.4 -1.3 355.9 1511.7 1.3 453.5 1511.7 -1.1 151.2
YDL137W ARF2 6638_at YDL137W 1842.3 -1.1 175.8 1842.3 -1.2 360.8 0.0 0.0 0.0 0.0 0.0 0.0
YDL192W ARF1 6671_at YDL192W 3045.6 -1.2 609.1 3045.6 -1.1 453.5 3689.1 1.2 737.8 3689.1 1.0 0.0
YOR270C VPH1 8291_at YOR270C 1344.7 -1.3 403.4 1344.7 -1.3 469.4 1771.5 1.3 531.5 1771.5 -1.0 0.0
proteolytic degradation
YLR423C APG17 9914_at YLR423C 65.2 2.9 127.0 65.2 2.9 123.8 21.9 -2.9 42.7 21.9 1.0 0.0
YKL158W APE2 YKL157W 10715_at Leucyl ami 14.5 6.7 82.6 14.5 5.9 70.7 1.8 -6.7 10.3 1.8 1.4 0.7
YNR069C ?? 8781_at Similarity t 13.7 5.1 56.5 13.7 5.3 58.9 0.0 -5.1 0.0 0.0 1.7 0.0
YMR119W ASI1 9517_g_at YMR119W 361.6 -1.2 90.0 361.6 -1.3 126.2 414.2 1.2 103.1 414.2 -1.1 41.4
YNL015W PBI2 YSCB, I2B,8880_at YNL015W 683.7 1.3 205.1 683.7 1.0 33.4 507.9 -1.3 152.4 507.9 -1.3 152.4
cytoplasmic and nuclear degradation
YBR082C UBC4 7260_at YBR082C u 946.7 1.1 94.7 946.7 1.5 473.3 840.4 -1.1 84.0 840.4 1.3 252.1
YIL148W 4253_i_at YIL148W 822.0 -1.2 198.1 822.0 -1.0 0.0 1017.9 1.2 245.3 1017.9 1.2 203.6
YIL075C RPN2 SEN3 4189_at YIL075C 0.0 0.0 0.0 0.0 0.0 0.0 385.5 1.2 77.1 385.5 1.4 154.2
YNL172W APC1 9041_at YNL172W 102.1 1.3 34.9 102.1 2.2 121.6 76.1 -1.3 26.0 76.1 1.6 45.7
YER098W UBP9 5629_at YER098W 13.9 1.9 12.4 13.9 2.4 20.0 0.0 0.0 0.0 0.0 0.0 0.0
YER094C PUP3 SCS32 5625_at YER094C 2 928.9 -1.1 92.9 928.9 -1.1 138.3 0.0 0.0 0.0 0.0 0.0 0.0
YGL048C RPT6 CIM3, CR 5059_at YGL048C 697.5 -1.0 0.0 697.5 -1.1 103.9 734.5 -1.0 0.0 734.5 -1.2 146.9
YDR328C SKP1 MGO1 6160_at YDR328C 487.2 1.2 121.3 487.2 -1.1 48.7 386.5 -1.2 96.2 386.5 -1.4 154.6
YLL039C UBI4 SCD2 10392_at YLL039C 432.6 1.3 151.0 432.6 -1.1 64.4 321.2 -1.3 112.1 321.2 -1.5 160.6
YDL126C CDC48 6604_at YDL126C 655.9 -1.1 65.6 655.9 -1.3 229.0 652.5 1.1 65.3 652.5 -1.3 195.8
YKR094C 10474_s_ YKR094C R 1812.2 -1.2 358.7 1812.2 -1.1 266.2 2208.2 1.2 437.0 2208.2 1.1 210.8
lysosomal and vacuolar degradation
YBR105C VID24 7241_at YBR105C i 89.7 2.0 89.7 89.7 2.8 165.9 43.4 -2.0 43.4 43.4 1.4 17.4
YPL154C PEP4 PHO9, PR 7916_at YPL154C 1033.3 -1.2 206.7 1033.3 -1.1 103.3 1221.5 1.2 244.3 1221.5 1.1 122.2
YKL054C VID31 10642_at YKL054C 199.3 1.2 39.9 199.3 1.6 119.6 0.0 0.0 0.0 0.0 0.0 0.0
YBL078C AUT7 APG8, CV 7464_at YBL078C 230.6 1.4 102.0 230.6 1.5 114.5 167.6 -1.4 74.1 167.6 1.0 0.0
YNR007C AUT1 APG3 8855_at AUT1 is e 44.1 1.5 22.1 44.1 2.5 68.3 28.9 -1.5 14.5 28.9 1.6 17.3
YGL180W APG1 AUT3 5200_at YGL180W 21.5 1.7 16.1 21.5 2.1 24.7 0.0 0.0 0.0 0.0 0.0 0.0
YJR044C VPS55 10973_at YJR044C 773.9 -1.0 0.0 773.9 -1.1 115.2 0.0 0.0 0.0 0.0 0.0 0.0
YBR286W APE3 APY1 7059_at YBR286W 1238.0 -1.2 242.4 1238.0 -1.2 242.4 1456.7 1.2 285.3 1456.7 -1.0 0.0
YMR297W PRC1 LBC1 9348_at YMR297W 999.2 -1.1 148.8 999.2 -1.2 248.8 1135.5 1.1 169.1 1135.5 -1.1 113.6
other proteolytic degradation
YBR201W DER1 3940_at YBR201W 96.1 1.7 71.7 96.1 2.0 92.2 58.1 -1.7 43.4 58.1 1.1 6.9
other protein fate related activities
YDR258C HSP78 6223_at YDR258C 201.3 1.2 50.1 201.3 1.9 180.6 0.0 0.0 0.0 0.0 0.0 0.0
YDL185W TFP1 CLS8, VM 6679_at YDL185W 690.5 -1.3 207.2 690.5 -1.3 241.0 892.6 1.3 267.8 892.6 -1.0 0.0
CELLULAR TRANSPORT AND TRANSPORT MECHANISM
nuclear transport
YOR098C NUP1 8435_at YOR098C 0.0 0.0 0.0 0.0 0.0 0.0 87.8 1.5 48.2 87.8 2.5 131.7
YDR432W NPL3 MTR13, M 6039_g_at YDR432W 442.1 1.2 106.8 442.1 1.1 53.2 326.8 -1.2 78.9 326.8 -1.2 54.8
YMR308C PSE1 KAP121 9316_at YMR308C 734.5 -1.1 109.4 734.5 -1.2 143.8 822.2 1.1 122.4 822.2 -1.1 82.2
YER009W NTF2 5709_at YER009W 834.6 -1.2 163.4 834.6 -1.2 163.4 957.1 1.2 187.4 957.1 1.0 0.0
YDR002W YRB1 CST20, H 6463_at YDR002W 912.6 -1.2 182.5 912.6 -1.2 227.2 0.0 0.0 0.0 0.0 0.0 0.0
YAL005C SSA1 YG100 11315_i_a YAL005C 2682.4 -1.0 127.0 2682.4 -1.1 391.6 2804.4 1.0 132.8 2804.4 -1.3 866.8
mitochondrial transport
YNL055C POR1 OMP2 8932_at YNL055C 1947.9 1.1 194.8 1947.9 1.2 485.0 0.0 0.0 0.0 0.0 0.0 0.0
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YDL198C YHM1 6665_at YDL198C 982.5 -1.0 0.0 982.5 1.4 441.3 964.8 -1.0 0.0 964.8 1.4 385.9
YKL120W OAC1 10709_at YKL120W o 519.5 1.3 181.3 519.5 1.5 285.3 376.9 -1.3 131.6 376.9 1.1 37.7
YNL070W TOM7 MOM7, Y 8917_at YNL070W 828.9 -1.1 123.4 828.9 1.1 123.4 927.8 1.1 138.2 927.8 1.3 278.3
YKL016C ATP7 10591_at YKL016C 689.5 1.2 171.7 689.5 1.3 240.7 546.0 -1.2 136.0 546.0 1.1 54.6
YPR058W YMC1 7678_at YPR058W 624.9 1.1 62.5 624.9 1.3 187.5 569.7 -1.1 57.0 569.7 1.2 113.9
YOR045W TOM6 ISP6, MO 8518_at YOR045W 1407.9 -1.1 209.6 1407.9 -1.1 140.8 1605.3 1.1 239.0 1605.3 1.1 160.5
YOR316C COT1 8206_at YOR316C 280.8 1.4 111.3 280.8 1.5 152.4 0.0 0.0 0.0 0.0 0.0 0.0
YER053C ?? 5665_at YER053C i 227.7 1.6 136.6 227.7 1.3 79.5 141.7 -1.6 85.0 141.7 -1.2 28.3
YGR028W MSP1 YTA4 4956_at YGR028W 231.7 1.5 127.2 231.7 1.2 46.3 147.3 -1.5 80.9 147.3 -1.3 44.2
YBL099W ATP1 7487_at YBL099W 1009.5 -1.1 150.3 1009.5 -1.0 0.0 1258.4 1.1 187.4 1258.4 1.1 125.8
YLR348C DIC1 9972_at YLR348C 231.9 1.5 115.9 231.9 1.3 69.6 0.0 0.0 0.0 0.0 0.0 0.0
YJL054W TIM54 11058_at YJL054W 105.3 1.4 41.7 105.3 2.0 105.0 0.0 0.0 0.0 0.0 0.0 0.0
YPL134C ODC1 7891_at YPL134C 139.0 1.7 104.2 139.0 1.4 62.4 80.6 -1.7 60.4 80.6 -1.2 16.1
YOR100C CRC1 8437_at Mitochond 30.0 1.4 11.9 30.0 3.2 67.3 21.3 -1.4 8.4 21.3 2.3 27.7
YBR085W AAC3 ANC3 7263_at YBR085W 47.0 -2.0 48.6 47.0 -1.9 43.8 99.8 2.0 103.3 99.8 1.1 10.0
YIL114C POR2 4197_at YIL114C v 123.8 -1.8 105.1 123.8 -1.8 105.1 0.0 0.0 0.0 0.0 0.0 0.0
YBR039W ATP3 7307_at YBR039W 630.5 1.2 126.1 630.5 -1.0 0.0 526.3 -1.2 105.3 526.3 -1.2 105.3
YJR077C MIR1 10961_at YJR077C i 1731.2 1.1 257.8 1731.2 1.0 84.5 1524.8 -1.1 227.1 1524.8 -1.1 152.5
YLR295C ATP14 10010_at YLR295C 630.6 1.6 376.4 630.6 1.1 93.9 394.9 -1.6 235.7 394.9 -1.4 158.0
YDR322C TIM11 6154_at YDR322C s 975.4 1.2 195.1 975.4 1.1 97.5 799.4 -1.2 159.9 799.4 -1.2 159.9
YDL004W ATP16 6503_at YDL004W 720.0 1.2 179.3 720.0 1.0 35.1 558.7 -1.2 139.1 558.7 -1.3 167.6
YPL271W ATP15 ATPEPSIL 8024_at YPL271W 1021.8 1.1 152.2 1021.8 -1.0 49.9 899.9 -1.1 134.0 899.9 -1.2 180.0
YNL064C YDJ1 MAS5 8924_at YNL064C 979.7 1.0 47.8 979.7 -1.1 145.9 959.6 -1.0 46.8 959.6 -1.2 191.9
Q0310 3976_at F1F0-ATP 804.9 1.2 200.4 804.9 -1.0 39.3 644.5 -1.2 160.5 644.5 -1.3 193.4
YOR222W ODC2 8334_at YOR222W 506.1 -1.3 149.9 506.1 -1.5 274.6 689.7 1.3 204.3 689.7 -1.2 137.9
YLL024C SSA2 10362_at YLL024C 1750.5 -1.3 525.2 1750.5 -1.4 700.2 2199.2 1.3 659.8 2199.2 -1.1 219.9
vesicular transport (Golgi network, etc.)
YNL272C SEC2 9122_at Protein wit 57.0 1.0 2.8 57.0 3.8 159.2 56.4 -1.0 2.8 56.4 3.8 157.9
YNL006W LST8 8889_at YNL006W 316.8 1.5 158.4 316.8 1.2 63.4 242.1 -1.5 121.1 242.1 -1.2 48.4
YKR068C BET3 10493_at YKR068C H 0.0 0.0 0.0 0.0 0.0 0.0 657.0 -1.0 0.0 657.0 1.2 131.4
YDL195W SEC31 WEB1 6668_at YDL195W 233.6 1.4 104.9 233.6 -1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
YPL145C KES1 LPI3, OSH47880_at YPL145C 405.0 1.2 100.8 405.0 -1.0 19.8 0.0 0.0 0.0 0.0 0.0 0.0
YNL304W YPT11 9180_at YNL304W 28.2 1.1 2.7 28.2 2.8 51.8 27.4 -1.1 2.6 27.4 2.5 41.1
YNL044W YIP3 3949_i_at YNL044W 299.9 -1.2 66.6 299.9 -1.0 0.5 427.8 1.2 95.0 427.8 1.2 78.4
YLR262C YPT6 10066_s_ YLR262C 408.9 -1.1 40.9 408.9 -1.2 101.8 0.0 0.0 0.0 0.0 0.0 0.0
YOR327C SNC2 8217_at YOR327C 431.6 -1.1 64.3 431.6 -1.2 107.5 0.0 0.0 0.0 0.0 0.0 0.0
YER031C YPT31 YPT8 5686_at YER031C r 252.5 -1.0 12.3 252.5 -1.4 113.4 0.0 0.0 0.0 0.0 0.0 0.0
YML001W YPT7 AST4, VA 9622_at YML001W 822.3 -1.0 40.1 822.3 -1.1 122.4 0.0 0.0 0.0 0.0 0.0 0.0
YFL005W SEC4 SRO6 5383_at Ras-like s 416.8 -1.0 0.0 416.8 -1.3 123.4 416.5 -1.0 0.0 416.5 -1.3 125.0
YPL218W SAR1 7986_at YPL218W 590.6 -1.2 118.1 590.6 -1.1 59.1 712.8 1.2 142.6 712.8 1.1 71.3
YPR028W YOP1 YIP2 7735_at YPR028W 874.0 -1.2 196.0 874.0 -1.2 171.1 1064.0 1.2 238.6 1064.0 1.0 0.0
YNL064C YDJ1 MAS5 8924_at YNL064C 979.7 1.0 47.8 979.7 -1.1 145.9 959.6 -1.0 46.8 959.6 -1.2 191.9
YML012W ERV25 9653_at YML012W 1340.8 -1.1 134.1 1340.8 -1.1 199.7 0.0 0.0 0.0 0.0 0.0 0.0
YGL225W VRG4 VAN2, GO 5245_at YGL225W 800.7 -1.3 279.5 800.7 -1.3 237.1 1065.2 1.3 371.8 1065.2 1.0 0.0
YDL137W ARF2 6638_at YDL137W 1842.3 -1.1 175.8 1842.3 -1.2 360.8 0.0 0.0 0.0 0.0 0.0 0.0
YGL200C EMP24 BST2 5225_at YGL200C 1255.6 -1.1 125.6 1255.6 -1.3 376.7 0.0 0.0 0.0 0.0 0.0 0.0
YDL192W ARF1 6671_at YDL192W 3045.6 -1.2 609.1 3045.6 -1.1 453.5 3689.1 1.2 737.8 3689.1 1.0 0.0
YLL024C SSA2 10362_at YLL024C 1750.5 -1.3 525.2 1750.5 -1.4 700.2 2199.2 1.3 659.8 2199.2 -1.1 219.9
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YBR082C UBC4 7260_at YBR082C u 946.7 1.1 94.7 946.7 1.5 473.3 840.4 -1.1 84.0 840.4 1.3 252.1
YBR105C VID24 7241_at YBR105C i 89.7 2.0 89.7 89.7 2.8 165.9 43.4 -2.0 43.4 43.4 1.4 17.4
YNR007C AUT1 APG3 8855_at  AUT1 is e 44.1 1.5 22.1 44.1 2.5 68.3 28.9 -1.5 14.5 28.9 1.6 17.3
YGL180W APG1 AUT3 5200_at YGL180W 21.5 1.7 16.1 21.5 2.1 24.7 0.0 0.0 0.0 0.0 0.0 0.0
YER031C YPT31 YPT8 5686_at YER031C r 252.5 -1.0 12.3 252.5 -1.4 113.4 0.0 0.0 0.0 0.0 0.0 0.0
YGR020C VMA7 4993_at YGR020C 462.1 -1.4 184.8 462.1 -1.3 138.6 648.7 1.4 259.5 648.7 1.1 64.9
YLR447C VMA6 9851_at YLR447C 508.6 -1.0 24.8 508.6 -1.3 150.6 518.0 1.0 25.3 518.0 -1.3 155.4
YKL080W VMA5 CSL5, VA 10660_at YKL080W V 713.6 -1.3 249.1 713.6 -1.2 177.7 957.0 1.3 334.1 957.0 1.1 95.7
YPR036W VMA13 CLS11 7699_at YPR036W 437.6 1.1 43.8 437.6 -1.3 152.7 403.1 -1.1 40.3 403.1 -1.5 201.6
YDL185W TFP1 CLS8, VM 6679_at YDL185W 690.5 -1.3 207.2 690.5 -1.3 241.0 892.6 1.3 267.8 892.6 -1.0 0.0
YBR127C VMA2 ATPVS, V 7218_at YBR127C H 734.2 -1.5 367.1 734.2 -1.4 329.7 1021.3 1.5 510.7 1021.3 1.0 0.0
YEL027W CUP5 5763_at YEL027W V 2242.6 -1.3 664.1 2242.6 -1.1 334.0 2929.6 1.3 867.6 2929.6 1.1 293.0
YOR332W VMA4 8222_at YOR332W 978.3 -1.3 341.5 978.3 -1.3 341.5 1290.1 1.3 450.3 1290.1 -1.0 0.0
YHR039C MSC7 VMA10 4514_at YHR039C 783.6 -1.3 235.1 783.6 -1.4 351.9 1017.3 1.3 305.2 1017.3 -1.1 101.7
YPL234C TFP3 CLS9, VM 7970_at YPL234C 1186.4 -1.3 355.9 1186.4 -1.3 355.9 1511.7 1.3 453.5 1511.7 -1.1 151.2
YOR270C VPH1 8291_at YOR270C 1344.7 -1.3 403.4 1344.7 -1.3 469.4 1771.5 1.3 531.5 1771.5 -1.0 0.0
extracellular transport, exocytosis and secretion
YDR524C AGE1 SAT1 5926_g_at YDR524C A 3729.0 -1.3 1015.6 3729.0 -1.1 539.0 4720.7 1.3 1285.7 4720.7 1.1 703.0
YNL272C SEC2 9122_at Protein wit 57.0 1.0 2.8 57.0 3.8 159.2 56.4 -1.0 2.8 56.4 3.8 157.9
YNL036W NCE103 8905_at YNL036W 705.6 1.2 141.1 705.6 1.1 70.6 596.1 -1.2 119.2 596.1 -1.1 59.6
cellular import
YDR046C BAP3 6415_at Valine trans 670.0 2.6 1072.0 670.0 178.1 118656.5 297.2 -2.6 475.5 297.2 81.3 23865.2
YBR068C BAP2 7291_at Major AA 646.7 2.3 839.2 646.7 133.8 85884.2 280.3 -2.3 363.8 280.3 58.7 16173.3
YGR055W MUP1 4936_at High affinity 968.3 2.0 968.3 968.3 9.0 7745.5 486.4 -2.0 486.4 486.4 4.5 1702.4
YBR069C TAT1 VAP1, WA 7292_at Amino aci 164.5 3.1 345.1 164.5 11.2 1685.2 53.1 -3.1 111.4 53.1 4.1 164.6
YMR058W FET3 9588_at YMR058W 900.7 2.1 988.6 900.7 2.4 1259.1 422.2 -2.1 463.4 422.2 1.1 42.2
YBR021W FUR4 7334_at Uracil per 208.8 4.1 656.1 208.8 6.4 1124.9 41.4 -4.1 130.1 41.4 1.5 20.7
YNL268W LYP1 9126_at YNL268W 580.1 -1.0 0.0 580.1 2.3 782.8 570.8 -1.0 0.0 570.8 2.3 742.0
YDR524C AGE1 SAT1 5926_g_at YDR524C A 3729.0 -1.3 1015.6 3729.0 -1.1 539.0 4720.7 1.3 1285.7 4720.7 1.1 703.0
YER056C FCY2 BRA7 5668_at YER056C p 1819.5 -1.1 238.3 1819.5 1.0 19.9 2117.5 1.1 277.4 2117.5 1.1 311.1
YBR294W SUL1 7067_at Putative s 97.3 1.3 33.9 97.3 4.0 291.6 70.8 -1.3 24.7 70.8 2.9 134.5
YOL020W TAT2 LTG3, SA 8587_at YOL020W 216.0 1.7 151.2 216.0 2.3 291.5 127.2 -1.7 89.0 127.2 1.4 50.9
YDR497C ITR1 5966_at Myo-inosit 1187.5 -1.2 237.5 1187.5 -1.0 0.0 1358.0 1.2 271.6 1358.0 1.2 271.6
YMR011W HXT2 9633_at YMR011W 809.5 -1.3 242.8 809.5 -1.0 0.0 1029.2 1.3 308.8 1029.2 1.2 205.8
YGL077C HNM1 5074_at YGL077C 544.7 -1.5 272.3 544.7 -1.2 108.9 924.4 1.5 462.2 924.4 1.2 184.9
YHR094C HXT1 HOR4 4430_at YHR094C 540.4 -1.0 0.0 540.4 1.3 162.1 525.9 -1.0 0.0 525.9 1.3 157.8
YDR345C HXT3 6131_at YDR345C 1351.7 -1.2 264.7 1351.7 -1.1 129.0 1606.0 1.2 314.5 1606.0 1.1 160.6
YKR039W GAP1 10511_at YKR039W 46.7 -2.4 65.2 46.7 -1.4 21.0 110.8 2.4 154.9 110.8 1.7 77.6
YCL040W GLK1 HOR3 6937_at YCL040W 686.5 1.6 411.9 686.5 1.2 137.3 437.3 -1.6 262.4 437.3 -1.3 131.2
YHR175W CTR2 4335_at YHR175W 453.1 1.2 112.8 453.1 1.2 88.7 0.0 0.0 0.0 0.0 0.0 0.0
YFL011W HXT10 5377_at YFL011W H 4.7 -1.9 4.1 4.7 1.1 0.6 10.8 1.9 9.4 10.8 2.0 10.8
YER031C YPT31 YPT8 5686_at YER031C r 252.5 -1.0 12.3 252.5 -1.4 113.4 0.0 0.0 0.0 0.0 0.0 0.0
YMR243C ZRC1 OSR1 9382_at YMR243C 815.0 -1.0 39.8 815.0 -1.1 121.4 0.0 0.0 0.0 0.0 0.0 0.0
YML001W YPT7 AST4, VA 9622_at YML001W 822.3 -1.0 40.1 822.3 -1.1 122.4 0.0 0.0 0.0 0.0 0.0 0.0
YBR109C CMD1 7245_at YBR109C c 758.7 -1.1 75.9 758.7 -1.2 151.7 0.0 0.0 0.0 0.0 0.0 0.0
YGR121C MEP1 AMT1 4866_at Ammonia 42.9 -4.6 155.0 42.9 -5.4 189.0 195.4 4.6 706.8 195.4 -1.2 39.1
YDR342C HXT7 6128_f_at YDR342C 1141.2 -1.1 114.1 1141.2 -1.2 228.2 0.0 0.0 0.0 0.0 0.0 0.0
YFL039C ACT1 ABY1, EN 5392_at YFL039C 2061.4 -1.2 403.7 2061.4 -1.2 403.7 2477.1 1.2 485.1 2477.1 1.0 0.0
YDR343C HXT6 6129_f_at YDR343C 1105.6 -1.1 110.6 1105.6 -1.4 442.2 1197.1 1.1 119.7 1197.1 -1.3 359.1
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YNL142W MEP2 9026_at Ammonia t 75.9 -17.2 1229.5 75.9 -14.8 1051.2 1305.0 17.2 21139.5 1305.0 1.2 261.0
cytoskeleton-dependent transport
YBL078C AUT7 APG8, CV 7464_at YBL078C 230.6 1.4 102.0 230.6 1.5 114.5 167.6 -1.4 74.1 167.6 1.0 0.0
YCR068W CVT17 AUT5 6809_at Teter et al. 24.0 5.6 110.5 24.0 4.7 89.4 5.6 -4.4 18.9 5.6 -1.2 1.1
YIL062C ARC15 4155_at YIL062C A 655.4 1.0 32.0 655.4 -1.2 128.3 617.0 -1.0 30.1 617.0 -1.3 185.1
other intracellular transport activities
YKR093W PTR2 10472_at YKR093W 148.2 2.7 258.7 148.2 5.8 718.0 48.2 -2.7 84.2 48.2 2.1 53.0
YJL034W KAR2 BIP, GRP 11078_at Homologu 1978.5 1.1 188.8 1978.5 1.2 492.6 1802.2 -1.1 172.0 1802.2 1.2 360.4
YDR086C SSS1 6410_at YDR086C 557.7 -1.3 165.2 557.7 -1.1 83.0 727.0 1.3 215.3 727.0 1.2 145.4
YKL198C PTK1 KKT8, ST 3948_s_at YKL198C 6.7 2.2 8.4 6.7 2.6 10.6 4.3 -2.2 5.4 4.3 1.5 2.2
YNL079C TPM1 8953_at YNL079C 713.2 1.0 34.8 713.2 -1.2 142.6 676.8 -1.0 33.0 676.8 -1.2 135.4
YCR075C ERS1 6816_at YCR075C 185.0 -1.2 33.9 185.0 -1.9 162.0 0.0 0.0 0.0 0.0 0.0 0.0
CELLULAR COMMUNICATION/SIGNAL TRANSDUCTION MECHANISM
intracellular signalling
unspecified signal transduction
YIL071C PCI8 YIH1 4148_at YIL071C P 9.3 -1.0 0.0 9.3 2.1 9.8 0.0 0.0 0.0 0.0 0.0 0.0
YER177W BMH1 5525_at YER177W 1125.3 -1.1 112.5 1125.3 -1.3 392.8 1252.2 1.1 125.2 1252.2 -1.2 250.4
enzyme mediated signal transduction
G-protein mediated signal transduction
YOR107W RGS2 8444_at YOR107W 5.8 2.9 11.1 5.8 2.3 7.8 2.1 -2.9 4.0 2.1 -1.3
YNL098C RAS2 8979_at YNL098C 0.0 0.0 0.0 0.0 0.0 0.0 478.7 -1.1 47.9 478.7 -1.3
YPR165W RHO1 7563_at Ras homolo 819.3 -1.0 0.0 819.3 -1.2 163.9 828.3 -1.0 0.0 828.3 -1.2
YLR229C CDC42 10121_at Member of 1147.0 -1.0 56.0 1147.0 -1.3 400.4 1103.3 1.0 53.9 1103.3 -1.3
other intracellular signal transduction activities
YFL031W HAC1 ERN4, IR 5318_s_at bZIP Tran 398.7 1.9 355.4 398.7 2.2 484.5 284.7 -1.9 253.8 284.7 1.2 53.7
YNL138W SRV2 8984_at YNL138W 473.5 1.1 70.5 473.5 1.9 424.9 409.0 -1.1 60.9 409.0 1.6 245.4
YNL128W TEP1 8994_at Tyrosine p 15.9 1.3 4.8 15.9 14.6 216.4 12.5 -1.3 3.8 12.5 13.6 157.5
YDL212W SHR3 APF1 6696_at YDL212W 1059.4 -1.2 211.9 1059.4 -1.1 157.8 1263.7 1.2 252.7 1263.7 1.0 0.0
transmembrane signal transduction 1 4 ORFs
YKL178C STE3 10741_at YKL178C 887.2 -1.1 132.1 887.2 -1.4 351.7 1048.9 1.1 156.2 1048.9 -1.2 209.8
CELL RESCUE, DEFENSE AND VIRULENCE
stress response
YMR096W SNZ1 9538_at Encodes hi 1883.5 1.5 941.7 1883.5 6.2 9787.9 1095.7 -1.5 547.9 1095.7 4.2 3506.2
YMR095C SNO1 9537_at Upstream 887.2 2.0 887.2 887.2 9.8 7806.9 439.8 -2.0 439.8 439.8 5.0 1759.2
YKR042W UTH1 10514_at YKR042W 1982.9 -1.0 0.0 1982.9 1.2 396.6 2155.3 -1.0 0.0 2155.3 1.2 431.1
YMR251W HOR7 9390_at YMR251W 3669.8 -1.1 546.5 3669.8 -1.0 179.1 4175.2 1.1 621.7 4175.2 1.1 417.5
YMR186W HSC82 9456_at YMR186W 1536.6 -1.2 300.9 1536.6 -1.0 0.0 1859.1 1.2 364.1 1859.1 1.2 371.8
YDR077W SED1 6401_at YDR077W 1872.7 1.3 561.8 1872.7 1.5 1028.5 1464.7 -1.3 439.4 1464.7 1.2 292.9
YER011W TIR1 SRP1 5711_at YER011W 690.6 -1.2 172.0 690.6 1.1 69.1 684.8 1.2 170.5 684.8 1.4 273.9
YBR082C UBC4 7260_at YBR082C u 946.7 1.1 94.7 946.7 1.5 473.3 840.4 -1.1 84.0 840.4 1.3 252.1
YLR109W AHP1 cTPxIII 10228_at YLR109W 1813.1 -1.2 451.4 1813.1 -1.2 362.6 2293.7 1.2 571.1 2293.7 1.1 229.4
YJL159W HSP150 CCW7, O 11179_at Kex2-proc 1519.4 1.0 74.2 1519.4 1.1 226.3 1451.1 -1.0 70.8 1451.1 1.1 145.1
YNL160W YGP1 9008_at YNL160W 1172.5 2.3 1524.2 1172.5 2.8 2168.5 474.9 -2.3 617.4 474.9 1.3 142.5
YOR010C TIR2 SRP2 8527_at YOR010C 0.0 0.0 0.0 0.0 0.0 0.0 244.1 1.1 24.4 244.1 1.5 122.1
YIL011W TIR3 4114_at YIL011W 0.0 0.0 0.0 0.0 0.0 0.0 357.9 1.3 107.4 357.9 1.1 35.8
YPL240C HSP82 HSP83, H 8010_i_at YPL240C 0.0 0.0 0.0 0.0 0.0 0.0 514.6 -1.0 0.0 514.6 1.2 102.9
YJR147W HMS2 10895_at Heat shoc 8.6 -2.0 9.0 8.6 2.0 8.7 16.7 2.0 17.5 16.7 4.2 53.4
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YNL328C MDJ2 9202_at YNL328C 0.0 0.0 0.0 0.0 0.0 0.0 4.5 -1.7 3.3 4.5 -2.5 6.8
YNL241C ZWF1 MET19, P 9108_at Glucose-6 206.9 1.3 62.1 206.9 -1.0 0.0 157.1 -1.3 47.1 157.1 -1.3 47.1
YIR037W HYR1 GPX3 4073_at YIR037W 436.4 -1.1 43.6 436.4 -1.3 130.9 482.3 1.1 48.2 482.3 -1.2 96.5
YIR038C GTT1 4074_at YIR038C 252.0 -1.0 12.3 252.0 -1.5 138.4 251.6 1.0 12.3 251.6 -1.4 100.6
YOR027W STI1 8545_at YOR027W 0.0 0.0 0.0 0.0 0.0 0.0 288.3 -1.1 42.9 288.3 -1.4 115.3
YDR214W AHA1 6271_at YDR214W 0.0 0.0 0.0 0.0 0.0 0.0 295.8 -1.1 28.2 295.8 -1.4 118.3
YPL106C SSE1 LPG3, MS 7874_at YPL106C 672.7 -1.0 0.0 672.7 -1.2 134.5 633.8 -1.0 0.0 633.8 -1.2 126.8
YDL022W GPD1 DAR1, HO 6485_at YDL022W 763.2 1.1 113.7 763.2 -1.0 0.0 647.3 -1.1 96.4 647.3 -1.2 129.5
YNL098C RAS2 8979_at YNL098C 0.0 0.0 0.0 0.0 0.0 0.0 478.7 -1.1 47.9 478.7 -1.3 143.6
YLL039C UBI4 SCD2 10392_at YLL039C 432.6 1.3 151.0 432.6 -1.1 64.4 321.2 -1.3 112.1 321.2 -1.5 160.6
YNL064C YDJ1 MAS5 8924_at YNL064C 979.7 1.0 47.8 979.7 -1.1 145.9 959.6 -1.0 46.8 959.6 -1.2 191.9
YBR067C TIP1 7290_at YBR067C c 1652.2 -1.1 246.0 1652.2 -1.2 411.4 1934.7 1.1 288.1 1934.7 -1.1 193.5
YFL014W HSP12 5372_at YFL014W 625.4 1.8 493.3 625.4 -1.2 122.5 350.2 -1.8 276.3 350.2 -2.1 385.2
YAL005C SSA1 YG100 11315_i_a YAL005C 2682.4 -1.0 127.0 2682.4 -1.1 391.6 2804.4 1.0 132.8 2804.4 -1.3 866.8
YBR054W YRO2 7322_at Homolog t 334.3 2.3 451.1 334.3 3.6 869.2 153.8 -2.3 207.5 153.8 1.5 76.9
YKL163W PIR3 CCW8 10756_at Protein co 144.4 4.2 461.2 144.4 3.3 338.7 34.4 -4.2 109.9 34.4 -1.1 3.4
YMR173W DDR48 FSP 9442_s_at YMR173W 852.0 1.5 401.1 852.0 1.4 333.2 596.9 -1.5 281.0 596.9 -1.0 29.1
YDR258C HSP78 6223_at YDR258C 201.3 1.2 50.1 201.3 1.9 180.6 0.0 0.0 0.0 0.0 0.0 0.0
YAL015C NTG1 FUN33 11352_at YAL015C 144.8 1.7 108.5 144.8 2.0 144.4 82.6 -1.7 61.9 82.6 1.1 8.3
YGR234W YHB1 YHB4 4754_at YGR234W 274.2 1.4 121.3 274.2 1.5 136.2 0.0 0.0 0.0 0.0 0.0 0.0
YNL333W SNZ2 9198_s_at YNL333W 159.9 1.9 143.4 159.9 1.8 134.9 86.0 -1.9 77.2 86.0 -1.1 8.6
YAL040C CLN3 DAF1, FU 11369_at YAL040C 188.8 1.2 37.8 188.8 1.7 132.1 0.0 0.0 0.0 0.0 0.0 0.0
YKL164C CCW6 PIR1 10755_at Ccw protein 1316.5 1.1 131.7 1316.5 1.0 64.3 1226.1 -1.1 122.6 1226.1 -1.0 0.0
YDL025C YDL025C 6482_at YDL025C 237.2 1.5 130.3 237.2 1.3 82.8 0.0 0.0 0.0 0.0 0.0 0.0
YPL188W POS5 7926_at YPL188W 136.1 1.6 81.7 136.1 1.9 122.5 97.0 -1.6 58.2 97.0 1.3 29.1
YHR030C SLT2 BYC2, MP 4504_at YHR030C 187.6 1.6 111.9 187.6 1.6 121.8 118.8 -1.6 70.9 118.8 1.1 11.9
YHR104W GRE3 4442_at YHR104W 279.7 1.4 111.9 279.7 -1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
YDR074W TPS2 HOG2, PF 6398_at YDR074W 224.7 1.5 111.6 224.7 -1.0 11.0 140.6 -1.5 69.8 140.6 -1.6 84.4
YFL016C MDJ1 5370_at YFL016C 158.6 1.6 95.2 158.6 1.7 111.0 108.1 -1.6 64.9 108.1 1.1 10.8
YBR072W HSP26 7295_at YBR072W 88.4 2.2 105.9 88.4 1.4 39.7 41.9 -2.2 50.2 41.9 -1.5 21.0
YMR043W MCM1 FUN80 9576_at Putative tr 90.2 1.6 58.6 90.2 2.0 94.7 54.3 -1.6 35.3 54.3 1.2 10.9
YDR404C RPB7 6055_at YDR404C d 422.4 -1.1 42.2 422.4 -1.3 126.7 0.0 0.0 0.0 0.0 0.0 0.0
YDR155C CPR1 CYP1, CP 6301_at YDR155C c 1671.5 -1.2 327.3 1671.5 -1.1 159.5 0.0 0.0 0.0 0.0 0.0 0.0
YER057C HMF1 5672_at YER057C I 665.2 -1.1 63.5 665.2 -1.2 165.6 0.0 0.0 0.0 0.0 0.0 0.0
YLR259C HSP60 CPN60, M 10061_at YLR259C 1822.6 -1.1 182.3 1822.6 -1.1 271.4 0.0 0.0 0.0 0.0 0.0 0.0
detoxification
YOL109W ZEO1 8679_at YOL109W 2052.6 -1.0 100.2 2052.6 1.1 305.7 2118.1 1.0 103.4 2118.1 1.2 423.6
YBR145W ADH5 7236_at YBR145W 1213.1 1.0 59.2 1213.1 1.3 423.4 1149.0 -1.0 56.1 1149.0 1.3 344.7
YLL028W TPO1 10358_at YLL028W 714.9 -1.0 0.0 714.9 1.5 357.4 613.7 -1.0 0.0 613.7 1.5 306.9
YEL027W CUP5 5763_at YEL027W V 2242.6 -1.3 664.1 2242.6 -1.1 334.0 2929.6 1.3 867.6 2929.6 1.1 293.0
YOL158C ENB1 ARN4 8723_at YOL158C 881.4 1.4 395.8 881.4 2.0 924.9 600.5 -1.4 269.7 600.5 1.4 240.2
YML116W ATR1 SNQ1 9771_at YML116W 507.3 1.1 50.7 507.3 1.6 329.4 459.7 -1.1 46.0 459.7 1.5 229.9
YBR043C AQR2 7311_at YBR043C A 373.6 1.5 186.8 373.6 2.5 560.4 256.8 -1.5 128.4 256.8 1.7 179.8
YNL065W AQR1 8923_at A(acids, a 200.2 1.9 180.2 200.2 4.5 700.5 105.2 -1.9 94.7 105.2 2.4 147.3
YNL296W KRE25 9143_at Killer toxin Resistant 0.0 0.0 11.2 2.1 12.3 11.2 3.0 22.4
YPR156C TPO3 7599_i_at Polyamine 1.7 -3.0 3.4 1.7 -1.0 0.1 8.1 3.0 16.2 8.1 2.9 15.4
YIL120W QDR1 4236_at Multidrug re 41.4 9.5 351.8 41.4 3.6 109.7 3.3 -9.5 28.0 3.3 -2.6 5.3
YNL241C ZWF1 MET19, P 9108_at Glucose-6 206.9 1.3 62.1 206.9 -1.0 0.0 157.1 -1.3 47.1 157.1 -1.3 47.1
YIR038C GTT1 4074_at YIR038C 252.0 -1.0 12.3 252.0 -1.5 138.4 251.6 1.0 12.3 251.6 -1.4 100.6
YGR138C TPO2 4884_i_at YGR138C 146.9 -1.3 50.2 146.9 -2.1 166.8 193.0 1.3 65.9 193.0 -1.6 115.8
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YEL065W SIT1 ARN3 5769_at Sideropho 407.0 6.4 2204.5 407.0 12.4 4625.1 67.8 -6.4 367.3 67.8 1.8 54.2
YHL040C ARN1 4568_at Siderochro 271.7 5.7 1288.9 271.7 6.7 1546.6 43.8 -5.7 207.8 43.8 1.3 13.1
YPL092W SSU1 LPG16 7843_at YPL092W s 279.1 1.3 83.7 279.1 2.3 362.8 0.0 0.0 0.0 0.0 0.0 0.0
YHR053C CUP1-1 CUP1 4483_s_at YHR053C c 1985.9 1.2 397.2 1985.9 1.1 295.7 0.0 0.0 0.0 0.0 0.0 0.0
YNL259C ATX1 9135_at YNL259C 701.7 1.1 70.2 701.7 1.3 210.5 0.0 0.0 0.0 0.0 0.0 0.0
RTM1 RTM1 3934_at RTM1 Prot 55.2 2.2 69.0 55.2 3.5 140.7 22.1 -2.2 27.6 22.1 1.6 13.3
YMR043W MCM1 FUN80 9576_at Putative tr 90.2 1.6 58.6 90.2 2.0 94.7 54.3 -1.6 35.3 54.3 1.2 10.9
YFL007W BLM3 5381_at YFL007W m 34.7 2.7 59.9 34.7 2.5 52.0 12.9 -2.7 22.3 12.9 -1.0 0.0
YNR070W PDR18 8782_at YNR070W 6.7 2.3 8.6 6.7 2.8 12.3 3.7 -2.3 4.7 3.7 1.5 1.9
YMR243C ZRC1 OSR1 9382_at YMR243C 815.0 -1.0 39.8 815.0 -1.1 121.4 0.0 0.0 0.0 0.0 0.0 0.0
YLR043C TRX1 LMA1 10295_at YLR043C 1339.6 -1.2 267.9 1339.6 -1.1 199.5 1597.3 1.2 319.5 1597.3 1.0 0.0
YOR153W PDR5 LEM1, YD 8400_at Multidrug re 707.7 -1.3 209.6 707.7 -1.3 209.6 916.0 1.3 271.3 916.0 1.0 0.0
YJR104C SOD1 CRS4 10897_at YJR104C 1864.3 -1.1 186.4 1864.3 -1.1 277.6 0.0 0.0 0.0 0.0 0.0 0.0
detoxification involving cytochrome P450
YHR007C ERG11 4525_at YHR007C c 0.0 0.0 0.0 0.0 0.0 0.0 1087.9 1.0 53.1 1087.9 1.2 217.6
other cell rescue activities
YGR213C RTA1 4778_at YGR213C 10.4 2.4 15.0 10.4 1.7 7.2 4.2 -2.4 6.1 4.2 -1.4 1.7
REGULATION OF / INTERACTION WITH CELLULAR ENVIRONMENT
ionic homeostasis
homeostasis of cations
YDR276C PMP3 SNA1 6196_at YDR276C c 1952.2 -1.2 486.1 1952.2 -1.0 95.3 2416.2 1.2 601.6 2416.2 1.1 241.6
homeostasis of metal ions (Na, K, Ca etc.) 20 63 ORFs
YMR058W FET3 9588_at YMR058W 900.7 2.1 988.6 900.7 2.4 1259.1 422.2 -2.1 463.4 422.2 1.1
YPL135W ISU1 NUA1 7890_at YPL135W 907.5 1.9 861.5 907.5 1.7 635.3 464.8 -1.9 441.3 464.8 -1.1
YLR034C SMF3 10286_at YLR034C 700.6 1.1 104.3 700.6 1.3 244.5 596.7 -1.1 88.9 596.7 1.2
YNL259C ATX1 9135_at YNL259C 701.7 1.1 70.2 701.7 1.3 210.5 0.0 0.0 0.0 0.0 0.0
YOR316C COT1 8206_at YOR316C 280.8 1.4 111.3 280.8 1.5 152.4 0.0 0.0 0.0 0.0 0.0
YDR270W CCC2 6190_at Accessory 150.0 1.9 135.0 150.0 1.9 135.0 92.0 -1.9 82.8 92.0 1.0
YER145C FTR1 5585_at YER145C I 260.0 1.1 30.5 260.0 1.5 124.6 143.9 -1.1 18.6 143.9 1.4
YER145C FTR1 5585_at YER145C I 260.0 1.1 30.5 260.0 1.5 124.6 143.9 -1.1 18.6 143.9 1.4
YLL009C COX17 10334_at YLL009C i 551.2 1.2 110.2 551.2 1.1 82.1 0.0 0.0 0.0 0.0 0.0
YOR381W FRE3 8180_at Cell surface 42.4 2.8 77.9 42.4 3.2 92.6 14.9 -2.8 27.4 14.9 1.1
YHR175W CTR2 4335_at YHR175W 453.1 1.2 112.8 453.1 1.2 88.7 0.0 0.0 0.0 0.0 0.0
YLR214W FRE1 10106_at Ferric (and 107.8 1.5 59.2 107.8 1.7 80.8 63.6 -1.5 34.9 63.6 1.1
YJR049C UTR1 10978_at Shown to 32.6 1.2 7.9 32.6 2.2 40.3 26.7 -1.2 6.4 26.7 1.8
YCR044C PER1 6832_at YCR044C 324.0 -1.2 64.8 324.0 -1.3 113.1 0.0 0.0 0.0 0.0 0.0
YMR243C ZRC1 OSR1 9382_at YMR243C 815.0 -1.0 39.8 815.0 -1.1 121.4 0.0 0.0 0.0 0.0 0.0
YLR411W CTR3 9902_at YLR411W 78.5 -1.8 62.4 78.5 -2.9 145.5 135.3 1.8 107.5 135.3 -1.6
YLR130C ZRT2 10204_at YLR130C 498.4 -1.5 249.2 498.4 -1.3 174.0 750.0 1.5 375.0 750.0 1.1
YKL080W VMA5 CSL5, VA 10660_at YKL080W V 713.6 -1.3 249.1 713.6 -1.2 177.7 957.0 1.3 334.1 957.0 1.1
YOR153W PDR5 LEM1, YD 8400_at Multidrug re 707.7 -1.3 209.6 707.7 -1.3 209.6 916.0 1.3 271.3 916.0 1.0
YGL255W ZRT1 5258_at YGL255W 147.7 -1.7 103.0 147.7 -2.6 243.1 279.2 1.7 194.6 279.2 -1.6
YLR109W AHP1 cTPxIII 10228_at YLR109W 1813.1 -1.2 451.4 1813.1 -1.2 362.6 2293.7 1.2 571.1 2293.7 1.1
homeostasis of protons
YGL008C PMA1 5009_at YGL008C 0.0 0.0 0.0 0.0 0.0 0.0 2122.2 1.1 212.2 2122.2 1.2
YCR024C PMP1 6858_f_at YCR024C a 897.8 -1.3 313.4 897.8 -1.0 0.0 1190.8 1.3 415.7 1190.8 1.3
YKL016C ATP7 10591_at YKL016C 689.5 1.2 171.7 689.5 1.3 240.7 546.0 -1.2 136.0 546.0 1.1
YBL099W ATP1 7487_at YBL099W 1009.5 -1.1 150.3 1009.5 -1.0 0.0 1258.4 1.1 187.4 1258.4 1.1
YBR039W ATP3 7307_at YBR039W 630.5 1.2 126.1 630.5 -1.0 0.0 526.3 -1.2 105.3 526.3 -1.2
YGR020C VMA7 4993_at YGR020C 462.1 -1.4 184.8 462.1 -1.3 138.6 648.7 1.4 259.5 648.7 1.1
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YLR447C VMA6 9851_at YLR447C 508.6 -1.0 24.8 508.6 -1.3 150.6 518.0 1.0 25.3 518.0 -1.3
YLR295C ATP14 10010_at YLR295C 630.6 1.6 376.4 630.6 1.1 93.9 394.9 -1.6 235.7 394.9 -1.4
YDL004W ATP16 6503_at YDL004W 720.0 1.2 179.3 720.0 1.0 35.1 558.7 -1.2 139.1 558.7 -1.3
YPL271W ATP15 ATPEPSIL 8024_at YPL271W 1021.8 1.1 152.2 1021.8 -1.0 49.9 899.9 -1.1 134.0 899.9 -1.2
Q0310 3976_at F1F0-ATP 804.9 1.2 200.4 804.9 -1.0 39.3 644.5 -1.2 160.5 644.5 -1.3
YPR036W VMA13 CLS11 7699_at YPR036W 437.6 1.1 43.8 437.6 -1.3 152.7 403.1 -1.1 40.3 403.1 -1.5
YDL185W TFP1 CLS8, VM 6679_at YDL185W 690.5 -1.3 207.2 690.5 -1.3 241.0 892.6 1.3 267.8 892.6 -1.0
YBR127C VMA2 ATPVS, V 7218_at YBR127C H 734.2 -1.5 367.1 734.2 -1.4 329.7 1021.3 1.5 510.7 1021.3 1.0
YEL027W CUP5 5763_at YEL027W V 2242.6 -1.3 664.1 2242.6 -1.1 334.0 2929.6 1.3 867.6 2929.6 1.1
YOR332W VMA4 8222_at YOR332W 978.3 -1.3 341.5 978.3 -1.3 341.5 1290.1 1.3 450.3 1290.1 -1.0
YHR039C MSC7 VMA10 4514_at YHR039C 783.6 -1.3 235.1 783.6 -1.4 351.9 1017.3 1.3 305.2 1017.3 -1.1
YPL234C TFP3 CLS9, VM 7970_at YPL234C 1186.4 -1.3 355.9 1186.4 -1.3 355.9 1511.7 1.3 453.5 1511.7 -1.1
YOR270C VPH1 8291_at YOR270C 1344.7 -1.3 403.4 1344.7 -1.3 469.4 1771.5 1.3 531.5 1771.5 -1.0
homeostasis of other cations
YKL190W CNB1 10772_at YKL190W T 0.0 0.0 0.0 0.0 0.0 0.0 575.0 1.1 57.5 575.0 1.2
homeostasis of anions
homeostasis of sulfates
YBR294W SUL1 7067_at Putative s 97.3 1.3 33.9 97.3 4.0 291.6 70.8 -1.3 24.7 70.8 2.9
YLR092W SUL2 10256_at YLR092W 560.9 1.1 56.1 560.9 1.2 112.2 545.7 -1.1 54.6 545.7 1.1
homeostasis of phosphate
YJL117W PHO86 11132_at YJL117W 0.0 0.0 0.0 0.0 0.0 0.0 473.2 1.0 23.1 473.2 1.3
YJR077C MIR1 10961_at YJR077C i 1731.2 1.1 257.8 1731.2 1.0 84.5 1524.8 -1.1 227.1 1524.8 -1.1
cellular sensing and response
chemoperception and response
perception of nutrients and nutritional adaptation
YKL198C PTK1 KKT8, ST 3948_s_at YKL198C 6.7 2.2 8.4 6.7 2.6 10.6 4.3 -2.2 5.4 4.3 1.5
YPL106C SSE1 LPG3, MS 7874_at YPL106C 672.7 -1.0 0.0 672.7 -1.2 134.5 633.8 -1.0 0.0 633.8 -1.2
YNL098C RAS2 8979_at YNL098C 0.0 0.0 0.0 0.0 0.0 0.0 478.7 -1.1 47.9 478.7 -1.3
pheromone response
YIL117C PRM5 4194_at YIL117C ph 67.2 1.2 16.2 67.2 2.7 113.0 59.1 -1.2 14.2 59.1 2.2
YDR461W MFA1 6021_f_at YDR461W 31.6 2.2 39.3 31.6 1.9 28.3 11.8 -2.2 14.7 11.8 -1.1
YIL037C PRM2 4134_at Pheromon 7.6 -4.0 22.6 7.6 -2.6 11.9 29.4 4.0 87.5 29.4 1.8
YAR031W PRM9 11293_at YAR031W 10.8 -1.0 0.5 10.8 2.7 18.1 11.4 1.0 0.5 11.4 2.9
YJL157C FAR1 11181_at YJL157C 346.1 -1.3 120.8 346.1 -1.6 206.5 476.4 1.3 166.3 476.4 -1.2
YKL178C STE3 10741_at YKL178C 887.2 -1.1 132.1 887.2 -1.4 351.7 1048.9 1.1 156.2 1048.9 -1.2
YLR229C CDC42 10121_at Member of 1147.0 -1.0 56.0 1147.0 -1.3 400.4 1103.3 1.0 53.9 1103.3 -1.3
osmosensing
YHR030C SLT2 BYC2, MP 4504_at YHR030C 187.6 1.6 111.9 187.6 1.6 121.8 118.8 -1.6 70.9 118.8 1.1
YDL022W GPD1 DAR1, HO 6485_at YDL022W 763.2 1.1 113.7 763.2 -1.0 0.0 647.3 -1.1 96.4 647.3 -1.2
YFL014W HSP12 5372_at YFL014W 625.4 1.8 493.3 625.4 -1.2 122.5 350.2 -1.8 276.3 350.2 -2.1
CELL FATE
cell growth / morphogenesis
YLR175W CBF5 10155_at YLR175W 795.5 -1.0 0.0 795.5 1.4 318.2 829.9 -1.0 0.0 829.9 1.4 332.0
YNL138W SRV2 8984_at YNL138W 473.5 1.1 70.5 473.5 1.9 424.9 409.0 -1.1 60.9 409.0 1.6 245.4
YKL190W CNB1 10772_at YKL190W T 0.0 0.0 0.0 0.0 0.0 0.0 575.0 1.1 57.5 575.0 1.2 115.0
YOR027W STI1 8545_at YOR027W 0.0 0.0 0.0 0.0 0.0 0.0 288.3 -1.1 42.9 288.3 -1.4 115.3
YNL079C TPM1 8953_at YNL079C 713.2 1.0 34.8 713.2 -1.2 142.6 676.8 -1.0 33.0 676.8 -1.2 135.4
YER177W BMH1 5525_at YER177W 1125.3 -1.1 112.5 1125.3 -1.3 392.8 1252.2 1.1 125.2 1252.2 -1.2 250.4
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YPR052C NHP6A 7717_at YPR052C 530.1 -1.1 65.8 530.1 -1.6 328.4 596.6 1.1 74.1 596.6 -1.4 265.9
YLR300W EXG1 BGL1 10015_at YLR300W 1585.6 1.0 77.4 1585.6 1.1 236.1 0.0 0.0 0.0 0.0 0.0 0.0
YJL174W KRE9 11209_at YJL174W 643.5 1.2 128.7 643.5 1.2 160.2 581.8 -1.2 116.4 581.8 1.0 0.0
YAL040C CLN3 DAF1, FU 11369_at YAL040C 188.8 1.2 37.8 188.8 1.7 132.1 0.0 0.0 0.0 0.0 0.0 0.0
YCR034W FEN1 ELO2, GN 6869_at YCR034W 728.3 -1.1 72.8 728.3 -1.2 145.7 0.0 0.0 0.0 0.0 0.0 0.0
YDR284C DPP1 6204_at YDR284C 276.7 -1.2 55.3 276.7 -1.5 151.9 0.0 0.0 0.0 0.0 0.0 0.0
directional cell growth (morphogenesis)
YHR030C SLT2 BYC2, MP 4504_at YHR030C 187.6 1.6 111.9 187.6 1.6 121.8 118.8 -1.6 70.9 118.8 1.1 11.9
YPR165W RHO1 7563_at Ras homolo 819.3 -1.0 0.0 819.3 -1.2 163.9 828.3 -1.0 0.0 828.3 -1.2 165.7
YLR229C CDC42 10121_at Member of 1147.0 -1.0 56.0 1147.0 -1.3 400.4 1103.3 1.0 53.9 1103.3 -1.3 331.0
other morphogenetic activities  
YPL106C SSE1 LPG3, MS 7874_at YPL106C 672.7 -1.0 0.0 672.7 -1.2 134.5 633.8 -1.0 0.0 633.8 -1.2
YBR109C CMD1 7245_at YBR109C c 758.7 -1.1 75.9 758.7 -1.2 151.7 0.0 0.0 0.0 0.0 0.0
cell differentiation
fungal cell differentiation
budding, cell polarity and filament formation
YLR372W SUR4 ELO3, SR 9953_at YLR372W 1590.9 -1.2 318.2 1590.9 -1.0 0.0 1910.0 1.2 382.0 1910.0 1.2
YNL138W SRV2 8984_at YNL138W 473.5 1.1 70.5 473.5 1.9 424.9 409.0 -1.1 60.9 409.0 1.6
YGR214W 4780_at YGR214W 1457.7 -1.2 285.4 1457.7 -1.1 217.1 1570.5 1.2 307.5 1570.5 1.1
YJL159W HSP150 CCW7, O 11179_at Kex2-proc 1519.4 1.0 74.2 1519.4 1.1 226.3 1451.1 -1.0 70.8 1451.1 1.1
YNL271C BNI1 PPF3 9123_at Cytoskelet 94.5 1.3 28.0 94.5 3.4 229.7 108.6 -1.3 32.2 108.6 2.1
YLR267W BOP2 10072_at Bypass of 21.8 1.8 18.5 21.8 7.2 136.2 12.0 -1.8 10.2 12.0 4.3
YCL068C ?? 6957_s_at YCL068C 27.3 1.3 7.2 27.3 2.5 41.8 20.9 -1.3 5.5 20.9 2.0
YMR063W RIM9 9593_at Required f 14.5 3.3 33.8 14.5 6.0 72.3 5.6 -3.3 13.1 5.6 2.6
YIL159W BNR1 4242_at Bni1p-rela 3.3 -2.0 3.3 3.3 -1.7 2.2 6.5 2.0 6.5 6.5 1.1
YPL255W BBP1 7994_at YPL255W 0.0 0.0 0.0 0.0 0.0 0.0 4.1 -1.5 2.0 4.1 -2.4
YJL157C FAR1 11181_at YJL157C 346.1 -1.3 120.8 346.1 -1.6 206.5 476.4 1.3 166.3 476.4 -1.2
YFL005W SEC4 SRO6 5383_at Ras-like s 416.8 -1.0 0.0 416.8 -1.3 123.4 416.5 -1.0 0.0 416.5 -1.3
YNL079C TPM1 8953_at YNL079C 713.2 1.0 34.8 713.2 -1.2 142.6 676.8 -1.0 33.0 676.8 -1.2
YPR165W RHO1 7563_at Ras homolo 819.3 -1.0 0.0 819.3 -1.2 163.9 828.3 -1.0 0.0 828.3 -1.2
YPR052C NHP6A 7717_at YPR052C 530.1 -1.1 65.8 530.1 -1.6 328.4 596.6 1.1 74.1 596.6 -1.4
YLR229C CDC42 10121_at Member of 1147.0 -1.0 56.0 1147.0 -1.3 400.4 1103.3 1.0 53.9 1103.3 -1.3
YJL174W KRE9 11209_at YJL174W 643.5 1.2 128.7 643.5 1.2 160.2 581.8 -1.2 116.4 581.8 1.0
YAL040C CLN3 DAF1, FU 11369_at YAL040C 188.8 1.2 37.8 188.8 1.7 132.1 0.0 0.0 0.0 0.0 0.0
YHR030C SLT2 BYC2, MP 4504_at YHR030C 187.6 1.6 111.9 187.6 1.6 121.8 118.8 -1.6 70.9 118.8 1.1
YER133W GLC7 CID1, DIS 5573_at protein ph 242.7 1.2 40.7 242.7 1.3 84.2 217.2 -1.2 36.4 217.2 1.1
YOR030W DFG16 ECM41, Z 8503_at YOR030W 4.4 2.1 4.8 4.4 2.2 5.5 1.1 -2.1 1.2 1.1 1.3
YMR238W DFG5 9377_at YMR238W 292.8 -1.0 14.3 292.8 -1.4 116.1 0.0 0.0 0.0 0.0 0.0
YCR034W FEN1 ELO2, GN 6869_at YCR034W 728.3 -1.1 72.8 728.3 -1.2 145.7 0.0 0.0 0.0 0.0 0.0
YBR109C CMD1 7245_at YBR109C c 758.7 -1.1 75.9 758.7 -1.2 151.7 0.0 0.0 0.0 0.0 0.0
YFL039C ACT1 ABY1, EN 5392_at YFL039C 2061.4 -1.2 403.7 2061.4 -1.2 403.7 2477.1 1.2 485.1 2477.1 1.0
pheromone response, mating-type determination, sex-specific proteins
YCL067C HMLALPH ALPHA2, 6958_s_at Mating typ 210.9 1.0 10.3 210.9 6.2 1106.8 201.1 -1.0 9.8 201.1 6.0
YLR441C 9890_s_at YLR441C 2182.4 -1.2 431.9 2182.4 -1.1 42.2 2569.5 1.2 508.5 2569.5 1.1
YPL187W MF(ALPHA)1 7927_at YPL187W 2437.9 -1.1 363.0 2437.9 -1.0 119.0 2754.2 1.1 410.1 2754.2 1.1
YBR082C UBC4 7260_at YBR082C u 946.7 1.1 94.7 946.7 1.5 473.3 840.4 -1.1 84.0 840.4 1.3
YNL238W KEX2 QDS1, VMA9110_at Ca2+-dep 189.7 1.2 37.1 189.7 3.0 385.1 156.4 -1.2 30.6 156.4 2.5
YJR004C SAG1 AG(ALPH 11026_at YJR004C 1562.2 -1.3 545.3 1562.2 -1.2 312.4 2131.1 1.3 743.9 2131.1 1.1
YNR044W AGA1 8802_at YNR044W 473.1 -1.3 140.1 473.1 -1.0 23.1 650.6 1.3 192.7 650.6 1.2
YNL145W MFA2 9023_at Mating a-f 22.9 1.0 1.0 22.9 7.0 137.4 21.9 -1.0 1.0 21.9 6.8
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YNL271C BNI1 PPF3 9123_at Cytoskelet 94.5 1.3 28.0 94.5 3.4 229.7 108.6 -1.3 32.2 108.6 2.1
YKL190W CNB1 10772_at YKL190W T 0.0 0.0 0.0 0.0 0.0 0.0 575.0 1.1 57.5 575.0 1.2
YPL240C HSP82 HSP83, H 8010_i_at YPL240C 0.0 0.0 0.0 0.0 0.0 0.0 514.6 -1.0 0.0 514.6 1.2
YCR097W HMRA1 YCR097WB6792_s_at YCR097W 0.0 0.0 0.0 0.0 0.0 0.0 2.4 1.2 0.4 2.4 2.1
YJL157C FAR1 11181_at YJL157C 346.1 -1.3 120.8 346.1 -1.6 206.5 476.4 1.3 166.3 476.4 -1.2
YDR214W AHA1 6271_at YDR214W 0.0 0.0 0.0 0.0 0.0 0.0 295.8 -1.1 28.2 295.8 -1.4
YNL079C TPM1 8953_at YNL079C 713.2 1.0 34.8 713.2 -1.2 142.6 676.8 -1.0 33.0 676.8 -1.2
YNL307C MCK1 9177_at YNL307C 624.7 -1.1 93.0 624.7 -1.3 218.1 701.8 1.1 104.5 701.8 -1.2
YKL178C STE3 10741_at YKL178C 887.2 -1.1 132.1 887.2 -1.4 351.7 1048.9 1.1 156.2 1048.9 -1.2
YLR229C CDC42 10121_at Member of 1147.0 -1.0 56.0 1147.0 -1.3 400.4 1103.3 1.0 53.9 1103.3 -1.3
YJL212C OPT1 HGT1 11260_at Oligopepti 238.5 2.1 274.1 238.5 3.4 571.9 113.1 -2.1 130.0 113.1 1.6
YKL104C GFA1 10680_at YKL104C 276.7 1.6 179.6 276.7 1.9 262.6 169.2 -1.6 109.9 169.2 1.1
YLR300W EXG1 BGL1 10015_at YLR300W 1585.6 1.0 77.4 1585.6 1.1 236.1 0.0 0.0 0.0 0.0 0.0
YJL174W KRE9 11209_at YJL174W 643.5 1.2 128.7 643.5 1.2 160.2 581.8 -1.2 116.4 581.8 1.0
YMR043W MCM1 FUN80 9576_at Putative tr 90.2 1.6 58.6 90.2 2.0 94.7 54.3 -1.6 35.3 54.3 1.2
YDR461W MFA1 6021_f_at YDR461W 31.6 2.2 39.3 31.6 1.9 28.3 11.8 -2.2 14.7 11.8 -1.1
YBR040W FIG1 7308_at Integral m 18.7 -5.3 81.1 18.7 -2.7 32.6 99.9 5.3 434.4 99.9 1.9
YDL227C HO 6725_at YDL227C 163.5 -1.4 73.4 163.5 -1.8 138.9 234.2 1.4 105.2 234.2 -1.3
YCR034W FEN1 ELO2, GN 6869_at YCR034W 728.3 -1.1 72.8 728.3 -1.2 145.7 0.0 0.0 0.0 0.0 0.0
YBR109C CMD1 7245_at YBR109C c 758.7 -1.1 75.9 758.7 -1.2 151.7 0.0 0.0 0.0 0.0 0.0
YGL089C MF(ALPHA)2 5108_at YGL089C 1468.1 -1.5 729.2 1468.1 -1.4 659.4 2220.7 1.5 1102.9 2220.7 1.0
sporulation and germination
YBR082C UBC4 7260_at YBR082C u 946.7 1.1 94.7 946.7 1.5 473.3 840.4 -1.1 84.0 840.4 1.3
YKL165C MCD4 ZRG16 10754_at YKL165C 637.9 1.2 127.6 637.9 1.4 255.2 584.3 -1.2 116.9 584.3 1.2
YPL240C HSP82 HSP83, H 8010_i_at YPL240C 0.0 0.0 0.0 0.0 0.0 0.0 514.6 -1.0 0.0 514.6 1.2
YNR019W ARE2 SAT1 8867_at YNR019W 2.1 -2.1 2.4 2.1 -1.7 1.6 8.4 2.1 9.6 8.4 1.2
YMR063W RIM9 9593_at Required f 14.5 3.3 33.8 14.5 6.0 72.3 5.6 -3.3 13.1 5.6 2.6
YBR148W YSW1 7194_at YBR148W 7.5 1.0 0.3 7.5 2.5 11.4 6.2 -1.0 0.2 6.2 2.4
YDR523C SPS1 5947_at YDR523C d 5.0 2.0 5.2 5.0 -1.2 0.9 2.0 -2.0 2.1 2.0 -2.3
YBL066C SEF1 7430_at Putative tr 9.5 4.0 28.5 9.5 1.8 7.6 5.2 -4.0 15.6 5.2 -2.2
YDR214W AHA1 6271_at YDR214W 0.0 0.0 0.0 0.0 0.0 0.0 295.8 -1.1 28.2 295.8 -1.4
YNL307C MCK1 9177_at YNL307C 624.7 -1.1 93.0 624.7 -1.3 218.1 701.8 1.1 104.5 701.8 -1.2
YNL098C RAS2 8979_at YNL098C 0.0 0.0 0.0 0.0 0.0 0.0 478.7 -1.1 47.9 478.7 -1.3
YLL039C UBI4 SCD2 10392_at YLL039C 432.6 1.3 151.0 432.6 -1.1 64.4 321.2 -1.3 112.1 321.2 -1.5
YBR078W ECM33 7302_at YBR078W 1606.6 -1.2 321.3 1606.6 -1.2 400.0 1885.9 1.2 377.2 1885.9 -1.1
YLR300W EXG1 BGL1 10015_at YLR300W 1585.6 1.0 77.4 1585.6 1.1 236.1 0.0 0.0 0.0 0.0 0.0
YCR048W ARE1 SAT2 6837_at YCR048W 178.6 1.3 62.3 178.6 1.6 107.2 0.0 0.0 0.0 0.0 0.0
YMR043W MCM1 FUN80 9576_at Putative tr 90.2 1.6 58.6 90.2 2.0 94.7 54.3 -1.6 35.3 54.3 1.2
YIL099W SGA1 4212_g_at Intracellula 40.4 2.4 56.6 40.4 2.3 52.4 25.6 -2.4 35.8 25.6 -1.0
YGL180W APG1 AUT3 5200_at YGL180W 21.5 1.7 16.1 21.5 2.1 24.7 0.0 0.0 0.0 0.0 0.0
YNL012W SPO1 8883_at YNL012W 10.8 2.2 13.1 10.8 1.3 3.2 4.3 -2.2 5.3 4.3 -1.8
YMR154C RIM13 CPL1 9465_at YMR154C 8.5 2.1 9.5 8.5 -1.0 0.0 2.7 -2.1 3.0 2.7 -1.9
YIL084C SDS3 4182_at YIL084C F 4.6 2.0 4.8 4.6 -1.2 0.9 0.0 0.0 0.0 0.0 0.0
YNL204C SPS18 SPX18 9055_at YNL204C 4.2 -1.8 3.4 4.2 -2.7 7.2 0.0 0.0 0.0 0.0 0.0
YCR034W FEN1 ELO2, GN 6869_at YCR034W 728.3 -1.1 72.8 728.3 -1.2 145.7 0.0 0.0 0.0 0.0 0.0
YOL139C CDC33 TIF45 8695_at YOL139C 1080.1 -1.1 108.0 1080.1 -1.2 216.0 0.0 0.0 0.0 0.0 0.0
cell death
YKR042W UTH1 10514_at YKR042W 1982.9 -1.0 0.0 1982.9 1.2 396.6 2155.3 -1.0 0.0 2155.3 1.2 431.1
YJL116C NCA3 11133_at YJL116C 138.4 2.0 144.6 138.4 2.8 255.5 67.9 -2.0 70.9 67.9 1.4 27.2
YMR190C SGS1 9461_at YMR190C 0.0 0.0 0.0 0.0 0.0 0.0 11.3 -1.4 4.5 11.3 -2.1 12.4
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YKL008C LAC1 10599_at YKL008C 420.6 -1.2 104.7 420.6 -1.1 62.6 518.8 1.2 129.2 518.8 1.1 51.9
YNL098C RAS2 8979_at YNL098C 0.0 0.0 0.0 0.0 0.0 0.0 478.7 -1.1 47.9 478.7 -1.3 143.6
CONTROL OF CELLULAR ORGANIZATION
cell wall
YKL184W SPE1 ORD1, SP 10779_at YKL184W 159.9 1.8 127.9 159.9 2.4 231.8 89.2 -1.8 71.4 89.2 1.4 35.7
YAL054C ACS1 11356_at YAL054C i 350.3 1.2 87.2 350.3 1.3 122.3 0.0 0.0 0.0 0.0 0.0 0.0
YGR008C STF2 4980_at YGR008C 783.8 1.3 235.1 783.8 1.1 116.7 605.4 -1.3 181.6 605.4 -1.1 60.5
YER150W SPI1 5544_at YER150W 194.0 1.6 115.8 194.0 1.1 28.9 121.0 -1.6 72.2 121.0 -1.4 48.4
YML048W GSF2 ECM6 9709_at YML048W 0.0 0.0 0.0 0.0 0.0 0.0 33.1 1.3 9.2 33.1 2.2 39.7
YOR030W DFG16 ECM41, Z 8503_at YOR030W 4.4 2.1 4.8 4.4 2.2 5.5 1.1 -2.1 1.2 1.1 1.3 0.3
YCL004W PGS1 PEL1 6875_at 17-kDa Pho 6.6 3.2 14.7 6.6 1.4 2.5 0.0 -3.2 0.0 0.0 -2.4 0.0
YPR069C SPE3 7689_at YPR069C p 167.8 -1.4 75.4 167.8 -1.6 100.2 242.2 1.4 108.8 242.2 -1.1 24.2
YPL053C KTR6 MNN6 7790_at YPL053C 0.0 0.0 0.0 0.0 0.0 0.0 406.6 1.2 101.2 406.6 1.1 40.7
YBR078W ECM33 7302_at YBR078W 1606.6 -1.2 321.3 1606.6 -1.2 400.0 1885.9 1.2 377.2 1885.9 -1.1 188.6
YLR249W YEF3 TEF3 10097_at YLR249W 2805.7 -1.1 417.8 2805.7 -1.1 417.8 3188.9 1.1 474.9 3188.9 1.0 0.0
YMR307W GAS1 CWH52, G 9315_at YMR307W 2126.2 -1.2 425.2 2126.2 -1.2 425.2 2549.2 1.2 509.8 2549.2 -1.0 0.0
YDL055C PSA1 MPG1, VI 6543_at YDL055C 1894.9 -1.2 471.8 1894.9 -1.2 471.8 2378.1 1.2 592.1 2378.1 1.0 0.0
YLR110C CCW12 10229_at YLR110C 4285.1 -1.2 1067.0 4285.1 -1.1 638.1 5335.7 1.2 1328.6 5335.7 1.1 533.6
cytoskeleton
YPL250C ICY2 7999_at YPL250C I 734.1 1.1 109.3 734.1 1.8 587.3 630.2 -1.1 93.8 630.2 1.5 315.1
YLR175W CBF5 10155_at YLR175W 795.5 -1.0 0.0 795.5 1.4 318.2 829.9 -1.0 0.0 829.9 1.4 332.0
YMR195W ICY1 9422_at YMR195W 815.3 1.3 244.6 815.3 1.3 244.6 645.9 -1.3 193.8 645.9 1.0 0.0
YKL004W AUR1 10560_at YKL004W 618.5 -1.2 123.7 618.5 -1.0 0.0 749.2 1.2 149.8 749.2 1.2 149.8
YLL038C ENT4 10393_at YLL038C 4.3 2.2 5.4 4.3 -1.2 1.0 0.0 0.0 0.0 0.0 0.0 0.0
Golgi
YDL137W ARF2 6638_at YDL137W 1842.3 -1.1 175.8 1842.3 -1.2 360.8 0.0 0.0 0.0 0.0 0.0 0.0
nucleus
organization of chromosome structure 2 19 ORFs
YLR453C RIF2 9857_at YLR453C 12.2 2.0 12.8 12.2 2.3 16.5 5.9 -2.0 6.2 5.9 1.1 0.6
YBL032W HEK2 KHD1 7420_at YBL032W 115.2 -1.6 69.1 115.2 -2.0 120.9 0.0 0.0 0.0 0.0 0.0 0.0
mitochondrion
YIL051C MMF1 IBM1 4166_at YIL051C 768.9 -1.0 37.5 768.9 1.2 150.6 816.6 1.0 39.9 816.6 1.3 245.0
YCL004W PGS1 PEL1 6875_at 17-kDa Pho 6.6 3.2 14.7 6.6 1.4 2.5 0.0 -3.2 0.0 0.0 -2.4 0.0
other control of cellular organization 1 7
YMR131C RRB1 9484_at YMR131C 431.3 1.3 150.6 431.3 1.1 64.2 322.8 -1.3 112.7 322.8 -1.2 64.6
SUBCELLULAR LOCALISATION
cell wall
YKL097W ?? 10688_at YKL097W c 3109.4 -1.2 608.9 3109.4 1.0 151.8 3690.9 1.2 722.8 3690.9 1.2 738.2
YGR189C CRH1 4799_at YGR189C 582.5 1.2 116.5 582.5 1.6 378.2 470.8 -1.2 94.2 470.8 1.3 141.2
YKL163W PIR3 CCW8 10756_at Protein co 144.4 4.2 461.2 144.4 3.3 338.7 34.4 -4.2 109.9 34.4 -1.1 3.4
YER011W TIR1 SRP1 5711_at YER011W 690.6 -1.2 172.0 690.6 1.1 69.1 684.8 1.2 170.5 684.8 1.4 273.9
YJL159W HSP150 CCW7, O 11179_at Kex2-proc 1519.4 1.0 74.2 1519.4 1.1 226.3 1451.1 -1.0 70.8 1451.1 1.1 145.1
YGR282C BGL2 4712_at YGR282C 1370.4 -1.1 204.1 1370.4 -1.0 66.9 1589.9 1.1 236.8 1589.9 1.1 159.0
YKL164C CCW6 PIR1 10755_at Ccw protein 1316.5 1.1 131.7 1316.5 1.0 64.3 1226.1 -1.1 122.6 1226.1 -1.0 0.0
YOR010C TIR2 SRP2 8527_at YOR010C 0.0 0.0 0.0 0.0 0.0 0.0 244.1 1.1 24.4 244.1 1.5 122.1
YBR040W FIG1 7308_at Integral m 18.7 -5.3 81.1 18.7 -2.7 32.6 99.9 5.3 434.4 99.9 1.9 89.9
YAR050W FLO1 FLO2, FL 11301_i_a Putative c 2.3 3.0 4.7 2.3 -3.2 5.1 -3.7 -3.0 -7.5 -3.7 -5.3 -15.9
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YMR305C SCW10 9312_at YMR305C 1138.9 -1.0 0.0 1138.9 -1.2 227.8 1022.2 -1.0 0.0 1022.2 -1.2 204.4
YGR279C SCW4 4709_at YGR279C 1742.7 -1.1 259.5 1742.7 -1.1 259.5 2027.2 1.1 301.9 2027.2 1.0 0.0
YBR067C TIP1 7290_at YBR067C c 1652.2 -1.1 246.0 1652.2 -1.2 411.4 1934.7 1.1 288.1 1934.7 -1.1 193.5
YLR110C CCW12 10229_at YLR110C 4285.1 -1.2 1067.0 4285.1 -1.1 638.1 5335.7 1.2 1328.6 5335.7 1.1 533.6
plasma membrane
YDR046C BAP3 6415_at Valine trans 670.0 2.6 1072.0 670.0 178.1 118656.5 297.2 -2.6 475.5 297.2 81.3 23865.2
YBR068C BAP2 7291_at Major AA 646.7 2.3 839.2 646.7 133.8 85884.2 280.3 -2.3 363.8 280.3 58.7 16173.3
YPL265W DIP5 8030_at Dicarboxyli 911.4 2.2 1085.3 911.4 18.4 15885.5 416.4 -2.2 495.9 416.4 8.5 3123.0
YGR055W MUP1 4936_at High affinity 968.3 2.0 968.3 968.3 9.0 7745.5 486.4 -2.0 486.4 486.4 4.5 1702.4
YBR069C TAT1 VAP1, WA 7292_at Amino aci 164.5 3.1 345.1 164.5 11.2 1685.2 53.1 -3.1 111.4 53.1 4.1 164.6
YBL042C FUI1 7410_at High affinity 254.7 7.2 1578.8 254.7 7.4 1629.8 31.8 -7.2 197.2 31.8 1.0 0.0
YMR058W FET3 9588_at YMR058W 900.7 2.1 988.6 900.7 2.4 1259.1 422.2 -2.1 463.4 422.2 1.1 42.2
YBR021W FUR4 7334_at Uracil per 208.8 4.1 656.1 208.8 6.4 1124.9 41.4 -4.1 130.1 41.4 1.5 20.7
YDR077W SED1 6401_at YDR077W 1872.7 1.3 561.8 1872.7 1.5 1028.5 1464.7 -1.3 439.4 1464.7 1.2 292.9
YNL268W LYP1 9126_at YNL268W 580.1 -1.0 0.0 580.1 2.3 782.8 570.8 -1.0 0.0 570.8 2.3 742.0
YKR093W PTR2 10472_at YKR093W 148.2 2.7 258.7 148.2 5.8 718.0 48.2 -2.7 84.2 48.2 2.1 53.0
YGL008C PMA1 5009_at YGL008C 0.0 0.0 0.0 0.0 0.0 0.0 2122.2 1.1 212.2 2122.2 1.2 424.4
YPL092W SSU1 LPG16 7843_at YPL092W s 279.1 1.3 83.7 279.1 2.3 362.8 0.0 0.0 0.0 0.0 0.0 0.0
YEL017C PMP2 5728_i_at YEL017C 1819.7 -1.3 488.1 1819.7 -1.1 214.0 2277.6 1.3 611.0 2277.6 1.1 339.2
YML116W ATR1 SNQ1 9771_at YML116W 507.3 1.1 50.7 507.3 1.6 329.4 459.7 -1.1 46.0 459.7 1.5 229.9
YER056C FCY2 BRA7 5668_at YER056C p 1819.5 -1.1 238.3 1819.5 1.0 19.9 2117.5 1.1 277.4 2117.5 1.1 311.1
YBR294W SUL1 7067_at Putative s 97.3 1.3 33.9 97.3 4.0 291.6 70.8 -1.3 24.7 70.8 2.9 134.5
YOL020W TAT2 LTG3, SA 8587_at YOL020W 216.0 1.7 151.2 216.0 2.3 291.5 127.2 -1.7 89.0 127.2 1.4 50.9
YLR120C YPS1 10193_at YLR120C 331.0 1.8 281.1 331.0 1.8 281.1 178.2 -1.8 151.3 178.2 -1.0 0.0
YDR497C ITR1 5966_at Myo-inosit 1187.5 -1.2 237.5 1187.5 -1.0 0.0 1358.0 1.2 271.6 1358.0 1.2 271.6
YDR276C PMP3 SNA1 6196_at YDR276C c 1952.2 -1.2 486.1 1952.2 -1.0 95.3 2416.2 1.2 601.6 2416.2 1.1 241.6
YCL025C AGP1 YCC5 6907_at YCL025C 249.7 1.3 87.2 249.7 1.8 212.1 186.9 -1.3 65.2 186.9 1.4 74.8
YMR011W HXT2 9633_at YMR011W 809.5 -1.3 242.8 809.5 -1.0 0.0 1029.2 1.3 308.8 1029.2 1.2 205.8
YCR011C ADP1 6888_at YCR011C S 0.0 0.0 0.0 0.0 0.0 0.0 282.6 1.0 13.8 282.6 1.7 197.8
YGL077C HNM1 5074_at YGL077C 544.7 -1.5 272.3 544.7 -1.2 108.9 924.4 1.5 462.2 924.4 1.2 184.9
YHR094C HXT1 HOR4 4430_at YHR094C 540.4 -1.0 0.0 540.4 1.3 162.1 525.9 -1.0 0.0 525.9 1.3 157.8
YDR345C HXT3 6131_at YDR345C 1351.7 -1.2 264.7 1351.7 -1.1 129.0 1606.0 1.2 314.5 1606.0 1.1 160.6
YKR039W GAP1 10511_at YKR039W 46.7 -2.4 65.2 46.7 -1.4 21.0 110.8 2.4 154.9 110.8 1.7 77.6
YMR008C PLB1 9630_at YMR008C 605.9 1.4 272.1 605.9 1.2 150.9 379.7 -1.4 170.5 379.7 -1.1 38.0
YNR044W AGA1 8802_at YNR044W 473.1 -1.3 140.1 473.1 -1.0 23.1 650.6 1.3 192.7 650.6 1.2 130.1
YER145C FTR1 5585_at YER145C I 260.0 1.1 30.5 260.0 1.5 124.6 143.9 -1.1 18.6 143.9 1.4 58.6
YLR214W FRE1 10106_at Ferric (and 107.8 1.5 59.2 107.8 1.7 80.8 63.6 -1.5 34.9 63.6 1.1 6.4
YER123W YCK3 CKI3 5608_at YER123W 35.8 1.4 16.1 35.8 2.3 48.2 0.0 0.0 0.0 0.0 0.0 0.0
YCL068C ?? 6957_s_at YCL068C 27.3 1.3 7.2 27.3 2.5 41.8 20.9 -1.3 5.5 20.9 2.0 20.9
YFL011W HXT10 5377_at YFL011W H 4.7 -1.9 4.1 4.7 1.1 0.6 10.8 1.9 9.4 10.8 2.0 10.8
YMR243C ZRC1 OSR1 9382_at YMR243C 815.0 -1.0 39.8 815.0 -1.1 121.4 0.0 0.0 0.0 0.0 0.0 0.0
YFL005W SEC4 SRO6 5383_at Ras-like s 416.8 -1.0 0.0 416.8 -1.3 123.4 416.5 -1.0 0.0 416.5 -1.3 125.0
YNL098C RAS2 8979_at YNL098C 0.0 0.0 0.0 0.0 0.0 0.0 478.7 -1.1 47.9 478.7 -1.3 143.6
YCR034W FEN1 ELO2, GN 6869_at YCR034W 728.3 -1.1 72.8 728.3 -1.2 145.7 0.0 0.0 0.0 0.0 0.0 0.0
YGR121C MEP1 AMT1 4866_at Ammonia 42.9 -4.6 155.0 42.9 -5.4 189.0 195.4 4.6 706.8 195.4 -1.2 39.1
YOR153W PDR5 LEM1, YD 8400_at Multidrug re 707.7 -1.3 209.6 707.7 -1.3 209.6 916.0 1.3 271.3 916.0 1.0 0.0
YDR342C HXT7 6128_f_at YDR342C 1141.2 -1.1 114.1 1141.2 -1.2 228.2 0.0 0.0 0.0 0.0 0.0 0.0
YLR342W FKS1 9966_at YLR342W 726.7 -1.1 69.4 726.7 -1.3 253.7 861.6 1.1 82.2 861.6 -1.2 172.3
YJR004C SAG1 AG(ALPH 11026_at YJR004C 1562.2 -1.3 545.3 1562.2 -1.2 312.4 2131.1 1.3 743.9 2131.1 1.1 213.1
YKL178C STE3 10741_at YKL178C 887.2 -1.1 132.1 887.2 -1.4 351.7 1048.9 1.1 156.2 1048.9 -1.2 209.8
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YLR229C CDC42 10121_at Member of 1147.0 -1.0 56.0 1147.0 -1.3 400.4 1103.3 1.0 53.9 1103.3 -1.3 331.0
YMR307W GAS1 CWH52, G 9315_at YMR307W 2126.2 -1.2 425.2 2126.2 -1.2 425.2 2549.2 1.2 509.8 2549.2 -1.0 0.0
YDR343C HXT6 6129_f_at YDR343C 1105.6 -1.1 110.6 1105.6 -1.4 442.2 1197.1 1.1 119.7 1197.1 -1.3 359.1
YNL142W MEP2 9026_at Ammonia t 75.9 -17.2 1229.5 75.9 -14.8 1051.2 1305.0 17.2 21139.5 1305.0 1.2 261.0
cytoplasm
YHR128W FUR1 4422_at Uracil pho 441.7 48.6 21042.7 441.7 18.9 7891.4 9.1 -48.6 433.6 9.1 -2.8 16.4
YNL104C LEU4 8973_at YNL104C 1720.8 1.1 172.1 1720.8 2.0 1720.8 1616.3 -1.1 161.6 1616.3 1.8 1293.0
YPR145W ASN1 7588_at YPR145W 1054.4 1.3 368.1 1054.4 2.6 1685.0 757.0 -1.3 264.2 757.0 1.9 681.3
YJR145C 10893_s_ YJR145C 2528.9 -1.2 505.8 2528.9 1.1 376.6 3067.1 1.2 613.4 3067.1 1.4 1226.8
YOL058W ARG1 ARG10 8593_at YOL058W 1917.4 1.1 191.7 1917.4 1.6 1150.4 1715.0 -1.1 171.5 1715.0 1.5 857.5
YPL079W 7811_at YPL079W 3889.3 -1.2 968.4 3889.3 -1.0 189.8 4786.7 1.2 1191.9 4786.7 1.2 957.3
YGR192C TDH3 GLD1, HS 4802_i_at Glyceralde 3727.1 -1.2 898.1 3727.1 -1.0 165.7 4578.3 1.2 1103.2 4578.3 1.2 915.7
YPL111W CAR1 LPH15 7869_at Arginase / S 304.8 2.1 350.3 304.8 3.8 853.4 142.4 -2.1 163.7 142.4 1.9 128.2
YJR009C TDH2 GLD2 11031_s_ YJR009C 3547.9 -1.1 528.3 3547.9 -1.0 0.0 4151.9 1.1 618.3 4151.9 1.2 830.4
YLR344W 9968_s_at YLR344W 3362.5 -1.2 837.2 3362.5 -1.0 164.1 4066.5 1.2 1012.6 4066.5 1.2 813.3
YHR174W ENO2 4334_i_at YHR174W 2988.8 -1.3 1043.3 2988.8 -1.1 445.1 4037.7 1.3 1409.5 4037.7 1.2 807.5
YLR075W 10239_at YLR075W 2845.6 -1.2 708.6 2845.6 -1.0 138.9 3518.0 1.2 876.0 3518.0 1.2 703.6
YKL180W 10738_i_a YKL180W 2817.6 -1.2 563.5 2817.6 -1.0 0.0 3486.2 1.2 697.2 3486.2 1.2 697.2
YHR021C 4494_at YHR021C 4 2555.9 -1.2 636.4 2555.9 -1.0 124.7 3188.4 1.2 793.9 3188.4 1.2 637.7
YLR340W 9964_at YLR340W 2536.8 -1.2 631.6 2536.8 -1.0 123.8 3106.9 1.2 773.6 3106.9 1.2 621.4
YDR382W 6080_at YDR382W 2413.6 -1.3 714.8 2413.6 -1.1 230.4 3071.7 1.3 909.7 3071.7 1.2 614.3
YJL136C 11158_i_a YJL136C 3299.5 -1.2 808.3 3299.5 -1.0 79.6 4054.7 1.2 993.3 4054.7 1.1 603.8
YGL189C 5191_f_at YGL189C 2355.7 -1.3 636.4 2355.7 -1.1 230.2 2883.3 1.3 778.9 2883.3 1.2 564.6
YLR303W MET17 MET15, M 10018_at YLR303W 2391.4 -1.1 356.1 2391.4 -1.0 0.0 2776.8 1.1 413.5 2776.8 1.2 555.4
YLR044C PDC1 10296_at YLR044C 2283.0 -1.2 456.6 2283.0 -1.0 0.0 2763.9 1.2 552.8 2763.9 1.2 552.8
YDL075W 6569_at YDL075W 1960.6 -1.4 777.2 1960.6 -1.1 283.4 2750.1 1.4 1090.2 2750.1 1.2 550.0
YOR293W 8269_f_at YOR293W 1286.0 -1.2 320.2 1286.0 1.1 122.7 1609.6 1.2 400.8 1609.6 1.3 549.9
YMR143W 9497_i_at YMR143W 849.7 -1.2 211.6 849.7 1.2 175.1 1025.4 1.2 255.3 1025.4 1.5 533.1
YPR080W TEF1 7656_s_at YPR080W 2055.9 -1.3 608.9 2055.9 -1.1 196.2 2619.5 1.3 775.8 2619.5 1.2 523.9
YIL052C 4165_i_at YIL052C 2049.3 -1.3 606.9 2049.3 -1.0 0.0 2582.5 1.3 764.8 2582.5 1.2 516.5
YMR242C 9381_s_at YMR242C 1408.7 -1.2 281.7 1408.7 1.0 68.8 1685.4 1.2 337.1 1685.4 1.3 505.6
YGL147C 5142_i_at YGL147C 472.5 -1.4 173.6 472.5 1.4 173.6 629.9 1.4 231.5 629.9 1.8 503.9
YNL301C 9183_s_at YNL301C 1971.2 -1.2 490.8 1971.2 -1.0 47.5 2419.5 1.2 602.5 2419.5 1.2 483.9
YBR082C UBC4 7260_at YBR082C u 946.7 1.1 94.7 946.7 1.5 473.3 840.4 -1.1 84.0 840.4 1.3 252.1
YEL054C 5781_i_at YEL054C 1913.3 -1.2 476.4 1913.3 -1.0 93.4 2365.3 1.2 589.0 2365.3 1.2 473.1
YHL001W 4515_i_at YHL001W 1047.4 -1.3 285.3 1047.4 1.1 65.1 1278.9 1.3 348.3 1278.9 1.4 470.0
YMR230W 9413_f_at YMR230W 798.7 -1.2 126.4 798.7 1.3 219.4 958.6 1.2 151.7 958.6 1.5 450.2
YML063W 9691_i_at YML063W 1232.7 -1.2 306.9 1232.7 1.0 60.2 1493.1 1.2 371.8 1493.1 1.3 447.9
YLR333C 10002_i_a YLR333C 1534.6 -1.2 267.3 1534.6 1.0 65.4 1832.1 1.2 319.1 1832.1 1.2 441.5
YLL018C DPS1 9868_at YLL018C 496.3 1.7 328.2 496.3 1.9 433.5 408.8 -1.7 270.3 408.8 1.1 60.9
YGL031C 5031_at YGL031C 1705.7 -1.3 505.1 1705.7 -1.1 162.8 2163.7 1.3 640.8 2163.7 1.2 432.7
YGL030W 5032_at YGL030W 1709.5 -1.2 411.9 1709.5 -1.0 0.0 2125.5 1.2 512.2 2125.5 1.2 425.1
YKL006W 10558_s_ YKL006W 2624.3 -1.3 687.1 2624.3 -1.1 293.1 3341.8 1.3 874.9 3341.8 1.1 423.1
YBR196C PGI1 CDC30 7152_at Glucose-6 1683.3 -1.2 419.1 1683.3 -1.0 82.2 2100.2 1.2 522.9 2100.2 1.2 420.0
YDR035W ARO3 6450_at YDR035W 1396.4 1.1 139.6 1396.4 1.3 418.9 1273.6 -1.1 127.4 1273.6 1.2 254.7
YIR034C LYS1 4070_at YIR034C s 1335.0 -1.0 65.2 1335.0 1.2 332.4 1385.0 1.0 67.6 1385.0 1.3 415.5
YBR031W 7344_i_at YBR031W 903.3 -1.5 411.8 903.3 -1.2 172.4 1175.7 1.5 536.0 1175.7 1.3 401.6
YLR048W 10301_at YLR048W 2484.7 -1.2 533.5 2484.7 -1.1 159.3 3017.4 1.2 647.8 3017.4 1.1 399.4
YNL162W 9006_s_at YNL162W 1629.0 -1.2 325.8 1629.0 -1.0 79.5 1986.6 1.2 397.3 1986.6 1.2 397.3
YLR287C 10047_f_a YLR287C 3167.8 -1.2 788.8 3167.8 -1.0 154.6 3855.8 1.2 960.1 3855.8 1.1 385.6
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YML073C 9726_at YML073C R 1002.1 -1.2 249.5 1002.1 1.0 48.9 1281.1 1.2 319.0 1281.1 1.3 384.3
YLR406C 9897_f_at YLR406C 1821.9 -1.2 453.6 1821.9 -1.1 147.9 2302.1 1.2 573.2 2302.1 1.2 381.4
YDR418W 6069_i_at YDR418W 1443.6 -1.4 524.7 1443.6 -1.1 199.9 1942.5 1.4 706.0 1942.5 1.2 380.4
YMR186W HSC82 9456_at YMR186W 1536.6 -1.2 300.9 1536.6 -1.0 0.0 1859.1 1.2 364.1 1859.1 1.2 371.8
YCR012W PGK1 6890_at 3-Phospho 3009.0 -1.2 589.2 3009.0 -1.1 287.2 3629.6 1.2 710.8 3629.6 1.1 363.0
YOR182C 8384_f_at YOR182C 2871.4 -1.2 715.0 2871.4 -1.1 274.1 3570.6 1.2 889.1 3570.6 1.1 357.1
YKL152C GPM1 10721_at Phosphogly 3118.6 -1.1 464.4 3118.6 -1.0 152.2 3538.3 1.1 526.9 3538.3 1.1 353.8
YMR116C ASC1 CPC2 9512_at YMR116C 2863.4 -1.2 572.7 2863.4 -1.1 286.3 3505.4 1.2 701.1 3505.4 1.1 350.5
YKL211C TRP3 10801_at YKL211C 465.6 1.2 115.9 465.6 1.7 348.9 337.3 -1.2 84.0 337.3 1.4 134.9
YLR388W 9923_f_at YLR388W 2857.6 -1.1 425.5 2857.6 -1.0 139.5 3370.6 1.1 501.9 3370.6 1.1 337.1
YDR012W 6473_i_at YDR012W 1178.7 -1.4 529.4 1178.7 -1.2 293.5 1664.0 1.4 747.4 1664.0 1.2 332.8
YER074W 5647_s_at YER074W 1173.0 -1.3 409.4 1173.0 -1.1 174.7 1562.3 1.3 545.4 1562.3 1.2 312.5
YER056C FCY2 BRA7 5668_at YER056C p 1819.5 -1.1 238.3 1819.5 1.0 19.9 2117.5 1.1 277.4 2117.5 1.1 311.1
YOL126C MDH2 8663_at Cytosolic 126.7 1.9 113.7 126.7 3.4 309.9 66.1 -1.9 59.3 66.1 1.8 52.9
YNR050C LYS9 LYS13 8808_at YNR050C S 0.0 0.0 0.0 0.0 0.0 0.0 1516.0 1.1 151.6 1516.0 1.2 303.2
YNL016W PUB1 8879_at YNL016W 329.2 1.6 197.5 329.2 1.9 296.2 203.9 -1.6 122.3 203.9 1.2 40.8
YHR053C CUP1-1 CUP1 4483_s_at YHR053C c 1985.9 1.2 397.2 1985.9 1.1 295.7 0.0 0.0 0.0 0.0 0.0 0.0
YML024W 9686_s_at YML024W 2444.4 -1.1 364.0 2444.4 -1.0 119.3 2901.7 1.1 432.1 2901.7 1.1 290.2
YOR369C 8168_at YOR369C 2272.3 -1.2 445.0 2272.3 -1.0 110.9 2671.6 1.2 523.2 2671.6 1.1 267.2
YKL104C GFA1 10680_at YKL104C 276.7 1.6 179.6 276.7 1.9 262.6 169.2 -1.6 109.9 169.2 1.1 16.9
YOR204W DED1 SPP81 8361_at YOR204W 325.4 1.8 260.3 325.4 1.3 97.6 169.7 -1.8 135.8 169.7 -1.3 50.9
YNL302C 9182_s_at YNL302C 2205.2 -1.1 328.4 2205.2 -1.0 107.6 2531.0 1.1 376.9 2531.0 1.1 253.1
YNL096C 8981_at YNL096C 1165.4 -1.0 56.9 1165.4 1.1 173.5 1260.1 1.0 61.5 1260.1 1.2 252.0
YDL215C GDH2 6693_at YDL215C 199.9 1.8 169.7 199.9 2.2 249.7 107.7 -1.8 91.5 107.7 1.2 21.5
YCR053W THR4 6841_at YCR053W 0.0 0.0 0.0 0.0 0.0 0.0 802.0 1.1 80.2 802.0 1.3 240.6
YJL138C TIF2 11156_s_ YJL138C t 1972.0 -1.1 293.7 1972.0 -1.0 96.3 2291.9 1.1 341.3 2291.9 1.1 229.2
YNL259C ATX1 9135_at YNL259C 701.7 1.1 70.2 701.7 1.3 210.5 0.0 0.0 0.0 0.0 0.0 0.0
YCL018W LEU2 6909_at YCL018W 1041.6 1.3 312.5 1041.6 1.2 208.3 805.3 -1.3 241.6 805.3 -1.0 0.0
YIL148W 4253_i_at YIL148W 822.0 -1.2 198.1 822.0 -1.0 0.0 1017.9 1.2 245.3 1017.9 1.2 203.6
YOR167C 8369_f_at YOR167C 1763.8 -1.2 352.8 1763.8 -1.0 38.8 2079.9 1.2 416.0 2079.9 1.1 198.5
YJL189W 11237_at YJL189W 1683.5 -1.2 336.7 1683.5 -1.1 168.3 1974.3 1.2 394.9 1974.3 1.1 197.4
YGL103W 5094_at YGL103W 1673.9 -1.2 334.8 1673.9 -1.1 167.4 1962.7 1.2 392.5 1962.7 1.1 196.3
YJR109C CPA2 10902_at YJR109C 778.2 1.1 115.9 778.2 1.2 193.8 0.0 0.0 0.0 0.0 0.0 0.0
YOR096W 8479_at YOR096W 1643.4 -1.1 244.7 1643.4 -1.0 80.2 1915.7 1.1 285.3 1915.7 1.1 191.6
YPR102C 7632_i_at YPR102C R 1550.4 -1.2 310.1 1550.4 -1.1 155.0 1849.3 1.2 369.9 1849.3 1.1 184.9
YOL127W 8662_at YOL127W 1394.8 -1.2 347.3 1394.8 -1.1 139.5 1828.8 1.2 455.4 1828.8 1.1 182.9
YPL090C 7845_s_at YPL090C 1431.8 -1.2 286.4 1431.8 -1.1 143.2 1768.0 1.2 353.6 1768.0 1.1 176.8
YDR354W TRP4 6095_at YDR354W 321.6 1.2 80.1 321.6 1.5 176.6 0.0 0.0 0.0 0.0 0.0 0.0
YNL272C SEC2 9122_at Protein wit 57.0 1.0 2.8 57.0 3.8 159.2 56.4 -1.0 2.8 56.4 3.8 157.9
YPL262W FUM1 8033_at YPL262W 770.2 1.2 150.8 770.2 1.1 73.5 627.8 -1.2 122.9 627.8 -1.1 62.8
YDL130W RPP1B RPL44', R 6600_at YDL130W 1812.2 -1.0 89.9 1812.2 -1.0 11.0 2258.3 1.3 635.7 2258.3 1.1 148.1
YJR148W BAT2 TWT2, EC 10896_at YJR148W 0.0 0.0 0.0 0.0 0.0 0.0 204.4 -2.0 214.5 204.4 1.7 143.1
YCL040W GLK1 HOR3 6937_at YCL040W 686.5 1.6 411.9 686.5 1.2 137.3 437.3 -1.6 262.4 437.3 -1.3 131.2
YGR234W YHB1 YHB4 4754_at YGR234W 274.2 1.4 121.3 274.2 1.5 136.2 0.0 0.0 0.0 0.0 0.0 0.0
YKL081W TEF4 EFC1 10658_at YKL081W T 389.0 -1.3 130.3 389.0 1.2 74.6 471.5 1.3 157.9 471.5 1.3 134.1
YDR188W CCT6 HTR3, TC 6290_at YDR188W 379.4 1.3 132.4 379.4 1.2 75.9 0.0 0.0 0.0 0.0 0.0 0.0
YAL040C CLN3 DAF1, FU 11369_at YAL040C 188.8 1.2 37.8 188.8 1.7 132.1 0.0 0.0 0.0 0.0 0.0 0.0
YPR074C TKL1 7694_at YPR074C T 1097.1 -1.1 163.4 1097.1 -1.0 53.5 1280.0 1.1 190.6 1280.0 1.1 128.0
YNL007C SIS1 8888_at YNL007C 635.8 1.2 127.2 635.8 1.1 63.6 519.0 -1.2 103.8 519.0 -1.1 51.9
YKL067W YNK1 NDK1 10629_at YKL067W 846.5 1.1 126.1 846.5 -1.0 0.0 677.9 -1.1 100.9 677.9 -1.1 67.8
YGL026C TRP5 5036_at YGL026C 1026.9 -1.2 201.1 1026.9 -1.1 98.0 1215.8 1.2 238.1 1215.8 1.1 121.6
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YER091C MET6 5620_at YER091C v 966.8 -1.2 240.7 966.8 -1.1 96.7 1207.0 1.2 300.5 1207.0 1.1 120.7
YKL190W CNB1 10772_at YKL190W T 0.0 0.0 0.0 0.0 0.0 0.0 575.0 1.1 57.5 575.0 1.2 115.0
YBL078C AUT7 APG8, CV 7464_at YBL078C 230.6 1.4 102.0 230.6 1.5 114.5 167.6 -1.4 74.1 167.6 1.0 0.0
YDR074W TPS2 HOG2, PF 6398_at YDR074W 224.7 1.5 111.6 224.7 -1.0 11.0 140.6 -1.5 69.8 140.6 -1.6 84.4
YLL009C COX17 10334_at YLL009C i 551.2 1.2 110.2 551.2 1.1 82.1 0.0 0.0 0.0 0.0 0.0 0.0
YBR072W HSP26 7295_at YBR072W 88.4 2.2 105.9 88.4 1.4 39.7 41.9 -2.2 50.2 41.9 -1.5 21.0
YDR007W TRP1 6468_at YDR007W 233.8 1.4 105.0 233.8 1.1 34.8 0.0 0.0 0.0 0.0 0.0 0.0
YPL240C HSP82 HSP83, H 8010_i_at YPL240C 0.0 0.0 0.0 0.0 0.0 0.0 514.6 -1.0 0.0 514.6 1.2 102.9
YPL145C KES1 LPI3, OSH47880_at YPL145C 405.0 1.2 100.8 405.0 -1.0 19.8 0.0 0.0 0.0 0.0 0.0 0.0
YOR202W HIS3 8359_at YOR202W 673.6 1.1 67.4 673.6 1.1 100.3 0.0 0.0 0.0 0.0 0.0 0.0
YDR037W KRS1 GCD5 6452_at YDR037W 756.0 -1.2 148.0 756.0 -1.0 36.9 901.7 1.2 176.6 901.7 1.1 90.2
YCR068W CVT17 AUT5 6809_at Teter et al. 24.0 5.6 110.5 24.0 4.7 89.4 5.6 -4.4 18.9 5.6 -1.2 1.1
YER133W GLC7 CID1, DIS 5573_at protein ph 242.7 1.2 40.7 242.7 1.3 84.2 217.2 -1.2 36.4 217.2 1.1 30.4
YIL167W SDL1 4284_at Serine deh 13.4 4.2 42.7 13.4 3.8 37.9 1.6 -4.2 5.1 1.6 -1.5 0.8
YGL180W APG1 AUT3 5200_at YGL180W 21.5 1.7 16.1 21.5 2.1 24.7 0.0 0.0 0.0 0.0 0.0 0.0
YFR034C PHO4 5333_at YFR034C 9.9 2.3 12.4 9.9 1.4 4.0 3.3 -2.3 4.1 3.3 -1.2 0.7
YIL066C RNR3 DIN1, RIR 4045_s_at YIL066C 7.3 2.2 8.5 7.3 -1.1 1.0 2.2 -2.2 2.6 2.2 -1.2 0.4
YOR178C GAC1 8380_at YOR178C 5.2 1.7 3.5 5.2 -1.3 1.8 3.1 -1.7 2.1 3.1 -2.1 3.4
YBR189W 7191_f_at YBR189W 1255.6 -1.2 312.6 1255.6 -1.1 46.6 1693.8 1.2 421.8 1693.8 1.1 42.2
YNL241C ZWF1 MET19, P 9108_at Glucose-6 206.9 1.3 62.1 206.9 -1.0 0.0 157.1 -1.3 47.1 157.1 -1.3 47.1
YMR105C PGM2 9547_at YMR105C 0.0 0.0 0.0 0.0 0.0 0.0 157.8 -1.3 55.1 157.8 -1.6 94.7
YMR260C TIF11 9354_at YMR260C 392.1 -1.3 136.9 392.1 -1.2 97.6 539.5 1.3 188.3 539.5 1.1 54.0
YDR044W HEM13 6413_at YDR044W 202.2 -1.2 50.3 202.2 -1.5 101.1 0.0 0.0 0.0 0.0 0.0 0.0
YJR047C ANB1 HYP1, TIF 10976_at YJR047C 180.8 -1.8 153.6 180.8 -1.6 108.5 332.5 1.8 282.4 332.5 1.2 66.5
YBL076C ILS1 7421_at YBL076C 367.9 -1.1 35.1 367.9 -1.3 109.0 0.0 0.0 0.0 0.0 0.0 0.0
YKL024C URA6 10583_at YKL024C 314.8 1.1 30.0 314.8 -1.3 93.2 273.6 -1.1 26.1 273.6 -1.4 109.4
YKL156W 10717_at YKL156W 4 1167.3 -1.1 173.8 1167.3 -1.1 116.7 1337.0 1.1 199.1 1337.0 1.0 0.0
YDR214W AHA1 6271_at YDR214W 0.0 0.0 0.0 0.0 0.0 0.0 295.8 -1.1 28.2 295.8 -1.4 118.3
YIL078W THS1 4186_at YIL078W 799.3 -1.1 79.9 799.3 -1.1 119.0 0.0 0.0 0.0 0.0 0.0 0.0
YDL022W GPD1 DAR1, HO 6485_at YDL022W 763.2 1.1 113.7 763.2 -1.0 0.0 647.3 -1.1 96.4 647.3 -1.2 129.5
YJL052W TDH1 GLD3 11061_g_ YJL052W 1811.4 -1.0 77.3 1811.4 -1.1 134.2 2067.3 -1.0 88.2 2067.3 1.0 0.0
YPL106C SSE1 LPG3, MS 7874_at YPL106C 672.7 -1.0 0.0 672.7 -1.2 134.5 633.8 -1.0 0.0 633.8 -1.2 126.8
YER131W 5571_at YER131W 475.1 -1.2 93.0 475.1 -1.3 135.2 563.2 1.2 110.3 563.2 -1.0 0.0
YJL121C RPE1 EPI1, POS 11128_at YJL121C 688.8 -1.3 240.4 688.8 -1.2 137.8 905.1 1.3 315.9 905.1 1.1 90.5
YLR354C TAL1 9978_at YLR354C 946.7 -1.0 46.2 946.7 -1.1 141.0 0.0 0.0 0.0 0.0 0.0 0.0
YBR121C GRS1 7257_at YBR121C G 709.4 -1.2 141.9 709.4 -1.2 141.9 776.5 1.2 155.3 776.5 1.0 0.0
YOR335C ALA1 8225_at YOR335C 579.8 -1.2 144.4 579.8 -1.2 144.4 722.2 1.2 179.8 722.2 -1.0 0.0
YGL253W HXK2 HEX1, HK 5260_at YGL253W 751.4 -1.3 262.3 751.4 -1.2 150.3 981.0 1.3 342.4 981.0 1.1 98.1
YNL015W PBI2 yscB, I2B, L8880_at YNL015W 683.7 1.3 205.1 683.7 1.0 33.4 507.9 -1.3 152.4 507.9 -1.3 152.4
YFR053C HXK1 5307_at YFR053C 271.0 1.0 13.2 271.0 -1.5 135.5 259.3 -1.0 12.7 259.3 -1.6 155.6
YER003C PMI40 PMI 5702_at YER003C m 630.6 -1.1 63.1 630.6 -1.2 157.0 694.4 1.1 69.4 694.4 -1.2 138.9
YDR155C CPR1 CYP1, CP 6301_at YDR155C c 1671.5 -1.2 327.3 1671.5 -1.1 159.5 0.0 0.0 0.0 0.0 0.0 0.0
YLL039C UBI4 SCD2 10392_at YLL039C 432.6 1.3 151.0 432.6 -1.1 64.4 321.2 -1.3 112.1 321.2 -1.5 160.6
YER009W NTF2 5709_at YER009W 834.6 -1.2 163.4 834.6 -1.2 163.4 957.1 1.2 187.4 957.1 1.0 0.0
YDR226W ADK1 6237_at YDR226W 1116.1 -1.1 166.2 1116.1 -1.1 166.2 1457.8 1.1 217.1 1457.8 1.0 0.0
YDR321W ASP1 6152_at YDR321W 670.4 -1.3 234.0 670.4 -1.2 166.9 901.4 1.3 314.7 901.4 1.1 90.1
YMR146C TIF34 9501_at YMR146C 380.6 -1.0 18.6 380.6 -1.4 170.9 385.5 1.0 18.8 385.5 -1.4 154.2
YPL081W 7854_i_at YPL081W 563.9 -1.3 163.7 563.9 -1.3 176.7 717.0 1.3 208.2 717.0 -1.0 35.0
YOR276W CAF20 CAF2, CA 8252_at YOR276W 722.3 -1.1 72.2 722.3 -1.2 179.8 0.0 0.0 0.0 0.0 0.0 0.0
YGR204W ADE3 4814_at YGR204W 724.6 -1.2 144.9 724.6 -1.2 180.4 901.8 1.2 180.4 901.8 -1.0 0.0
YGL062W PYC1 5090_at YGL062W 142.4 -1.7 106.7 142.4 -2.3 185.1 291.0 1.7 218.0 291.0 -1.3 87.3
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YNL244C SUI1 MOF2, RF 9105_at YNL244C 939.7 -1.1 94.0 939.7 -1.2 187.9 0.0 0.0 0.0 0.0 0.0 0.0
YBR048W 7316_s_at YBR048W 1977.1 -1.1 294.4 1977.1 -1.1 188.7 2248.8 1.1 334.9 2248.8 1.0 0.0
YHL015W 4547_at YHL015W 1285.1 -1.2 251.7 1285.1 -1.1 191.4 1504.1 1.2 294.5 1504.1 1.0 0.0
YNL064C YDJ1 MAS5 8924_at YNL064C 979.7 1.0 47.8 979.7 -1.1 145.9 959.6 -1.0 46.8 959.6 -1.2 191.9
YPR132W 7619_s_at YPR132W 2790.2 -1.1 415.5 2790.2 -1.1 200.5 3197.7 1.1 476.2 3197.7 1.0 156.1
YFL045C SEC53 ALG4 5435_at YFL045C 1356.7 -1.1 202.0 1356.7 -1.1 202.0 1549.8 1.1 230.8 1549.8 -1.0 0.0
YAL003W EFB1 TEF5 11320_at YAL003W T 1673.1 -1.2 331.1 1673.1 -1.1 203.9 2018.1 1.2 399.4 2018.1 1.0 98.5
YJL157C FAR1 11181_at YJL157C 346.1 -1.3 120.8 346.1 -1.6 206.5 476.4 1.3 166.3 476.4 -1.2 95.3
YDR471W 5985_at YDR471W 1396.6 -1.2 279.3 1396.6 -1.1 208.0 1697.3 1.2 339.5 1697.3 1.1 169.7
YPL028W ERG10 LPB3, TS 7770_at YPL028W a 1419.8 -1.1 211.4 1419.8 -1.1 211.4 1632.9 1.1 243.2 1632.9 -1.0 0.0
YDL184C 6680_s_at YDL184C 1060.2 -1.3 318.1 1060.2 -1.2 212.0 1389.1 1.3 416.7 1389.1 1.1 138.9
YOL139C CDC33 TIF45 8695_at YOL139C 1080.1 -1.1 108.0 1080.1 -1.2 216.0 0.0 0.0 0.0 0.0 0.0 0.0
YPR033C HTS1 TSM4572 7741_at YPR033C c 720.9 -1.1 72.1 720.9 -1.3 216.3 795.2 1.1 79.5 795.2 -1.2 159.0
YCR031C 6866_at YCR031C 1455.3 -1.2 362.4 1455.3 -1.1 216.7 1839.9 1.2 458.1 1839.9 1.1 184.0
YGR214W 4780_at YGR214W 1457.7 -1.2 285.4 1457.7 -1.1 217.1 1570.5 1.2 307.5 1570.5 1.1 157.1
YJR123W 10916_at YJR123W 2208.1 -1.1 328.8 2208.1 -1.1 220.8 2589.4 1.1 385.6 2589.4 1.0 0.0
YHR183W GND1 4343_at YHR183W 1485.6 -1.1 221.2 1485.6 -1.1 221.2 1682.4 1.1 250.5 1682.4 1.0 0.0
YDR212W TCP1 CCT1 6269_at YDR212W 560.2 -1.2 112.0 560.2 -1.4 224.1 677.8 1.2 135.6 677.8 -1.1 67.8
YDR002W YRB1 CST20, H 6463_at YDR002W 912.6 -1.2 182.5 912.6 -1.2 227.2 0.0 0.0 0.0 0.0 0.0 0.0
YLR058C SHM2 SHMT2 10267_at YLR058C 1548.0 -1.1 230.5 1548.0 -1.1 230.5 1780.5 1.1 265.1 1780.5 -1.0 0.0
YLR027C AAT2 ASP5 10323_at YLR027C 1551.3 -1.1 231.0 1551.3 -1.1 231.0 1722.6 1.1 256.5 1722.6 -1.0 0.0
YJL026W RNR2 CRT6 11041_at YJL026W 665.7 -1.1 66.6 665.7 -1.3 232.4 774.7 1.1 77.5 774.7 -1.2 154.9
YFR032C 5331_at YFR032C 1564.0 -1.2 389.4 1564.0 -1.1 232.9 1715.2 1.2 427.1 1715.2 1.1 171.5
YBR143C SUP45 SAL4, SU 7234_at YBR143C T 569.1 -1.0 0.0 569.1 -1.4 227.6 583.2 -1.0 0.0 583.2 -1.4 233.3
YKL182W FAS1 10781_at YKL182W  802.1 -1.0 39.1 802.1 -1.3 237.5 931.3 1.0 45.5 931.3 -1.2 186.3
YDL061C 6537_f_at YDL061C 1608.4 -1.2 321.7 1608.4 -1.1 239.5 2021.8 1.2 404.4 2021.8 1.0 0.0
YLR325C 9994_at YLR325C 2428.1 -1.1 361.6 2428.1 -1.1 242.8 2763.9 1.1 411.6 2763.9 1.0 0.0
YBR011C IPP1 7370_at YBR011C I 1251.3 -1.2 250.3 1251.3 -1.2 250.3 1505.0 1.2 301.0 1505.0 1.0 0.0
YLR264W 10068_i_a YLR264W 2584.2 -1.1 384.8 2584.2 -1.1 252.5 2952.9 1.1 439.7 2952.9 1.0 144.1
YNL067W 8921_s_at YNL067W 1726.3 -1.0 84.3 1726.3 -1.1 257.1 0.0 0.0 0.0 0.0 0.0 0.0
YPL143W 7882_f_at YPL143W 1752.7 -1.2 436.4 1752.7 -1.1 261.0 2153.6 1.2 536.2 2153.6 1.1 215.4
YOR063W 8491_at YOR063W 1309.3 -1.1 130.9 1309.3 -1.2 261.9 0.0 0.0 0.0 0.0 0.0 0.0
YPL061W ALD6 7828_at YPL061W c 750.5 -1.1 111.8 750.5 -1.3 262.0 859.1 1.1 127.9 859.1 -1.2 171.8
YKR094C 10474_s_ YKR094C R 1812.2 -1.2 358.7 1812.2 -1.1 266.2 2208.2 1.2 437.0 2208.2 1.1 210.8
YPL249C 8000_i_at YPL249C 907.7 -1.3 268.8 907.7 -1.3 268.8 1184.0 1.3 350.6 1184.0 1.0 0.0
YLR060W FRS1 10269_at YLR060W 1379.2 -1.1 205.4 1379.2 -1.2 275.8 1572.9 1.1 234.2 1572.9 -1.1 157.3
YJR104C SOD1 CRS4 10897_at YJR104C 1864.3 -1.1 186.4 1864.3 -1.1 277.6 0.0 0.0 0.0 0.0 0.0 0.0
YHR193C EGD2 4353_at YHR193C c 1137.1 -1.1 169.3 1137.1 -1.2 283.1 1294.9 1.1 192.8 1294.9 -1.1 129.5
YJL191W 11235_at YJL191W 642.2 -1.4 288.4 642.2 -1.4 288.4 945.5 1.4 424.7 945.5 1.0 0.0
YLR448W 9852_at YLR448W 1941.5 -1.1 194.2 1941.5 -1.1 289.1 0.0 0.0 0.0 0.0 0.0 0.0
YBL092W 7448_at YBL092W 1463.1 -1.2 292.6 1463.1 -1.2 292.6 1879.3 1.2 375.9 1879.3 1.0 0.0
YPL220W 7984_s_at YPL220W 2002.5 -1.2 498.6 2002.5 -1.1 298.2 2442.9 1.2 608.3 2442.9 1.1 244.3
YGR061C ADE6 4942_at YGR061C 543.9 -1.1 81.0 543.9 -1.5 298.7 604.9 1.1 90.1 604.9 -1.3 181.5
YGR240C PFK1 4760_at Phosphofr 1005.6 -1.2 250.4 1005.6 -1.3 301.7 1258.0 1.2 313.2 1258.0 -1.1 125.8
YPL231W FAS2 7973_at YPL231W a 396.9 1.0 19.4 396.9 -1.7 297.4 377.5 -1.0 18.4 377.5 -1.8 302.0
YDL191W 6672_s_at YDL191W 1556.5 -1.2 304.8 1556.5 -1.2 304.8 1877.9 1.2 367.7 1877.9 -1.0 0.0
YMR142C 9496_at YMR142C 1229.5 -1.3 429.2 1229.5 -1.2 306.1 1708.6 1.3 596.4 1708.6 1.1 170.9
YGL123W 5119_at YGL123W 2085.1 -1.2 519.2 2085.1 -1.1 310.5 2617.9 1.2 651.9 2617.9 1.1 261.8
YNL209W SSB2 9094_s_at YNL209W 2100.0 -1.1 312.7 2100.0 -1.1 312.7 2488.7 1.1 370.6 2488.7 1.0 0.0
YPR035W GLN1 7698_at YPR035W 1270.0 -1.4 508.0 1270.0 -1.2 316.2 1721.7 1.4 688.7 1721.7 1.1 172.2
YGR118W 4909_f_at YGR118W 2127.7 -1.1 316.8 2127.7 -1.1 316.8 2514.3 1.1 374.4 2514.3 1.0 0.0
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YDR500C 5969_at YDR500C 6 2208.7 -1.3 654.1 2208.7 -1.1 328.9 2914.7 1.3 863.2 2914.7 1.1 291.5
YLL045C 10386_s_ YLL045C 1659.8 -1.2 289.1 1659.8 -1.1 26.4 1906.1 1.2 332.0 1906.1 1.0 14.8
YBL072C 7425_s_at YBL072C 2290.7 -1.2 570.4 2290.7 -1.1 341.1 2779.9 1.2 692.2 2779.9 1.1 278.0
YDR064W 6433_at YDR064W 1722.3 -1.2 344.5 1722.3 -1.2 344.5 2085.3 1.2 417.1 2085.3 1.0 0.0
YER023W PRO3 ORE2 5678_at YER023W 771.7 -1.2 192.1 771.7 -1.4 346.6 961.5 1.2 239.4 961.5 -1.2 192.3
YOL120C 8668_at YOL120C 1845.5 -1.2 459.5 1845.5 -1.2 361.4 2308.9 1.2 574.9 2308.9 1.1 230.9
YLR185W 10166_at YLR185W 1831.8 -1.3 639.4 1831.8 -1.2 366.4 2462.9 1.3 859.7 2462.9 1.1 246.3
YDL083C 6559_f_at YDL083C 1335.4 -1.2 299.5 1335.4 -1.1 44.6 1641.7 1.2 368.2 1641.7 1.0 18.0
YMR194W 9420_i_at YMR194W 2154.9 -1.2 527.9 2154.9 -1.2 375.3 2714.2 1.2 664.9 2714.2 1.1 259.1
YGL076C 5075_i_at YGL076C 1397.4 -1.0 68.2 1397.4 -1.3 380.6 1462.8 1.0 71.4 1462.8 -1.1 217.8
YDR050C TPI1 6419_at Triosepho 2559.9 -1.2 637.4 2559.9 -1.1 381.2 3338.3 1.2 831.2 3338.3 1.1 333.8
YOR133W EFT1 8425_s_at YOR133W 1558.5 -1.1 232.1 1558.5 -1.2 388.1 1852.7 1.1 275.9 1852.7 -1.0 0.0
YOL040C 8612_at YOL040C 1952.9 -1.2 390.6 1952.9 -1.2 390.6 2270.9 1.2 454.2 2270.9 -1.0 0.0
YHL033C 4575_i_at YHL033C 1955.4 -1.1 195.5 1955.4 -1.2 391.1 0.0 0.0 0.0 0.0 0.0 0.0
YEL034W HYP2 TIF51A 5756_at YEL034W T 2636.4 -1.2 656.5 2636.4 -1.1 392.6 3320.4 1.2 826.8 3320.4 1.1 332.0
YNL069C 8918_at YNL069C 2660.9 -1.2 662.6 2660.9 -1.1 396.2 3325.4 1.2 828.0 3325.4 1.1 332.5
YPL131W 7894_at YPL131W 2684.5 -1.2 536.9 2684.5 -1.1 399.7 3209.3 1.2 641.9 3209.3 1.0 0.0
YHR010W 4528_i_at YHR010W 1525.0 -1.2 332.7 1525.0 -1.1 23.9 1850.0 1.2 403.6 1850.0 1.2 79.0
YDL081C 6561_at YDL081C 2074.7 -1.2 499.9 2074.7 -1.2 406.3 2727.7 1.2 657.3 2727.7 1.0 0.0
YGR027C 5001_f_at YGR027C 1532.4 -1.2 340.4 1532.4 -1.1 24.5 1862.8 1.2 413.8 1862.8 1.1 61.6
YLR249W YEF3 TEF3 10097_at YLR249W 2805.7 -1.1 417.8 2805.7 -1.1 417.8 3188.9 1.1 474.9 3188.9 1.0 0.0
YJL177W 11205_i_a YJL177W 2100.3 -1.2 523.0 2100.3 -1.2 420.1 2639.5 -1.2 657.2 2639.5 1.0 128.8
YDL082W 6560_at YDL082W 1468.9 -1.2 365.8 1468.9 -1.3 435.0 1816.6 1.2 452.3 1816.6 -1.0 0.0
YPR043W 7708_f_at YPR043W 1791.2 -1.2 446.0 1791.2 -1.1 44.6 2186.7 1.2 544.5 2186.7 1.1 54.4
YKL060C FBA1 10636_at Aldolase 3014.1 -1.2 750.5 3014.1 -1.1 448.8 3801.9 1.2 946.7 3801.9 1.1 380.2
YOL039W 8613_at YOL039W 2361.0 -1.2 587.9 2361.0 -1.2 472.2 2988.9 1.2 744.2 2988.9 1.1 298.9
YBR191W 7147_at YBR191W 2492.3 -1.3 738.1 2492.3 -1.2 488.1 3246.8 1.3 961.5 3246.8 1.1 324.7
YGR254W ENO1 HSP48 4730_s_at Enolase I 2833.6 -1.2 493.5 2833.6 -1.2 493.5 3244.5 1.2 565.1 3244.5 1.0 158.4
YGR148C 4848_at YGR148C 3354.9 -1.2 835.4 3354.9 -1.1 499.6 4259.1 1.2 1060.5 4259.1 1.1 425.9
YLR029C 10325_at YLR029C 1856.7 -1.2 416.4 1856.7 -1.3 505.7 2276.3 1.2 510.5 2276.3 -1.0 111.1
YLR441C 9890_s_at YLR441C 2182.4 -1.2 431.9 2182.4 -1.1 42.2 2569.5 1.2 508.5 2569.5 1.1 48.5
YMR205C PFK2 9432_at YMR205C 1287.5 -1.2 252.1 1287.5 -1.4 510.4 1558.7 1.2 305.2 1558.7 -1.2 311.7
YEL071W DLD3 5813_at YEL071W 934.3 -1.4 419.6 934.3 -1.5 513.1 1352.6 1.4 607.5 1352.6 -1.1 135.3
YOL086C ADH1 ADC1 8657_at YOL086C 3553.5 -1.2 695.9 3553.5 -1.1 529.2 4293.4 1.2 840.8 4293.4 1.1 429.3
YIL133C 4223_at YIL133C 2311.2 -1.2 575.5 2311.2 -1.2 575.5 2889.0 1.2 719.4 2889.0 1.0 0.0
YJL190C 11236_at YJL190C 3932.3 -1.1 585.6 3932.3 -1.1 585.6 4680.2 1.1 696.9 4680.2 1.0 0.0
YAL038W CDC19 PYK1 11371_at Pyruvate ki 3016.0 -1.2 751.0 3016.0 -1.2 590.6 3721.2 1.2 926.6 3721.2 1.0 0.0
YLR304C ACO1 GLU1 10019_at YLR304C 1066.5 -1.4 479.0 1066.5 -1.6 636.6 1602.0 1.4 719.5 1602.0 -1.1 160.2
YBL027W 7378_s_at YBL027W 1885.8 -1.2 377.2 1885.8 -1.3 658.3 2238.6 1.2 447.7 2238.6 -1.2 447.7
YBL087C 7454_s_at YBL087C 2647.6 -1.1 394.3 2647.6 -1.2 659.3 2964.6 1.1 441.5 2964.6 -1.1 296.5
YML026C 9684_s_at YML026C R 2948.1 -1.1 439.0 2948.1 -1.2 734.1 3458.0 1.1 514.9 3458.0 -1.1 345.8
YAL005C SSA1 YG100 11315_i_a YAL005C 2682.4 -1.0 127.0 2682.4 -1.1 391.6 2804.4 1.0 132.8 2804.4 -1.3 866.8
YKR057W 10529_i_a YKR057W 4839.1 -1.2 947.6 4839.1 -1.2 947.6 5831.4 1.2 1141.9 5831.4 1.0 0.0
YOR375C GDH1 URE1 8174_at YOR375C 662.8 -2.4 927.9 662.8 -2.5 994.1 1441.3 2.4 2017.8 1441.3 -1.0 0.0
YGR085C 4921_i_at YGR085C 3199.3 -1.2 796.6 3199.3 -1.4 1268.3 3846.1 1.2 957.7 3846.1 -1.2 769.2
cytoskeleton
YNL138W SRV2 8984_at YNL138W 473.5 1.1 70.5 473.5 1.9 424.9 409.0 -1.1 60.9 409.0 1.6 245.4
YNL271C BNI1 PPF3 9123_at Cytoskelet 94.5 1.3 28.0 94.5 3.4 229.7 108.6 -1.3 32.2 108.6 2.1 119.5
YFL037W TUB2 ARM10, S 5394_at YFL037W b 727.1 1.1 108.3 727.1 1.3 218.1 0.0 0.0 0.0 0.0 0.0 0.0
YCR091W KIN82 6786_at YCR091W 5.7 1.4 2.3 5.7 2.0 5.8 0.0 0.0 0.0 0.0 0.0 0.0
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YIL159W BNR1 4242_at Bni1p-rela 3.3 -2.0 3.3 3.3 -1.7 2.2 6.5 2.0 6.5 6.5 1.1 0.7
YCL024W KCC4 6762_s_at YCL024W 12.4 2.4 17.2 12.4 1.2 2.4 5.1 -2.4 7.1 5.1 -2.0 5.1
YNL079C TPM1 8953_at YNL079C 713.2 1.0 34.8 713.2 -1.2 142.6 676.8 -1.0 33.0 676.8 -1.2 135.4
YBR109C CMD1 7245_at YBR109C c 758.7 -1.1 75.9 758.7 -1.2 151.7 0.0 0.0 0.0 0.0 0.0 0.0
YPR165W RHO1 7563_at Ras homolo 819.3 -1.0 0.0 819.3 -1.2 163.9 828.3 -1.0 0.0 828.3 -1.2 165.7
YIL062C ARC15 4155_at YIL062C A 655.4 1.0 32.0 655.4 -1.2 128.3 617.0 -1.0 30.1 617.0 -1.3 185.1
YFL039C ACT1 ABY1, EN 5392_at YFL039C 2061.4 -1.2 403.7 2061.4 -1.2 403.7 2477.1 1.2 485.1 2477.1 1.0 0.0
centrosome
YPL255W BBP1 7994_at YPL255W 0.0 0.0 0.0 0.0 0.0 0.0 4.1 -1.5 2.0 4.1 -2.4 5.7
YER018C SPC25 5718_at YER018C S 0.0 0.0 0.0 0.0 0.0 0.0 25.0 -1.7 18.7 25.0 -2.9 47.5
YBR109C CMD1 7245_at YBR109C c 758.7 -1.1 75.9 758.7 -1.2 151.7 0.0 0.0 0.0 0.0 0.0 0.0
endoplasmic reticulum
YJL034W KAR2 BIP, GRP 11078_at Homologu 1978.5 1.1 188.8 1978.5 1.2 492.6 1802.2 -1.1 172.0 1802.2 1.2 360.4
YAL023C PMT2 FUN25 11344_at YAL023C 1047.0 1.1 104.7 1047.0 1.3 365.5 859.8 -1.1 86.0 859.8 1.2 172.0
YML130C ERO1 9802_at YML130C r 365.0 2.0 383.0 365.0 1.8 292.0 129.8 -2.0 136.2 129.8 -1.1 13.0
YHR007C ERG11 4525_at YHR007C c 0.0 0.0 0.0 0.0 0.0 0.0 1087.9 1.0 53.1 1087.9 1.2 217.6
YDL095W PMT1 6591_at YDL095W 415.6 1.4 166.2 415.6 1.4 166.2 299.5 -1.4 119.8 299.5 1.0 0.0
YIL075C RPN2 SEN3 4189_at YIL075C 0.0 0.0 0.0 0.0 0.0 0.0 385.5 1.2 77.1 385.5 1.4 154.2
YOR067C ALG8 8495_at YOR067C 598.7 -1.2 149.1 598.7 -1.0 0.0 730.4 1.2 181.9 730.4 1.2 146.1
YDR086C SSS1 6410_at YDR086C 557.7 -1.3 165.2 557.7 -1.1 83.0 727.0 1.3 215.3 727.0 1.2 145.4
YHR190W ERG9 4350_at YHR190W 534.8 1.1 79.6 534.8 1.2 104.7 390.9 -1.1 58.2 390.9 1.0 0.0
YKL073W LHS1 CER1, SS 10668_at YKL073W 144.8 1.6 94.0 144.8 1.2 36.0 77.9 -1.6 50.6 77.9 -1.3 23.4
YGR175C ERG1 4830_at YGR175C 828.8 -1.1 123.4 828.8 -1.0 40.5 926.4 1.1 138.0 926.4 1.1 92.6
YBR201W DER1 3940_at YBR201W 96.1 1.7 71.7 96.1 2.0 92.2 58.1 -1.7 43.4 58.1 1.1 6.9
YGR157W CHO2 PEM1 4858_at Phosphati 579.5 -1.1 86.3 579.5 -1.1 57.9 665.4 1.1 99.1 665.4 1.0 0.0
YBR265W TSC10 7085_at YBR265W 220.6 -1.0 10.8 220.6 -1.5 109.6 0.0 0.0 0.0 0.0 0.0 0.0
YBR177C EHT1 7179_at YBR177C l 369.1 -1.0 0.0 369.1 -1.3 110.7 335.1 -1.0 0.0 335.1 -1.3 100.5
YKL065C YET1 10631_at YKL065C 635.4 1.2 127.1 635.4 -1.0 0.0 573.3 -1.2 114.7 573.3 -1.2 114.7
YJL002C OST1 NLT1 11019_at YJL002C 1148.9 -1.1 171.1 1148.9 -1.1 114.9 1315.8 1.1 195.9 1315.8 1.0 0.0
YML075C HMG1 9724_at YML075C 3 412.1 -1.1 39.3 412.1 -1.3 122.0 0.0 0.0 0.0 0.0 0.0 0.0
YDR410C STE14 6061_at YDR410C f 325.8 -1.4 130.3 325.8 -1.2 81.1 459.0 1.4 183.6 459.0 1.1 45.9
YER094C PUP3 SCS32 5625_at YER094C 2 928.9 -1.1 92.9 928.9 -1.1 138.3 0.0 0.0 0.0 0.0 0.0 0.0
YEL002C WBP1 5744_at YEL002C 953.0 -1.0 46.5 953.0 -1.1 141.9 0.0 0.0 0.0 0.0 0.0 0.0
YDR304C CPR5 CYP5 6178_at YDR304C 962.7 -1.1 96.3 962.7 -1.1 143.4 0.0 0.0 0.0 0.0 0.0 0.0
YPR113W PIS1 7645_at YPR113W 962.8 -1.1 143.4 962.8 -1.1 143.4 1132.6 1.1 168.7 1132.6 1.0 0.0
YGL048C RPT6 CIM3, CR 5059_at YGL048C 697.5 -1.0 0.0 697.5 -1.1 103.9 734.5 -1.0 0.0 734.5 -1.2 146.9
YMR149W SWP1 9504_at YMR149W 783.3 -1.1 116.6 783.3 -1.2 153.4 883.5 1.1 131.6 883.5 -1.1 88.4
YJR143C PMT4 10891_at YJR143C 771.0 -1.1 77.1 771.0 -1.2 154.2 0.0 0.0 0.0 0.0 0.0 0.0
YDL212W SHR3 APF1 6696_at YDL212W 1059.4 -1.2 211.9 1059.4 -1.1 157.8 1263.7 1.2 252.7 1263.7 1.0 0.0
YCR075C ERS1 6816_at YCR075C 185.0 -1.2 33.9 185.0 -1.9 162.0 0.0 0.0 0.0 0.0 0.0 0.0
YNL064C YDJ1 MAS5 8924_at YNL064C 979.7 1.0 47.8 979.7 -1.1 145.9 959.6 -1.0 46.8 959.6 -1.2 191.9
YJL080C SCP160 11122_at YJL080C 403.0 -1.1 60.0 403.0 -1.5 221.3 472.9 1.1 70.4 472.9 -1.3 141.9
YNL130C CPT1 8992_at YNL130C 553.9 -1.4 221.6 553.9 -1.4 221.6 791.4 1.4 316.6 791.4 1.0 0.0
YMR202W ERG2 9429_at YMR202W 1288.1 -1.1 191.8 1288.1 -1.3 449.6 1456.0 1.1 216.8 1456.0 -1.2 291.2
YNR016C ACC1 8864_at YNR016C a 893.1 -1.2 178.6 893.1 -1.5 490.5 1077.2 1.2 215.4 1077.2 -1.3 323.2
YJR073C OPI3 PEM2 10957_at Methylene 1629.4 -1.3 568.8 1629.4 -1.4 651.8 2223.8 1.3 776.3 2223.8 -1.0 0.0
Golgi
YNL238W KEX2 QDS1, VMA9110_at Ca2+-dep 189.7 1.2 37.1 189.7 3.0 385.1 156.4 -1.2 30.6 156.4 2.5 234.6
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YMR272C SCS7 FAH1 9366_at YMR272C 774.6 -1.0 37.8 774.6 1.2 151.7 845.3 1.0 41.3 845.3 1.3 253.6
YLR034C SMF3 10286_at YLR034C 700.6 1.1 104.3 700.6 1.3 244.5 596.7 -1.1 88.9 596.7 1.2 119.3
YDR270W CCC2 6190_at Accessory 150.0 1.9 135.0 150.0 1.9 135.0 92.0 -1.9 82.8 92.0 1.0 0.0
YKR068C BET3 10493_at YKR068C H 0.0 0.0 0.0 0.0 0.0 0.0 657.0 -1.0 0.0 657.0 1.2 131.4
YGR143W SKN1 4843_at YGR143W 145.7 1.8 123.7 145.7 1.7 102.0 79.0 -1.8 67.1 79.0 -1.1 7.9
YKR061W KTR2 10532_at YKR061W 52.6 2.3 70.7 52.6 1.9 49.6 22.7 -2.3 30.5 22.7 -1.2 4.5
YER123W YCK3 CKI3 5608_at YER123W 35.8 1.4 16.1 35.8 2.3 48.2 0.0 0.0 0.0 0.0 0.0 0.0
YLR262C YPT6 10066_s_ YLR262C 408.9 -1.1 40.9 408.9 -1.2 101.8 0.0 0.0 0.0 0.0 0.0 0.0
YEL042W GDA1 5748_at YEL042W 223.0 -1.1 33.2 223.0 -1.5 111.5 0.0 0.0 0.0 0.0 0.0 0.0
YER031C YPT31 YPT8 5686_at YER031C r 252.5 -1.0 12.3 252.5 -1.4 113.4 0.0 0.0 0.0 0.0 0.0 0.0
YPR113W PIS1 7645_at YPR113W 962.8 -1.1 143.4 962.8 -1.1 143.4 1132.6 1.1 168.7 1132.6 1.0 0.0
YPR165W RHO1 7563_at Ras homolo 819.3 -1.0 0.0 819.3 -1.2 163.9 828.3 -1.0 0.0 828.3 -1.2 165.7
YNL130C CPT1 8992_at YNL130C 553.9 -1.4 221.6 553.9 -1.4 221.6 791.4 1.4 316.6 791.4 1.0 0.0
YGL225W VRG4 VAN2, GO 5245_at YGL225W 800.7 -1.3 279.5 800.7 -1.3 237.1 1065.2 1.3 371.8 1065.2 1.0 0.0
YDL137W ARF2 6638_at YDL137W 1842.3 -1.1 175.8 1842.3 -1.2 360.8 0.0 0.0 0.0 0.0 0.0 0.0
YDL192W ARF1 6671_at YDL192W 3045.6 -1.2 609.1 3045.6 -1.1 453.5 3689.1 1.2 737.8 3689.1 1.0 0.0
intracellular transport vesicles
YBR105C VID24 7241_at YBR105C i 89.7 2.0 89.7 89.7 2.8 165.9 43.4 -2.0 43.4 43.4 1.4 17.4
YNL272C SEC2 9122_at Protein wit 57.0 1.0 2.8 57.0 3.8 159.2 56.4 -1.0 2.8 56.4 3.8 157.9
YGR284C ERV29 4714_at YGR284C 0.0 0.0 0.0 0.0 0.0 0.0 639.9 -1.0 0.0 639.9 1.2 128.0
YIL117C PRM5 4194_at YIL117C ph 67.2 1.2 16.2 67.2 2.7 113.0 59.1 -1.2 14.2 59.1 2.2 70.9
YDL195W SEC31 WEB1 6668_at YDL195W 233.6 1.4 104.9 233.6 -1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
YAR031W PRM9 11293_at YAR031W 10.8 -1.0 0.5 10.8 2.7 18.1 11.4 1.0 0.5 11.4 2.9 21.7
YIL037C PRM2 4134_at Pheromon 7.6 -4.0 22.6 7.6 -2.6 11.9 29.4 4.0 87.5 29.4 1.8 23.5
YOR327C SNC2 8217_at YOR327C 431.6 -1.1 64.3 431.6 -1.2 107.5 0.0 0.0 0.0 0.0 0.0 0.0
YML001W YPT7 AST4, VA 9622_at YML001W 822.3 -1.0 40.1 822.3 -1.1 122.4 0.0 0.0 0.0 0.0 0.0 0.0
YFL005W SEC4 SRO6 5383_at Ras-like s 416.8 -1.0 0.0 416.8 -1.3 123.4 416.5 -1.0 0.0 416.5 -1.3 125.0
YPL218W SAR1 7986_at YPL218W 590.6 -1.2 118.1 590.6 -1.1 59.1 712.8 1.2 142.6 712.8 1.1 71.3
YML012W ERV25 9653_at YML012W 1340.8 -1.1 134.1 1340.8 -1.1 199.7 0.0 0.0 0.0 0.0 0.0 0.0
YDL137W ARF2 6638_at YDL137W 1842.3 -1.1 175.8 1842.3 -1.2 360.8 0.0 0.0 0.0 0.0 0.0 0.0
YGL200C EMP24 BST2 5225_at YGL200C 1255.6 -1.1 125.6 1255.6 -1.3 376.7 0.0 0.0 0.0 0.0 0.0 0.0
nucleus
YCL067C HMLALPH ALPHA2, 6958_s_at Mating typ 210.9 1.0 10.3 210.9 6.2 1106.8 201.1 -1.0 9.8 201.1 6.0 1005.5
YDR524C AGE1 SAT1 5926_g_at YDR524C A 3729.0 -1.3 1015.6 3729.0 -1.1 539.0 4720.7 1.3 1285.7 4720.7 1.1 703.0
YJL130C URA2 11165_at YJL130C 1459.3 1.4 655.4 1459.3 1.3 509.4 928.3 -1.4 416.9 928.3 -1.0 0.0
YFL031W HAC1 ERN4, IR 5318_s_at bZIP Tran 398.7 1.9 355.4 398.7 2.2 484.5 284.7 -1.9 253.8 284.7 1.2 53.7
YDL182W LYS20 6683_g_at YDL182W 2082.9 -1.0 101.7 2082.9 1.1 310.2 2189.0 1.0 106.8 2189.0 1.2 437.8
YLR175W CBF5 10155_at YLR175W 795.5 -1.0 0.0 795.5 1.4 318.2 829.9 -1.0 0.0 829.9 1.4 332.0
YCR014C POL4 POLX 6891_at DNA poly 15.3 -3.0 30.5 15.3 1.4 6.1 67.8 3.0 135.1 67.8 5.5 305.1
YNL016W PUB1 8879_at YNL016W 329.2 1.6 197.5 329.2 1.9 296.2 203.9 -1.6 122.3 203.9 1.2 40.8
YOR204W DED1 SPP81 8361_at YOR204W 325.4 1.8 260.3 325.4 1.3 97.6 169.7 -1.8 135.8 169.7 -1.3 50.9
YLR094C GIS3 10258_at Cyclin C a 40.0 3.8 111.6 40.0 6.0 199.5 9.8 -3.8 27.4 9.8 1.6 5.9
YCR042C TSM1 TAF150 6830_at "Essential 31.2 -1.0 0.0 31.2 6.3 165.3 34.4 -1.0 0.0 34.4 6.1 175.4
YOR344C TYE7 SGC1 8188_at 33 kDa se 66.1 2.8 121.6 66.1 3.6 174.1 23.0 -2.8 42.3 23.0 1.3 6.9
YIL075C RPN2 SEN3 4189_at YIL075C 0.0 0.0 0.0 0.0 0.0 0.0 385.5 1.2 77.1 385.5 1.4 154.2
YHR089C GAR1 4425_at YHR089C s 1304.6 -1.1 194.3 1304.6 -1.0 63.7 1525.6 1.1 227.2 1525.6 1.1 152.6
YMR039C SUB1 TSP1 9617_at YMR039C 306.3 1.1 29.2 306.3 1.4 137.6 0.0 0.0 0.0 0.0 0.0 0.0
YNL039W BDP1 TFC5 8902_at Subunit of 62.2 1.2 15.5 62.2 3.2 136.5 56.3 -1.2 14.0 56.3 2.5 84.5
YNL220W ADE12 BRA9 9083_at YNL220W 1163.7 -1.1 173.3 1163.7 -1.0 0.0 1347.0 1.1 200.6 1347.0 1.1 134.7
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YDR123C INO2 DIE1, SCS 6358_at Transcripti 18.7 2.4 26.3 18.7 8.1 132.6 9.1 -2.4 12.8 9.1 4.9 35.5
YOR098C NUP1 8435_at YOR098C 0.0 0.0 0.0 0.0 0.0 0.0 87.8 1.5 48.2 87.8 2.5 131.7
YHL027W RIM101 4581_at YHL027W 326.7 1.2 65.3 326.7 1.4 130.7 0.0 0.0 0.0 0.0 0.0 0.0
YNL007C SIS1 8888_at YNL007C 635.8 1.2 127.2 635.8 1.1 63.6 519.0 -1.2 103.8 519.0 -1.1 51.9
YDL140C RPO21 RPB1, RP 6635_at YDL140C 247.9 1.2 61.7 247.9 1.5 123.1 0.0 0.0 0.0 0.0 0.0 0.0
YNL172W APC1 9041_at YNL172W 102.1 1.3 34.9 102.1 2.2 121.6 76.1 -1.3 26.0 76.1 1.6 45.7
YOR230W WTM1 8342_at YOR230W 812.5 1.0 39.7 812.5 1.1 121.0 0.0 0.0 0.0 0.0 0.0 0.0
YLR197W SIK1 10132_at YLR197W 0.0 0.0 0.0 0.0 0.0 0.0 402.0 1.1 40.2 402.0 1.3 120.6
YDR432W NPL3 MTR13, M 6039_g_at YDR432W 442.1 1.2 106.8 442.1 1.1 53.2 326.8 -1.2 78.9 326.8 -1.2 54.8
YIR017C MET28 4098_at YIR017C 353.7 1.2 88.1 353.7 1.3 106.1 0.0 0.0 0.0 0.0 0.0 0.0
YBR072W HSP26 7295_at YBR072W 88.4 2.2 105.9 88.4 1.4 39.7 41.9 -2.2 50.2 41.9 -1.5 21.0
YGR288W MAL13 4718_at YGR288W 60.3 1.7 45.1 60.3 2.7 105.4 30.5 -1.7 22.9 30.5 1.6 18.3
YNL282W POP3 9157_at Structural 21.9 1.4 9.4 21.9 5.6 101.6 20.1 -1.4 8.6 20.1 3.5 50.3
YBR034C HMT1 7348_at YBR034C n 340.4 1.3 100.8 340.4 1.2 84.8 0.0 0.0 0.0 0.0 0.0 0.0
YKL109W HAP4 10675_at YKL109W t 192.2 1.8 153.2 192.2 1.5 95.4 106.7 -1.8 85.1 106.7 -1.2 21.3
YMR043W MCM1 FUN80 9576_at Putative tr 90.2 1.6 58.6 90.2 2.0 94.7 54.3 -1.6 35.3 54.3 1.2 10.9
YGL066W SGF73 5086_at YGL066W 60.2 1.4 23.8 60.2 2.4 86.4 0.0 0.0 0.0 0.0 0.0 0.0
YMR182C RGM1 9452_at Putative tr 14.8 1.9 12.9 14.8 6.1 75.1 7.3 -1.9 6.4 7.3 4.1 22.6
YMR042W ARG80 ARGR1 9575_at Regulator 57.3 1.8 45.8 57.3 1.9 51.5 31.3 -1.8 25.0 31.3 1.0 0.0
YER123W YCK3 CKI3 5608_at YER123W 35.8 1.4 16.1 35.8 2.3 48.2 0.0 0.0 0.0 0.0 0.0 0.0
YOR074C CDC21 CRT9, TM 8152_f_at YOR074C 29.7 1.1 4.0 29.7 2.0 31.0 29.4 -1.1 3.9 29.4 1.8 23.2
YDL154W MSH5 6621_at YDL154W 20.5 1.7 15.2 20.5 2.1 23.3 0.0 0.0 0.0 0.0 0.0 0.0
YDR216W ADR1 6273_at YDR216W 13.6 1.5 7.4 13.6 2.7 23.0 8.6 -1.5 4.7 8.6 1.8 6.9
YLR055C SPT8 10264_at YLR055C 0.0 0.0 0.0 0.0 0.0 0.0 22.9 -2.0 22.7 22.9 -1.7 16.0
YOL067C RTG1 8630_at YOL067C 11.2 1.1 1.7 11.2 2.7 19.5 9.6 -1.1 1.4 9.6 2.4 13.4
YLR453C RIF2 9857_at YLR453C 12.2 2.0 12.8 12.2 2.3 16.5 5.9 -2.0 6.2 5.9 1.1 0.6
YPR168W NUT2 MED10 7566_at YPR168W 14.1 2.2 17.6 14.1 2.0 14.7 6.3 -2.2 7.9 6.3 -1.1 0.6
YNL012W SPO1 8883_at YNL012W 10.8 2.2 13.1 10.8 1.3 3.2 4.3 -2.2 5.3 4.3 -1.8 3.4
YFR034C PHO4 5333_at YFR034C 9.9 2.3 12.4 9.9 1.4 4.0 3.3 -2.3 4.1 3.3 -1.2 0.7
YBL026W LSM2 SMX5, SN 7380_f_at YBL026W s 6.6 1.2 1.0 6.6 2.8 12.1 5.5 -1.2 0.9 5.5 2.6 8.8
YML010W SPT5 9655_at YML010W 15.2 2.9 29.0 15.2 1.6 9.6 3.0 -2.9 5.7 3.0 -2.3 3.9
YFL003C MSH4 5385_at YFL003C 5.6 2.2 6.9 5.6 -1.2 0.9 0.0 0.0 0.0 0.0 0.0 0.0
YCL010C SGF29 6870_at YCL010C 11.0 2.0 11.1 11.0 1.5 5.7 5.6 -2.0 5.7 5.6 -1.3 1.7
YIL084C SDS3 4182_at YIL084C F 4.6 2.0 4.8 4.6 -1.2 0.9 0.0 0.0 0.0 0.0 0.0 0.0
YJR021C REC107 MER2 10999_at YJR021C 2.3 2.0 2.4 2.3 2.4 3.2 0.0 0.0 0.0 0.0 0.0 0.0
YCR097W HMRA1 YCR097WB6792_s_at YCR097W 0.0 0.0 0.0 0.0 0.0 0.0 2.4 1.2 0.4 2.4 2.1 2.6
YKR034W DAL80 UGA43 10551_at YKR034W 0.0 0.0 0.0 0.0 0.0 0.0 1.8 2.0 1.9 1.8 -2.0 1.8
YCR018C SRD1 6755_i_at YCR018C 1.6 -2.4 2.2 1.6 -1.7 1.2 5.7 2.4 8.0 5.7 1.3 1.7
YMR167W MLH1 PMS2 9479_at YMR167W 10.2 2.7 17.6 10.2 1.2 2.4 3.0 -2.7 5.2 3.0 -2.1 3.3
YBL066C SEF1 7430_at Putative tr 9.5 4.0 28.5 9.5 1.8 7.6 5.2 -4.0 15.6 5.2 -2.2 6.2
YNL204C SPS18 SPX18 9055_at YNL204C 4.2 -1.8 3.4 4.2 -2.7 7.2 0.0 0.0 0.0 0.0 0.0 0.0
YFL021W GAT1 NIL1 5409_at YFL021W t 52.6 -2.5 81.2 52.6 -2.1 60.2 119.0 2.5 183.9 119.0 1.2 23.8
YPR182W SMX3 7580_at YPR182W 0.0 0.0 0.0 0.0 0.0 0.0 206.3 -1.0 10.1 206.3 -1.5 103.2
YAL033W POP5 FUN53 11333_at YAL033W A 232.6 -1.3 69.8 232.6 -1.4 104.5 0.0 0.0 0.0 0.0 0.0 0.0
YOR224C RPB8 8336_at YOR224C 710.6 -1.1 105.8 710.6 -1.1 105.8 816.1 1.1 121.5 816.1 -1.0 0.0
YGR063C SPT4 4944_at YGR063C 239.6 -1.2 59.6 239.6 -1.4 107.6 0.0 0.0 0.0 0.0 0.0 0.0
YKL024C URA6 10583_at YKL024C 314.8 1.1 30.0 314.8 -1.3 93.2 273.6 -1.1 26.1 273.6 -1.4 109.4
YHL034C SBP1 SSBR1 4574_at YHL034C 0.0 0.0 0.0 0.0 0.0 0.0 743.6 1.1 110.7 743.6 -1.1 74.4
YHR041C SRB2 HRS2 4470_at YHR041C 188.0 -1.6 112.2 188.0 -1.6 112.2 343.7 1.6 205.1 343.7 1.0 0.0
YOR151C RPB2 RPB150, 8398_at YOR151C 378.0 1.2 74.0 378.0 -1.1 56.3 281.6 -1.2 55.1 281.6 -1.4 112.6
YBR088C POL30 7266_at YBR088C p 191.6 -1.2 38.3 191.6 -1.6 115.0 0.0 0.0 0.0 0.0 0.0 0.0
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YDR404C RPB7 6055_at YDR404C d 422.4 -1.1 42.2 422.4 -1.3 126.7 0.0 0.0 0.0 0.0 0.0 0.0
YOR341W RPA190 RRN1 8185_at YOR341W 328.5 -1.1 48.9 328.5 -1.4 130.2 383.7 1.1 57.1 383.7 -1.2 76.7
YER094C PUP3 SCS32 5625_at YER094C 2 928.9 -1.1 92.9 928.9 -1.1 138.3 0.0 0.0 0.0 0.0 0.0 0.0
YDL227C HO 6725_at YDL227C 163.5 -1.4 73.4 163.5 -1.8 138.9 234.2 1.4 105.2 234.2 -1.3 70.3
YEL009C GCN4 AAS3, AR 5737_at 1433.2 1.0 70.0 1433.2 -1.1 136.8 1390.5 -1.0 67.9 1390.5 -1.1 139.1
RPR1 5413_at RPR1 RN 0.0 0.0 0.0 0.0 0.0 0.0 155.0 1.9 139.1 155.0 1.2 31.0
YPR010C RPA135 RPA2, RR 7762_at YPR010C R 352.9 -1.0 17.2 352.9 -1.4 139.9 379.1 1.0 18.5 379.1 -1.3 113.7
YGR180C RNR4 4835_at YGR180C 942.0 -1.0 46.0 942.0 -1.1 140.3 0.0 0.0 0.0 0.0 0.0 0.0
YDR381W YRA1 SHE11 6078_at YDR381W 400.7 1.1 59.7 400.7 -1.2 99.8 355.9 -1.1 53.0 355.9 -1.4 142.4
YMR308C PSE1 KAP121 9316_at YMR308C 734.5 -1.1 109.4 734.5 -1.2 143.8 822.2 1.1 122.4 822.2 -1.1 82.2
YGL048C RPT6 CIM3, CR 5059_at YGL048C 697.5 -1.0 0.0 697.5 -1.1 103.9 734.5 -1.0 0.0 734.5 -1.2 146.9
YGL253W HXK2 HEX1, HK 5260_at YGL253W 751.4 -1.3 262.3 751.4 -1.2 150.3 981.0 1.3 342.4 981.0 1.1 98.1
YPR187W RPO26 RPB6 7539_at YPR187W 335.7 -1.2 83.6 335.7 -1.4 150.8 429.1 1.2 106.8 429.1 -1.2 85.8
YNL112W DBP2 8965_at YNL112W 510.9 -1.2 102.2 510.9 -1.3 153.3 604.6 1.2 120.9 604.6 -1.1 60.5
YDR328C SKP1 MGO1 6160_at YDR328C 487.2 1.2 121.3 487.2 -1.1 48.7 386.5 -1.2 96.2 386.5 -1.4 154.6
YLL039C UBI4 SCD2 10392_at YLL039C 432.6 1.3 151.0 432.6 -1.1 64.4 321.2 -1.3 112.1 321.2 -1.5 160.6
YER009W NTF2 5709_at YER009W 834.6 -1.2 163.4 834.6 -1.2 163.4 957.1 1.2 187.4 957.1 1.0 0.0
YOR310C NOP58 NOP5 8247_at YOR310C 757.9 -1.2 151.6 757.9 -1.0 37.0 888.7 1.2 177.7 888.7 1.1 88.9
YDL208W NHP2 6700_at YDL208W 821.0 -1.1 122.3 821.0 -1.2 204.4 930.8 1.1 138.6 930.8 -1.1 93.1
YJL157C FAR1 11181_at YJL157C 346.1 -1.3 120.8 346.1 -1.6 206.5 476.4 1.3 166.3 476.4 -1.2 95.3
YPR033C HTS1 TSM4572 7741_at YPR033C c 720.9 -1.1 72.1 720.9 -1.3 216.3 795.2 1.1 79.5 795.2 -1.2 159.0
YJL080C SCP160 11122_at YJL080C 403.0 -1.1 60.0 403.0 -1.5 221.3 472.9 1.1 70.4 472.9 -1.3 141.9
YER146W LSM5 5586_at YER146W 523.1 -1.1 77.9 523.1 -1.6 312.2 612.3 1.1 91.2 612.3 -1.3 183.7
YFR031C SMC2 5329_s_at YFR031C 3309.1 -1.2 824.0 3309.1 -1.1 492.8 4068.5 1.2 1013.1 4068.5 1.1 406.9
YPL037C EGD1 7806_at YPL037C 1962.5 -1.2 392.5 1962.5 -1.3 588.8 2272.2 1.2 454.4 2272.2 -1.1 227.2
chromosome
YDR225W HTA1 H2A1, SP 6236_i_at YDR225W 1800.8 -1.1 268.2 1800.8 1.1 268.2 2018.3 1.1 300.6 2018.3 1.3 605.5
YNL031C HHT2 8910_at YNL031C 2640.6 -1.1 393.2 2640.6 -1.0 128.9 3123.3 1.1 465.1 3123.3 1.1 312.3
YNL030W HHF2 8911_s_at YNL030W 0.0 0.0 0.0 0.0 0.0 0.0 1477.0 1.1 147.7 1477.0 1.2 295.4
YMR094W CTF13 CBF3C 9536_at 58 kd com 30.0 1.4 12.0 30.0 8.2 215.6 21.4 -1.4 8.6 21.4 5.9 104.9
YDR224C HTB1 SPT12 6235_at YDR224C 0.0 0.0 0.0 0.0 0.0 0.0 839.3 1.1 83.9 839.3 1.2 167.9
YOL012C HTZ1 HTA3 8550_at YOL012C 193.0 -1.0 9.4 193.0 -1.7 144.6 204.4 1.0 10.0 204.4 -1.7 143.1
YMR241W YHM2 9380_at YMR241W 739.4 -1.3 221.8 739.4 -1.3 221.8 974.2 1.3 292.3 974.2 1.0 0.0
YGR285C ZUO1 4715_at YGR285C 650.8 -1.2 130.2 650.8 -1.3 227.2 776.2 1.2 155.2 776.2 -1.1 77.6
YBL002W HTB2 7359_at YBL002W 541.0 -1.1 54.1 541.0 -1.5 270.5 614.9 1.1 61.5 614.9 -1.3 184.5
YPR052C NHP6A 7717_at YPR052C 530.1 -1.1 65.8 530.1 -1.6 328.4 596.6 1.1 74.1 596.6 -1.4 265.9
YBL003C HTA2 H2A2 7358_s_at YBL003C 1320.7 -1.2 258.6 1320.7 -1.2 328.9 1555.2 1.2 304.5 1555.2 -1.0 0.0
YBR010W HHT1 BUR5, SI 7368_i_at YBR010W 2568.7 -1.1 382.5 2568.7 -1.1 382.5 2912.9 1.1 433.8 2912.9 -1.0 0.0
mitochondrion
YNL104C LEU4 8973_at YNL104C 1720.8 1.1 172.1 1720.8 2.0 1720.8 1616.3 -1.1 161.6 1616.3 1.8 1293.0
YNL005C MRP7 8890_at Peptidyltran 200.5 1.3 70.0 200.5 7.0 1212.7 151.3 -1.3 52.8 151.3 5.4 665.7
YNL137C NAM9 MNA6 8985_at Structural 251.5 1.2 49.3 251.5 4.9 990.3 215.5 -1.2 42.2 215.5 4.3 711.2
YMR145C NDE1 NDH1 9500_at YMR145C 1003.9 1.5 502.0 1003.9 1.5 551.3 664.3 -1.5 332.2 664.3 1.0 0.0
YER073W ALD5 5646_at YER073W 453.5 1.2 109.3 453.5 2.2 540.1 360.2 -1.2 86.8 360.2 1.7 252.1
YNL055C POR1 OMP2 8932_at YNL055C 1947.9 1.1 194.8 1947.9 1.2 485.0 0.0 0.0 0.0 0.0 0.0 0.0
YDL198C YHM1 6665_at YDL198C 982.5 -1.0 0.0 982.5 1.4 441.3 964.8 -1.0 0.0 964.8 1.4 385.9
YDR035W ARO3 6450_at YDR035W 1396.4 1.1 139.6 1396.4 1.3 418.9 1273.6 -1.1 127.4 1273.6 1.2 254.7
YMR286W 9335_at YMR286W 496.5 1.0 24.2 496.5 1.6 296.3 456.1 -1.0 22.3 456.1 1.5 228.1
YKL120W OAC1 10709_at YKL120W o 519.5 1.3 181.3 519.5 1.5 285.3 376.9 -1.3 131.6 376.9 1.1 37.7
YLR355C ILV5 9979_at YLR355C 1911.6 1.0 93.3 1911.6 1.1 284.7 0.0 0.0 0.0 0.0 0.0 0.0
Od
A
I
S
s
P
M
S
a
m
m
C
u
K
D
n
p
T
4
YNL070W TOM7 MOM7, Y 8917_at YNL070W 828.9 -1.1 123.4 828.9 1.1 123.4 927.8 1.1 138.2 927.8 1.3 278.3
YPR191W QCR2 COR2, UCR7543_at YPR191W 497.9 1.9 448.1 497.9 1.5 273.4 238.5 -1.9 214.7 238.5 -1.2 47.7
YKL085W MDH1 10654_at YKL085W 1063.9 1.1 158.4 1063.9 1.2 264.9 866.5 -1.1 129.0 866.5 1.1 86.7
YJR016C ILV3 10993_at YJR016C 1257.3 1.1 125.7 1257.3 1.2 251.5 0.0 0.0 0.0 0.0 0.0 0.0
YKL016C ATP7 10591_at YKL016C 689.5 1.2 171.7 689.5 1.3 240.7 546.0 -1.2 136.0 546.0 1.1 54.6
YKL150W MCR1 10723_at YKL150W 476.9 1.6 286.1 476.9 1.5 238.4 291.2 -1.6 174.7 291.2 -1.1 29.1
YMR256C COX7 9350_at YMR256C 1167.2 1.1 116.7 1167.2 1.2 233.4 0.0 0.0 0.0 0.0 0.0 0.0
YMR108W ILV2 SMR1, TH 9550_at YMR108W 502.3 1.1 74.8 502.3 1.4 225.6 448.3 -1.1 66.8 448.3 1.3 134.5
YLL041C SDH2 10390_at YLL041C 1047.5 1.6 628.5 1047.5 1.2 209.5 654.7 -1.6 392.8 654.7 -1.3 196.4
YDR019C GCV1 GSD1 6480_at YDR019C g 443.3 1.4 199.1 443.3 1.2 86.8 318.4 -1.4 143.0 318.4 -1.2 63.7
YEL024W RIP1 5766_at YEL024W 767.0 1.4 344.5 767.0 1.2 191.0 600.6 -1.4 269.8 600.6 -1.2 120.1
YPR058W YMC1 7678_at YPR058W 624.9 1.1 62.5 624.9 1.3 187.5 569.7 -1.1 57.0 569.7 1.2 113.9
YLR038C COX12 10290_at YLR038C 1869.2 1.1 278.3 1869.2 1.1 186.9 1626.8 -1.1 242.3 1626.8 -1.0 0.0
YDR258C HSP78 6223_at YDR258C 201.3 1.2 50.1 201.3 1.9 180.6 0.0 0.0 0.0 0.0 0.0 0.0
YGL125W MET13 MET11 5117_at YGL125W 579.3 1.1 86.3 579.3 1.3 173.8 0.0 0.0 0.0 0.0 0.0 0.0
YLR203C MSS51 10141_at YLR203C 244.8 1.7 171.3 244.8 1.3 85.4 144.6 -1.7 101.2 144.6 -1.3 43.4
YML054C CYB2 9702_at YML054C C 95.6 2.7 166.8 95.6 1.2 18.7 37.7 -2.7 65.8 37.7 -2.4 52.8
YOR045W TOM6 ISP6, MO 8518_at YOR045W 1407.9 -1.1 209.6 1407.9 -1.1 140.8 1605.3 1.1 239.0 1605.3 1.1 160.5
YGR183C QCR9 UCR9 4838_at YGR183C 1046.0 1.1 155.8 1046.0 1.0 51.1 903.1 -1.1 134.5 903.1 -1.1 90.3
YOR316C COT1 8206_at YOR316C 280.8 1.4 111.3 280.8 1.5 152.4 0.0 0.0 0.0 0.0 0.0 0.0
YPL262W FUM1 8033_at YPL262W 770.2 1.2 150.8 770.2 1.1 73.5 627.8 -1.2 122.9 627.8 -1.1 62.8
YDL130W STF1 6600_at YDL130W 1812.2 -1.0 89.9 1812.2 -1.0 11.0 2258.3 1.3 635.7 2258.3 1.1 148.1
YOR065W CYT1 CTC1 8493_at YOR065W 269.6 1.5 133.9 269.6 1.5 148.0 0.0 0.0 0.0 0.0 0.0 0.0
YBR282W 7100_at YBR282W 266.4 1.3 91.0 266.4 1.5 144.6 0.0 0.0 0.0 0.0 0.0 0.0
YMR083W ADH3 9569_at YMR083W 1156.0 -1.2 231.2 1156.0 -1.0 56.4 1403.8 1.2 280.8 1403.8 1.1 140.4
YDR178W SDH4 6279_at YDR178W 695.1 1.2 139.0 695.1 1.0 33.9 586.8 -1.2 117.4 586.8 -1.1 58.7
YCL009C ILV6 6871_at YCL009C 1187.4 -1.1 176.8 1187.4 -1.0 0.0 1351.5 1.1 201.3 1351.5 1.1 135.2
YOL059W GPD2 GPD3 8592_at YOL059W 166.1 1.7 115.8 166.1 1.8 132.4 98.2 -1.7 68.5 98.2 1.1 9.8
YML091C RPM2 9754_at Rpm2p is 187.9 1.7 131.5 187.9 1.4 75.1 120.0 -1.7 84.0 120.0 -1.2 24.0
YER086W ILV1 ISO1 5614_at YER086W 655.1 -1.0 0.0 655.1 1.2 131.0 0.0 0.0 0.0 0.0 0.0 0.0
YGR029W ERV1 3946_at YGR029W 370.4 1.2 82.3 370.4 1.3 129.3 307.9 -1.2 68.4 307.9 1.1 30.8
YGR028W MSP1 YTA4 4956_at YGR028W 231.7 1.5 127.2 231.7 1.2 46.3 147.3 -1.5 80.9 147.3 -1.3 44.2
YBL099W ATP1 7487_at YBL099W 1009.5 -1.1 150.3 1009.5 -1.0 0.0 1258.4 1.1 187.4 1258.4 1.1 125.8
YAL054C ACS1 11356_at YAL054C i 350.3 1.2 87.2 350.3 1.3 122.3 0.0 0.0 0.0 0.0 0.0 0.0
YER069W ARG5,6 5642_at YER069W 592.0 1.2 118.4 592.0 1.0 28.9 499.6 -1.2 99.9 499.6 -1.1 50.0
YGR008C STF2 4980_at YGR008C 783.8 1.3 235.1 783.8 1.1 116.7 605.4 -1.3 181.6 605.4 -1.1 60.5
YLR348C DIC1 9972_at YLR348C 231.9 1.5 115.9 231.9 1.3 69.6 0.0 0.0 0.0 0.0 0.0 0.0
YLR163C MAS1 MIF1 10188_at YLR163C 166.2 1.7 115.8 166.2 1.2 41.4 85.4 -1.7 59.5 85.4 -1.3 25.6
YLR395C COX8 9930_at YLR395C 1205.1 1.1 179.5 1205.1 1.1 115.0 1054.3 -1.1 157.0 1054.3 -1.0 0.0
YFR033C QCR6 COR3, UCR5332_at YFR033C 563.1 1.2 112.6 563.1 -1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
YDR074W TPS2 HOG2, PF 6398_at YDR074W 224.7 1.5 111.6 224.7 -1.0 11.0 140.6 -1.5 69.8 140.6 -1.6 84.4
YFL016C MDJ1 5370_at YFL016C 158.6 1.6 95.2 158.6 1.7 111.0 108.1 -1.6 64.9 108.1 1.1 10.8
YLL009C COX17 10334_at YLL009C i 551.2 1.2 110.2 551.2 1.1 82.1 0.0 0.0 0.0 0.0 0.0 0.0
YLR168C MSF1 10148_at YLR168C 269.3 1.4 107.7 269.3 1.4 107.7 0.0 0.0 0.0 0.0 0.0 0.0
YBR146W 7237_at YBR146W 214.7 1.2 42.9 214.7 1.5 107.3 0.0 0.0 0.0 0.0 0.0 0.0
YOR158W PET123 8405_at YOR158W 210.3 1.2 42.1 210.3 1.5 105.2 0.0 0.0 0.0 0.0 0.0 0.0
YJL054W TIM54 11058_at YJL054W 105.3 1.4 41.7 105.3 2.0 105.0 0.0 0.0 0.0 0.0 0.0 0.0
YNL073W MSK1 8914_at YNL073W 54.4 1.2 10.9 54.4 2.9 103.3 50.6 -1.2 10.1 50.6 2.4 70.8
YML120C NDI1 9765_at YML120C m 207.2 1.9 186.5 207.2 1.2 41.4 108.0 -1.9 97.2 108.0 -1.6 64.8
YBL045C COR1 QCR1 7407_at YBL045C 624.4 1.3 184.9 624.4 1.1 93.0 476.8 -1.3 141.2 476.8 -1.1 47.7
YDR405W 6056_at YDR405W 27.5 1.3 9.6 27.5 2.3 35.5 0.0 0.0 0.0 0.0 0.0 0.0
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Q0185 ?? 4001_at Cytochrom 22.9 2.3 30.5 22.9 2.2 28.1 10.6 -2.3 14.1 10.6 -1.0 0.2
YPR001W CIT3 7753_at YPR001W 11.9 2.6 18.9 11.9 1.4 5.3 5.5 -2.6 8.8 5.5 -1.8 4.4
YLR393W ATP10 9928_at YLR393W 8.6 1.9 8.1 8.6 2.5 12.8 0.0 0.0 0.0 0.0 0.0 0.0
YBL013W FMT1 7394_at YBL013W 2.8 1.1 0.3 2.8 2.3 3.6 2.6 -1.1 0.3 2.6 2.2 3.1
YCL004W PGS1 PEL1 6875_at 17-kDa Pho 6.6 3.2 14.7 6.6 1.4 2.5 0.0 -3.2 0.0 0.0 -2.4 0.0
Q0325 3979_i_at mitochond 2.4 1.5 1.1 2.4 -2.4 3.4 0.8 -1.5 0.4 0.8 -2.9 1.5
YNL328C MDJ2 9202_at YNL328C 0.0 0.0 0.0 0.0 0.0 0.0 4.5 -1.7 3.3 4.5 -2.5 6.8
YAR035W YAT1 11297_at Outer carni 48.8 -1.4 21.6 48.8 -1.3 16.7 79.9 1.4 35.3 79.9 1.1 8.0
YBR085W AAC3 ANC3 7263_at YBR085W 47.0 -2.0 48.6 47.0 -1.9 43.8 99.8 2.0 103.3 99.8 1.1 10.0
YGR222W PET54 4788_at YGR222W 0.0 0.0 0.0 0.0 0.0 0.0 136.2 -1.4 54.0 136.2 -1.7 95.3
YDR148C KGD2 6339_at YDR148C d 0.0 0.0 0.0 0.0 0.0 0.0 206.5 -1.2 41.3 206.5 -1.5 103.3
YIL114C POR2 4197_at YIL114C v 123.8 -1.8 105.1 123.8 -1.8 105.1 0.0 0.0 0.0 0.0 0.0 0.0
YBR039W ATP3 7307_at YBR039W 630.5 1.2 126.1 630.5 -1.0 0.0 526.3 -1.2 105.3 526.3 -1.2 105.3
YIL070C MAM33 4149_at YIL070C 33 369.8 1.4 147.9 369.8 -1.0 0.0 270.4 -1.4 108.2 270.4 -1.4 108.2
YML110C COQ5 DBI56 9777_at YML110C D 0.0 0.0 0.0 0.0 0.0 0.0 729.9 1.1 108.7 729.9 1.1 73.0
YGL191W COX13 5188_at YGL191W 0.0 0.0 0.0 0.0 0.0 0.0 560.7 -1.1 83.5 560.7 -1.2 112.1
YGL068W 5084_at YGL068W 0.0 0.0 0.0 0.0 0.0 0.0 283.9 -1.2 56.8 283.9 -1.4 113.6
YOR187W TUF1 8343_at YOR187W 687.5 1.2 137.5 687.5 -1.0 0.0 586.9 -1.2 117.4 586.9 -1.2 117.4
YHR051W COX6 4481_at YHR051W 904.0 1.3 271.2 904.0 1.1 90.4 652.9 -1.3 195.9 652.9 -1.2 130.6
YFL018C LPD1 HPD1 5367_at YFL018C 871.1 1.2 216.9 871.1 -1.0 0.0 700.8 -1.2 174.5 700.8 -1.2 140.2
YER141W COX15 5581_at YER141W 491.1 -1.0 0.0 491.1 -1.2 122.3 484.7 -1.0 0.0 484.7 -1.3 145.4
YCR028C FEN2 6863_at YCR028C 375.2 -1.2 93.4 375.2 -1.4 148.7 465.8 1.2 116.0 465.8 -1.1 46.6
YNL052W COX5A 8935_at YNL052W 606.5 1.2 121.3 606.5 -1.0 29.6 501.4 -1.2 100.3 501.4 -1.3 150.4
YJR077C MIR1 10961_at YJR077C i 1731.2 1.1 257.8 1731.2 1.0 84.5 1524.8 -1.1 227.1 1524.8 -1.1 152.5
YLR295C ATP14 10010_at YLR295C 630.6 1.6 376.4 630.6 1.1 93.9 394.9 -1.6 235.7 394.9 -1.4 158.0
YDL181W INH1 6684_at YDL181W 140.3 1.2 28.1 140.3 -2.0 140.3 113.1 -1.2 22.6 113.1 -2.4 158.3
YDR322C TIM11 6154_at YDR322C s 975.4 1.2 195.1 975.4 1.1 97.5 799.4 -1.2 159.9 799.4 -1.2 159.9
YDL004W ATP16 6503_at YDL004W 720.0 1.2 179.3 720.0 1.0 35.1 558.7 -1.2 139.1 558.7 -1.3 167.6
YBR263W SHM1 SHMT1, T 7083_at YBR263W 338.5 -1.2 84.3 338.5 -1.5 169.2 423.2 1.2 105.4 423.2 -1.2 84.6
YPL271W ATP15 ATPEPSIL 8024_at YPL271W 1021.8 1.1 152.2 1021.8 -1.0 49.9 899.9 -1.1 134.0 899.9 -1.2 180.0
Q0310 3976_at F1F0-ATP 804.9 1.2 200.4 804.9 -1.0 39.3 644.5 -1.2 160.5 644.5 -1.3 193.4
YGL187C COX4 5193_at YGL187C 759.1 1.1 75.9 759.1 -1.2 151.8 691.0 -1.1 69.1 691.0 -1.3 207.3
YJR048W CYC1 10977_at YJR048W 827.3 1.1 123.2 827.3 -1.1 79.0 697.0 -1.1 103.8 697.0 -1.3 209.1
YMR241W YHM2 9380_at YMR241W 739.4 -1.3 221.8 739.4 -1.3 221.8 974.2 1.3 292.3 974.2 1.0 0.0
YDL067C COX9 6531_at YDL067C 687.3 -1.0 33.5 687.3 -1.3 239.9 707.7 1.0 34.5 707.7 -1.3 212.3
YLR259C HSP60 CPN60, M 10061_at YLR259C 1822.6 -1.1 182.3 1822.6 -1.1 271.4 0.0 0.0 0.0 0.0 0.0 0.0
YLR304C ACO1 GLU1 10019_at YLR304C 1066.5 -1.4 479.0 1066.5 -1.6 636.6 1602.0 1.4 719.5 1602.0 -1.1 160.2
peroxisome
YAL054C ACS1 11356_at YAL054C i 350.3 1.2 87.2 350.3 1.3 122.3 0.0 0.0 0.0 0.0 0.0 0.0
YDL078C MDH3 6565_at YDL078C 270.4 -1.0 13.2 270.4 -1.4 121.4 258.3 1.0 12.6 258.3 -1.4 103.3
YLR027C AAT2 ASP5 10323_at YLR027C 1551.3 -1.1 231.0 1551.3 -1.1 231.0 1722.6 1.1 256.5 1722.6 -1.0 0.0
YLR109W AHP1 cTPxIII 10228_at YLR109W 1813.1 -1.2 451.4 1813.1 -1.2 362.6 2293.7 1.2 571.1 2293.7 1.1 229.4
YCR005C CIT2 6883_at YCR005C 1341.0 -1.1 199.7 1341.0 -1.3 468.1 1588.0 1.1 236.5 1588.0 -1.1 158.8
vacuole or lysosome
YLR034C SMF3 10286_at YLR034C 700.6 1.1 104.3 700.6 1.3 244.5 596.7 -1.1 88.9 596.7 1.2 119.3
YHR026W PPA1 VMA16 4500_at YHR026W 1541.2 -1.3 462.3 1541.2 -1.1 154.1 1942.4 1.3 582.7 1942.4 1.1 194.2
YPL154C PEP4 PHO9, PR 7916_at YPL154C 1033.3 -1.2 206.7 1033.3 -1.1 103.3 1221.5 1.2 244.3 1221.5 1.1 122.2
YGL156W AMS1 5179_at Alpha man 58.3 4.3 192.3 58.3 2.7 102.0 12.2 -4.3 40.2 12.2 -1.6 7.3
YIL099W SGA1 4212_g_at Intracellula 40.4 2.4 56.6 40.4 2.3 52.4 25.6 -2.4 35.8 25.6 -1.0 1.1
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YCR044C PER1 6832_at YCR044C 324.0 -1.2 64.8 324.0 -1.3 113.1 0.0 0.0 0.0 0.0 0.0 0.0
YGR020C VMA7 4993_at YGR020C 462.1 -1.4 184.8 462.1 -1.3 138.6 648.7 1.4 259.5 648.7 1.1 64.9
YLR447C VMA6 9851_at YLR447C 508.6 -1.0 24.8 508.6 -1.3 150.6 518.0 1.0 25.3 518.0 -1.3 155.4
YKL080W VMA5 CSL5, VA 10660_at YKL080W V 713.6 -1.3 249.1 713.6 -1.2 177.7 957.0 1.3 334.1 957.0 1.1 95.7
YPR036W VMA13 CLS11 7699_at YPR036W 437.6 1.1 43.8 437.6 -1.3 152.7 403.1 -1.1 40.3 403.1 -1.5 201.6
YDL185W TFP1 CLS8, VM 6679_at YDL185W 690.5 -1.3 207.2 690.5 -1.3 241.0 892.6 1.3 267.8 892.6 -1.0 0.0
YBR286W APE3 APY1 7059_at YBR286W 1238.0 -1.2 242.4 1238.0 -1.2 242.4 1456.7 1.2 285.3 1456.7 -1.0 0.0
YMR297W PRC1 LBC1 9348_at YMR297W 999.2 -1.1 148.8 999.2 -1.2 248.8 1135.5 1.1 169.1 1135.5 -1.1 113.6
YBR127C VMA2 ATPVS, V 7218_at YBR127C H 734.2 -1.5 367.1 734.2 -1.4 329.7 1021.3 1.5 510.7 1021.3 1.0 0.0
YEL027W CUP5 5763_at YEL027W V 2242.6 -1.3 664.1 2242.6 -1.1 334.0 2929.6 1.3 867.6 2929.6 1.1 293.0
YOR332W VMA4 8222_at YOR332W 978.3 -1.3 341.5 978.3 -1.3 341.5 1290.1 1.3 450.3 1290.1 -1.0 0.0
YHR039C MSC7 VMA10 4514_at YHR039C 783.6 -1.3 235.1 783.6 -1.4 351.9 1017.3 1.3 305.2 1017.3 -1.1 101.7
YPL234C TFP3 CLS9, VM 7970_at YPL234C 1186.4 -1.3 355.9 1186.4 -1.3 355.9 1511.7 1.3 453.5 1511.7 -1.1 151.2
YOR270C VPH1 8291_at YOR270C 1344.7 -1.3 403.4 1344.7 -1.3 469.4 1771.5 1.3 531.5 1771.5 -1.0 0.0
extracellular / secretion proteins
YNL160W YGP1 9008_at YNL160W 1172.5 2.3 1524.2 1172.5 2.8 2168.5 474.9 -2.3 617.4 474.9 1.3 142.5
YBR092C PHO3 7273_at Acid phos 356.2 1.4 141.2 356.2 4.4 1226.2 257.9 -1.4 102.2 257.9 3.2 567.4
YPL187W MF(ALPHA)1 7927_at YPL187W 2437.9 -1.1 363.0 2437.9 -1.0 119.0 2754.2 1.1 410.1 2754.2 1.1 275.4
YLR300W EXG1 BGL1 10015_at YLR300W 1585.6 1.0 77.4 1585.6 1.1 236.1 0.0 0.0 0.0 0.0 0.0 0.0
YJL159W HSP150 CCW7, O 11179_at Kex2-proc 1519.4 1.0 74.2 1519.4 1.1 226.3 1451.1 -1.0 70.8 1451.1 1.1 145.1
YJL174W KRE9 11209_at YJL174W 643.5 1.2 128.7 643.5 1.2 160.2 581.8 -1.2 116.4 581.8 1.0 0.0
YNL145W MFA2 9023_at Mating a-f 22.9 1.0 1.0 22.9 7.0 137.4 21.9 -1.0 1.0 21.9 6.8 127.0
YDR461W MFA1 6021_f_at YDR461W 31.6 2.2 39.3 31.6 1.9 28.3 11.8 -2.2 14.7 11.8 -1.1 1.2
YLR286C CTS1 10045_at YLR286C 2323.9 -1.1 346.1 2323.9 -1.1 346.1 2400.2 1.1 357.4 2400.2 -1.1 240.0
YGL089C MF(ALPHA)2 5108_at YGL089C 1468.1 -1.5 729.2 1468.1 -1.4 659.4 2220.7 1.5 1102.9 2220.7 1.0 0.0
other subcellular localisation
YGR175C ERG1 4830_at YGR175C 828.8 -1.1 123.4 828.8 -1.0 40.5 926.4 1.1 138.0 926.4 1.1 92.6
YBR177C EHT1 7179_at YBR177C l 369.1 -1.0 0.0 369.1 -1.3 110.7 335.1 -1.0 0.0 335.1 -1.3 100.5
PROTEIN ACTIVITY REGULATION
target of regulation
regulator of G-protein signalling
YOR107W RGS2 8444_at YOR107W 5.8 2.9 11.1 5.8 2.3 7.8 2.1 -2.9 4.0 2.1 -1.3
TRANSPORT FACILITATION
channel / pore class transporters
ion channels
YLL052C AQY2 10378_at YLL052C 50.0 1.0 2.4 50.0 2.6 80.6 55.1 -1.0 2.7 55.1 2.0 55.1
YPR192W AQY1 7544_at YPR192W 0.0 0.0 0.0 0.0 0.0 0.0 6.2 -1.7 4.0 6.2 -2.4 8.7
YIL114C POR2 4197_at YIL114C v 123.8 -1.8 105.1 123.8 -1.8 105.1 0.0 0.0 0.0 0.0 0.0 0.0
ion transporters
cation transporters
YOR087W YVC1 8468_at Calcium-a 40.1 4.9 154.9 40.1 3.5 98.4 10.2 -4.9 39.5 10.2 -1.6 6.2
heavy metal ion transporters (Cu, Fe, etc.)
YOR382W FIT2 8181_at Facilitator 727.5 11.0 7240.4 727.5 12.0 7996.5 62.0 -11.0 617.1 62.0 1.1
YEL065W SIT1 ARN3 5769_at Sideropho 407.0 6.4 2204.5 407.0 12.4 4625.1 67.8 -6.4 367.3 67.8 1.8
YMR058W FET3 9588_at YMR058W 900.7 2.1 988.6 900.7 2.4 1259.1 422.2 -2.1 463.4 422.2 1.1
YOR383C FIT3 8182_at YOR383C 832.9 1.5 413.6 832.9 1.8 702.8 559.8 -1.5 278.0 559.8 1.2
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YNL259C ATX1 9135_at YNL259C 701.7 1.1 70.2 701.7 1.3 210.5 0.0 0.0 0.0 0.0 0.0
YOR316C COT1 8206_at YOR316C 280.8 1.4 111.3 280.8 1.5 152.4 0.0 0.0 0.0 0.0 0.0
YDR270W CCC2 6190_at Accessory 150.0 1.9 135.0 150.0 1.9 135.0 92.0 -1.9 82.8 92.0 1.0
YER145C FTR1 5585_at YER145C I 260.0 1.1 30.5 260.0 1.5 124.6 143.9 -1.1 18.6 143.9 1.4
YER145C FTR1 5585_at YER145C I 260.0 1.1 30.5 260.0 1.5 124.6 143.9 -1.1 18.6 143.9 1.4
YHR175W CTR2 4335_at YHR175W 453.1 1.2 112.8 453.1 1.2 88.7 0.0 0.0 0.0 0.0 0.0
YMR243C ZRC1 OSR1 9382_at YMR243C 815.0 -1.0 39.8 815.0 -1.1 121.4 0.0 0.0 0.0 0.0 0.0
YLR411W CTR3 9902_at YLR411W 78.5 -1.8 62.4 78.5 -2.9 145.5 135.3 1.8 107.5 135.3 -1.6
YLR130C ZRT2 10204_at YLR130C 498.4 -1.5 249.2 498.4 -1.3 174.0 750.0 1.5 375.0 750.0 1.1
YGL255W ZRT1 5258_at YGL255W 147.7 -1.7 103.0 147.7 -2.6 243.1 279.2 1.7 194.6 279.2 -1.6
other cation transporters (Na, K, Ca , NH4, etc.)
YGL008C PMA1 5009_at YGL008C 0.0 0.0 0.0 0.0 0.0 0.0 2122.2 1.1 212.2 2122.2 1.2
YCR024C PMP1 6858_f_at YCR024C a 897.8 -1.3 313.4 897.8 -1.0 0.0 1190.8 1.3 415.7 1190.8 1.3
YEL017C PMP2 5728_i_at YEL017C 1819.7 -1.3 488.1 1819.7 -1.1 214.0 2277.6 1.3 611.0 2277.6 1.1
YGR065C VHT1 4946_at YGR065C 433.6 1.3 128.4 433.6 1.5 215.4 0.0 0.0 0.0 0.0 0.0
YHR026W PPA1 VMA16 4500_at YHR026W 1541.2 -1.3 462.3 1541.2 -1.1 154.1 1942.4 1.3 582.7 1942.4 1.1
YGR020C VMA7 4993_at YGR020C 462.1 -1.4 184.8 462.1 -1.3 138.6 648.7 1.4 259.5 648.7 1.1
YLR447C VMA6 9851_at YLR447C 508.6 -1.0 24.8 508.6 -1.3 150.6 518.0 1.0 25.3 518.0 -1.3
YKL080W VMA5 CSL5, VA 10660_at YKL080W V 713.6 -1.3 249.1 713.6 -1.2 177.7 957.0 1.3 334.1 957.0 1.1
YGR121C MEP1 AMT1 4866_at Ammonia 42.9 -4.6 155.0 42.9 -5.4 189.0 195.4 4.6 706.8 195.4 -1.2
YPR036W VMA13 CLS11 7699_at YPR036W 437.6 1.1 43.8 437.6 -1.3 152.7 403.1 -1.1 40.3 403.1 -1.5
YOR153W PDR5 LEM1, YD 8400_at Multidrug re 707.7 -1.3 209.6 707.7 -1.3 209.6 916.0 1.3 271.3 916.0 1.0
YDL185W TFP1 CLS8, VM 6679_at YDL185W 690.5 -1.3 207.2 690.5 -1.3 241.0 892.6 1.3 267.8 892.6 -1.0
YBR127C VMA2 ATPVS, V 7218_at YBR127C H 734.2 -1.5 367.1 734.2 -1.4 329.7 1021.3 1.5 510.7 1021.3 1.0
YEL027W CUP5 5763_at YEL027W V 2242.6 -1.3 664.1 2242.6 -1.1 334.0 2929.6 1.3 867.6 2929.6 1.1
YOR332W VMA4 8222_at YOR332W 978.3 -1.3 341.5 978.3 -1.3 341.5 1290.1 1.3 450.3 1290.1 -1.0
YHR039C MSC7 VMA10 4514_at YHR039C 783.6 -1.3 235.1 783.6 -1.4 351.9 1017.3 1.3 305.2 1017.3 -1.1
YPL234C TFP3 CLS9, VM 7970_at YPL234C 1186.4 -1.3 355.9 1186.4 -1.3 355.9 1511.7 1.3 453.5 1511.7 -1.1
YOR270C VPH1 8291_at YOR270C 1344.7 -1.3 403.4 1344.7 -1.3 469.4 1771.5 1.3 531.5 1771.5 -1.0
YNL142W MEP2 9026_at Ammonia t 75.9 -17.2 1229.5 75.9 -14.8 1051.2 1305.0 17.2 21139.5 1305.0 1.2
anion transporters (Cl, SO4, PO4, etc.)
YBR294W SUL1 7067_at Putative s 97.3 1.3 33.9 97.3 4.0 291.6 70.8 -1.3 24.7 70.8 2.9 134.5
YKL120W OAC1 10709_at YKL120W o 519.5 1.3 181.3 519.5 1.5 285.3 376.9 -1.3 131.6 376.9 1.1 37.7
YAL067C SEO1 11379_at Suppresso 92.1 1.6 59.8 92.1 3.7 252.9 50.8 -1.6 33.0 50.8 2.5 76.2
YJL117W PHO86 11132_at YJL117W 0.0 0.0 0.0 0.0 0.0 0.0 473.2 1.0 23.1 473.2 1.3 142.0
YER053C ?? 5665_at YER053C i 227.7 1.6 136.6 227.7 1.3 79.5 141.7 -1.6 85.0 141.7 -1.2 28.3
YLR348C DIC1 9972_at YLR348C 231.9 1.5 115.9 231.9 1.3 69.6 0.0 0.0 0.0 0.0 0.0 0.0
YLR092W SUL2 10256_at YLR092W 560.9 1.1 56.1 560.9 1.2 112.2 545.7 -1.1 54.6 545.7 1.1 54.6
YJR077C MIR1 10961_at YJR077C i 1731.2 1.1 257.8 1731.2 1.0 84.5 1524.8 -1.1 227.1 1524.8 -1.1 152.5
YGR121C MEP1 AMT1 4866_at Ammonia 42.9 -4.6 155.0 42.9 -5.4 189.0 195.4 4.6 706.8 195.4 -1.2 39.1
YNL142W MEP2 9026_at Ammonia t 75.9 -17.2 1229.5 75.9 -14.8 1051.2 1305.0 17.2 21139.5 1305.0 1.2 261.0
C-compound and carbohydrate transporters
YDL198C YHM1 6665_at YDL198C 982.5 -1.0 0.0 982.5 1.4 441.3 964.8 -1.0 0.0 964.8 1.4 385.9
YDR497C ITR1 5966_at Myo-inosit 1187.5 -1.2 237.5 1187.5 -1.0 0.0 1358.0 1.2 271.6 1358.0 1.2 271.6
YMR011W HXT2 9633_at YMR011W 809.5 -1.3 242.8 809.5 -1.0 0.0 1029.2 1.3 308.8 1029.2 1.2 205.8
YHR094C HXT1 HOR4 4430_at YHR094C 540.4 -1.0 0.0 540.4 1.3 162.1 525.9 -1.0 0.0 525.9 1.3 157.8
YDR345C HXT3 6131_at YDR345C 1351.7 -1.2 264.7 1351.7 -1.1 129.0 1606.0 1.2 314.5 1606.0 1.1 160.6
YLR348C DIC1 9972_at YLR348C 231.9 1.5 115.9 231.9 1.3 69.6 0.0 0.0 0.0 0.0 0.0 0.0
YFL011W HXT10 5377_at YFL011W H 4.7 -1.9 4.1 4.7 1.1 0.6 10.8 1.9 9.4 10.8 2.0 10.8
YDL247W ?? 6709_i_at YDL247W 2.0 2.3 2.6 2.0 -1.0 0.1 -2.2 -2.3 2.9 -2.2 -2.1 2.4
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YDR342C HXT7 6128_f_at YDR342C 1141.2 -1.1 114.1 1141.2 -1.2 228.2 0.0 0.0 0.0 0.0 0.0 0.0
YGL225W VRG4 VAN2, GO 5245_at YGL225W 800.7 -1.3 279.5 800.7 -1.3 237.1 1065.2 1.3 371.8 1065.2 1.0 0.0
YDR343C HXT6 6129_f_at YDR343C 1105.6 -1.1 110.6 1105.6 -1.4 442.2 1197.1 1.1 119.7 1197.1 -1.3 359.1
amino-acid transporters
YDR046C BAP3 6415_at Valine trans 670.0 2.6 1072.0 670.0 178.1 118656.5 297.2 -2.6 475.5 297.2 81.3 23865.2
YBR068C BAP2 7291_at Major AA 646.7 2.3 839.2 646.7 133.8 85884.2 280.3 -2.3 363.8 280.3 58.7 16173.3
YPL265W DIP5 8030_at Dicarboxyli 911.4 2.2 1085.3 911.4 18.4 15885.5 416.4 -2.2 495.9 416.4 8.5 3123.0
YGR055W MUP1 4936_at High affinity 968.3 2.0 968.3 968.3 9.0 7745.5 486.4 -2.0 486.4 486.4 4.5 1702.4
YDR508C GNP1 5977_at High-affinity 434.0 1.7 302.5 434.0 5.8 2102.6 256.4 -1.7 178.7 256.4 3.5 641.0
YBR069C TAT1 VAP1, WA 7292_at Amino aci 164.5 3.1 345.1 164.5 11.2 1685.2 53.1 -3.1 111.4 53.1 4.1 164.6
YNL268W LYP1 9126_at YNL268W 580.1 -1.0 0.0 580.1 2.3 782.8 570.8 -1.0 0.0 570.8 2.3 742.0
YOL020W TAT2 LTG3, SA 8587_at YOL020W 216.0 1.7 151.2 216.0 2.3 291.5 127.2 -1.7 89.0 127.2 1.4 50.9
YCL025C AGP1 YCC5 6907_at YCL025C 249.7 1.3 87.2 249.7 1.8 212.1 186.9 -1.3 65.2 186.9 1.4 74.8
YGL077C HNM1 5074_at YGL077C 544.7 -1.5 272.3 544.7 -1.2 108.9 924.4 1.5 462.2 924.4 1.2 184.9
YKR039W GAP1 10511_at YKR039W 46.7 -2.4 65.2 46.7 -1.4 21.0 110.8 2.4 154.9 110.8 1.7 77.6
YFL055W AGP3 5425_at General a 16.0 1.6 10.4 16.0 4.8 61.6 9.6 -1.6 6.2 9.6 3.0 19.2
YBR132C AGP2 7223_at Amino aci 13.8 3.5 34.3 13.8 3.5 34.4 4.0 -3.5 9.9 4.0 -1.2 0.8
YLL061W MMP1 10415_at YLL061W 16.8 2.5 25.1 16.8 2.2 20.1 6.6 -2.5 9.9 6.6 -1.2 1.3
nucleotide transporters
YBR021W FUR4 7334_at Uracil per 208.8 4.1 656.1 208.8 6.4 1124.9 41.4 -4.1 130.1 41.4 1.5 20.7
YER056C FCY2 BRA7 5668_at YER056C p 1819.5 -1.1 238.3 1819.5 1.0 19.9 2117.5 1.1 277.4 2117.5 1.1 311.1
YPL134C ODC1 7891_at YPL134C 139.0 1.7 104.2 139.0 1.4 62.4 80.6 -1.7 60.4 80.6 -1.2 16.1
YBR085W AAC3 ANC3 7263_at YBR085W 47.0 -2.0 48.6 47.0 -1.9 43.8 99.8 2.0 103.3 99.8 1.1 10.0
YOR222W ODC2 8334_at YOR222W 506.1 -1.3 149.9 506.1 -1.5 274.6 689.7 1.3 204.3 689.7 -1.2 137.9
allantoin and allantoate transporters
YGR260W TNA1 4736_at YGR260W 549.7 -1.1 55.0 549.7 -1.2 109.9 186.9 -1.3 65.2 186.9 1.4 74.8
YCR028C FEN2 6863_at YCR028C 375.2 -1.2 93.4 375.2 -1.4 148.7 465.8 1.2 116.0 465.8 -1.1 46.6
drug transporters
YEL065W SIT1 ARN3 5769_at Sideropho 407.0 6.4 2204.5 407.0 12.4 4625.1 67.8 -6.4 367.3 67.8 1.8 54.2
YHL040C ARN1 4568_at Siderochro 271.7 5.7 1288.9 271.7 6.7 1546.6 43.8 -5.7 207.8 43.8 1.3 13.1
YOL158C ENB1 ARN4 8723_at YOL158C 881.4 1.4 395.8 881.4 2.0 924.9 600.5 -1.4 269.7 600.5 1.4 240.2
YNL065W AQR1 8923_at A(acids, a 200.2 1.9 180.2 200.2 4.5 700.5 105.2 -1.9 94.7 105.2 2.4 147.3
YBR043C AQR2 7311_at YBR043C A 373.6 1.5 186.8 373.6 2.5 560.4 256.8 -1.5 128.4 256.8 1.7 179.8
YLL028W TPO1 10358_at YLL028W 714.9 -1.0 0.0 714.9 1.5 357.4 613.7 -1.0 0.0 613.7 1.5 306.9
YML116W ATR1 SNQ1 9771_at YML116W 507.3 1.1 50.7 507.3 1.6 329.4 459.7 -1.1 46.0 459.7 1.5 229.9
YIL120W QDR1 4236_at Multidrug re 41.4 9.5 351.8 41.4 3.6 109.7 3.3 -9.5 28.0 3.3 -2.6 5.3
YPR156C TPO3 7599_i_at Polyamine 1.7 -3.0 3.4 1.7 -1.0 0.1 8.1 3.0 16.2 8.1 2.9 15.4
YGR138C TPO2 4884_i_at YGR138C 146.9 -1.3 50.2 146.9 -2.1 166.8 193.0 1.3 65.9 193.0 -1.6 115.8
transport mechanism
transport ATPases
YGL008C PMA1 5009_at YGL008C 0.0 0.0 0.0 0.0 0.0 0.0 2122.2 1.1 212.2 2122.2 1.2 424.4
YCR024C PMP1 6858_f_at YCR024C a 897.8 -1.3 313.4 897.8 -1.0 0.0 1190.8 1.3 415.7 1190.8 1.3 357.2
YEL017C PMP2 5728_i_at YEL017C 1819.7 -1.3 488.1 1819.7 -1.1 214.0 2277.6 1.3 611.0 2277.6 1.1 339.2
YEL027W CUP5 5763_at YEL027W V 2242.6 -1.3 664.1 2242.6 -1.1 334.0 2929.6 1.3 867.6 2929.6 1.1 293.0
YHR026W PPA1 VMA16 4500_at YHR026W 1541.2 -1.3 462.3 1541.2 -1.1 154.1 1942.4 1.3 582.7 1942.4 1.1 194.2
YBL099W ATP1 7487_at YBL099W 1009.5 -1.1 150.3 1009.5 -1.0 0.0 1258.4 1.1 187.4 1258.4 1.1 125.8
YKL080W VMA5 CSL5, VA 10660_at YKL080W V 713.6 -1.3 249.1 713.6 -1.2 177.7 957.0 1.3 334.1 957.0 1.1 95.7
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YHR039C MSC7 VMA10 4514_at YHR039C 783.6 -1.3 235.1 783.6 -1.4 351.9 1017.3 1.3 305.2 1017.3 -1.1 101.7
YBR039W ATP3 7307_at YBR039W 630.5 1.2 126.1 630.5 -1.0 0.0 526.3 -1.2 105.3 526.3 -1.2 105.3
YPL234C TFP3 CLS9, VM 7970_at YPL234C 1186.4 -1.3 355.9 1186.4 -1.3 355.9 1511.7 1.3 453.5 1511.7 -1.1 151.2
YLR447C VMA6 9851_at YLR447C 508.6 -1.0 24.8 508.6 -1.3 150.6 518.0 1.0 25.3 518.0 -1.3 155.4
YLR295C ATP14 10010_at YLR295C 630.6 1.6 376.4 630.6 1.1 93.9 394.9 -1.6 235.7 394.9 -1.4 158.0
YDL004W ATP16 6503_at YDL004W 720.0 1.2 179.3 720.0 1.0 35.1 558.7 -1.2 139.1 558.7 -1.3 167.6
YPL271W ATP15 ATPEPSIL 8024_at YPL271W 1021.8 1.1 152.2 1021.8 -1.0 49.9 899.9 -1.1 134.0 899.9 -1.2 180.0
Q0310 3976_at F1F0-ATP 804.9 1.2 200.4 804.9 -1.0 39.3 644.5 -1.2 160.5 644.5 -1.3 193.4
YPR036W VMA13 CLS11 7699_at YPR036W 437.6 1.1 43.8 437.6 -1.3 152.7 403.1 -1.1 40.3 403.1 -1.5 201.6
YKL016C ATP7 10591_at YKL016C 689.5 1.2 171.7 689.5 1.3 240.7 546.0 -1.2 136.0 546.0 1.1 54.6
YDR270W CCC2 6190_at Accessory 150.0 1.9 135.0 150.0 1.9 135.0 92.0 -1.9 82.8 92.0 1.0 0.0
YGR020C VMA7 4993_at YGR020C 462.1 -1.4 184.8 462.1 -1.3 138.6 648.7 1.4 259.5 648.7 1.1 64.9
YDL185W TFP1 CLS8, VM 6679_at YDL185W 690.5 -1.3 207.2 690.5 -1.3 241.0 892.6 1.3 267.8 892.6 -1.0 0.0
YBR127C VMA2 ATPVS, V 7218_at YBR127C H 734.2 -1.5 367.1 734.2 -1.4 329.7 1021.3 1.5 510.7 1021.3 1.0 0.0
YOR332W VMA4 8222_at YOR332W 978.3 -1.3 341.5 978.3 -1.3 341.5 1290.1 1.3 450.3 1290.1 -1.0 0.0
YOR270C VPH1 8291_at YOR270C 1344.7 -1.3 403.4 1344.7 -1.3 469.4 1771.5 1.3 531.5 1771.5 -1.0 0.0
ABC transporters
YPL058C PDR12 7831_at Multidrug re 266.9 1.6 159.3 266.9 3.4 653.0 167.9 -1.6 100.2 2.2 0.0 -2.2
YCR011C ADP1 6888_at YCR011C S 0.0 0.0 0.0 0.0 0.0 0.0 282.6 1.0 13.8 282.6 1.7 197.8
YNR070W PDR18 8782_at YNR070W 6.7 2.3 8.6 6.7 2.8 12.3 3.7 -2.3 4.7 3.7 1.5 1.9
YNL014W HEF3 ZRG7 8881_at Translatio 3.5 1.5 1.8 3.5 -2.4 4.9 -1.9 -1.5 -1.0 -1.9 -3.7 -5.1
YPL226W NEW1 7978_at YPL226W s 453.2 -1.1 67.5 453.2 -1.3 158.2 519.5 1.1 77.4 519.5 -1.2 103.9
YOR153W PDR5 LEM1, YD 8400_at Multidrug re 707.7 -1.3 209.6 707.7 -1.3 209.6 916.0 1.3 271.3 916.0 1.0 0.0
other transport facilitators
YPR194C OPT2 7546_at Oligopepti 78.8 2.8 141.8 78.8 31.3 2387.5 34.1 -2.8 61.4 34.1 12.7 399.0
YNL125C ESBP6 MCH3 8997_at Protein wit 566.5 2.5 848.6 566.5 4.4 1953.0 225.6 -2.5 337.9 225.6 1.8 180.5
YER064C ?? 5635_at Mutation l 121.6 3.7 328.3 121.6 7.5 796.5 38.1 -3.7 102.9 38.1 2.5 57.2
YKR093W PTR2 10472_at YKR093W 148.2 2.7 258.7 148.2 5.8 718.0 48.2 -2.7 84.2 48.2 2.1 53.0
YJL034W KAR2 BIP, GRP 11078_at Homologu 1978.5 1.1 188.8 1978.5 1.2 492.6 1802.2 -1.1 172.0 1802.2 1.2 360.4
YNL055C POR1 OMP2 8932_at YNL055C 1947.9 1.1 194.8 1947.9 1.2 485.0 0.0 0.0 0.0 0.0 0.0 0.0
YNL070W TOM7 MOM7, Y 8917_at YNL070W 828.9 -1.1 123.4 828.9 1.1 123.4 927.8 1.1 138.2 927.8 1.3 278.3
YAL067C SEO1 11379_at Suppresso 92.1 1.6 59.8 92.1 3.7 252.9 50.8 -1.6 33.0 50.8 2.5 76.2
YGR065C VHT1 4946_at YGR065C 433.6 1.3 128.4 433.6 1.5 215.4 0.0 0.0 0.0 0.0 0.0 0.0
YOL119C MCH4 8669_at YOL119C 179.2 1.7 134.2 179.2 2.0 188.0 100.7 -1.7 75.5 100.7 1.2 20.1
YPR058W YMC1 7678_at YPR058W 624.9 1.1 62.5 624.9 1.3 187.5 569.7 -1.1 57.0 569.7 1.2 113.9
YOR045W TOM6 ISP6, MO 8518_at YOR045W 1407.9 -1.1 209.6 1407.9 -1.1 140.8 1605.3 1.1 239.0 1605.3 1.1 160.5
YDR086C SSS1 6410_at YDR086C 557.7 -1.3 165.2 557.7 -1.1 83.0 727.0 1.3 215.3 727.0 1.2 145.4
YJL054W TIM54 11058_at YJL054W 105.3 1.4 41.7 105.3 2.0 105.0 0.0 0.0 0.0 0.0 0.0 0.0
YDR322C TIM11 6154_at YDR322C s 975.4 1.2 195.1 975.4 1.1 97.5 799.4 -1.2 159.9 799.4 -1.2 159.9
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